|  |  |
| --- | --- |
| I | I |
| **CHAPITRE I** | **HOOFDSTUK I** |
|  |  |
| **A. Modalités d’application** | **A. Toepassingsmodaliteiten** |
|  |  |
| L’intervention de l’assurance maladie-invalidité est accordée dans le coût des produits radio-pharmaceutiques utilisés à titre thérapeutique pour autant que le produit soit inscrit sur la liste qui suit et pour autant que l’utilisation chez le bénéficiaire remplit, le cas échéant, les conditions de remboursement supplémentaires, comme stipulé dans la liste. | De tegemoetkoming van de ziekte- en invaliditeitsverzekering wordt toegestaan in de kosten van de therapeutisch aangewende radiofarmaceutische producten voor zover het product opgenomen is op de lijst die volgt en voor zover het gebruik bij de begunstigde, in voorkomend geval, voldoet aan de bijkomende vergoedingsvoorwaarden zoals bepaald in de lijst. |
|  |  |
| Les produits inscrits au § 1er sont facturés individuellement par bénéficiaire traité en se référant à la facture du producteur. | De producten ingeschreven in § 1 worden individueel gefactureerd per behandelde rechthebbende onder referte naar de factuur van de voortbrenger. |
|  |  |
| Le prix facturé est la base de remboursement, montant qui est entièrement remboursé par l’assurance. | De gefactureerde prijs is de basis van tegemoetkoming, bedrag dat volledig door de verzekering wordt vergoed. |
|  |  |
| L’intervention de l’assurance pour les produits inscrits dans § 2 consiste en un montant forfaitaire, fixée selon les catégories de remboursement mentionnées ci-après (Ri-Tn) et est calculée à partir des montants donnés par unité. | De verzekeringstegemoetkoming voor de producten ingeschreven in § 2, bestaat uit een forfaitair bedrag, vastgesteld volgens de hierna vermelde vergoedingscategorieën (Ri-Tn) en wordt berekend aan de per eenheid opgegeven bedragen. |
|  |  |
| **B. Liste des produits radio-pharmaceutiques utilisés à titre thérapeutique** | **B. Lijst van de therapeutisch aangewende radiofarmaceutische producten** |

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Paragraphe 10001** | | | | **Paragraaf 10001** | | | | | |
| § 10001 est supprimé au 01/05/2018. | | | | § 10001 is geschrapt op 01/05/2018. | | | | | |
|  | | | |  | | | | | |
| **Paragraphe 10002** | | | | **Paragraaf 10002** | | | | | |
| Produits radio-pharmaceutiques à base de samarium (Sm-153) lexidronam - catégorie de remboursement Ri-T1 | | | | Radiofarmaceutische producten op basis van samarium (Sm-153) lexidronaat - vergoedingscategorie Ri-T1 | | | | | |
|  | | | |  | | | | | |
| Dénomination / Benaming (Demandeur/Aanvrager) | | | | | | | | | |
| Cat. | Code | Conditionnements | Verpakkingen | | Obs  Opm | Prix  Prijs  ***ex-usine / buiten bedrijf*** | Base de remb  Basis v tegem  ***ex-usine / buiten bedrijf*** | I | II |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| QUADRAMET 1,3 GBq/ml | | | CIS BIO INTERNATIONAL SAS | |  | | | | ATC: V10BX02 | | |
|  | ***0745-032*** | ***1 flacon injectable 3,1 ml solution injectable, 3,1 ml*** | | ***1 injectieflacon 3,1 ml oplossing voor injectie, 3,1 ml*** | |  | ***1299,55*** |  | |  |  |
| Ri-T1 **\*** | 0745-032 | 1 administration 3,1 mL solution injectable, 1,3 GBq/mL | | 1 toediening 3,1 mL oplossing voor injectie, 1,3 GBq/mL | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-043 | 1 administration 3,1 mL solution injectable, 1,3 GBq/mL | | 1 toediening 3,1 mL oplossing voor injectie, 1,3 GBq/mL | |  |  |  | |  |  |
|  |  |  | |  | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | | |  | | | | | |
| **Paragraphe 10003** | | | | **Paragraaf 10003** | | | | | |
| Produits radio-pharmaceutiques à base de iodure (I-131) de sodium - catégorie de remboursement Ri-T1 | | | | Radiofarmaceutische producten op basis van natriumjodide (I-131) - vergoedingscategorie Ri-T1 | | | | | |
|  | | | |  | | | | | |
| Dénomination / Benaming (Demandeur/Aanvrager) | | | | | | | | | |
| Cat. | Code | Conditionnements | Verpakkingen | | Obs  Opm | Prix  Prijs  ***ex-usine / buiten bedrijf*** | Base de remb  Basis v tegem  ***ex-usine / buiten bedrijf*** | I | II |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 1017,50 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 1017,5 MBq*** | | ***1 capsule, hard, 1017,5 MBq*** | |  | ***270,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 1017,5 MBq | | 1 toediening, 1017,5 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 1017,5 MBq | | 1 toediening, 1017,5 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 1036 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 1036 MBq*** | | ***1 capsule, hard, 1036 MBq*** | |  | ***272,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 1036 MBq | | 1 toediening, 1036 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 1036 MBq | | 1 toediening, 1036 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 1054,50 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 1054,5 MBq*** | | ***1 capsule, hard, 1054,5 MBq*** | |  | ***274,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 1054,5 MBq | | 1 toediening, 1054,5 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 1054,5 MBq | | 1 toediening, 1054,5 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 1073 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 1073 MBq*** | | ***1 capsule, hard, 1073 MBq*** | |  | ***276,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 1073 MBq | | 1 toediening, 1073 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 1073 MBq | | 1 toediening, 1073 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 1091,50 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 1091,5 MBq*** | | ***1 capsule, hard, 1091,5 MBq*** | |  | ***278,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 1091,5 MBq | | 1 toediening, 1091,5 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 1091,5 MBq | | 1 toediening, 1091,5 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 1110 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 1110 MBq*** | | ***1 capsule, hard, 1110 MBq*** | |  | ***280,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 1110 MBq | | 1 toediening, 1110 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 1110 MBq | | 1 toediening, 1110 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 1128,50 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 1128,5 MBq*** | | ***1 capsule, hard, 1128,5 MBq*** | |  | ***282,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 1128,5 MBq | | 1 toediening, 1128,5 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 1128,5 MBq | | 1 toediening, 1128,5 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 1147 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 1147 MBq*** | | ***1 capsule, hard, 1147 MBq*** | |  | ***284,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 1147 MBq | | 1 toediening, 1147 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 1147 MBq | | 1 toediening, 1147 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 1165,50 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 1165,5 MBq*** | | ***1 capsule, hard, 1165,5 MBq*** | |  | ***286,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 1165,5 MBq | | 1 toediening, 1165,5 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 1165,5 MBq | | 1 toediening, 1165,5 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 1184 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 1184 MBq*** | | ***1 capsule, hard, 1184 MBq*** | |  | ***288,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 1184 MBq | | 1 toediening, 1184 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 1184 MBq | | 1 toediening, 1184 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 1202,50 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 1202,5 MBq*** | | ***1 capsule, hard, 1202,5 MBq*** | |  | ***290,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 1202,5 MBq | | 1 toediening, 1202,5 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 1202,5 MBq | | 1 toediening, 1202,5 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 1221 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 1221 MBq*** | | ***1 capsule, hard, 1221 MBq*** | |  | ***292,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 1221 MBq | | 1 toediening, 1221 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 1221 MBq | | 1 toediening, 1221 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 1239,50 Mbq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 1239,5 MBq*** | | ***1 capsule, hard, 1239,5 MBq*** | |  | ***294,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 1239,5 MBq | | 1 toediening, 1239,5 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 1239,5 MBq | | 1 toediening, 1239,5 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 1258 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 1258 MBq*** | | ***1 capsule, hard, 1258 MBq*** | |  | ***296,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 1258 MBq | | 1 toediening, 1258 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 1258 MBq | | 1 toediening, 1258 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 1276,50 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 1276,5 MBq*** | | ***1 capsule, hard, 1276,5 MBq*** | |  | ***298,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 1276,5 MBq | | 1 toediening, 1276,5 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 1276,5 MBq | | 1 toediening, 1276,5 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 129,5 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 129,5 MBq*** | | ***1 capsule, hard, 129,5 MBq*** | |  | ***174,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 129,5 MBq | | 1 toediening, 129,5 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 129,5 MBq | | 1 toediening, 129,5 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 1295 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 1295 MBq*** | | ***1 capsule, hard, 1295 MBq*** | |  | ***300,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 1295 MBq | | 1 toediening, 1295 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 1295 MBq | | 1 toediening, 1295 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 1313,50 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 1313,5 MBq*** | | ***1 capsule, hard, 1313,5 MBq*** | |  | ***302,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 1313,5 MBq | | 1 toediening, 1313,5 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 1313,5 MBq | | 1 toediening, 1313,5 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 1332 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 1332 MBq*** | | ***1 capsule, hard, 1332 MBq*** | |  | ***304,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 1332 MBq | | 1 toediening, 1332 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 1332 MBq | | 1 toediening, 1332 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 1350,50 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 1350,5 MBq*** | | ***1 capsule, hard, 1350,5 MBq*** | |  | ***306,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 1350,5 MBq | | 1 toediening, 1350,5 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 1350,5 MBq | | 1 toediening, 1350,5 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 1369 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 1369 MBq*** | | ***1 capsule, hard, 1369 MBq*** | |  | ***308,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 1369 MBq | | 1 toediening, 1369 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 1369 MBq | | 1 toediening, 1369 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 1387,50 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 1387,5 MBq*** | | ***1 capsule, hard, 1387,5 MBq*** | |  | ***310,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 1387,5 MBq | | 1 toediening, 1387,5 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 1387,5 MBq | | 1 toediening, 1387,5 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 1406 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 1406 MBq*** | | ***1 capsule, hard, 1406 MBq*** | |  | ***312,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 1406 MBq | | 1 toediening, 1406 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 1406 MBq | | 1 toediening, 1406 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 1424,50 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 1424,5 MBq*** | | ***1 capsule, hard, 1424,5 MBq*** | |  | ***314,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 1424,5 MBq | | 1 toediening, 1424,5 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 1424,5 MBq | | 1 toediening, 1424,5 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 1443 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 1443 MBq*** | | ***1 capsule, hard, 1443 MBq*** | |  | ***316,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 1443 MBq | | 1 toediening, 1443 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 1443 MBq | | 1 toediening, 1443 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 1461,50 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 1461,5 MBq*** | | ***1 capsule, hard, 1461,5 MBq*** | |  | ***318,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 1461,5 MBq | | 1 toediening, 1461,5 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 1461,5 MBq | | 1 toediening, 1461,5 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 1480 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 1480 MBq*** | | ***1 capsule, hard, 1480 MBq*** | |  | ***320,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 1480 MBq | | 1 toediening, 1480 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 1480 MBq | | 1 toediening, 1480 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 1498,50 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 1498,5 MBq*** | | ***1 capsule, hard, 1498,5 MBq*** | |  | ***322,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 1498,5 MBq | | 1 toediening, 1498,5 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 1498,5 MBq | | 1 toediening, 1498,5 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 1517 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 1517 MBq*** | | ***1 capsule, hard, 1517 MBq*** | |  | ***324,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 1517 MBq | | 1 toediening, 1517 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 1517 MBq | | 1 toediening, 1517 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 1535,50 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 1535,5 MBq*** | | ***1 capsule, hard, 1535,5 MBq*** | |  | ***326,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 1535,5 MBq | | 1 toediening, 1535,5 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 1535,5 MBq | | 1 toediening, 1535,5 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 1554 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 1554 MBq*** | | ***1 capsule, hard, 1554 MBq*** | |  | ***328,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 1554 MBq | | 1 toediening, 1554 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 1554 MBq | | 1 toediening, 1554 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 1572,50 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 1572,5 MBq*** | | ***1 capsule, hard, 1572,5 MBq*** | |  | ***330,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 1572,5 MBq | | 1 toediening, 1572,5 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 1572,5 MBq | | 1 toediening, 1572,5 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 1591 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 1591 MBq*** | | ***1 capsule, hard, 1591 MBq*** | |  | ***332,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 1591 MBq | | 1 toediening, 1591 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 1591 MBq | | 1 toediening, 1591 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 1609,50 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 1609,5 MBq*** | | ***1 capsule, hard, 1609,5 MBq*** | |  | ***334,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 1609,5 MBq | | 1 toediening, 1609,5 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 1609,5 MBq | | 1 toediening, 1609,5 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 1628 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 1628 MBq*** | | ***1 capsule, hard, 1628 MBq*** | |  | ***336,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 1628 MBq | | 1 toediening, 1628 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 1628 MBq | | 1 toediening, 1628 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 1646,50 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 1646,5 MBq*** | | ***1 capsule, hard, 1646,5 MBq*** | |  | ***338,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 1646,5 MBq | | 1 toediening, 1646,5 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 1646,5 MBq | | 1 toediening, 1646,5 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 166,5 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 166,5 MBq*** | | ***1 capsule, hard, 166,5 MBq*** | |  | ***178,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 166,5 MBq | | 1 toediening, 166,5 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 166,5 MBq | | 1 toediening, 166,5 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 1665 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 1665 MBq*** | | ***1 capsule, hard, 1665 MBq*** | |  | ***340,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 1665 MBq | | 1 toediening, 1665 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 1665 MBq | | 1 toediening, 1665 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 1683,50 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 1683,5 MBq*** | | ***1 capsule, hard, 1683,5 MBq*** | |  | ***342,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 1683,5 MBq | | 1 toediening, 1683,5 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 1683,5 MBq | | 1 toediening, 1683,5 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 1702 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 1702 MBq*** | | ***1 capsule, hard, 1702 MBq*** | |  | ***344,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 1702 MBq | | 1 toediening, 1702 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 1702 MBq | | 1 toediening, 1702 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 1720,50 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 1720,5 MBq*** | | ***1 capsule, hard, 1720,5 MBq*** | |  | ***346,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 1720,5 MBq | | 1 toediening, 1720,5 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 1720,5 MBq | | 1 toediening, 1720,5 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 1739 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 1739 MBq*** | | ***1 capsule, hard, 1739 MBq*** | |  | ***348,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 1739 MBq | | 1 toediening, 1739 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 1739 MBq | | 1 toediening, 1739 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 1757,50 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 1757,5 MBq*** | | ***1 capsule, hard, 1757,5 MBq*** | |  | ***350,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 1757,5 MBq | | 1 toediening, 1757,5 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 1757,5 MBq | | 1 toediening, 1757,5 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 1776 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 1776 MBq*** | | ***1 capsule, hard, 1776 MBq*** | |  | ***352,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 1776 MBq | | 1 toediening, 1776 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 1776 MBq | | 1 toediening, 1776 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 1794,50 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 1794,5 MBq*** | | ***1 capsule, hard, 1794,5 MBq*** | |  | ***354,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 1794,5 MBq | | 1 toediening, 1794,5 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 1794,5 MBq | | 1 toediening, 1794,5 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 1813 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 1813 MBq*** | | ***1 capsule, hard, 1813 MBq*** | |  | ***356,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 1813 MBq | | 1 toediening, 1813 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 1813 MBq | | 1 toediening, 1813 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 1831,50 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 1831,5 MBq*** | | ***1 capsule, hard, 1831,5 MBq*** | |  | ***358,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 1831,5 MBq | | 1 toediening, 1831,5 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 1831,5 MBq | | 1 toediening, 1831,5 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 185 MBq | | | CURIUM BELGIUM BV | | (voir aussi chapitre: II / zie ook hoofdstuk: II) | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 185 MBq*** | | ***1 capsule, hard, 185 MBq*** | |  | ***180,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 185 MBq | | 1 toediening, 185 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 185 MBq | | 1 toediening, 185 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 1850 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 1850 MBq*** | | ***1 capsule, hard, 1850 MBq*** | |  | ***360,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 1850 MBq | | 1 toediening, 1850 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 1850 MBq | | 1 toediening, 1850 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 1887 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 1887 MBq*** | | ***1 capsule, hard, 1887 MBq*** | |  | ***364,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 1887 MBq | | 1 toediening, 1887 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 1887 MBq | | 1 toediening, 1887 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 1924 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 1924 MBq*** | | ***1 capsule, hard, 1924 MBq*** | |  | ***368,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 1924 MBq | | 1 toediening, 1924 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 1924 MBq | | 1 toediening, 1924 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 1961 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 1961 MBq*** | | ***1 capsule, hard, 1961 MBq*** | |  | ***372,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 1961 MBq | | 1 toediening, 1961 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 1961 MBq | | 1 toediening, 1961 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 1998 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 1998 MBq*** | | ***1 capsule, hard, 1998 MBq*** | |  | ***376,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 1998 MBq | | 1 toediening, 1998 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 1998 MBq | | 1 toediening, 1998 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 203,50 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 203,5 MBq*** | | ***1 capsule, hard, 203,5 MBq*** | |  | ***182,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 203,5 MBq | | 1 toediening, 203,5 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 203,5 MBq | | 1 toediening, 203,5 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 2035 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 2035 MBq*** | | ***1 capsule, hard, 2035 MBq*** | |  | ***380,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 2035 MBq | | 1 toediening, 2035 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 2035 MBq | | 1 toediening, 2035 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 2072 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 2072 MBq*** | | ***1 capsule, hard, 2072 MBq*** | |  | ***384,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 2072 MBq | | 1 toediening, 2072 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 2072 MBq | | 1 toediening, 2072 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 2109 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 2109 MBq*** | | ***1 capsule, hard, 2109 MBq*** | |  | ***388,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 2109 MBq | | 1 toediening, 2109 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 2109 MBq | | 1 toediening, 2109 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 2146 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 2146 MBq*** | | ***1 capsule, hard, 2146 MBq*** | |  | ***392,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 2146 MBq | | 1 toediening, 2146 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 2146 MBq | | 1 toediening, 2146 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 2183 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 2183 MBq*** | | ***1 capsule, hard, 2183 MBq*** | |  | ***396,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 2183 MBq | | 1 toediening, 2183 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 2183 MBq | | 1 toediening, 2183 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 222 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 222 MBq*** | | ***1 capsule, hard, 222 MBq*** | |  | ***184,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 222 MBq | | 1 toediening, 222 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 222 MBq | | 1 toediening, 222 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 2220 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 2220 MBq*** | | ***1 capsule, hard, 2220 MBq*** | |  | ***400,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 2220 MBq | | 1 toediening, 2220 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 2220 MBq | | 1 toediening, 2220 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 2257 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 2257 MBq*** | | ***1 capsule, hard, 2257 MBq*** | |  | ***404,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 2257 MBq | | 1 toediening, 2257 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 2257 MBq | | 1 toediening, 2257 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 2294 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 2294 MBq*** | | ***1 capsule, hard, 2294 MBq*** | |  | ***408,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 2294 MBq | | 1 toediening, 2294 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 2294 MBq | | 1 toediening, 2294 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 2331 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 2331 MBq*** | | ***1 capsule, hard, 2331 MBq*** | |  | ***412,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 2331 MBq | | 1 toediening, 2331 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 2331 MBq | | 1 toediening, 2331 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 2368 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 2368 MBq*** | | ***1 capsule, hard, 2368 MBq*** | |  | ***416,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 2368 MBq | | 1 toediening, 2368 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 2368 MBq | | 1 toediening, 2368 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 240,50 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 240,5 MBq*** | | ***1 capsule, hard, 240,5 MBq*** | |  | ***186,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 240,5 MBq | | 1 toediening, 240,5 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 240,5 MBq | | 1 toediening, 240,5 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 2405 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 2405 MBq*** | | ***1 capsule, hard, 2405 MBq*** | |  | ***420,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 2405 MBq | | 1 toediening, 2405 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 2405 MBq | | 1 toediening, 2405 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 2442 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 2442 MBq*** | | ***1 capsule, hard, 2442 MBq*** | |  | ***424,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 2442 MBq | | 1 toediening, 2442 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 2442 MBq | | 1 toediening, 2442 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 2479 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 2479 MBq*** | | ***1 capsule, hard, 2479 MBq*** | |  | ***428,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 2479 MBq | | 1 toediening, 2479 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 2479 MBq | | 1 toediening, 2479 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 2516 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 2516 MBq*** | | ***1 capsule, hard, 2516 MBq*** | |  | ***432,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 2516 MBq | | 1 toediening, 2516 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 2516 MBq | | 1 toediening, 2516 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 2553 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 2553 MBq*** | | ***1 capsule, hard, 2553 MBq*** | |  | ***436,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 2553 MBq | | 1 toediening, 2553 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 2553 MBq | | 1 toediening, 2553 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 259 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 259 MBq*** | | ***1 capsule, hard, 259 MBq*** | |  | ***188,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 259 MBq | | 1 toediening, 259 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 259 MBq | | 1 toediening, 259 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 2590 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 2590 MBq*** | | ***1 capsule, hard, 2590 MBq*** | |  | ***440,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 2590 MBq | | 1 toediening, 2590 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 2590 MBq | | 1 toediening, 2590 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 2627 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 2627 MBq*** | | ***1 capsule, hard, 2627 MBq*** | |  | ***444,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 2627 MBq | | 1 toediening, 2627 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 2627 MBq | | 1 toediening, 2627 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 2664 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 2664 MBq*** | | ***1 capsule, hard, 2664 MBq*** | |  | ***448,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 2664 MBq | | 1 toediening, 2664 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 2664 MBq | | 1 toediening, 2664 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 2701 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 2701 MBq*** | | ***1 capsule, hard, 2701 MBq*** | |  | ***452,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 2701 MBq | | 1 toediening, 2701 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 2701 MBq | | 1 toediening, 2701 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 2738 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 2738 MBq*** | | ***1 capsule, hard, 2738 MBq*** | |  | ***456,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 2738 MBq | | 1 toediening, 2738 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 2738 MBq | | 1 toediening, 2738 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 277,50 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 277,5 MBq*** | | ***1 capsule, hard, 277,5 MBq*** | |  | ***190,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 277,5 MBq | | 1 toediening, 277,5 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 277,5 MBq | | 1 toediening, 277,5 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 2775 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 2775 MBq*** | | ***1 capsule, hard, 2775 MBq*** | |  | ***460,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 2775 MBq | | 1 toediening, 2775 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 2775 MBq | | 1 toediening, 2775 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 2812 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 2812 MBq*** | | ***1 capsule, hard, 2812 MBq*** | |  | ***464,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 2812 MBq | | 1 toediening, 2812 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 2812 MBq | | 1 toediening, 2812 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 2849 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 2849 MBq*** | | ***1 capsule, hard, 2849 MBq*** | |  | ***468,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 2849 MBq | | 1 toediening, 2849 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 2849 MBq | | 1 toediening, 2849 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 2886 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 2886 MBq*** | | ***1 capsule, hard, 2886 MBq*** | |  | ***472,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 2886 MBq | | 1 toediening, 2886 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 2886 MBq | | 1 toediening, 2886 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 2923 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 2923 MBq*** | | ***1 capsule, hard, 2923 MBq*** | |  | ***476,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 2923 MBq | | 1 toediening, 2923 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 2923 MBq | | 1 toediening, 2923 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 296 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 296 MBq*** | | ***1 capsule, hard, 296 MBq*** | |  | ***192,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 296 MBq | | 1 toediening, 296 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 296 MBq | | 1 toediening, 296 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 2960 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 2960 MBq*** | | ***1 capsule, hard, 2960 MBq*** | |  | ***480,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 2960 MBq | | 1 toediening, 2960 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 2960 MBq | | 1 toediening, 2960 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 2997 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 2997 MBq*** | | ***1 capsule, hard, 2997 MBq*** | |  | ***484,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 2997 MBq | | 1 toediening, 2997 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 2997 MBq | | 1 toediening, 2997 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 3034 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 3034 MBq*** | | ***1 capsule, hard, 3034 MBq*** | |  | ***488,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 3034 MBq | | 1 toediening, 3034 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 3034 MBq | | 1 toediening, 3034 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 3071 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 3071 MBq*** | | ***1 capsule, hard, 3071 MBq*** | |  | ***492,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 3071 MBq | | 1 toediening, 3071 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 3071 MBq | | 1 toediening, 3071 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 3108 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 3108 MBq*** | | ***1 capsule, hard, 3108 MBq*** | |  | ***496,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 3108 MBq | | 1 toediening, 3108 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 3108 MBq | | 1 toediening, 3108 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 314,50 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 314,5 MBq*** | | ***1 capsule, hard, 314,5 MBq*** | |  | ***194,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 314,5 MBq | | 1 toediening, 314,5 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 314,5 MBq | | 1 toediening, 314,5 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 3145 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 3145 MBq*** | | ***1 capsule, hard, 3145 MBq*** | |  | ***500,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 3145 MBq | | 1 toediening, 3145 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 3145 MBq | | 1 toediening, 3145 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 3182 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 3182 MBq*** | | ***1 capsule, hard, 3182 MBq*** | |  | ***504,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 3182 MBq | | 1 toediening, 3182 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 3182 MBq | | 1 toediening, 3182 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 3219 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 3219 MBq*** | | ***1 capsule, hard, 3219 MBq*** | |  | ***508,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 3219 MBq | | 1 toediening, 3219 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 3219 MBq | | 1 toediening, 3219 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 3256 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 3256 MBq*** | | ***1 capsule, hard, 3256 MBq*** | |  | ***512,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 3256 MBq | | 1 toediening, 3256 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 3256 MBq | | 1 toediening, 3256 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 3293 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 3293 MBq*** | | ***1 capsule, hard, 3293 MBq*** | |  | ***516,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 3293 MBq | | 1 toediening, 3293 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 3293 MBq | | 1 toediening, 3293 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 333 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 333 MBq*** | | ***1 capsule, hard, 333 MBq*** | |  | ***196,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 333 MBq | | 1 toediening, 333 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 333 MBq | | 1 toediening, 333 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 3330 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 3330 MBq*** | | ***1 capsule, hard, 3330 MBq*** | |  | ***520,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 3330 MBq | | 1 toediening, 3330 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 3330 MBq | | 1 toediening, 3330 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 3367 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 3367 MBq*** | | ***1 capsule, hard, 3367 MBq*** | |  | ***524,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 3367 MBq | | 1 toediening, 3367 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 3367 MBq | | 1 toediening, 3367 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 3404 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 3404 MBq*** | | ***1 capsule, hard, 3404 MBq*** | |  | ***528,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 3404 MBq | | 1 toediening, 3404 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 3404 MBq | | 1 toediening, 3404 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 3441 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 3441 MBq*** | | ***1 capsule, hard, 3441 MBq*** | |  | ***532,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 3441 MBq | | 1 toediening, 3441 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 3441 MBq | | 1 toediening, 3441 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 3478 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 3478 MBq*** | | ***1 capsule, hard, 3478 MBq*** | |  | ***536,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 3478 MBq | | 1 toediening, 3478 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 3478 MBq | | 1 toediening, 3478 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 351,50 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 351,5 MBq*** | | ***1 capsule, hard, 351,5 MBq*** | |  | ***198,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 351,5 MBq | | 1 toediening, 351,5 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 351,5 MBq | | 1 toediening, 351,5 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 3515 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 3515 MBq*** | | ***1 capsule, hard, 3515 MBq*** | |  | ***540,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 3515 MBq | | 1 toediening, 3515 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 3515 MBq | | 1 toediening, 3515 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 3552 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 3552 MBq*** | | ***1 capsule, hard, 3552 MBq*** | |  | ***544,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 3552 MBq | | 1 toediening, 3552 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 3552 MBq | | 1 toediening, 3552 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 3589 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 3589 MBq*** | | ***1 capsule, hard, 3589 MBq*** | |  | ***548,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 3589 MBq | | 1 toediening, 3589 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 3589 MBq | | 1 toediening, 3589 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 3626 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 3626 MBq*** | | ***1 capsule, hard, 3626 MBq*** | |  | ***552,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 3626 MBq | | 1 toediening, 3626 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 3626 MBq | | 1 toediening, 3626 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 3663 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 3663 MBq*** | | ***1 capsule, hard, 3663 MBq*** | |  | ***556,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 3663 MBq | | 1 toediening, 3663 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 3663 MBq | | 1 toediening, 3663 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 370 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 370 MBq*** | | ***1 capsule, hard, 370 MBq*** | |  | ***200,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 370 MBq | | 1 toediening, 370 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 370 MBq | | 1 toediening, 370 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 3700 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 3700 MBq*** | | ***1 capsule, hard, 3700 MBq*** | |  | ***560,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 3700 MBq | | 1 toediening, 3700 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 3700 MBq | | 1 toediening, 3700 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 3737 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 3737 MBq*** | | ***1 capsule, hard, 3737 MBq*** | |  | ***564,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 3737 MBq | | 1 toediening, 3737 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 3737 MBq | | 1 toediening, 3737 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 3774 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 3774 MBq*** | | ***1 capsule, hard, 3774 MBq*** | |  | ***568,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 3774 MBq | | 1 toediening, 3774 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 3774 MBq | | 1 toediening, 3774 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 3811 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 3811 MBq*** | | ***1 capsule, hard, 3811 MBq*** | |  | ***572,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 3811 MBq | | 1 toediening, 3811 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 3811 MBq | | 1 toediening, 3811 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 3848 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 3848 MBq*** | | ***1 capsule, hard, 3848 MBq*** | |  | ***576,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 3848 MBq | | 1 toediening, 3848 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 3848 MBq | | 1 toediening, 3848 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 388,50 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 388,5 MBq*** | | ***1 capsule, hard, 388,5 MBq*** | |  | ***202,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 388,5 MBq | | 1 toediening, 388,5 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 388,5 MBq | | 1 toediening, 388,5 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 3885 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 3885 MBq*** | | ***1 capsule, hard, 3885 MBq*** | |  | ***580,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 3885 MBq | | 1 toediening, 3885 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 3885 MBq | | 1 toediening, 3885 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 3922 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 3922 MBq*** | | ***1 capsule, hard, 3922 MBq*** | |  | ***584,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 3922 MBq | | 1 toediening, 3922 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 3922 MBq | | 1 toediening, 3922 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 3959 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 3959 MBq*** | | ***1 capsule, hard, 3959 MBq*** | |  | ***588,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 3959 MBq | | 1 toediening, 3959 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 3959 MBq | | 1 toediening, 3959 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 3996 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 3996 MBq*** | | ***1 capsule, hard, 3996 MBq*** | |  | ***592,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 3996 MBq | | 1 toediening, 3996 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 3996 MBq | | 1 toediening, 3996 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 4033 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 4033 MBq*** | | ***1 capsule, hard, 4033 MBq*** | |  | ***596,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 4033 MBq | | 1 toediening, 4033 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 4033 MBq | | 1 toediening, 4033 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 407 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 407 MBq*** | | ***1 capsule, hard, 407 MBq*** | |  | ***204,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 407 MBq | | 1 toediening, 407 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 407 MBq | | 1 toediening, 407 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 4070 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 4070 MBq*** | | ***1 capsule, hard, 4070 MBq*** | |  | ***600,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 4070 MBq | | 1 toediening, 4070 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 4070 MBq | | 1 toediening, 4070 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 4107 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 4107 MBq*** | | ***1 capsule, hard, 4107 MBq*** | |  | ***604,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 4107 MBq | | 1 toediening, 4107 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 4107 MBq | | 1 toediening, 4107 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 4144 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 4144 MBq*** | | ***1 capsule, hard, 4144 MBq*** | |  | ***608,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 4144 MBq | | 1 toediening, 4144 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 4144 MBq | | 1 toediening, 4144 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 4181 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 4181 MBq*** | | ***1 capsule, hard, 4181 MBq*** | |  | ***612,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 4181 MBq | | 1 toediening, 4181 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 4181 MBq | | 1 toediening, 4181 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 4218 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 4218 MBq*** | | ***1 capsule, hard, 4218 MBq*** | |  | ***616,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 4218 MBq | | 1 toediening, 4218 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 4218 MBq | | 1 toediening, 4218 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 425,50 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 425,5 MBq*** | | ***1 capsule, hard, 425,5 MBq*** | |  | ***206,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 425,5 MBq | | 1 toediening, 425,5 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 425,5 MBq | | 1 toediening, 425,5 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 4255 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 4255 MBq*** | | ***1 capsule, hard, 4255 MBq*** | |  | ***620,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 4255 MBq | | 1 toediening, 4255 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 4255 MBq | | 1 toediening, 4255 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 4292 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 4292 MBq*** | | ***1 capsule, hard, 4292 MBq*** | |  | ***624,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 4292 MBq | | 1 toediening, 4292 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 4292 MBq | | 1 toediening, 4292 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 4329 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 4329 MBq*** | | ***1 capsule, hard, 4329 MBq*** | |  | ***628,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 4329 MBq | | 1 toediening, 4329 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 4329 MBq | | 1 toediening, 4329 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 4366 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 4366 MBq*** | | ***1 capsule, hard, 4366 MBq*** | |  | ***632,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 4366 MBq | | 1 toediening, 4366 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 4366 MBq | | 1 toediening, 4366 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 4403 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 4403 MBq*** | | ***1 capsule, hard, 4403 MBq*** | |  | ***636,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 4403 MBq | | 1 toediening, 4403 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 4403 MBq | | 1 toediening, 4403 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 444 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 444 MBq*** | | ***1 capsule, hard, 444 MBq*** | |  | ***208,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 444 MBq | | 1 toediening, 444 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 444 MBq | | 1 toediening, 444 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 4440 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 4400 MBq*** | | ***1 capsule, hard, 4400 MBq*** | |  | ***640,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 4400 MBq | | 1 toediening, 4400 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 4400 MBq | | 1 toediening, 4400 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 4477 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 4477 MBq*** | | ***1 capsule, hard, 4477 MBq*** | |  | ***644,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 4477 MBq | | 1 toediening, 4477 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 4477 MBq | | 1 toediening, 4477 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 4514 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 4514 MBq*** | | ***1 capsule, hard, 4514 MBq*** | |  | ***648,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 4514 MBq | | 1 toediening, 4514 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 4514 MBq | | 1 toediening, 4514 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 4551 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 4551 MBq*** | | ***1 capsule, hard, 4551 MBq*** | |  | ***652,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 4551 MBq | | 1 toediening, 4551 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 4551 MBq | | 1 toediening, 4551 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 4588 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 4588 MBq*** | | ***1 capsule, hard, 4588 MBq*** | |  | ***656,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 4588 MBq | | 1 toediening, 4588 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 4588 MBq | | 1 toediening, 4588 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 462,5 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 462,5 MBq*** | | ***1 capsule, hard, 462,5 MBq*** | |  | ***210,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 462,5 MBq | | 1 toediening, 462,5 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 462,5 MBq | | 1 toediening, 462,5 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 4625 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 4625 MBq*** | | ***1 capsule, hard, 4625 MBq*** | |  | ***660,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 4625 MBq | | 1 toediening, 4625 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 4625 MBq | | 1 toediening, 4625 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 4662 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 4662 MBq*** | | ***1 capsule, hard, 4662 MBq*** | |  | ***664,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 4662 MBq | | 1 toediening, 4662 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 4662 MBq | | 1 toediening, 4662 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 4699 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 4699 MBq*** | | ***1 capsule, hard, 4699 MBq*** | |  | ***668,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 4699 MBq | | 1 toediening, 4699 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 4699 MBq | | 1 toediening, 4699 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 4736 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 4736 MBq*** | | ***1 capsule, hard, 4736 MBq*** | |  | ***672,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 4736 MBq | | 1 toediening, 4736 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 4736 MBq | | 1 toediening, 4736 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 4773 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 4773 MBq*** | | ***1 capsule, hard, 4773 MBq*** | |  | ***676,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 4773 MBq | | 1 toediening, 4773 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 4773 MBq | | 1 toediening, 4773 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 481 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 481 MBq*** | | ***1 capsule, hard, 481 MBq*** | |  | ***212,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 481 MBq | | 1 toediening, 481 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 481 MBq | | 1 toediening, 481 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 4810 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 4810 MBq*** | | ***1 capsule, hard, 4810 MBq*** | |  | ***680,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 4810 MBq | | 1 toediening, 4810 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 4810 MBq | | 1 toediening, 4810 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 4847 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 4847 MBq*** | | ***1 capsule, hard, 4847 MBq*** | |  | ***684,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 4847 MBq | | 1 toediening, 4847 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 4847 MBq | | 1 toediening, 4847 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 4884 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 4884 MBq*** | | ***1 capsule, hard, 4884 MBq*** | |  | ***688,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 4884 MBq | | 1 toediening, 4884 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 4884 MBq | | 1 toediening, 4884 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 4921 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 4921 MBq*** | | ***1 capsule, hard, 4921 MBq*** | |  | ***692,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 4921 MBq | | 1 toediening, 4921 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 4921 MBq | | 1 toediening, 4921 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 4958 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 4958 MBq*** | | ***1 capsule, hard, 4958 MBq*** | |  | ***696,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 4958 MBq | | 1 toediening, 4958 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 4958 MBq | | 1 toediening, 4958 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 499,50 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 499,5 MBq*** | | ***1 capsule, hard, 499,5 MBq*** | |  | ***214,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 499,5 MBq | | 1 toediening, 499,5 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 499,5 MBq | | 1 toediening, 499,5 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 4995 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 4995 MBq*** | | ***1 capsule, hard, 4995 MBq*** | |  | ***700,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 4995 MBq | | 1 toediening, 4995 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 4995 MBq | | 1 toediening, 4995 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 5032 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 5032 MBq*** | | ***1 capsule, hard, 5032 MBq*** | |  | ***704,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 5032 MBq | | 1 toediening, 5032 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 5032 MBq | | 1 toediening, 5032 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 5069 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 5069 MBq*** | | ***1 capsule, hard, 5069 MBq*** | |  | ***708,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 5069 MBq | | 1 toediening, 5069 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 5069 MBq | | 1 toediening, 5069 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 5106 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 5106 MBq*** | | ***1 capsule, hard, 5106 MBq*** | |  | ***712,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 5106 MBq | | 1 toediening, 5106 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 5106 MBq | | 1 toediening, 5106 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 5143 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 5143 MBq*** | | ***1 capsule, hard, 5143 MBq*** | |  | ***716,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 5143 MBq | | 1 toediening, 5143 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 5143 MBq | | 1 toediening, 5143 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 518 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 518 MBq*** | | ***1 capsule, hard, 518 MBq*** | |  | ***216,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 518 MBq | | 1 toediening, 518 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 518 MBq | | 1 toediening, 518 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 5180 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 5180 MBq*** | | ***1 capsule, hard, 5180 MBq*** | |  | ***720,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 5180 MBq | | 1 toediening, 5180 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 5180 MBq | | 1 toediening, 5180 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 5217 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 5217 MBq*** | | ***1 capsule, hard, 5217 MBq*** | |  | ***724,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 5217 MBq | | 1 toediening, 5217 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 5217 MBq | | 1 toediening, 5217 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 5254 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 5254 MBq*** | | ***1 capsule, hard, 5254 MBq*** | |  | ***728,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 5254 MBq | | 1 toediening, 5254 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 5254 MBq | | 1 toediening, 5254 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 5291 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 5291 MBq*** | | ***1 capsule, hard, 5291 MBq*** | |  | ***732,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 5291 MBq | | 1 toediening, 5291 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 5291 MBq | | 1 toediening, 5291 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 5328 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 5328 MBq*** | | ***1 capsule, hard, 5328 MBq*** | |  | ***736,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 5328 MBq | | 1 toediening, 5328 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 5328 MBq | | 1 toediening, 5328 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 536,50 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 536,5 MBq*** | | ***1 capsule, hard, 536,5 MBq*** | |  | ***218,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 536,5 MBq | | 1 toediening, 536,5 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 536,5 MBq | | 1 toediening, 536,5 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 5365 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 5365 MBq*** | | ***1 capsule, hard, 5365 MBq*** | |  | ***740,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 5365 MBq | | 1 toediening, 5365 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 5365 MBq | | 1 toediening, 5365 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 5402 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 5402 MBq*** | | ***1 capsule, hard, 5402 MBq*** | |  | ***744,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 5402 MBq | | 1 toediening, 5402 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 5402 MBq | | 1 toediening, 5402 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 5439 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 5439 MBq*** | | ***1 capsule, hard, 5439 MBq*** | |  | ***748,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 5439 MBq | | 1 toediening, 5439 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 5439 MBq | | 1 toediening, 5439 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 5476 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 5476 MBq*** | | ***1 capsule, hard, 5476 MBq*** | |  | ***752,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 5476 MBq | | 1 toediening, 5476 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 5476 MBq | | 1 toediening, 5476 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 55,50 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 55,5 MBq*** | | ***1 capsule, hard, 55,5 MBq*** | |  | ***166,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 55,5 MBq | | 1 toediening, 55,5 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 55,5 MBq | | 1 toediening, 55,5 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 5513 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 5513 MBq*** | | ***1 capsule, hard, 5513 MBq*** | |  | ***756,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 5513 MBq | | 1 toediening, 5513 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 5513 MBq | | 1 toediening, 5513 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 555 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 555 MBq*** | | ***1 capsule, hard, 555 MBq*** | |  | ***220,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 555 MBq | | 1 toediening, 555 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 555 MBq | | 1 toediening, 555 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 5550 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 5550 MBq*** | | ***1 capsule, hard, 5550 MBq*** | |  | ***760,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 5550 MBq | | 1 toediening, 5550 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 5550 MBq | | 1 toediening, 5550 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 5587 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 5587 MBq*** | | ***1 capsule, hard, 5587 MBq*** | |  | ***764,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 5587 MBq | | 1 toediening, 5587 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 5587 MBq | | 1 toediening, 5587 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 5624 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 5624 MBq*** | | ***1 capsule, hard, 5624 MBq*** | |  | ***768,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 5624 MBq | | 1 toediening, 5624 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 5624 MBq | | 1 toediening, 5624 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 5661 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 5661 MBq*** | | ***1 capsule, hard, 5661 MBq*** | |  | ***772,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 5661 MBq | | 1 toediening, 5661 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 5661 MBq | | 1 toediening, 5661 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 5698 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 5698 MBq*** | | ***1 capsule, hard, 5698 MBq*** | |  | ***776,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 5698 MBq | | 1 toediening, 5698 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 5698 MBq | | 1 toediening, 5698 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 573,50 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 573,5 MBq*** | | ***1 capsule, hard, 573,5 MBq*** | |  | ***222,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 573,5 MBq | | 1 toediening, 573,5 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 573,5 MBq | | 1 toediening, 573,5 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 5735 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 5735 MBq*** | | ***1 capsule, hard, 5735 MBq*** | |  | ***780,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 5735 MBq | | 1 toediening, 5735 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 5735 MBq | | 1 toediening, 5735 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 5772 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 5772 MBq*** | | ***1 capsule, hard, 5772 MBq*** | |  | ***784,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 5772 MBq | | 1 toediening, 5772 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 5772 MBq | | 1 toediening, 5772 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 5809 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 5809 MBq*** | | ***1 capsule, hard, 5809 MBq*** | |  | ***788,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 5809 MBq | | 1 toediening, 5809 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 5809 MBq | | 1 toediening, 5809 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 5846 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 5846 MBq*** | | ***1 capsule, hard, 5846 MBq*** | |  | ***792,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 5846 MBq | | 1 toediening, 5846 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 5846 MBq | | 1 toediening, 5846 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 5883 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 5883 MBq*** | | ***1 capsule, hard, 5883 MBq*** | |  | ***796,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 5883 MBq | | 1 toediening, 5883 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 5883 MBq | | 1 toediening, 5883 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 592 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 592 MBq*** | | ***1 capsule, hard, 592 MBq*** | |  | ***224,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 592 MBq | | 1 toediening, 592 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 592 MBq | | 1 toediening, 592 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 5920 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 5920 MBq*** | | ***1 capsule, hard, 5920 MBq*** | |  | ***800,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 5920 MBq | | 1 toediening, 5920 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 5920 MBq | | 1 toediening, 5920 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 5957 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 5957 MBq*** | | ***1 capsule, hard, 5957 MBq*** | |  | ***804,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 5957 MBq | | 1 toediening, 5957 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 5957 MBq | | 1 toediening, 5957 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 5994 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 5994 MBq*** | | ***1 capsule, hard, 5994 MBq*** | |  | ***808,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 5994 MBq | | 1 toediening, 5994 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 5994 MBq | | 1 toediening, 5994 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 6031 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 6031 MBq*** | | ***1 capsule, hard, 6031 MBq*** | |  | ***812,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 6031 MBq | | 1 toediening, 6031 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 6031 MBq | | 1 toediening, 6031 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 6068 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 6068 MBq*** | | ***1 capsule, hard, 6068 MBq*** | |  | ***816,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 6068 MBq | | 1 toediening, 6068 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 6068 MBq | | 1 toediening, 6068 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 610,5 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 610,5 MBq*** | | ***1 capsule, hard, 610,5 MBq*** | |  | ***226,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 610,5 MBq | | 1 toediening, 610,5 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 610,5 MBq | | 1 toediening, 610,5 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 6105 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 6105 MBq*** | | ***1 capsule, hard, 6105 MBq*** | |  | ***820,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 6105 MBq | | 1 toediening, 6105 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 6105 MBq | | 1 toediening, 6105 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 6142 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 6142 MBq*** | | ***1 capsule, hard, 6142 MBq*** | |  | ***824,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 6142 MBq | | 1 toediening, 6142 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 6142 MBq | | 1 toediening, 6142 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 6179 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 6179 MBq*** | | ***1 capsule, hard, 6179 MBq*** | |  | ***828,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 6179 MBq | | 1 toediening, 6179 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 6179 MBq | | 1 toediening, 6179 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 6216 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 6216 MBq*** | | ***1 capsule, hard, 6216 MBq*** | |  | ***832,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 6216 MBq | | 1 toediening, 6216 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 6216 MBq | | 1 toediening, 6216 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 6253 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 6253 MBq*** | | ***1 capsule, hard, 6253 MBq*** | |  | ***836,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 6253 MBq | | 1 toediening, 6253 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 6253 MBq | | 1 toediening, 6253 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 629 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 629 MBq*** | | ***1 capsule, hard, 629 MBq*** | |  | ***228,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 629 MBq | | 1 toediening, 629 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 629 MBq | | 1 toediening, 629 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 6290 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 6290 MBq*** | | ***1 capsule, hard, 6290 MBq*** | |  | ***840,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 6290 MBq | | 1 toediening, 6290 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 6290 MBq | | 1 toediening, 6290 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 6327 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 6327 MBq*** | | ***1 capsule, hard, 6327 MBq*** | |  | ***844,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 6327 MBq | | 1 toediening, 6327 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 6327 MBq | | 1 toediening, 6327 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 6364 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 6364 MBq*** | | ***1 capsule, hard, 6364 MBq*** | |  | ***848,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 6364 MBq | | 1 toediening, 6364 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 6364 MBq | | 1 toediening, 6364 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 6401 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 6401 MBq*** | | ***1 capsule, hard, 6401 MBq*** | |  | ***852,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 6401 MBq | | 1 toediening, 6401 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 6401 MBq | | 1 toediening, 6401 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 6438 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 6438 MBq*** | | ***1 capsule, hard, 6438 MBq*** | |  | ***856,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 6438 MBq | | 1 toediening, 6438 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 6438 MBq | | 1 toediening, 6438 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 647,50 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 647,5 MBq*** | | ***1 capsule, hard, 647,5 MBq*** | |  | ***230,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 647,5 MBq | | 1 toediening, 647,5 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 647,5 MBq | | 1 toediening, 647,5 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 6475 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 6475 MBq*** | | ***1 capsule, hard, 6475 MBq*** | |  | ***860,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 6475 MBq | | 1 toediening, 6475 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 6475 MBq | | 1 toediening, 6475 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 6512 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 6512 MBq*** | | ***1 capsule, hard, 6512 MBq*** | |  | ***864,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 6512 MBq | | 1 toediening, 6512 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 6512 MBq | | 1 toediening, 6512 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 6549 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 6549 MBq*** | | ***1 capsule, hard, 6549 MBq*** | |  | ***868,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 6549 MBq | | 1 toediening, 6549 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 6549 MBq | | 1 toediening, 6549 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 6586 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 6586 MBq*** | | ***1 capsule, hard, 6586 MBq*** | |  | ***872,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 6586 MBq | | 1 toediening, 6586 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 6586 MBq | | 1 toediening, 6586 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 6623 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 6623 MBq*** | | ***1 capsule, hard, 6623 MBq*** | |  | ***876,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 6623 MBq | | 1 toediening, 6623 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 6623 MBq | | 1 toediening, 6623 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 666 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 666 MBq*** | | ***1 capsule, hard, 666 MBq*** | |  | ***232,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 666 MBq | | 1 toediening, 666 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 666 MBq | | 1 toediening, 666 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 6660 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 6660 MBq*** | | ***1 capsule, hard, 6660 MBq*** | |  | ***880,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 6660 MBq | | 1 toediening, 6660 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 6660 MBq | | 1 toediening, 6660 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 6697 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 6697 MBq*** | | ***1 capsule, hard, 6697 MBq*** | |  | ***884,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 6697 MBq | | 1 toediening, 6697 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 6697 MBq | | 1 toediening, 6697 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 6734 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 6734 MBq*** | | ***1 capsule, hard, 6734 MBq*** | |  | ***888,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 6734 MBq | | 1 toediening, 6734 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 6734 MBq | | 1 toediening, 6734 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 6771 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 6771 MBq*** | | ***1 capsule, hard, 6771 MBq*** | |  | ***892,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 6771 MBq | | 1 toediening, 6771 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 6771 MBq | | 1 toediening, 6771 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 6808 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 6808 MBq*** | | ***1 capsule, hard, 6808 MBq*** | |  | ***896,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 6808 MBq | | 1 toediening, 6808 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 6808 MBq | | 1 toediening, 6808 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 684,50 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 684,5 MBq*** | | ***1 capsule, hard, 684,5 MBq*** | |  | ***234,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 684,5 MBq | | 1 toediening, 684,5 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 684,5 MBq | | 1 toediening, 684,5 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 6845 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 6845 MBq*** | | ***1 capsule, hard, 6845 MBq*** | |  | ***900,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 6845 MBq | | 1 toediening, 6845 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 6845 MBq | | 1 toediening, 6845 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 6882 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 6882 MBq*** | | ***1 capsule, hard, 6882 MBq*** | |  | ***904,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 6882 MBq | | 1 toediening, 6882 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 6882 MBq | | 1 toediening, 6882 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 6919 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 6919 MBq*** | | ***1 capsule, hard, 6919 MBq*** | |  | ***908,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 6919 MBq | | 1 toediening, 6919 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 6919 MBq | | 1 toediening, 6919 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 6956 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 6956 MBq*** | | ***1 capsule, hard, 6956 MBq*** | |  | ***912,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 6956 MBq | | 1 toediening, 6956 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 6956 MBq | | 1 toediening, 6956 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 6993 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 6993 MBq*** | | ***1 capsule, hard, 6993 MBq*** | |  | ***916,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 6993 MBq | | 1 toediening, 6993 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 6993 MBq | | 1 toediening, 6993 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 703 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 703 MBq*** | | ***1 capsule, hard, 703 MBq*** | |  | ***236,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 703 MBq | | 1 toediening, 703 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 703 MBq | | 1 toediening, 703 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 7030 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 7030 MBq*** | | ***1 capsule, hard, 7030 MBq*** | |  | ***920,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 7030 MBq | | 1 toediening, 7030 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 7030 MBq | | 1 toediening, 7030 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 7067 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 7067 MBq*** | | ***1 capsule, hard, 7067 MBq*** | |  | ***924,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 7067 MBq | | 1 toediening, 7067 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 7067 MBq | | 1 toediening, 7067 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 7104 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 7104 MBq*** | | ***1 capsule, hard, 7104 MBq*** | |  | ***928,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 7104 MBq | | 1 toediening, 7104 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 7104 MBq | | 1 toediening, 7104 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 7141 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 7141 MBq*** | | ***1 capsule, hard, 7141 MBq*** | |  | ***932,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 7141 MBq | | 1 toediening, 7141 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 7141 MBq | | 1 toediening, 7141 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 7178 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 7178 MBq*** | | ***1 capsule, hard, 7178 MBq*** | |  | ***936,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 7178 MBq | | 1 toediening, 7178 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 7178 MBq | | 1 toediening, 7178 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 721,50 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 721,5 MBq*** | | ***1 capsule, hard, 721,5 MBq*** | |  | ***238,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 721,5 MBq | | 1 toediening, 721,5 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 721,5 MBq | | 1 toediening, 721,5 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 7215 Mbq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 7215 MBq*** | | ***1 capsule, hard, 7215 MBq*** | |  | ***940,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 7215 MBq | | 1 toediening, 7215 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 7215 MBq | | 1 toediening, 7215 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 7252 Mbq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 7252 MBq*** | | ***1 capsule, hard, 7252 MBq*** | |  | ***944,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 7252 MBq | | 1 toediening, 7252 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 7252 MBq | | 1 toediening, 7252 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 7289 Mbq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 7289 MBq*** | | ***1 capsule, hard, 7289 MBq*** | |  | ***948,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 7289 MBq | | 1 toediening, 7289 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 7289 MBq | | 1 toediening, 7289 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 7326 Mbq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 7326 MBq*** | | ***1 capsule, hard, 7326 MBq*** | |  | ***952,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 7326 MBq | | 1 toediening, 7326 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 7326 MBq | | 1 toediening, 7326 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 7363 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 7363 MBq*** | | ***1 capsule, hard, 7363 MBq*** | |  | ***956,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 7363 MBq | | 1 toediening, 7363 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 7363 MBq | | 1 toediening, 7363 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 740 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 740 MBq*** | | ***1 capsule, hard, 740 MBq*** | |  | ***240,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 740 MBq | | 1 toediening, 740 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 740 MBq | | 1 toediening, 740 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 7400 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 7400 MBq*** | | ***1 capsule, hard, 7400 MBq*** | |  | ***960,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 7400 MBq | | 1 toediening, 7400 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 7400 MBq | | 1 toediening, 7400 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 758,50 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 758,5 MBq*** | | ***1 capsule, hard, 758,5 MBq*** | |  | ***242,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 758,5 MBq | | 1 toediening, 758,5 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 758,5 MBq | | 1 toediening, 758,5 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 777 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 777 MBq*** | | ***1 capsule, hard, 777 MBq*** | |  | ***244,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 777 MBq | | 1 toediening, 777 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 777 MBq | | 1 toediening, 777 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 795,50 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 795,5 MBq*** | | ***1 capsule, hard, 795,5 MBq*** | |  | ***246,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 795,5 MBq | | 1 toediening, 795,5 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 795,5 MBq | | 1 toediening, 795,5 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 814 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 814 MBq*** | | ***1 capsule, hard, 814 MBq*** | |  | ***248,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 814 MBq | | 1 toediening, 814 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 814 MBq | | 1 toediening, 814 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 832,50 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 832,5 MBq*** | | ***1 capsule, hard, 832,5 MBq*** | |  | ***250,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 832,5 MBq | | 1 toediening, 832,5 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 832,5 MBq | | 1 toediening, 832,5 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 851 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 851 MBq*** | | ***1 capsule, hard, 851 MBq*** | |  | ***252,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 851 MBq | | 1 toediening, 851 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 851 MBq | | 1 toediening, 851 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 869,50 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 869,5 MBq*** | | ***1 capsule, hard, 869,5 MBq*** | |  | ***254,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 869,5 MBq | | 1 toediening, 869,5 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 869,5 MBq | | 1 toediening, 869,5 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 888 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 888 MBq*** | | ***1 capsule, hard, 888 MBq*** | |  | ***256,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 888 MBq | | 1 toediening, 888 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 888 MBq | | 1 toediening, 888 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 906,50 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 906,5 MBq*** | | ***1 capsule, hard, 906,5 MBq*** | |  | ***258,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 906,5 MBq | | 1 toediening, 906,5 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 906,5 MBq | | 1 toediening, 906,5 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 92,50 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 92,5 MBq*** | | ***1 capsule, hard, 92,5 MBq*** | |  | ***170,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 92,5 MBq | | 1 toediening, 92,5 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 92,5 MBq | | 1 toediening, 92,5 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 925 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 925 MBq*** | | ***1 capsule, hard, 925 MBq*** | |  | ***260,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 925 MBq | | 1 toediening, 925 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 925 MBq | | 1 toediening, 925 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 943,50 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 943,5 MBq*** | | ***1 capsule, hard, 943,5 MBq*** | |  | ***262,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 943,5 MBq | | 1 toediening, 943,5 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 943,5 MBq | | 1 toediening, 943,5 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 962 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 962 MBq*** | | ***1 capsule, hard, 962 MBq*** | |  | ***264,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 962 MBq | | 1 toediening, 962 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 962 MBq | | 1 toediening, 962 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 980,50 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 980,5 MBq*** | | ***1 capsule, hard, 980,5 MBq*** | |  | ***266,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 980,5 MBq | | 1 toediening, 980,5 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 980,5 MBq | | 1 toediening, 980,5 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 999 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 999 MBq*** | | ***1 capsule, hard, 999 MBq*** | |  | ***268,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 999 MBq | | 1 toediening, 999 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 999 MBq | | 1 toediening, 999 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| THERACAP 1110 MBq | | | GE HEALTHCARE | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 1110 MBq*** | | ***1 capsule, hard, 1110 MBq*** | |  | ***216,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 1110 MBq | | 1 toediening, 1110 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 1110 MBq | | 1 toediening, 1110 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| THERACAP 1480 MBq | | | GE HEALTHCARE | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 1480 MBq*** | | ***1 capsule, hard, 1480 MBq*** | |  | ***236,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 1480 MBq | | 1 toediening, 1480 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 1480 MBq | | 1 toediening, 1480 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| THERACAP 185 MBq | | | GE HEALTHCARE | | (voir aussi chapitre: II / zie ook hoofdstuk: II) | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 185 MBq*** | | ***1 capsule, hard, 185 MBq*** | |  | ***166,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 185 MBq | | 1 toediening, 185 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 185 MBq | | 1 toediening, 185 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| THERACAP 1850 MBq | | | GE HEALTHCARE | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 1850 MBq*** | | ***1 capsule, hard, 1850 MBq*** | |  | ***256,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 1850 MBq | | 1 toediening, 1850 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 1850 MBq | | 1 toediening, 1850 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| THERACAP 222 MBq | | | GE HEALTHCARE | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 222 MBq*** | | ***1 capsule, hard, 222 MBq*** | |  | ***168,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 222 MBq | | 1 toediening, 222 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 222 MBq | | 1 toediening, 222 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| THERACAP 2220 Mbq | | | GE HEALTHCARE | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 2220 MBq*** | | ***1 capsule, hard, 2220 MBq*** | |  | ***276,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 2220 MBq | | 1 toediening, 2220 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 2220 MBq | | 1 toediening, 2220 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| THERACAP 259 Mbq | | | GE HEALTHCARE | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 259 MBq*** | | ***1 capsule, hard, 259 MBq*** | |  | ***170,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 259 MBq | | 1 toediening, 259 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 259 MBq | | 1 toediening, 259 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| THERACAP 2590 MBq | | | GE HEALTHCARE | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 2590 MBq*** | | ***1 capsule, hard, 2590 MBq*** | |  | ***296,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 2590 MBq | | 1 toediening, 2590 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 2590 MBq | | 1 toediening, 2590 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| THERACAP 296 MBq | | | GE HEALTHCARE | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 296 MBq*** | | ***1 capsule, hard, 296 MBq*** | |  | ***172,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 296 MBq | | 1 toediening, 296 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 296 MBq | | 1 toediening, 296 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| THERACAP 2960 MBq | | | GE HEALTHCARE | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 2960 MBq*** | | ***1 capsule, hard, 2960 MBq*** | |  | ***316,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 2960 MBq | | 1 toediening, 2960 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 2960 MBq | | 1 toediening, 2960 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| THERACAP 333 MBq | | | GE HEALTHCARE | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 333 MBq*** | | ***1 capsule, hard, 333 MBq*** | |  | ***174,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 333 MBq | | 1 toediening, 333 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 333 MBq | | 1 toediening, 333 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| THERACAP 370 MBq | | | GE HEALTHCARE | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 370 MBq*** | | ***1 capsule, hard, 370 MBq*** | |  | ***176,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 370 MBq | | 1 toediening, 370 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 370 MBq | | 1 toediening, 370 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| THERACAP 3700 Mbq | | | GE HEALTHCARE | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 3700 MBq*** | | ***1 capsule, hard, 3700 MBq*** | |  | ***336,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 3700 MBq | | 1 toediening, 3700 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 3700 MBq | | 1 toediening, 3700 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| THERACAP 407 MBq | | | GE HEALTHCARE | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 407 MBq*** | | ***1 capsule, hard, 407 MBq*** | |  | ***178,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 407 MBq | | 1 toediening, 407 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 407 MBq | | 1 toediening, 407 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| THERACAP 440 MBq | | | GE HEALTHCARE | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 440 MBq*** | | ***1 capsule, hard, 440 MBq*** | |  | ***180,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 440 MBq | | 1 toediening, 440 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 440 MBq | | 1 toediening, 440 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| THERACAP 481 MBq | | | GE HEALTHCARE | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 481 MBq*** | | ***1 capsule, hard, 481 MBq*** | |  | ***182,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 481 MBq | | 1 toediening, 481 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 481 MBq | | 1 toediening, 481 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| THERACAP 518 MBq | | | GE HEALTHCARE | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 518 MBq*** | | ***1 capsule, hard, 518 MBq*** | |  | ***184,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 518 MBq | | 1 toediening, 518 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 518 MBq | | 1 toediening, 518 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| THERACAP 555 MBq | | | GE HEALTHCARE | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 555 MBq*** | | ***1 capsule, hard, 555 MBq*** | |  | ***186,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 555 MBq | | 1 toediening, 555 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 555 MBq | | 1 toediening, 555 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| THERACAP 5550 Mbq | | | GE HEALTHCARE | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 5550 MBq*** | | ***1 capsule, hard, 5550 MBq*** | |  | ***436,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 5550 MBq | | 1 toediening, 5550 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 5550 MBq | | 1 toediening, 5550 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| THERACAP 592 MBq | | | GE HEALTHCARE | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 592 MBq*** | | ***1 capsule, hard, 592 MBq*** | |  | ***188,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 592 MBq | | 1 toediening, 592 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 592 MBq | | 1 toediening, 592 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| THERACAP 629 MBq | | | GE HEALTHCARE | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 629 MBq*** | | ***1 capsule, hard, 629 MBq*** | |  | ***190,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 629 MBq | | 1 toediening, 629 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 629 MBq | | 1 toediening, 629 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| THERACAP 666 Mbq | | | GE HEALTHCARE | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 666 MBq*** | | ***1 capsule, hard, 666 MBq*** | |  | ***192,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 666 MBq | | 1 toediening, 666 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 666 MBq | | 1 toediening, 666 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| THERACAP 703 MBq | | | GE HEALTHCARE | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 703 MBq*** | | ***1 capsule, hard, 703 MBq*** | |  | ***194,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 703 MBq | | 1 toediening, 703 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 703 MBq | | 1 toediening, 703 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| THERACAP 740 MBq | | | GE HEALTHCARE | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 740 MBq*** | | ***1 capsule, hard, 740 MBq*** | |  | ***196,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 740 MBq | | 1 toediening, 740 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 740 MBq | | 1 toediening, 740 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| THERACAP 925 BMq | | | GE HEALTHCARE | |  | | | | ATC: V10XA01 | | |
|  | ***0745-054*** | ***1 gélule, 925 MBq*** | | ***1 capsule, hard, 925 MBq*** | |  | ***206,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-054 | 1 administration, 925 MBq | | 1 toediening, 925 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-065 | 1 administration, 925 MBq | | 1 toediening, 925 MBq | |  |  |  | |  |  |
|  |  |  | |  | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | | |  | | | | | |
| **Paragraphe 10004** | | | | **Paragraaf 10004** | | | | | |
| Produits radio-pharmaceutiques à base de iobenguane (I-131) - catégorie de remboursement Ri-T1 | | | | Radiofarmaceutische producten op basis van iobenguaan (I-131) - vergoedingscategorie Ri-T1 | | | | | |
|  | | | |  | | | | | |
| Dénomination / Benaming (Demandeur/Aanvrager) | | | | | | | | | |
| Cat. | Code | Conditionnements | Verpakkingen | | Obs  Opm | Prix  Prijs  ***ex-usine / buiten bedrijf*** | Base de remb  Basis v tegem  ***ex-usine / buiten bedrijf*** | I | II |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| MIBG-I-131-T | | | CIS BIO INTERNATIONAL SAS | |  | | | | ATC: V10XA02 | | |
|  | ***0745-076*** | ***1 flacon injectable 10 ml solution pour perfusion, 3700 MBq*** | | ***1 injectieflacon 10 ml oplossing voor infusie, 3700 MBq*** | |  | ***4590,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-076 | 1 administration 10 mL solution pour perfusion, 3700 MBq | | 1 toediening 10 mL oplossing voor infusie, 3700 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-080 | 1 administration 10 mL solution pour perfusion, 3700 MBq | | 1 toediening 10 mL oplossing voor infusie, 3700 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| MIBG-I-131-T | | | CIS BIO INTERNATIONAL SAS | |  | | | | ATC: V10XA02 | | |
|  | ***0745-076*** | ***1 flacon injectable 5 ml solution pour perfusion, 1850 MBq*** | | ***1 injectieflacon 5 ml oplossing voor infusie, 1850 MBq*** | |  | ***3060,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-076 | 1 administration 5 mL solution pour perfusion, 1850 MBq | | 1 toediening 5 mL oplossing voor infusie, 1850 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-080 | 1 administration 5 mL solution pour perfusion, 1850 MBq | | 1 toediening 5 mL oplossing voor infusie, 1850 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| MIBG-I-131-T | | | CIS BIO INTERNATIONAL SAS | |  | | | | ATC: V10XA02 | | |
|  | ***0745-076*** | ***1 flacon injectable 20 ml solution pour perfusion, 7400 MBq*** | | ***1 injectieflacon 20 ml oplossing voor infusie, 7400 MBq*** | |  | ***7242,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-076 | 1 administration 20 mL solution pour perfusion, 7400 MBq | | 1 toediening 20 mL oplossing voor infusie, 7400 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-080 | 1 administration 20 mL solution pour perfusion, 7400 MBq | | 1 toediening 20 mL oplossing voor infusie, 7400 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| MIBG-I-131-T | | | CIS BIO INTERNATIONAL SAS | |  | | | | ATC: V10XA02 | | |
|  | ***0745-076*** | ***1 flacon injectable 15 ml solution pour perfusion, 5550 MBq*** | | ***1 injectieflacon 15 ml oplossing voor infusie, 5550 MBq*** | |  | ***5916,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-076 | 1 administration 15 mL solution pour perfusion, 5550 MBq | | 1 toediening 15 mL oplossing voor infusie, 5550 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-080 | 1 administration 15 mL solution pour perfusion, 5550 MBq | | 1 toediening 15 mL oplossing voor infusie, 5550 MBq | |  |  |  | |  |  |
|  |  |  | |  | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | | |  | | | | | |
| **Paragraphe 10006** | | | | **Paragraaf 10006** | | | | | |
| Produits radio-pharmaceutiques à base de citrate d'yttrium (Y-90) - catégorie de remboursement Ri-T1 | | | | Radiofarmaceutische producten op basis van yttrium (Y-90) citraat - vergoedingscategorie Ri-T1 | | | | | |
|  | | | |  | | | | | |
| Dénomination / Benaming (Demandeur/Aanvrager) | | | | | | | | | |
| Cat. | Code | Conditionnements | Verpakkingen | | Obs  Opm | Prix  Prijs  ***ex-usine / buiten bedrijf*** | Base de remb  Basis v tegem  ***ex-usine / buiten bedrijf*** | I | II |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| YTTRIUM (90Y) CITRAAT SUSPENSIE VOOR INTRA-ARTICULAIRE INJECTIE - YMM-1 | | | CIS BIO INTERNATIONAL SAS | |  | | | | ATC: V10AA01 | | |
|  | ***0745-113*** | ***1 suspension injectable, 296 MBq*** | | ***1 suspensie voor injectie, 296 MBq*** | |  | ***340,40*** |  | |  |  |
| Ri-T1 **\*** | 0745-113 | 1 administration 1 mL suspension injectable, 296 MBq | | 1 toediening 1 mL suspensie voor injectie, 296 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-124 | 1 administration 1 mL suspension injectable, 296 MBq | | 1 toediening 1 mL suspensie voor injectie, 296 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| YTTRIUM (90Y) CITRAAT SUSPENSIE VOOR INTRA-ARTICULAIRE INJECTIE - YMM-1 | | | CIS BIO INTERNATIONAL SAS | |  | | | | ATC: V10AA01 | | |
|  | ***0745-113*** | ***1 suspension injectable, 185 MBq*** | | ***1 suspensie voor injectie, 185 MBq*** | |  | ***281,90*** |  | |  |  |
| Ri-T1 **\*** | 0745-113 | 1 administration 1 mL suspension injectable, 185 MBq | | 1 toediening 1 mL suspensie voor injectie, 185 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-124 | 1 administration 1 mL suspension injectable, 185 MBq | | 1 toediening 1 mL suspensie voor injectie, 185 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| YTTRIUM (90Y) CITRAAT SUSPENSIE VOOR INTRA-ARTICULAIRE INJECTIE - YMM-1 | | | CIS BIO INTERNATIONAL SAS | |  | | | | ATC: V10AA01 | | |
|  | ***0745-113*** | ***1 suspension injectable, 592 MBq*** | | ***1 suspensie voor injectie, 592 MBq*** | |  | ***472,60*** |  | |  |  |
| Ri-T1 **\*** | 0745-113 | 1 administration 1 mL suspension injectable, 592 MBq | | 1 toediening 1 mL suspensie voor injectie, 592 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-124 | 1 administration 1 mL suspension injectable, 592 MBq | | 1 toediening 1 mL suspensie voor injectie, 592 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| YTTRIUM (90Y) CITRAAT SUSPENSIE VOOR INTRA-ARTICULAIRE INJECTIE - YMM-1 | | | CIS BIO INTERNATIONAL SAS | |  | | | | ATC: V10AA01 | | |
|  | ***0745-113*** | ***1 suspension injectable, 148 MBq*** | | ***1 suspensie voor injectie, 148 MBq*** | |  | ***264,10*** |  | |  |  |
| Ri-T1 **\*** | 0745-113 | 1 administration 1 mL suspension injectable, 148 MBq | | 1 toediening 1 mL suspensie voor injectie, 148 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-124 | 1 administration 1 mL suspension injectable, 148 MBq | | 1 toediening 1 mL suspensie voor injectie, 148 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| YTTRIUM (90Y) CITRAAT SUSPENSIE VOOR INTRA-ARTICULAIRE INJECTIE - YMM-1 | | | CIS BIO INTERNATIONAL SAS | |  | | | | ATC: V10AA01 | | |
|  | ***0745-113*** | ***1 suspension injectable, 444 MBq*** | | ***1 suspensie voor injectie, 444 MBq*** | |  | ***406,20*** |  | |  |  |
| Ri-T1 **\*** | 0745-113 | 1 administration 1 mL suspension injectable, 444 MBq | | 1 toediening 1 mL suspensie voor injectie, 444 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-124 | 1 administration 1 mL suspension injectable, 444 MBq | | 1 toediening 1 mL suspensie voor injectie, 444 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| YTTRIUM (90Y) CITRAAT SUSPENSIE VOOR INTRA-ARTICULAIRE INJECTIE - YMM-1 | | | CIS BIO INTERNATIONAL SAS | |  | | | | ATC: V10AA01 | | |
|  | ***0745-113*** | ***1 suspension injectable, 370 MBq*** | | ***1 suspensie voor injectie, 370 MBq*** | |  | ***363,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-113 | 1 administration 1 mL suspension injectable, 370 MBq | | 1 toediening 1 mL suspensie voor injectie, 370 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-124 | 1 administration 1 mL suspension injectable, 370 MBq | | 1 toediening 1 mL suspensie voor injectie, 370 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| YTTRIUM (90Y) CITRAAT SUSPENSIE VOOR INTRA-ARTICULAIRE INJECTIE - YMM-1 | | | CIS BIO INTERNATIONAL SAS | |  | | | | ATC: V10AA01 | | |
|  | ***0745-113*** | ***1 suspension injectable, 518 MBq*** | | ***1 suspensie voor injectie, 518 MBq*** | |  | ***437,10*** |  | |  |  |
| Ri-T1 **\*** | 0745-113 | 1 administration 1 mL suspension injectable, 518 MBq | | 1 toediening 1 mL suspensie voor injectie, 518 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-124 | 1 administration 1 mL suspension injectable, 518 MBq | | 1 toediening 1 mL suspensie voor injectie, 518 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| YTTRIUM (90Y) CITRAAT SUSPENSIE VOOR INTRA-ARTICULAIRE INJECTIE - YMM-1 | | | CIS BIO INTERNATIONAL SAS | |  | | | | ATC: V10AA01 | | |
|  | ***0745-113*** | ***1 suspension injectable, 222 MBq*** | | ***1 suspensie voor injectie, 222 MBq*** | |  | ***302,20*** |  | |  |  |
| Ri-T1 **\*** | 0745-113 | 1 administration 1 mL suspension injectable, 222 MBq | | 1 toediening 1 mL suspensie voor injectie, 222 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-124 | 1 administration 1 mL suspension injectable, 222 MBq | | 1 toediening 1 mL suspensie voor injectie, 222 MBq | |  |  |  | |  |  |
|  |  |  | |  | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | | |  | | | | | |
| **Paragraphe 10007** | | | | **Paragraaf 10007** | | | | | |
| Produits radio-pharmaceutiques à base de chlorure d’yttrium (Y-90) - catégorie de remboursement Ri-T1 | | | | Radiofarmaceutische producten op basis van yttrium (Y-90) chloride - vergoedingscategorie Ri-T1 | | | | | |
| Les produits inscrits dans ce paragraphe sont remboursables dans la catégorie de remboursement Ri-T1 s’ils sont utilisés pour le radiomarquage de la spécialité Zevalin pour le traitement en 3ème ligne ou plus, de patients adultes atteints d’un lymphome non hodgkinien (LNH) de type folliculaire à cellules B CD20+, stade III ou IV, en rechute ou réfractaire après un traitement par rituximab. | | | | De producten ingeschreven in deze paragraaf zijn vergoedbaar in de vergoedingscategorie Ri-T1 indien ze gebruikt worden voor de radioactieve labeling van de specialiteit Zevalin, voor de behandeling in 3de lijn of meer, van volwassen patiënten met een CD20+ folliculair B-cel non-Hodgkinlymfoom (NHL) stadium III of IV, die in recidief zijn na, of refractair zijn aan een behandeling met rituximab. | | | | | |
| A cet effet, et dans la mesure où cette démarche n’a pas encore été accomplie au moment de la facture, il y a lieu de joindre au relevé P, une attestation rédigée confidentiellement à l’intention du médecin-conseil de l’organisme assureur par le médecin spécialiste en radiothérapie ou par le médecin spécialiste dans la médecine nucléaire, responsable du traitement, confirmant que cette indication est rencontrée. | | | | Indien dit nog niet is gebeurd bij de facturering, moet hiertoe bij de staat P een vertrouwelijk attest worden gevoegd voor de adviserend geneesheer van de verzekeringsinstelling, opgesteld door de geneesheer-specialist in de radiotherapie of door de geneesheer-specialist in de nucleaire geneeskunde, verantwoordelijk voor de behandeling, waarin hij de behandeling van de voornoemde indicatie bevestigt. | | | | | |
|  | | | |  | | | | | |
| Dénomination / Benaming (Demandeur/Aanvrager) | | | | | | | | | |
| Cat. | Code | Conditionnements | Verpakkingen | | Obs  Opm | Prix  Prijs  ***ex-usine / buiten bedrijf*** | Base de remb  Basis v tegem  ***ex-usine / buiten bedrijf*** | I | II |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| YTRACIS | | | CIS BIO INTERNATIONAL SAS | |  | | | | ATC: | | |
|  | ***0745-135*** | ***1850 MBq solution injectable, 1850 MBq*** | | ***1850 MBq oplossing voor injectie, 1850 MBq*** | |  | ***2290,03*** |  | |  |  |
| Ri-T1 **\*** | 0745-135 | 1 administration, 1850 MBq | | 1 toediening, 1850 MBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-146 | 1 administration, 1850 MBq | | 1 toediening, 1850 MBq | |  |  |  | |  |  |
|  |  |  | |  | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | | |  | | | | | |
| **Paragraphe 10008** | | | | **Paragraaf 10008** | | | | | |
| Produits radio-pharmaceutiques à base de sphères d'yttrium (Y-90) - catégorie de remboursement Ri-T1 | | | | Radiofarmaceutische producten op basis van yttrium (Y-90) sferen - vergoedingscategorie Ri-T1 | | | | | |
|  | | | |  | | | | | |
| Dénomination / Benaming (Demandeur/Aanvrager) | | | | | | | | | |
| Cat. | Code | Conditionnements | Verpakkingen | | Obs  Opm | Prix  Prijs  ***ex-usine / buiten bedrijf*** | Base de remb  Basis v tegem  ***ex-usine / buiten bedrijf*** | I | II |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SIR-SPHERES | | | SIRTEX MEDICAL EUROPE GmbH | |  | | | | ATC: | | |
|  | ***0745-150*** | ***1 flacon injectable 5 ml solution injectable, 3 GBq*** | | ***1 injectieflacon 5 ml oplossing voor injectie, 3 GBq*** | |  | ***12000,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-150 | 1 administration 5 mL solution injectable, 3 GBq | | 1 toediening 5 mL oplossing voor injectie, 3 GBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-161 | 1 administration 5 mL solution injectable, 3 GBq | | 1 toediening 5 mL oplossing voor injectie, 3 GBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| THERASPHERE | | | BOSTON SCIENTIFIC BENELUX | |  | | | | ATC: | | |
|  | ***0745-150*** | ***1 solution injectable, 3 GBq*** | | ***1 oplossing voor injectie, 3 GBq*** | |  | ***15000,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-150 | 1 administration 1 mL solution injectable, 3 GBq | | 1 toediening 1 mL oplossing voor injectie, 3 GBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-161 | 1 administration 1 mL solution injectable, 3 GBq | | 1 toediening 1 mL oplossing voor injectie, 3 GBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| THERASPHERE | | | BOSTON SCIENTIFIC BENELUX | |  | | | | ATC: | | |
|  | ***0745-150*** | ***1 solution injectable, 7 GBq*** | | ***1 oplossing voor injectie, 7 GBq*** | |  | ***15000,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-150 | 1 administration 1 mL solution injectable, 7 GBq | | 1 toediening 1 mL oplossing voor injectie, 7 GBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-161 | 1 administration 1 mL solution injectable, 7 GBq | | 1 toediening 1 mL oplossing voor injectie, 7 GBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| THERASPHERE | | | BOSTON SCIENTIFIC BENELUX | |  | | | | ATC: | | |
|  | ***0745-150*** | ***1 solution injectable, 15 GBq*** | | ***1 oplossing voor injectie, 15 GBq*** | |  | ***15000,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-150 | 1 administration 1 mL solution injectable, 15 GBq | | 1 toediening 1 mL oplossing voor injectie, 15 GBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-161 | 1 administration 1 mL solution injectable, 15 GBq | | 1 toediening 1 mL oplossing voor injectie, 15 GBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| THERASPHERE | | | BOSTON SCIENTIFIC BENELUX | |  | | | | ATC: | | |
|  | ***0745-150*** | ***1 solution injectable, 20 GBq*** | | ***1 oplossing voor injectie, 20 GBq*** | |  | ***15000,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-150 | 1 administration 1 mL solution injectable, 20 GBq | | 1 toediening 1 mL oplossing voor injectie, 20 GBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-161 | 1 administration 1 mL solution injectable, 20 GBq | | 1 toediening 1 mL oplossing voor injectie, 20 GBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| THERASPHERE | | | BOSTON SCIENTIFIC BENELUX | |  | | | | ATC: | | |
|  | ***0745-150*** | ***1 solution injectable, 5 GBq*** | | ***1 oplossing voor injectie, 5 GBq*** | |  | ***15000,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-150 | 1 administration 1 mL solution injectable, 5 GBq | | 1 toediening 1 mL oplossing voor injectie, 5 GBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-161 | 1 administration 1 mL solution injectable, 5 GBq | | 1 toediening 1 mL oplossing voor injectie, 5 GBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| THERASPHERE | | | BOSTON SCIENTIFIC BENELUX | |  | | | | ATC: | | |
|  | ***0745-150*** | ***1 solution injectable, 10 GBq*** | | ***1 oplossing voor injectie, 10 GBq*** | |  | ***15000,00*** |  | |  |  |
| Ri-T1 **\*** | 0745-150 | 1 administration 1 mL solution injectable, 10 GBq | | 1 toediening 1 mL oplossing voor injectie, 10 GBq | |  |  |  | |  |  |
| Ri-T1 **\*\*** | 0745-161 | 1 administration 1 mL solution injectable, 10 GBq | | 1 toediening 1 mL oplossing voor injectie, 10 GBq | |  |  |  | |  |  |
|  |  |  | |  | |  |  |  | |  |  |

|  |  |  |  |
| --- | --- | --- | --- |
|  | |  | |
| **Paragraphe 20001** | | **Paragraaf 20001** | |
| Produits radio-pharmaceutiques à base de grains d'iode (I-125) - catégorie de remboursement Ri-T2 | | Radiofarmaceutische producten op basis van jood (I-125)-zaadjes - vergoedingscategorie Ri-T2 | |
| Les produits inscrits dans ce paragraphe sont remboursables dans la catégorie de remboursement Ri-T2 si les conditions mentionnées ci-dessous sont toutes remplies. | | De producten ingeschreven in deze paragraaf zijn vergoedbaar in de vergoedingscategorie Ri-T2 indien aan alle onderstaande voorwaarden is voldaan. | |
|  | a) L' intervention de l'assurance maladie-invalidité est accordée dans le coût des produits radio-pharmaceutiques uniquement s'ils sont administrés dans le cadre d'un traitement de patients atteints d'un carcinome de la prostate de stade T1-T2 avec un taux d'Antigènes prostatiques spécifiques (PSA) inférieur à 20, un Gleason-score inférieur à 8, et un volume prostatique inférieur à 50 ml. Le nombre d'unités remboursables est calculé comme suit : [volume de la prostate (en ml) x 2] + 10, le nombre maximal d'unités remboursables s'élevant toutefois à 100. Le volume prostatique utilisé pour ce calcul ne pas avoir été déterminé plus longtemps que deux mois avant l'implantation effective. La base de remboursement correspond à un montant forfaitaire, et couvre tous les coûts de ces produits radio-pharmaceutiques utilisés à titre thérapeutique, y compris les coûts de transport et de matériel d'administration, et ce indépendamment du type de conditionnement (grains individuels vs chaîne). Aucun supplément ne peut être porté en compte au patient. |  | a) De tegemoetkoming van de ziekte- en invaliditeitsverzekering in de kost van radiofarmaceutische producten wordt uitsluitend toegestaan indien toegediend in het kader van een behandeling van patiënten met een prostaatcarcinoom stadium T1-T2 met een gehalte prostaat specifiek antigen (PSA) lager dan 20, een Gleason-score lager dan 8 en een prostaatvolume lager dan 50 ml. Het aantal terugbetaalbare eenheden wordt als volgt berekend: [volume van de prostaat (in ml) x 2] + 10, het maximaal aantal terugbetaalbare eenheden bedraagt evenwel 100. Het prostaatvolume gebruikt voor deze berekening mag niet langer dan twee maanden voor de feitelijke implantatie bepaald worden. De basis van tegemoetkoming stemt overeen met een forfaitair bedrag en dekt het geheel van de kosten van deze therapeutisch aangewende radio-isotopen, inclusief transportkost en de kost van het toedieningsmateriaal en is ongeacht de wijze van verpakking (individuele zaadjes vs. strain). Aan de patiënt kan er geen enkel supplement ten laste gelegd worden. |
|  | b) Le remboursement est conditionné par la fourniture au pharmacien hospitalier concerné, préalablement à chaque facturation en tiers payant, d'un formulaire, dont le modèle est repris à l'annexe A du présent paragraphe, complété, daté et signé par un médecin spécialiste en radiothérapie. |  | b) De vergoeding is gebaseerd op de aflevering aan de betrokken ziekenhuisapotheker vooraleer aan de derde betaler gefactureerd wordt, van een formulier waarvan het model is opgenomen in bijlage A van deze paragraaf en ingevuld, gedateerd en ondertekend door de arts-specialist in de radiotherapie. |
|  | c) Le formulaire A devra être tenu à la disposition du médecin-conseil. |  | c) Het formulier A moet ter beschikking gehouden worden van de adviserend geneesheer. |

**ANNEXE A : Modèle du formulaire destiné au pharmacien hospitalier :**

Formulaire destiné au pharmacien hospitalier préalablement à la facturation de grains d’Iode 125, inscrite au § 20001 du chapitre I de l’A.R. du 22 mai 2014.

**I – Identification du bénéficiaire (nom, prénom, N° d’affiliation) :**

⊔⊔⊔⊔⊔⊔⊔⊔⊔⊔⊔⊔⊔ ⊔⊔⊔⊔⊔⊔⊔⊔⊔⊔⊔⊔⊔⊔ ⊔⊔⊔⊔⊔⊔⊔⊔⊔⊔⊔⊔⊔⊔⊔

**II – Eléments à attester par un médecin spécialiste responsable du traitement :**

Je soussigné, docteur en médecine, spécialiste en en radiothérapie

certifie que ce patient atteint d’un carcinome de la prostate entre en ligne de compte pour une thérapie avec des grains d’Iode 125 étant donné que les conditions figurant au point a) du § 20001 du chapitre I de l’A.R. du 22 mai 2014 chez ce patient sont toutes remplies et que l’ administration a été réalisée pour la situation attestée au point III ci-dessous.

**III – Situation du patient**

stade ………………………………… (T1-T2 tumor)

PSA ……………………………….. (inférieur à 20)

Gleason ……………………………….. (inférieur à 8)

Volume prostatique ………………………………. (inférieur à 50 ml)

Nombre de grains commandés ………………………………. (maximum 100)

**IV – Identification du médecin spécialiste responsable du traitement (nom, prénom, adresse, N°INAMI) :**

|  |  |  |  |
| --- | --- | --- | --- |
| ⊔⊔⊔⊔⊔⊔⊔⊔⊔⊔⊔⊔⊔⊔⊔⊔⊔ | (nom) |  |  |
| ⊔⊔⊔⊔⊔⊔⊔⊔⊔⊔⊔⊔⊔⊔⊔⊔⊔ | (prénom) |  |  |
| 1-⊔⊔⊔⊔⊔-⊔⊔-⊔⊔⊔ | (N° INAMI) |  |  |
| ⊔⊔ / ⊔⊔ / ⊔⊔⊔⊔ | (Date) |  |  |
|  | (CACHET) | *........................................* | (SIGNATURE DU MEDECIN) |

**BIJLAGE A : Model van formulier bestemd voor de ziekenhuisapotheker**

Formulier bestemd voor de ziekenhuisapotheker voorafgaand aan de facturatie van iodium 125, korrels ingeschreven in § 20001 van hoofdstuk I van het K.B. van 22 mei 2014.

**I – Identificatie van de rechthebbende (naam, voornaam, inschrijvingsnummer bij de verzekeringsinstelling):**

⊔⊔⊔⊔⊔⊔⊔⊔⊔⊔⊔⊔⊔ ⊔⊔⊔⊔⊔⊔⊔⊔⊔⊔⊔⊔⊔⊔ ⊔⊔⊔⊔⊔⊔⊔⊔⊔⊔⊔⊔⊔⊔⊔

**II – Elementen te bevestigen door de geneesheer-specialist verantwoordelijk voor de behandeling:**

Ik ondergetekende, arts, specialist in de radiotherapie;

verklaar dat deze patiënt met een prostaatcarcinoma in aanmerking komt voor een behandeling met iodium 125, korrels gezien de de voorwaarden onder punt a) van § 20001 van hoofdstuk I van het K.B. van 22 mei 2014 bij deze patiënt allen vervuld zijn en de toedienig gerealiseerd is in de situatie geattesteerd onder punt III hieronder.

**III – Situatie van de patiënt**

stadium ………………………………… (T1-T2 tumor)

PSA ……………………………….. (lager dan 20)

Gleason ……………………………….. (lager dan 8)

Prostaatvolume ………………………………. (lager dan 50 ml)

Besteld aantal zaadjes ………………………………. (maximaal 100)

**IV – Identificatie van de arts-specialist verantwoordelijk voor de behandeling (naam, voornaam, adres, RIZIV-nummer):**

|  |  |  |  |
| --- | --- | --- | --- |
| ⊔⊔⊔⊔⊔⊔⊔⊔⊔⊔⊔⊔⊔⊔⊔⊔⊔ | (naam) |  |  |
| ⊔⊔⊔⊔⊔⊔⊔⊔⊔⊔⊔⊔⊔⊔⊔⊔⊔ | (voornaam) |  |  |
| 1-⊔⊔⊔⊔⊔-⊔⊔-⊔⊔⊔ | (RIZIV nr.) |  |  |
| ⊔⊔ / ⊔⊔ / ⊔⊔⊔⊔ | (Datum) |  |  |
|  | (STEMPEL) | *........................................* | (HANDTEKENING VAN DE ARTS) |

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | | |  | | | | | |
| Dénomination / Benaming (Demandeur/Aanvrager) | | | | | | | | | |
| Cat. | Code | Conditionnements | Verpakkingen | | Obs  Opm | Prix  Prijs  ***ex-usine / buiten bedrijf*** | Base de remb  Basis v tegem  ***ex-usine / buiten bedrijf*** | I | II |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ANCHORLOAD | | | ECKERT & ZIEGLER | |  | | | | ATC: | | |
|  | ***0745-172*** | ***1 grain*** | | ***1 zaadje*** | |  | ***45,00*** |  | |  |  |
| Ri-T2 **\*** | 0745-172 | 1 grain, 1 grain | | 1 zaadje, 1 zaadje | |  |  | 47,7000 | |  |  |
| Ri-T2 **\*\*** | 0745-183 | 1 grain, 1 grain | | 1 zaadje, 1 zaadje | |  |  | 47,7000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ANCHORSEED | | | ECKERT & ZIEGLER | |  | | | | ATC: | | |
|  | ***0745-172*** | ***1 grain*** | | ***1 zaadje*** | |  | ***45,00*** |  | |  |  |
| Ri-T2 **\*** | 0745-172 | 1 grain, 1 grain | | 1 zaadje, 1 zaadje | |  |  | 47,7000 | |  |  |
| Ri-T2 **\*\*** | 0745-183 | 1 grain, 1 grain | | 1 zaadje, 1 zaadje | |  |  | 47,7000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| APPLICATOR KIT | | | ECKERT & ZIEGLER | |  | | | | ATC: | | |
|  | ***0745-172*** | ***1 grain*** | | ***1 zaadje*** | |  | ***45,00*** |  | |  |  |
| Ri-T2 **\*** | 0745-172 | 1 grain, 1 grain | | 1 zaadje, 1 zaadje | |  |  | 47,7000 | |  |  |
| Ri-T2 **\*\*** | 0745-183 | 1 grain, 1 grain | | 1 zaadje, 1 zaadje | |  |  | 47,7000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| BRACHYSOURCE SEED IMPLANT PROSEED | | | Becton Dickinson Benelux | |  | | | | ATC: | | |
|  | ***0745-172*** | ***1 grain*** | | ***1 zaadje*** | |  | ***45,00*** |  | |  |  |
| Ri-T2 **\*** | 0745-172 | 1 grain, 1 grain | | 1 zaadje, 1 zaadje | |  |  | 47,7000 | |  |  |
| Ri-T2 **\*\*** | 0745-183 | 1 grain, 1 grain | | 1 zaadje, 1 zaadje | |  |  | 47,7000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| BRACHYSOURCE SEED IMPLANT QUICKLINK | | | Becton Dickinson Benelux | |  | | | | ATC: | | |
|  | ***0745-172*** | ***1 grain*** | | ***1 zaadje*** | |  | ***45,00*** |  | |  |  |
| Ri-T2 **\*** | 0745-172 | 1 grain, 1 grain | | 1 zaadje, 1 zaadje | |  |  | 47,7000 | |  |  |
| Ri-T2 **\*\*** | 0745-183 | 1 grain, 1 grain | | 1 zaadje, 1 zaadje | |  |  | 47,7000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| BRACHYSOURCE SEED IMPLANT READYLINK | | | Becton Dickinson Benelux | |  | | | | ATC: | | |
|  | ***0745-172*** | ***1 grain*** | | ***1 zaadje*** | |  | ***45,00*** |  | |  |  |
| Ri-T2 **\*** | 0745-172 | 1 grain, 1 grain | | 1 zaadje, 1 zaadje | |  |  | 47,7000 | |  |  |
| Ri-T2 **\*\*** | 0745-183 | 1 grain, 1 grain | | 1 zaadje, 1 zaadje | |  |  | 47,7000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| IAI-125 - ADVANTAGE I-125 SEED | | | BRACHYSOLUTIONS | |  | | | | ATC: | | |
|  | ***0745-172*** | ***1 grain*** | | ***1 zaadje*** | |  | ***45,00*** |  | |  |  |
| Ri-T2 **\*** | 0745-172 | 1 grain, 1 grain | | 1 zaadje, 1 zaadje | |  |  | 47,7000 | |  |  |
| Ri-T2 **\*\*** | 0745-183 | 1 grain, 1 grain | | 1 zaadje, 1 zaadje | |  |  | 47,7000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ISOCORD I-125 | | | ECKERT & ZIEGLER | |  | | | | ATC: | | |
|  | ***0745-172*** | ***1 grain*** | | ***1 zaadje*** | |  | ***45,00*** |  | |  |  |
| Ri-T2 **\*** | 0745-172 | 1 grain, 1 grain | | 1 zaadje, 1 zaadje | |  |  | 47,7000 | |  |  |
| Ri-T2 **\*\*** | 0745-183 | 1 grain, 1 grain | | 1 zaadje, 1 zaadje | |  |  | 47,7000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ISOSEED I-125 | | | ECKERT & ZIEGLER | |  | | | | ATC: | | |
|  | ***0745-172*** | ***1 grain*** | | ***1 zaadje*** | |  | ***45,00*** |  | |  |  |
| Ri-T2 **\*** | 0745-172 | 1 grain, 1 grain | | 1 zaadje, 1 zaadje | |  |  | 47,7000 | |  |  |
| Ri-T2 **\*\*** | 0745-183 | 1 grain, 1 grain | | 1 zaadje, 1 zaadje | |  |  | 47,7000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ISOSTRAND | | | ECKERT & ZIEGLER | |  | | | | ATC: | | |
|  | ***0745-172*** | ***1 grain*** | | ***1 zaadje*** | |  | ***45,00*** |  | |  |  |
| Ri-T2 **\*** | 0745-172 | 1 grain, 1 grain | | 1 zaadje, 1 zaadje | |  |  | 47,7000 | |  |  |
| Ri-T2 **\*\*** | 0745-183 | 1 grain, 1 grain | | 1 zaadje, 1 zaadje | |  |  | 47,7000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| LOADED SHIELD MAGAZINES - AGX100 | | | THERAGENICS CORPORATION | |  | | | | ATC: | | |
|  | ***0745-172*** | ***1 grain*** | | ***1 zaadje*** | |  | ***45,00*** |  | |  |  |
| Ri-T2 **\*** | 0745-172 | 1 grain, 1 grain | | 1 zaadje, 1 zaadje | |  |  | 47,7000 | |  |  |
| Ri-T2 **\*\*** | 0745-183 | 1 grain, 1 grain | | 1 zaadje, 1 zaadje | |  |  | 47,7000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| MICK SHIELDED MAGAZINE | | | THERAGENICS CORPORATION | |  | | | | ATC: | | |
|  | ***0745-172*** | ***1 grain, 1 grain*** | | ***1 zaadje, 1 zaadje*** | |  | ***45,00*** |  | |  |  |
| Ri-T2 **\*** | 0745-172 | 1 administration, 1 grain | | 1 toediening, 1 zaadje | |  |  | 47,7000 | |  |  |
| Ri-T2 **\*\*** | 0745-183 | 1 administration, 1 grain | | 1 toediening, 1 zaadje | |  |  | 47,7000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| RTS REAL TIME STRANDS | | | ECKERT & ZIEGLER | |  | | | | ATC: | | |
|  | ***0745-172*** | ***1 grain*** | | ***1 zaadje*** | |  | ***45,00*** |  | |  |  |
| Ri-T2 **\*** | 0745-172 | 1 grain, 1 grain | | 1 zaadje, 1 zaadje | |  |  | 47,7000 | |  |  |
| Ri-T2 **\*\*** | 0745-183 | 1 grain, 1 grain | | 1 zaadje, 1 zaadje | |  |  | 47,7000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| THERAGENICS VERTICAL SEED MAGAZINE | | | THERAGENICS CORPORATION | |  | | | | ATC: | | |
|  | ***0745-172*** | ***1 grain, 1 grain*** | | ***1 zaadje, 1 zaadje*** | |  | ***45,00*** |  | |  |  |
| Ri-T2 **\*** | 0745-172 | 1 administration, 1 grain | | 1 toediening, 1 zaadje | |  |  | 47,7000 | |  |  |
| Ri-T2 **\*\*** | 0745-183 | 1 administration, 1 grain | | 1 toediening, 1 zaadje | |  |  | 47,7000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| THERALOAD | | | THERAGENICS CORPORATION | |  | | | | ATC: | | |
|  | ***0745-172*** | ***1 grain, 1 grain*** | | ***1 zaadje, 1 zaadje*** | |  | ***45,00*** |  | |  |  |
| Ri-T2 **\*** | 0745-172 | 1 administration, 1 grain | | 1 toediening, 1 zaadje | |  |  | 47,7000 | |  |  |
| Ri-T2 **\*\*** | 0745-183 | 1 administration, 1 grain | | 1 toediening, 1 zaadje | |  |  | 47,7000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| THERASLEEVE | | | THERAGENICS CORPORATION | |  | | | | ATC: | | |
|  | ***0745-172*** | ***1 grain, 1 grain*** | | ***1 zaadje, 1 zaadje*** | |  | ***45,00*** |  | |  |  |
| Ri-T2 **\*** | 0745-172 | 1 administration, 1 grain | | 1 toediening, 1 zaadje | |  |  | 47,7000 | |  |  |
| Ri-T2 **\*\*** | 0745-183 | 1 administration, 1 grain | | 1 toediening, 1 zaadje | |  |  | 47,7000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| THERASTRAND I-SEED - AGX100 | | | THERAGENICS CORPORATION | |  | | | | ATC: | | |
|  | ***0745-172*** | ***1 grain*** | | ***1 zaadje*** | |  | ***45,00*** |  | |  |  |
| Ri-T2 **\*** | 0745-172 | 1 grain, 1 grain | | 1 zaadje, 1 zaadje | |  |  | 47,7000 | |  |  |
| Ri-T2 **\*\*** | 0745-183 | 1 grain, 1 grain | | 1 zaadje, 1 zaadje | |  |  | 47,7000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| VARILOAD | | | ECKERT & ZIEGLER | |  | | | | ATC: | | |
|  | ***0745-172*** | ***1 grain*** | | ***1 zaadje*** | |  | ***45,00*** |  | |  |  |
| Ri-T2 **\*** | 0745-172 | 1 grain, 1 grain | | 1 zaadje, 1 zaadje | |  |  | 47,7000 | |  |  |
| Ri-T2 **\*\*** | 0745-183 | 1 grain, 1 grain | | 1 zaadje, 1 zaadje | |  |  | 47,7000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| VARISTRAND | | | ECKERT & ZIEGLER | |  | | | | ATC: | | |
|  | ***0745-172*** | ***1 grain*** | | ***1 zaadje*** | |  | ***45,00*** |  | |  |  |
| Ri-T2 **\*** | 0745-172 | 1 grain, 1 grain | | 1 zaadje, 1 zaadje | |  |  | 47,7000 | |  |  |
| Ri-T2 **\*\*** | 0745-183 | 1 grain, 1 grain | | 1 zaadje, 1 zaadje | |  |  | 47,7000 | |  |  |
|  |  |  | |  | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | | |  | | | | | |
| **Paragraphe 20002** | | | | **Paragraaf 20002** | | | | | |
| Produits radio-pharmaceutiques à base de ibritumomab tiuxétan - catégorie de remboursement Ri-T3 | | | | Radiofarmaceutische producten op basis van ibritumomabtiuxetan - vergoedingscategorie Ri-T3 | | | | | |
| Les produits inscrits dans ce paragraphe sont remboursables dans la catégorie de remboursement Ri-T3 s’ils sont administrés en milieu hospitalier : après radiomarquage avec Yttrium-90, pour le traitement en 3ème ligne ou plus, de patients adultes atteints d’un lymphome non hodgkinien (LNH) de type folliculaire à cellules B CD20+, stade III ou IV, en rechute ou réfractaire après un traitement par rituximab. | | | | De producten ingeschreven in deze paragraaf zijn vergoedbaar in de vergoedingscategorie Ri-T3 indien ze worden toegediend in een verplegingsinrichting: na radiolabeling met Yttrium-90, voor de behandeling in 3de lijn of meer, van volwassen patiënten met CD20+ folliculair B-cel non-Hodgkinlymfoom (NHL) stadium III of IV, die in recidief zijn na, of refractair aan een behandeling met rituximab. | | | | | |
| Le remboursement ne peut être accordé qu’une seule fois par bénéficiaire à condition que le médecin traitant, spécialiste en hématologie ou ayant une compétence particulière en oncologie ou en oncologie médicale, puisse démontrer que toutes les conditions visées au premier alinéa sont remplies | | | | De vergoeding kan maar 1 maal verleend worden per rechthebbende op voorwaarde dat de behandelende geneesheer-specialist in de haematologie of met een bijzondere bekwaamheid in de oncologie of de medische oncologie kan aantonen dat aan alle voorwaarden in de eerste alinea voldaan is. | | | | | |
|  | | | |  | | | | | |
| Dénomination / Benaming (Demandeur/Aanvrager) | | | | | | | | | |
| Cat. | Code | Conditionnements | Verpakkingen | | Obs  Opm | Prix  Prijs  ***ex-usine / buiten bedrijf*** | Base de remb  Basis v tegem  ***ex-usine / buiten bedrijf*** | I | II |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ZEVALIN 1,6 mg/ml | | | SPECTRUM PHARMACEUTICALS B.V. | |  | | | | ATC: V10XX02 | | |
|  | ***0745-194*** | ***1 flacon injectable 2 ml, 1,6 mg/ml*** | | ***1 injectieflacon 2 ml, 1,6 mg/ml*** | |  | ***8255,13*** |  | |  |  |
| Ri-T3 **\*** | 0745-194 | 1 administration 2 mL solution pour perfusion, 1,6 mg/mL/ 1,6 mg/mL | | 1 toediening 2 mL oplossing voor infusie, 1,6 mg/mL/ 1,6 mg/mL | |  |  | 8750,4400 | |  |  |
| Ri-T3 **\*\*** | 0745-205 | 1 administration 2 mL solution pour perfusion, 1,6 mg/mL/ 1,6 mg/mL | | 1 toediening 2 mL oplossing voor infusie, 1,6 mg/mL/ 1,6 mg/mL | |  |  | 8750,4400 | |  |  |
|  |  |  | |  | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | | | |  | | | | |
| **Paragraphe 20003** | | | | | **Paragraaf 20003** | | | | |
| Produits radio-pharmaceutiques à base de dichlorure de radium (Ra-223) - catégorie de remboursement Ri-T4 | | | | | Radiofarmaceutische producten op basis van radium (Ra-223) dichloride - vergoedingscategorie Ri-T4 | | | | |
| Les produits inscrits dans ce paragraphe sont remboursables dans la catégorie de remboursement Ri-T4 si les conditions mentionnées ci-dessous sont toutes remplies. | | | | | De producten ingeschreven in deze paragraaf zijn vergoedbaar in de vergoedingscategorie Ri-T4 indien aan alle onderstaande voorwaarden is voldaan. | | | | |
|  | a) La spécialité fait l’objet d’un remboursement si elle est administrée par un médecin spécialiste reconnu en médecine nucléaire, autorisé par l’AFCN pour l’administration de XOFIGO, pour le traitement de patients atteints de cancer de la prostate résistant à la castration, avec métastases osseuses symptomatiques et sans métastases viscérales connues, en progression après au moins deux lignes antérieures de traitement systémique (autres que les analogues de la LH-RH) ou inéligibles à un traitement systémique disponible du mCRPC. | | | |  | a) De specialiteit komt in aanmerking voor vergoeding indien zij wordt toegediend door een arts-specialist erkend in de nucleaire geneeskunde, vergund door het FANC voor de toediening van XOFIGO, voor de behandeling van een volwassen patiënt met castratieresistente prostaatkanker, symptomatische botmetastasen en geen bekende viscerale metastasen, progressief na ten minste twee voorafgaande systemische therapielijnen (andere dan LHRH-analogen), of die niet in aanmerking komt voor een beschikbare systemische behandeling voor mCRPC. | | | |
|  | La patient doit répondre à l’initiation du traitement par XOFIGO à chacun des critères suivants: | | | |  | De patiënt moet bij aanvang van de behandeling met XOFIGO beantwoorden aan elk van de volgende criteria: | | | |
|  | | - taux sérique de testostérone de castration < 50 ng/dL ou < 1,7 nmol/L après orchidectomie bilatérale ou sous traitement par privation androgénique; | | |  | | - serum castratiespiegels van testosteron < 50 ng/dL of < 1,7 nmol/L na bilaterale orchiëctomie of onder androgene ablatietherapie; | | |
|  | | - multiples métastases osseuses (>= 2 hot spots) sur la scintigraphie osseuse ou une autre imagerie médicale; | | |  | | - multipele botmetastasen (>= 2 hot spots) op botscintigrafie of andere medische beeldvorming; | | |
|  | | - utilisation d’analgésiques non-opioïdes ou opioïdes pour la douleur osseuse liée au cancer de manière régulière ou radiothérapie externe pour la douleur osseuse dans les 12 dernières semaines ou présence de symptômes neurologiques; | | |  | | - gebruik van niet-opioïde of opioïde analgetica voor kanker gerelateerde botpijn op reguliere basis of externe radiotherapie voor botpijn de afgelopen 12 weken of aanwezigheid van neurologische symptomen; | | |
|  | | - absence ou présence d’une adénopathie lymphatique maligne avec les plus gros ganglions lymphatiques < 3 cm (diamètre axe court); | | |  | | - afwezigheid van of aanwezigheid van maligne lymfadenopathie met grootste lymfeknopen < 3 cm (korte-as diameter); | | |
|  | | - absence de métastases viscérales confirmée par imagerie médicale de l’abdomen et du petit bassin (CT ou IRM) et du thorax (RX ou CT) ne datant pas de plus de 8 semaines; | | |  | | - afwezigheid van viscerale metastasen bevestigd d.m.v. medische beeldvorming van abdomen en klein bekken (CT of MRI) en thorax (RX of CT) niet meer dan 8 weken geleden; | | |
|  | | - présente au moins 1 des signes suivants de progression de la maladie: | | |  | | - heeft minstens 1 van de volgende tekens van ziekteprogressie: | | |
|  | | | 1. progression des lésions osseuses (apparition de lésions osseuses complémentaires sur la scintigraphie osseuse); | |  | | | 1. progressie van botletsels (ontstaan van bijkomende botletsels op botscan); | |
|  | | | 2. trois augmentations consécutives du PSA sérique (avec un intervalle de minimum 7 jours) dont au moins deux avec un PSA sérique > 2 ng/ml et représentant une augmentation d’au moins 50 % par rapport au nadir PSA; | |  | | | 2. drie opeenvolgende PSA stijgingen, met elk 1 week tussen, waarvan minstens 2 maal een PSA spiegel van > 2 ng/ml die tegelijkertijd een stijging met 50% ten opzichte van de nadir PSA vertegenwoordigt; | |
|  | | | 3. progression de la douleur osseuse (e.g. utilisation accrue d’analgésiques non-opioïdes ou opioïdes ou douleur osseuse après radiothérapie externe dans les 12 dernières semaines); | |  | | | 3. progressie van botpijn (b.v. toename van gebruik van niet-opioïde of opioïde analgetica of botpijn na externe radiotherapie de afgelopen 12 weken); | |
|  | | - Si le patient n’a pas encore été traité avec le docétaxel pour son cancer de la prostate: | | |  | | - Indien de patiënt voor zijn prostaatkanker nog niet met docetaxel werd behandeld: | | |
|  | | | o n’est pas éligible pour entamer un traitement avec le docétaxel : le patient présente un taux de temps de doublement du PSA de plus de 6 mois (calculé selon Arlen et al. J Urol. 2008 June; 179(6): 2181–2186) ou n’est pas éligible pour entamer un traitement avec le docétaxel pour d’autres raisons. | |  | | | o komt niet in aanmerking voor opstarten van een behandeling met docetaxel: de patiënt heeft een PSA verdubbelingstijd van langer dan 6 maand (te berekenen volgens Arlen et al. J Urol. 2008 June ; 179(6): 2127 – 2186) of komt om andere redenen niet in aanmerking voor opstarten van docetaxel. | |
|  | | - Si le patient a déjà été traité avec le docétaxel pour son cancer de la prostate : | | |  | | - Indien de patiënt voor zijn prostaatkanker reeds met docetaxel werd behandeld: | | |
|  | | | o a déjà reçu au moins 3 cycles de docétaxel pour ladite indication (à une dose de > ou = 225 mg/m2), à moins d’avoir démontré une intolérance durant le traitement de première ligne avec le docétaxel ; | |  | | | o heeft minstens 3 cycli docetaxel ontvangen voor genoemde aandoening (overeenkomst met een dosis > of = 225 mg/m2), tenzij aangetoonde intolerantie tijdens de eerstelijnsbehandeling met docetaxel; | |
|  | | | o n’est pas éligible pour un deuxième traitement avec le docétaxel en raison d’une des situations suivantes: | |  | | | o komt niet in aanmerking voor een tweede docetaxel behandeling omwille van één van de volgende situaties: | |
|  | | | |  |  | | | |  |
|  | | | |  |  | | | |  |
|  | | | |  |  | | | |  |
|  | b) Le nombre de conditionnements remboursables tiendra compte d’une posologie de XOFIGO correspondant à 55 kBq par kg de masse corporelle (maximum 1 flacon est remboursable par administration) administrée par une injection toutes les 4 semaines, avec un maximum de 6 injections. Si le patient a besoin de 2 flacons par administration, il sera tenu compte du remboursement de maximum 1 flacon par administration. Le deuxième flacon par administration sera dans ce cas fourni gratuitement par la firme (avec un maximum de 6 flacons gratuits pour le traitement total du patient). | | | |  | b) Het aantal vergoedbare verpakkingen houdt rekening met het doseringsschema van Xofigo welke 55 kBq per kg lichaamsgewicht is (per toediening is maximum 1 flacon vergoedbaar), gegeven als injectie om de 4 weken, met een maximum van 6 injecties. Indien de patiënt 2 flacons per toediening nodig heeft, zal rekening gehouden worden met een vergoeding van maximum 1 flacon per toediening. De tweede flacon per toediening zal in dat geval door de firma gratis geleverd worden (met een maximum van 6 gratis flacons voor de totale behandeling van de patiënt). | | | |
|  | c) Le remboursement ne peut être accordé que si le pharmacien hospitalier dispose, préalablement à la dispensation, d’un formulaire de demande, dont le modèle est repris à l’annexe A du présent paragraphe, complété et signé par le médecin spécialiste responsable du traitement et qui est agréé en oncologie médicale, en urologie ou en radiothérapie. | | | |  | c) De vergoeding kan slechts worden toegestaan als de afleverende ziekenhuisapotheker beschikt over het aanvraagformulier, waarvan het model in bijlage A van de huidige paragraaf is opgenomen, ingevuld en ondertekend door de arts-specialist verantwoordelijk voor de behandeling en die erkend is in medische oncologie, de urologie of radiotherapie. | | | |
|  | d) En complétant de la sorte les rubriques ad hoc de ce formulaire, le médecin spécialiste dont il est question ci-dessus mentionne également: | | | |  | d) Door het formulier volledig in te vullen in de ad hoc rubrieken, vermeldt de arts-specialist van wie hierboven sprake gelijktijdig: | | | |
|  | | - les éléments relatifs à l’état du patient; | | |  | | - de elementen die betrekking hebben op de toestand van de patiënt; | | |
|  | | - qu’il atteste disposer du rapport de la consultation oncologique multidisciplinaire (COM) (au moins constituée d’un médecin spécialiste en médecine nucléaire, un oncologue, un radiothérapeute et un urologue) autorisant le traitement qui est appliqué; avec une attention particulière avec attention particulière aux possibilités d’adapter ou appliquer les traitements hormonaux et/ou initier un traitement avec docétaxel ou d’autres options thérapeutiques; | | |  | | - dat hij bevestigt dat hij over het rapport van het multidisciplinair oncologisch consult (MOC) (minimaal bestaande uit een arts-specialist in nucleaire geneeskunde, een medisch oncoloog, een radiotherapeut en een uroloog) beschikt dat het akkoord geeft voor de behandeling die wordt toegepast; met specifieke aandacht voor de toepasbaarheid van bijkomende aanpassingen van hormonale therapie en/of het opstarten van docetaxel of andere mogelijke behandelingen; | | |
|  | | - qu’il confirme que l’établissement où le patient est traité, peut disposer des services d’un expert en radiophysique et un “Expert qualifié en contrôle physique”; | | |  | | - dat hij bevestigt dat de instelling waar de patiënt behandeld wordt, kan beschikken over de diensten van een expert in stralingsfysica en een “Deskundige bevoegd in de Fysische Controle”; | | |
|  | | - qu’il s’engage à tenir à la disposition du médecin-conseil les éléments de preuve qui attestent de la situation décrite; | | |  | | - dat hij zich ertoe verbindt om ten behoeve van de adviserend-geneesheer de bewijsstukken ter beschikking te houden die de geattesteerde gegevens bevestigen; | | |
|  | | - qu’il s’engage à évaluer l’état du patient avant chaque injection afin d évaluer si la poursuite du traitement est médicalement justifiée; | | |  | | - dat hij zich ertoe verbindt om voor elke injectie de toestand van de patiënt te beoordelen opdat de voortzetting van de behandeling medisch gerechtvaardigd is; | | |
|  | | - qu’il s’engage lors de l’initiation du traitement à fournir au pharmacien hospitalier dispensateur un formulaire de demande dont le modèle est repris à l’annexe A du présent paragraphe; | | |  | | - dat hij zich ertoe verbindt bij de start van de behandeling een aanvraagformulier, waarvan het model in bijlage A van de huidige paragraaf is opgenomen, af te geven aan de afleverende ziekenhuisapotheker; | | |
|  | | - qu’il s'engage a arrêter le traitement remboursé si un traitement par chimiothérapie ou par radiothérapie externe hemibody est instauré; | | |  | | - dat hij zich ertoe verbindt om de terugbetaalde behandeling te stoppen wanneer een behandeling met chemotherapie of met externe hemibody radiotherapie wordt ingesteld; | | |
|  | | - qu’il confirme que le schéma de traitement par XOFIGO ne dépassera pas un nombre de 6 injections. | | |  | | - dat hij bevestigt dat het volledige behandelingsschema met XOFIGO het aantal injecties van 6 niet zal overschrijden. | | |
|  | e) Le formulaire de demande rempli et signé repris à l’annexe A, devra être tenu à la disposition du médecin conseil. | | | |  | e) Het ingevulde en ondertekende aanvraagformulier opgenomen in bijlage A moet ter beschikking gehouden worden van de adviserend geneesheer. | | | |
|  | f) Le remboursement simultanée des spécialités XOFIGO, ZYTIGA, JEVTANA, XTANDI et les spécialités à base de docétaxel n’est jamais autorisé. | | | |  | f) De gelijktijdige vergoeding van de specialiteiten XOFIGO, ZYTIGA, JEVTANA, XTANDI en specialiteiten op basis van docetaxel is nooit toegestaan. | | | |

**ANNEXE A: Modèle du formulaire destiné au pharmacien hospitalier:**

Formulaire destiné au pharmacien hospitalier préalablement à la facturation de la spécialité XOFIGO (§ 20003 du chapitre I de l’A.R. du 22 mai 2014)

**I – Identification du bénéficiaire (nom, prénom, N° d’affiliation):**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (nom) |

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (prénom) |

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (numéro d’affiliation) |

**II – Eléments à attester par un médecin spécialiste en oncologie médicale, en urologie ou en radiothérapie:**

Je soussigné, docteur en médecine agréé en oncologie médicale, en urologie ou en radiothérapie, certifie le patient mentionné ci-dessus souffre d’un cancer de la prostate résistant à la castration, avec métastases osseuses symptomatiques et sans métastases viscérales connues, en progression après au moins deux lignes antérieures de traitement systémique (autres que les analogues de la LH-RH) ou inéligibles à un traitement systémique disponible du mCRPC, et que les conditions figurant au § 20003 du chapitre I de l’A.R. du 22 mai 2014 chez ce patient sont toutesremplies.

Le patient recevra XOFIGO aux conditions supplémentaires que, au début du traitement avec le radium-223-dichloride, il se trouve dans la condition suivante:

* + un taux sérique de testostérone de castration < 50 ng/dL ou < 1,7 nmol/L après orchidectomie bilatérale ou sous traitement par privation androgénique
  + multiples métastases osseuses (≥ 2 hot spots) sur la scintigraphie osseuse ou une autre imagerie médicale
  + utilisation d’analgésiques non-opioïdes ou opioïdes pour la douleur osseuse liée au cancer de manière régulière ou radiothérapie externe pour la douleur osseuse dans les 12 dernières semaines ou présence de symptômes neurologiques
  + absence ou présence d’une adénopathie lymphatique maligne avec les plus gros ganglions lymphatiques < 3 cm (diamètre axe court)
  + absence de métastases viscérales confirmée par imagerie médicale de l’abdomen et du petit bassin (CT ou IRM) et du thorax (RX ou CT) ne datant pas de plus de 8 semaines
  + présente au moins 1 des signes suivants de progression de la maladie:

progression des lésions osseuses (apparition de lésions osseuses complémentaires sur la scintigraphie osseuse)

trois augmentations consécutives du PSA sérique (avec un intervalle de minimum 7 jours) dont au moins deux avec un PSA sérique > 2 ng/ml et représentant une augmentation d’au moins 50 % par rapport au nadir PSA

progression de la douleur osseuse (e.g. utilisation accrue d’analgésiques non-opioïdes ou opioïdes ou douleur osseuse après radiothérapie externe dans les 12 dernières semaines)

* + Si le patient n’a pas encore été traité avec le docétaxel pour son cancer de la prostate:

o n’est pas éligible pour entamer un traitement avec le docétaxel : le patient présente un taux de temps de doublement du PSA de plus de 6 mois (calculé selon Arlen et al. J Urol. 2008 June; 179(6): 2181–2186) ou n’est pas éligible pour entamer un traitement avec le docétaxel pour d’autres raisons.

* + Si le patient a déjà été traité avec le docétaxel pour son cancer de la prostate :

o a déjà reçu au moins 3 cycles de docétaxel pour ladite indication (à une dose de > ou = 225 mg/m2), à moins d’avoir démontré une intolérance durant le traitement de première ligne avec le docétaxel ;

o n’est pas éligible pour un deuxième traitement avec le docétaxel en raison d’une des situations suivantes:

a présenté une progression durant le traitement de première ligne avec le docétaxel (au moins 3 cycles),

a présenté une progression < 5 mois après la dernière administration de docétaxel en première ligne

a présenté une intolérance démontrable durant le traitement de première ligne avec le docétaxel;

Je dispose dans mon dossier du rapport de la consultation oncologique multidisciplinaire (COM) (au moins constituée d’un médecin spécialiste en médecine nucléaire, un oncologue, un radiothérapeute et un urologue), daté du / / , date à laquelle le traitement avec XOFIGO a été décidé.

Je confirme que l’établissement où le patient est traité, peut disposer des services d’un expert en radiophysique et un “Expert qualifié en contrôle physique”.

Je sais que le remboursement simultané des spécialités XOFIGO, ZYTIGA, JEVTANA, XTANDI et les spécialités à base de docétaxel n’est jamais autorisé.

**III – Demande de remboursement**

Sur base des éléments mentionnés ci-dessus, je déclare que ce patient a besoin du remboursement de la spécialité XOFIGO pour l’initiation d’un traitement à une posologie correspondant à 55 kBq par kg de masse corporelle, administrée par injection toutes les 4 semaines, avec un maximum de 6 injections. Je suis conscient que si le patient nécessite 2 flacons par administration, il sera tenu compte du remboursement de maximum 1 flacon par administration. Le deuxième flacon par administration sera dans ce cas fourni gratuitement par la firme (avec un maximum de 6 flacons gratuits pour le traitement total du patient).

Je m’engage à tenir à la disposition du médecin-conseil les éléments de preuve établissant que mon patient se trouve dans la situation attestée.

Je confirme que le schéma de traitement par XOFIGO ne dépassera pas un nombre de 6 injections.

**IV – Identification du médecin spécialiste en oncologie médicale, en urologie ou en radiothérapie (nom, prénom, adresse, N°INAMI):**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (nom) |

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (prénom) |

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1 | - |  |  |  |  |  | - |  |  | - |  |  |  | (n° INAMI) |

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | / |  |  | / |  |  |  |  | (date) |

|  |  |  |  |
| --- | --- | --- | --- |
|  | (cachet) | .......................................... | (signature du médecin) |

**BIJLAGE A: model van gestandaardiseerd aanvraagformulier bestemd voor de ziekenhuisapotheker:**

Formulier bestemd voor de ziekenhuisapotheker voorafgaand aan de facturatie van de specialiteit XOFIGO (§ 20003 van hoofdstuk I van het K.B. van 22 mei 2014)

**I - Identificatie van de begunstigde (naam, voornaam, inschrijvingsnummer bij de verzekeringsinstelling):**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (naam) |

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (voornaam) |

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (aansluitingsnummer) |

**II - Elementen te bevestigen door een arts-specialist erkend in de medische oncologie, urologie of radiotherapie (kruis de passende vakjes aan):**

Ik ondergetekende, arts-specialisterkend in de medische oncologie, urologie of radiotherapie , verklaar dat de hierboven vermelde patiënt lijdt aan een castratieresistent prostaatcarcinoom, symptomatische botmetastasen en geen bekende viscerale metastasen, en progressie vertoont na ten minste twee voorafgaande systemische therapielijnen (andere dan LHRH-analogen), of niet in aanmerking komt voor een beschikbare systemische behandeling voor mCRPC, en aan alle voorwaarden gesteld in (§ 20003 van hoofdstuk I van het K.B. van 22 mei 2014), voldoet.

De patiënt zal XOFIGO krijgen op bijkomende voorwaarde dat, bij aanvang van de behandeling met radium-223-dichloride, hij zich in volgende toestand bevindt:

* + serum castratiespiegels van testosteron < 50 ng/dL of < 1,7 nmol/L na bilaterale orchiëctomie of onder androgene ablatietherapie
  + multipele botmetastasen (≥ 2 hot spots) op botscintigrafie of andere medische beeldvorming
  + gebruik van niet-opioïde of opioïde analgetica voor kanker gerelateerde botpijn op reguliere basis of externe radiotherapie voor botpijn de afgelopen 12 weken of aanwezigheid van neurologische symptomen
  + afwezigheid van of aanwezigheid van maligne lymfadenopathie met grootste lymfeknopen < 3 cm (korte-as diameter)
  + afwezigheid van viscerale metastasen bevestigd d.m.v. medische beeldvorming van abdomen en klein bekken (CT of MRI) en thorax (RX of CT) niet meer dan 8 weken geleden
  + heeft minstens 1 van de volgende tekens van ziekteprogressie:

progressie van botletsels (ontstaan van bijkomende botletsels op botscan)

drie opeenvolgende PSA stijgingen, met elk 1 week tussen, waarvan minstens 2 maal een PSA spiegel van > 2 ng/ml die tegelijkertijd een stijging met 50% ten opzichte van de nadir PSA vertegenwoordigt

progressie van botpijn (b.v. toename van gebruik van niet-opioïde of opioïde analgetica of botpijn na externe radiotherapie de afgelopen 12 weken)

* + Indien de patiënt voor zijn prostaatkanker nog niet met docetaxel werd behandeld:

o komt niet in aanmerking voor opstarten van een behandeling met docetaxel: de patiënt heeft een PSA verdubbelingstijd van langer dan 6 maand (te berekenen volgens Arlen et al. J Urol. 2008 June ; 179(6): 2127 – 2186) of komt om andere redenen niet in aanmerking voor opstarten van docetaxel

* + Indien de patiënt voor zijn prostaatkanker reeds met docetaxel werd behandeld:

o heeft minstens 3 cycli docetaxel ontvangen voor genoemde aandoening (overeenkomst met een dosis > of = 225 mg/m2), tenzij aangetoonde intolerantie tijdens de eerstelijnsbehandeling met docetaxel;

o komt niet in aanmerking voor een tweede docetaxel behandeling omwille van één van de volgende situaties:

vertoonde progressie tijdens de eerstelijns docetaxel behandeling (minstens 3 cycli),

vertoonde progressie < 5 maand na de laatste eerstelijns docetaxel toediening

vertoonde aantoonbare intolerantie tijdens de eerste lijnsbehandeling met docetaxel;

Ik beschik in mijn dossier over het rapport van het Medisch Oncologisch Consult (MOC) (minimaal bestaande uit een arts-specialist in nucleaire geneeskunde, een medisch oncoloog, een radiotherapeut en een uroloog), gedateerd op / / , datum waarop de behandeling met XOFIGO beslist werd.

Ik bevestig dat de instelling waar de patiënt behandeld wordt, kan beschikken over de diensten van een expert in stralingsfysica en een “Deskundige bevoegd in de Fysische Controle”.

Ik weet dat de gelijktijdige vergoeding van de specialiteiten XOFIGO, ZYTIGA, JEVTANA, XTANDI en specialiteiten op basis van docetaxel nooit is toegestaan.

**III – Aanvraag tot terugbetaling**

Op basis van de hierboven vermelde elementen, verklaar ik dat deze patiënt de terugbetaling van de specialiteit XOFIGO nodig heeft voor het opstarten van de behandeling aan een doseringsschema van Xofigo welke 55 kBq per kg lichaamsgewicht is, gegeven als injectie om de 4 weken, met een maximum van 6 injecties. Ik ben op de hoogte dat indien de patiënt 2 flacons per toediening nodig heeft, zal rekening gehouden worden met een vergoeding van maximum 1 flacon per toediening. De tweede flacon per toediening zal in dat geval door de firma gratis geleverd worden (met een maximum van 6 gratis flacons voor de totale behandeling van de patiënt).

Ik verbind mij ertoe de bewijsstukken ter beschikking te houden van de adviserend-geneesheer, die aantonen dat mijn patiënt zich in de geattesteerde situatie bevindt.

Ik bevestig dat het volledige behandelingsschema met Xofigo het aantal injecties van 6 niet zal overschrijden.

**IV - Identificatie van de arts-specialist in medische oncologie, urologie met of radiotherapie (naam, voornaam, adres, RIZIV nummer)**:

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (naam) |

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (voornaam) |

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1 | - |  |  |  |  |  | - |  |  | - |  |  |  | (RIZIV nummer) |

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | / |  |  | / |  |  |  |  | (datum) |

|  |  |  |  |
| --- | --- | --- | --- |
|  | (stempel) | .......................................... | (handtekening van de arts) |

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | | |  | | | | | |
| Dénomination / Benaming (Demandeur/Aanvrager) | | | | | | | | | |
| Cat. | Code | Conditionnements | Verpakkingen | | Obs  Opm | Prix  Prijs  ***ex-usine / buiten bedrijf*** | Base de remb  Basis v tegem  ***ex-usine / buiten bedrijf*** | I | II |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| XOFIGO | | | BAYER | |  | | | | ATC: V10XX03 | | |
|  | ***0747-670*** | ***1 flacon injectable 6 ml solution injectable, 1100 kBq/ml*** | | ***1 injectieflacon 6 ml oplossing voor injectie, 1100 kBq/ml*** | |  | ***4400,00*** |  | |  |  |
| Ri-T4 **\*** | 0747-670 | 1 administration 6 mL solution injectable, 1100 kBq/mL | | 1 toediening 6 mL oplossing voor injectie, 1100 kBq/mL | |  |  | 3714,2400 | |  |  |
| Ri-T4 **\*\*** | 0747-681 | 1 administration 6 mL solution injectable, 1100 kBq/mL | | 1 toediening 6 mL oplossing voor injectie, 1100 kBq/mL | |  |  | 3714,2400 | |  |  |
|  |  |  | |  | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | | |  | | | | | |
| **Paragraphe 20004** | | | | **Paragraaf 20004** | | | | | |
| Produits radio-pharmaceutiques à base de iridium (Ir-192) – catégorie de remboursement Ri-T5 | | | | Radiofarmaceutische produkten op basis van iridium (Ir-192) - vergoedingscategorie Ri-T5 | | | | | |
| Les produits inscrits dans ce paragraphe sont remboursables dans la catégorie de remboursement Ri-T5 s’il s’agit d’une première administration (première fraction de la dose totale de brachythérapie) dans le cycle de traitement. Les codes 0748-532 et 0748-543 ne peuvent être facturés qu’une seule fois par patient et par cycle de traitement. | | | | De producten ingeschreven in deze paragraaf zijn vergoedbaar in de vergoedingscategorie Ri-T5 indien het de eerste toediening (eerste fractie van de totale brachytherapiedosis) binnen een behandelcyclus betreft. De codes 0748-532 en 0748-543 mogen slechts 1 maal aangerekend worden per patiënt en per behandelingscyclus. | | | | | |
|  | | | |  | | | | | |
| Dénomination / Benaming (Demandeur/Aanvrager) | | | | | | | | | |
| Cat. | Code | Conditionnements | Verpakkingen | | Obs  Opm | Prix  Prijs  ***ex-usine / buiten bedrijf*** | Base de remb  Basis v tegem  ***ex-usine / buiten bedrijf*** | I | II |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| FLEXISOURCE Ir-192 | | | ELEKTA | |  | | | | ATC: | | |
|  | ***0748-532*** | ***1 source scellée, 370 GBq*** | | ***1 gesloten bron, 370 GBq*** | |  | ***5001,49*** |  | |  |  |
| Ri-T5 **\*** | 0748-532 | 1 administration, 370 GBq | | 1 toediening, 370 GBq | |  |  | 430,0000 | |  |  |
| Ri-T5 **\*\*** | 0748-543 | 1 administration, 370 GBq | | 1 toediening, 370 GBq | |  |  | 430,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| FLEXISOURCE Ir-192 | | | ELEKTA | |  | | | | ATC: | | |
|  | ***0748-532*** | ***1 source scellée, 37 GBq*** | | ***1 gesloten bron, 37 GBq*** | |  | ***5924,75*** |  | |  |  |
| Ri-T5 **\*** | 0748-532 | 1 administration, 37 GBq | | 1 toediening, 37 GBq | |  |  | 430,0000 | |  |  |
| Ri-T5 **\*\*** | 0748-543 | 1 administration, 37 GBq | | 1 toediening, 37 GBq | |  |  | 430,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| GAMMAMED HDR | | | VARIAN MEDICAL SYSTEMS BELGIUM | |  | | | | ATC: | | |
|  | ***0748-532*** | ***1 source scellée, 370 GBq*** | | ***1 gesloten bron, 370 GBq*** | |  | ***5500,00*** |  | |  |  |
| Ri-T5 **\*** | 0748-532 | 1 administration, 370 GBq | | 1 toediening, 370 GBq | |  |  | 430,0000 | |  |  |
| Ri-T5 **\*\*** | 0748-543 | 1 administration, 370 GBq | | 1 toediening, 370 GBq | |  |  | 430,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| GAMMAMED PDR | | | VARIAN MEDICAL SYSTEMS BELGIUM | |  | | | | ATC: | | |
|  | ***0748-532*** | ***1 source scellée, 37 GBq*** | | ***1 gesloten bron, 37 GBq*** | |  | ***5500,00*** |  | |  |  |
| Ri-T5 **\*** | 0748-532 | 1 administration, 37 GBq | | 1 toediening, 37 GBq | |  |  | 430,0000 | |  |  |
| Ri-T5 **\*\*** | 0748-543 | 1 administration, 37 GBq | | 1 toediening, 37 GBq | |  |  | 430,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Ir-192 SOURCE | | | ELEKTA | |  | | | | ATC: | | |
|  | ***0748-532*** | ***1 source scellée, 370 GBq*** | | ***1 gesloten bron, 370 GBq*** | |  | ***4758,38*** |  | |  |  |
| Ri-T5 **\*** | 0748-532 | 1 administration, 370 GBq | | 1 toediening, 370 GBq | |  |  | 430,0000 | |  |  |
| Ri-T5 **\*\*** | 0748-543 | 1 administration, 370 GBq | | 1 toediening, 370 GBq | |  |  | 430,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Ir-192 SOURCE SET | | | ELEKTA | |  | | | | ATC: | | |
|  | ***0748-532*** | ***1 source scellée, 74 GBq*** | | ***1 gesloten bron, 74 GBq*** | |  | ***4100,00*** |  | |  |  |
| Ri-T5 **\*** | 0748-532 | 1 administration, 74 GBq | | 1 toediening, 74 GBq | |  |  | 430,0000 | |  |  |
| Ri-T5 **\*\*** | 0748-543 | 1 administration, 74 GBq | | 1 toediening, 74 GBq | |  |  | 430,0000 | |  |  |
|  |  |  | |  | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | | |  | | | | | |
| **Paragraphe 20005** | | | | **Paragraaf 20005** | | | | | |
| Produits radio-pharmaceutiques à base de iridium (Ir-192) – catégorie de remboursement Ri-T6 | | | | Radiofarmaceutische produkten op basis van iridium (Ir-192) - vergoedingscategorie Ri-T6 | | | | | |
| Les produits inscrits dans ce paragraphe sont remboursables dans la catégorie de remboursement Ri-T6 s’il s’agit de la deuxième administration ou des suivantes (deuxième fraction ou fractions suivantes de la dose totale de brachythérapie) dans le cycle de traitement. | | | | De producten ingeschreven in deze paragraaf zijn vergoedbaar in de vergoedingscategorie Ri-T6 indien het de tweede of volgende toediening (tweede of volgende fractie van de totale brachytherapie dosis) binnen een behandelcyclus betreft. | | | | | |
|  | | | |  | | | | | |
| Dénomination / Benaming (Demandeur/Aanvrager) | | | | | | | | | |
| Cat. | Code | Conditionnements | Verpakkingen | | Obs  Opm | Prix  Prijs  ***ex-usine / buiten bedrijf*** | Base de remb  Basis v tegem  ***ex-usine / buiten bedrijf*** | I | II |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| FLEXISOURCE Ir-192 | | | ELEKTA | |  | | | | ATC: | | |
|  | ***0748-554*** | ***1 source scellée, 370 GBq*** | | ***1 gesloten bron, 370 GBq*** | |  | ***5001,49*** |  | |  |  |
| Ri-T6 **\*** | 0748-554 | 1 administration, 370 GBq | | 1 toediening, 370 GBq | |  |  | 1,0000 | |  |  |
| Ri-T6 **\*\*** | 0748-565 | 1 administration, 370 GBq | | 1 toediening, 370 GBq | |  |  | 1,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| FLEXISOURCE Ir-192 | | | ELEKTA | |  | | | | ATC: | | |
|  | ***0748-554*** | ***1 source scellée, 37 GBq*** | | ***1 gesloten bron, 37 GBq*** | |  | ***5924,75*** |  | |  |  |
| Ri-T6 **\*** | 0748-554 | 1 administration, 37 GBq | | 1 toediening, 37 GBq | |  |  | 1,0000 | |  |  |
| Ri-T6 **\*\*** | 0748-565 | 1 administration, 37 GBq | | 1 toediening, 37 GBq | |  |  | 1,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| GAMMAMED HDR | | | VARIAN MEDICAL SYSTEMS BELGIUM | |  | | | | ATC: | | |
|  | ***0748-554*** | ***1 source scellée, 370 GBq*** | | ***1 gesloten bron, 370 GBq*** | |  | ***5500,00*** |  | |  |  |
| Ri-T6 **\*** | 0748-554 | 1 administration, 370 GBq | | 1 toediening, 370 GBq | |  |  | 1,0000 | |  |  |
| Ri-T6 **\*\*** | 0748-565 | 1 administration, 370 GBq | | 1 toediening, 370 GBq | |  |  | 1,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| GAMMAMED PDR | | | VARIAN MEDICAL SYSTEMS BELGIUM | |  | | | | ATC: | | |
|  | ***0748-554*** | ***1 source scellée, 37 GBq*** | | ***1 gesloten bron, 37 GBq*** | |  | ***5500,00*** |  | |  |  |
| Ri-T6 **\*** | 0748-554 | 1 administration, 37 GBq | | 1 toediening, 37 GBq | |  |  | 1,0000 | |  |  |
| Ri-T6 **\*\*** | 0748-565 | 1 administration, 37 GBq | | 1 toediening, 37 GBq | |  |  | 1,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Ir-192 SOURCE | | | ELEKTA | |  | | | | ATC: | | |
|  | ***0748-554*** | ***1 source scellée, 370 GBq*** | | ***1 gesloten bron, 370 GBq*** | |  | ***4758,38*** |  | |  |  |
| Ri-T6 **\*** | 0748-554 | 1 administration, 370 GBq | | 1 toediening, 370 GBq | |  |  | 1,0000 | |  |  |
| Ri-T6 **\*\*** | 0748-565 | 1 administration, 370 GBq | | 1 toediening, 370 GBq | |  |  | 1,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Ir-192 SOURCE SET | | | ELEKTA | |  | | | | ATC: | | |
|  | ***0748-554*** | ***1 source scellée, 74 GBq*** | | ***1 gesloten bron, 74 GBq*** | |  | ***4100,00*** |  | |  |  |
| Ri-T6 **\*** | 0748-554 | 1 administration, 74 GBq | | 1 toediening, 74 GBq | |  |  | 1,0000 | |  |  |
| Ri-T6 **\*\*** | 0748-565 | 1 administration, 74 GBq | | 1 toediening, 74 GBq | |  |  | 1,0000 | |  |  |
|  |  |  | |  | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | | |  | | | | | |
| **Paragraphe 20006** | | | | **Paragraaf 20006** | | | | | |
| Produits radio-pharmaceutiques à base de ruthénium (Ru-106) – catégorie de remboursement Ri-T7 | | | | Radiofarmaceutische produkten op basis van ruthenium (Ru-106) - vergoedingscategorie Ri-T7 | | | | | |
| Les produits inscrits dans ce paragraphe sont remboursables dans la catégorie de remboursement Ri-T7 pour le traitement des tumeurs ophtalmologiques, si appliqués dans un centre médical universitaire avec expertise sur le plan de la ‘brachythérapie avec plaques’ et si appliqués par une équipe composée d’un(e) ophtalmologue, d’un(e) radiothérapeute et d’un(e) expert(e) agréé(e) en radiophysique médicale qui ont suivi une formation à cet effet et qui ont de l’expérience avec la brachythérapie avec plaques. Les centres doivent pouvoir prouver leur expertise par le traitement d’au moins 20 patients par an pendant les 5 dernières années. | | | | De producten ingeschreven in deze paragraaf zijn vergoedbaar in de vergoedingscategorie Ri-T7 voor de behandeling van oftalmologische tumoren indien toegepast in een gespecialiseerd medisch centrum met expertise op het gebied van ‘plaque brachytherapie’ en toegepast door een team bestaande uit een oftalmolo(o)g(e), een radiotherapeut en een erkend deskundige in de medische stralingsfysica, die hiervoor een opleiding gevolgd hebben en ervaring hebben met ‘plaque brachytherapie’. Deze centra moeten hun expertise kunnen aantonen door de behandeling van gemiddeld minstens 20 patiënten per jaar gedurende de laatste 5 jaar. | | | | | |
|  | | | |  | | | | | |
| Dénomination / Benaming (Demandeur/Aanvrager) | | | | | | | | | |
| Cat. | Code | Conditionnements | Verpakkingen | | Obs  Opm | Prix  Prijs  ***ex-usine / buiten bedrijf*** | Base de remb  Basis v tegem  ***ex-usine / buiten bedrijf*** | I | II |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Ru-106 OOGAPPLICATOR TYPE CCA | | | ECKERT & ZIEGLER | |  | | | | ATC: | | |
|  | ***0748-576*** | ***1 source encapsulée, 1 applicateur*** | | ***1 ingekapselde bron, 1 applicator*** | |  | ***19910,00*** |  | |  |  |
| Ri-T7 **\*** | 0748-576 | 1 administration, 1 applicateur | | 1 toediening, 1 applicator | |  |  | 2260,1700 | |  |  |
| Ri-T7 **\*\*** | 0748-580 | 1 administration, 1 applicateur | | 1 toediening, 1 applicator | |  |  | 2260,1700 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Ru-106 OOGAPPLICATOR TYPE CCB | | | ECKERT & ZIEGLER | |  | | | | ATC: | | |
|  | ***0748-576*** | ***1 source encapsulée, 1 applicateur*** | | ***1 ingekapselde bron, 1 applicator*** | |  | ***20602,00*** |  | |  |  |
| Ri-T7 **\*** | 0748-576 | 1 administration, 1 applicateur | | 1 toediening, 1 applicator | |  |  | 2260,1700 | |  |  |
| Ri-T7 **\*\*** | 0748-580 | 1 administration, 1 applicateur | | 1 toediening, 1 applicator | |  |  | 2260,1700 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Ru-106 OOGAPPLICATOR TYPE CCC | | | ECKERT & ZIEGLER | |  | | | | ATC: | | |
|  | ***0748-576*** | ***1 source encapsulée, 1 applicateur*** | | ***1 ingekapselde bron, 1 applicator*** | |  | ***26147,00*** |  | |  |  |
| Ri-T7 **\*** | 0748-576 | 1 administration, 1 applicateur | | 1 toediening, 1 applicator | |  |  | 2260,1700 | |  |  |
| Ri-T7 **\*\*** | 0748-580 | 1 administration, 1 applicateur | | 1 toediening, 1 applicator | |  |  | 2260,1700 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Ru-106 OOGAPPLICATOR TYPE CCD | | | ECKERT & ZIEGLER | |  | | | | ATC: | | |
|  | ***0748-576*** | ***1 source encapsulée, 1 applicateur*** | | ***1 ingekapselde bron, 1 applicator*** | |  | ***23081,00*** |  | |  |  |
| Ri-T7 **\*** | 0748-576 | 1 administration, 1 applicateur | | 1 toediening, 1 applicator | |  |  | 2260,1700 | |  |  |
| Ri-T7 **\*\*** | 0748-580 | 1 administration, 1 applicateur | | 1 toediening, 1 applicator | |  |  | 2260,1700 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Ru-106 OOGAPPLICATOR TYPE CCX | | | ECKERT & ZIEGLER | |  | | | | ATC: | | |
|  | ***0748-576*** | ***1 source encapsulée, 1 applicateur*** | | ***1 ingekapselde bron, 1 applicator*** | |  | ***19930,00*** |  | |  |  |
| Ri-T7 **\*** | 0748-576 | 1 administration, 1 applicateur | | 1 toediening, 1 applicator | |  |  | 2260,1700 | |  |  |
| Ri-T7 **\*\*** | 0748-580 | 1 administration, 1 applicateur | | 1 toediening, 1 applicator | |  |  | 2260,1700 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Ru-106 OOGAPPLICATOR TYPE CGD | | | ECKERT & ZIEGLER | |  | | | | ATC: | | |
|  | ***0748-576*** | ***1 source encapsulée, 1 applicateur*** | | ***1 ingekapselde bron, 1 applicator*** | |  | ***26147,00*** |  | |  |  |
| Ri-T7 **\*** | 0748-576 | 1 administration, 1 applicateur | | 1 toediening, 1 applicator | |  |  | 2260,1700 | |  |  |
| Ri-T7 **\*\*** | 0748-580 | 1 administration, 1 applicateur | | 1 toediening, 1 applicator | |  |  | 2260,1700 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Ru-106 OOGAPPLICATOR TYPE CIA | | | ECKERT & ZIEGLER | |  | | | | ATC: | | |
|  | ***0748-576*** | ***1 source encapsulée, 1 applicateur*** | | ***1 ingekapselde bron, 1 applicator*** | |  | ***23081,00*** |  | |  |  |
| Ri-T7 **\*** | 0748-576 | 1 administration, 1 applicateur | | 1 toediening, 1 applicator | |  |  | 2260,1700 | |  |  |
| Ri-T7 **\*\*** | 0748-580 | 1 administration, 1 applicateur | | 1 toediening, 1 applicator | |  |  | 2260,1700 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Ru-106 OOGAPPLICATOR TYPE CIB | | | ECKERT & ZIEGLER | |  | | | | ATC: | | |
|  | ***0748-576*** | ***1 source encapsulée, 1 applicateur*** | | ***1 ingekapselde bron, 1 applicator*** | |  | ***23081,00*** |  | |  |  |
| Ri-T7 **\*** | 0748-576 | 1 administration, 1 applicateur | | 1 toediening, 1 applicator | |  |  | 2260,1700 | |  |  |
| Ri-T7 **\*\*** | 0748-580 | 1 administration, 1 applicateur | | 1 toediening, 1 applicator | |  |  | 2260,1700 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Ru-106 OOGAPPLICATOR TYPE COB | | | ECKERT & ZIEGLER | |  | | | | ATC: | | |
|  | ***0748-576*** | ***1 source encapsulée, 1 applicateur*** | | ***1 ingekapselde bron, 1 applicator*** | |  | ***20333,00*** |  | |  |  |
| Ri-T7 **\*** | 0748-576 | 1 administration, 1 applicateur | | 1 toediening, 1 applicator | |  |  | 2260,1700 | |  |  |
| Ri-T7 **\*\*** | 0748-580 | 1 administration, 1 applicateur | | 1 toediening, 1 applicator | |  |  | 2260,1700 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Ru-106 OOGAPPLICATOR TYPE COC | | | ECKERT & ZIEGLER | |  | | | | ATC: | | |
|  | ***0748-576*** | ***1 source encapsulée, 1 applicateur*** | | ***1 ingekapselde bron, 1 applicator*** | |  | ***26147,00*** |  | |  |  |
| Ri-T7 **\*** | 0748-576 | 1 administration, 1 applicateur | | 1 toediening, 1 applicator | |  |  | 2260,1700 | |  |  |
| Ri-T7 **\*\*** | 0748-580 | 1 administration, 1 applicateur | | 1 toediening, 1 applicator | |  |  | 2260,1700 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Ru-106 OOGAPPLICATOR TYPE COD | | | ECKERT & ZIEGLER | |  | | | | ATC: | | |
|  | ***0748-576*** | ***1 source encapsulée, 1 applicateur*** | | ***1 ingekapselde bron, 1 applicator*** | |  | ***23621,00*** |  | |  |  |
| Ri-T7 **\*** | 0748-576 | 1 administration, 1 applicateur | | 1 toediening, 1 applicator | |  |  | 2260,1700 | |  |  |
| Ri-T7 **\*\*** | 0748-580 | 1 administration, 1 applicateur | | 1 toediening, 1 applicator | |  |  | 2260,1700 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Ru-106 OOGAPPLICATOR TYPE COE | | | ECKERT & ZIEGLER | |  | | | | ATC: | | |
|  | ***0748-576*** | ***1 source encapsulée, 1 applicateur*** | | ***1 ingekapselde bron, 1 applicator*** | |  | ***26147,00*** |  | |  |  |
| Ri-T7 **\*** | 0748-576 | 1 administration, 1 applicateur | | 1 toediening, 1 applicator | |  |  | 2260,1700 | |  |  |
| Ri-T7 **\*\*** | 0748-580 | 1 administration, 1 applicateur | | 1 toediening, 1 applicator | |  |  | 2260,1700 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Ru-106 OOGAPPLICATOR TYPE CXS | | | ECKERT & ZIEGLER | |  | | | | ATC: | | |
|  | ***0748-576*** | ***1 source encapsulée, 1 applicateur*** | | ***1 ingekapselde bron, 1 applicator*** | |  | ***21172,00*** |  | |  |  |
| Ri-T7 **\*** | 0748-576 | 1 administration, 1 applicateur | | 1 toediening, 1 applicator | |  |  | 2260,1700 | |  |  |
| Ri-T7 **\*\*** | 0478-580 | 1 administration, 1 applicateur | | 1 toediening, 1 applicator | |  |  | 2260,1700 | |  |  |
|  |  |  | |  | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | | |  | | | | | |
| **Paragraphe 20007** | | | | **Paragraaf 20007** | | | | | |
| Produits radio-pharmaceutiques à base de grains d’iode (I-125) – catégorie de remboursement Ri-T7 | | | | Radiofarmaceutische produkten op basis van jood (I-125) zaadjes - vergoedingscategorie Ri-T7 | | | | | |
| Les produits inscrits dans ce paragraphe sont remboursables dans la catégorie de remboursement Ri-T7 pour le traitement des tumeurs ophtalmologiques, si appliqués dans un centre médical universitaire avec expertise sur le plan de la ‘brachythérapie avec plaques’ et si appliqués par une équipe composée d’un(e) ophtalmologue, d’un(e) radiothérapeute, et d’un(e) expert(e) agréé(e) en radiophysique médicale qui ont suivi une formation à cet effet et qui ont de l’expérience avec la brachythérapie avec plaques. Les centres doivent pouvoir prouver leur expertise par le traitement d’au moins 20 patients par an pendant les 5 dernières années. | | | | De producten ingeschreven in deze paragraaf zijn vergoedbaar in de vergoedingscategorie Ri-T7 voor de behandeling van oftalmologische tumoren indien toegepast in een gespecialiseerd medisch centrum met expertise op het gebied van ‘plaque brachytherapie’ en toegepast door een team bestaande uit een oftalmolo(o)g(e), een radiotherapeut en een erkend deskundige in de medische stralingsfysica, die hiervoor een opleiding gevolgd hebben en ervaring hebben met ‘plaque brachytherapie’. Deze centra moeten hun expertise kunnen aantonen door de behandeling van gemiddeld minstens 20 patiënten per jaar gedurende de laatste 5 jaar. | | | | | |
|  | | | |  | | | | | |
| Dénomination / Benaming (Demandeur/Aanvrager) | | | | | | | | | |
| Cat. | Code | Conditionnements | Verpakkingen | | Obs  Opm | Prix  Prijs  ***ex-usine / buiten bedrijf*** | Base de remb  Basis v tegem  ***ex-usine / buiten bedrijf*** | I | II |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ISOSEED I-125 (I125.S16) | | | ECKERT & ZIEGLER | |  | | | | ATC: | | |
|  | ***0748-591*** | ***1 grain 5,6 à 6,5 mCi*** | | ***1 zaadje 5,6 tot 6,5 mCi*** | |  | ***303,00*** |  | |  |  |
| Ri-T7 **\*** | 0748-591 | 1 administration, 1 dose | | 1 toediening, 1 dosis | |  |  | 2260,1700 | |  |  |
| Ri-T7 **\*\*** | 0748-602 | 1 administration, 1 dose | | 1 toediening, 1 dosis | |  |  | 2260,1700 | |  |  |
|  |  |  | |  | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | | |  | | | | | |
| **Paragraphe 20008** | | | | **Paragraaf 20008** | | | | | |
| a) Produits radio-pharmaceutiques à base de sphères d’holmium (Ho-166) – catégorie de remboursement Ri-T8 | | | | a) Radiofarmaceutische producten op basis va n holmium (Ho-166) sferen – vergoedingscategorie Ri-T8 | | | | | |
|  | | | |  | | | | | |
| Dénomination / Benaming (Demandeur/Aanvrager) | | | | | | | | | |
| Cat. | Code | Conditionnements | Verpakkingen | | Obs  Opm | Prix  Prijs  ***ex-usine / buiten bedrijf*** | Base de remb  Basis v tegem  ***ex-usine / buiten bedrijf*** | I | II |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| QUIREMSPHERES 12 GBq | | | TERUMO EUROPE N.V. | |  | | | | ATC: | | |
|  | ***0748-672*** | ***1 flacon injectable 2 mL suspension injectable, 12 GBq*** | | ***1 injectieflacon 2 mL suspensie voor injectie, 12 GBq*** | |  | ***15000,00*** |  | |  |  |
| Ri-T8 **\*** | 0748-672 | 1 administration 2 mL suspension injectable, 12 GBq | | 1 toediening 2 mL suspensie voor injectie, 12 GBq | |  |  | 13800,0000 | |  |  |
| Ri-T8 **\*\*** | 0748-683 | 1 administration 2 mL suspension injectable, 12 GBq | | 1 toediening 2 mL suspensie voor injectie, 12 GBq | |  |  | 13800,0000 | |  |  |
|  |  |  | |  | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | | | | |  | | | | | | | |
| **Paragraphe 20009** | | | | | | **Paragraaf 20009** | | | | | | | |
| Produits radio-pharmaceutiques à base de lutétium (Lu-177)-PSMA – catégorie de remboursement Ri-T9 | | | | | | Radiofarmaceutische producten op basis van lutetium (Lu- 177)-PSMA - vergoedingscategorie Ri-T9 | | | | | | | |
| Les produits inscrits dans ce paragraphe sont remboursables dans la catégorie de remboursement Ri-T9 si les conditions mentionnées ci-dessous sont toutes remplies. | | | | | | De producten ingeschreven in deze paragraaf zijn vergoedbaar in de vergoedingscategorie Ri-T9 indien aan alle onderstaande voorwaarden is voldaan. | | | | | | | |
| a) Le produit radio-pharmaceutique est remboursable si il est administré par un médecin spécialiste en médecine nucléaire agréé par l'AFCN pour l'administration du Lu-177-PSMA (thérapie métabolique) avec hospitalisation à l'hôpital, pour le traitement d'un bénéficiaire adulte atteint d'un cancer métastatique de la prostate résistant à la castration (mCRPC) dont la maladie est en progression : | | | | | | a) Het radiofarmaceutisch product komt in aanmerking voor vergoeding indien het wordt toegediend door een arts-specialist erkend in de nucleaire geneeskunde, vergund door het FANC voor de toediening van Lu-177-PSMA (metabole therapie) met hospitalisatie in het desbetreffende ziekenhuis, voor de behandeling van een volwassen rechthebbende met gemetastaseerde castratieresistente prostaatkanker (mCRPC) met progressieve ziekte : | | | | | | | |
|  | - A été prétraité avec au moins une thérapie anti-androgénique de 2e génération (ARPI) et au moins une chimiothérapie à base de taxane, sauf si le bénéficiaire est inéligible à ces traitements. | | | | |  | - Voorbehandeling met minstens één 2de generatie antiandrogeen therapie (ARPI) en met minstens 1 taxaan-gebaseerde chemotherapie, tenzij de rechthebbende niet in aanmerking komt voor deze behandelingen. | | | | | | |
|  | - et chez qui la majorité des métastases démontre une captation des ligands au PSMA sur la base d'un examen d'imagerie pré-thérapeutique ; | | | | |  | - en bij wie voor de start van de behandeling de meerderheid van de metastasen PSMA-liganden op beeldvorming capteert ; | | | | | | |
|  | - et chez qui un bénéfice clinique est anticipé ; | | | | |  | - en bij wie een klinisch voordeel van de behandeling wordt verwacht. | | | | | | |
|  | Au début du traitement par Lu-177-PSMA, le bénéficiaire doit répondre à chacun des critères suivants : | | | | |  | De rechthebbende moet bij aanvang van de behandeling met Lu- 177-PSMA beantwoorden aan elk van de volgende criteria : | | | | | | |
|  | | - Consentement éclairé signé ; | | | |  | | - Ondertekende geïnformeerde toestemming ; | | | | | |
|  | | - Progression du mCRPC après les thérapies standards, y compris la chimiothérapie à base de taxane et la thérapie anti-androgénique de 2e génération sauf si le médicament précédent est inapproprié ou si le bénéficiaire l'a refusé ; | | | |  | | - Progressie van de mCRPC na standaard therapieën, inclusief taxaan-gebaseerde chemotherapie en 2de generatie antiandrogeen therapie tenzij eerdere medicatie ongeschikt is of als de rechthebbende deze weigerde ; | | | | | |
|  | | - Rapport de consultation multidisciplinaire en oncologie (CMO, composé au minimum d'un médecin spécialiste en médecine nucléaire, d'un oncologue médical, d'un radiothérapeute et d'un urologue) ; | | | |  | | - Rapport van het multidisciplinair oncologisch consult (MOC, minimaal bestaande uit een arts-specialist (staflid) in nucleaire geneeskunde, een medisch oncoloog, een radiotherapeut en een uroloog) ; | | | | | |
|  | | - Espérance de vie d'au moins 6 mois ; | | | |  | | - Levensverwachting van minimum 6 maanden ; | | | | | |
|  | | - Imagerie anatomique adéquate (par exemple, TDM et / ou IRM), pas plus de 3 mois ; | | | |  | | - Adequate anatomische beeldvorming (bv., CT en/of MRI), niet ouder dan 3 maanden ; | | | | | |
| b) Le remboursement ne peut être accordé que si le Lu- 177-PSMA synthétisé est libéré par un radiopharmacien agréé par l'AFCN habilité à libérer le Lu-177-PSMA (thérapie métabolique). | | | | | | b) De vergoeding kan slechts worden toegestaan als de gesynthetiseerde Lu-177-PSMA wordt vrijgegeven door een door het FANC erkende radiofarmaceut die bevoegd is voor de vrijgave van Lu-177-PSMA (metabole therapie). | | | | | | | |
| c) Parallèlement, le médecin spécialiste mentionne dans le dossier : | | | | | | c) De arts-specialist vermeldt gelijktijdig in het dossier : | | | | | | | |
|  | - Les éléments liés à l'état du bénéficiaire ; | | | | |  | - De elementen die betrekking hebben op de toestand van derechthebbende ; | | | | | | |
|  | - Une documentation claire indiquant que le bénéficiaire a été informé par les médecins concernés des risques potentiels associés au traitement ; | | | | |  | - Duidelijke documentatie dat de rechthebbende geïnformeerd werd door de betrokken artsen over de mogelijke risico’s die verbonden zijn aan de behandeling ; | | | | | | |
|  | - D’attester de disposer du rapport de la consultation oncologique multidisciplinaire (COM) (au moins constituée d'un médecin spécialiste en médecine nucléaire, un oncologue, un radiothérapeute et un urologue) autorisant le traitement qui est appliqué; avec une attention particulière avec attention particulière aux possibilités d'adapter ou appliquer les traitements hormonaux et/ou initier un traitement avec docétaxel ou d'autres options thérapeutiques ; | | | | |  | - Te bevestigen over het rapport van het multidisciplinair oncologisch consult (MOC) (minimaal bestaande uit een arts-specialist (staflid) in nucleaire geneeskunde, een medisch oncoloog, een radiotherapeut en een uroloog) te beschikken dat het akkoord geeft voor de behandeling die wordt toegepast; met specifieke aandacht voor de toepasbaarheid van bijkomende aanpassingen van hormonale therapie en/of het opstarten van docetaxel of andere mogelijke behandelingen ; | | | | | | |
|  | - De confirmer que l'établissement où le bénéficiaire est traité, peut disposer des services d'un expert agréé en radiophysique médicale et d’un expert agréé en contrôle physique ; | | | | |  | - Te bevestigen dat de instelling waar de rechthebbende behandeld wordt, kan beschikken over de diensten van een erkende deskundige in de medische stralingsfysica en een deskundige erkend in de fysische controle ; | | | | | | |
|  | - De s’engager à tenir à la disposition du médecin-conseil les éléments de preuve qui attestent de la situation décrite ; | | | | |  | - Zich ertoe te verbinden om ten behoeve van de adviserend arts de bewijsstukken ter beschikking te houden die de gegevens bevestigen ; | | | | | | |
|  | - De s’engager d’évaluer l'état du bénéficiaire avant chaque injection afin d évaluer si la poursuite du traitement est médicalement justifiée. Cette évaluation se fera e.a. en examinant l'expression des récepteurs PSMA par imagerie après 2 ou 3 injections ; | | | | |  | - Zich ertoe te verbinden om voor elke injectie de toestand van de rechthebbende te beoordelen opdat de voortzetting van de behandeling medisch gerechtvaardigd is. Deze evaluatie zal o.a. gebeuren a.h.v. de PSMA receptor expressie op beeldvorming na 2 of 3 injecties ; | | | | | | |
|  | - De s’engager à interrompre l'administration d'un nouveau cycle de traitement : | | | | |  | - Zich ertoe te verbinden om de nieuwe therapietoediening te staken : | | | | | | |
|  | | • lorsque le PSA après une diminution précédente augmente par rapport au nadir d'au moins 25% (relativement) et d'au moins 2 ng/ml en valeur absolue, et que cette augmentation est confirmée par une deuxième examen au moins 3 semaines plus tard ; | | | |  | | • wanneer de PSA na een eerdere daling toeneemt t.a.v. de nadir met minstens 25% (relatief) én minstens 2 ng/ml in absolute waarde, en deze toename bevestigd wordt door een tweede onderzoek minstens 3 weken later. | | | | | |
|  | | • Si, au cours des 12 premières semaines de traitement, il n'y a pas eu de diminution antérieure de la valeur de base du PSA, la valeur de base du PSA devient le point de référence pour la même augmentation relative et absolue. | | | |  | | • Indien er gedurende de eerste 12 weken van de behandeling geen voorafgaandelijke PSA daling is opgetreden t.a.v. de baseline PSA waarde wordt de baseline PSA waarde het referentiepunt voor dezelfde relatieve én absolute toename. | | | | | |
|  | - De s’engager à prolonger l'intervalle entre les cycles de traitement en cas de réduction significative des plaquettes ou des leucocytes ; | | | | |  | - Zich ertoe te verbinden om het therapie-interval te verlengen bij een relevante verlaging van de bloedplaatjes of de leukocyten ; | | | | | | |
|  | - De s’engager à arrêter le traitement remboursé si un traitement par chimiothérapie ou par radiothérapie externe hemibody est instauré ; | | | | |  | - Zich ertoe te verbinden om de vergoede behandeling te stoppen wanneer een behandeling met chemotherapie of met externe hemibody radiotherapie wordt ingesteld ; | | | | | | |
| d) Le remboursement simultané des spécialités Lu-177-PSMA, XOFIGO, ZYTIGA, JEVTANA, XTANDI et à base de docétaxel n'est jamais autorisé. | | | | | | d) De gelijktijdige vergoeding van Lu-177-PSMA, XOFIGO, ZYTIGA, JEVTANA, XTANDI en specialiteiten op basis van docetaxel is nooit toegestaan. | | | | | | | |
| e) Le nombre d'injections remboursables tient compte de la réponse du bénéficiaire au Lu-177-PSMA, administré en injection toutes les 6 à 8 semaines, avec un maximum de 4 injections par période de traitement. | | | | | | e) Het aantal vergoedbare injecties houdt rekening met de respons van de rechthebbende op Lu-177-PSMA, gegeven als injectie om de 6 tot 8 weken, met een maximum van 4 injecties per behandelingsperiode. | | | | | | | |
| f) Au cours d’une même période de traitement, le nombre total d’injections remboursées dans le présent paragraphe et le paragraphe 20013 du chapitre I est limité à un maximum de 4 injections. | | | | | | f) Binnen eenzelfde behandelingsperiode is het totaal aantal vergoede injecties binnen huidige paragraaf en paragraaf 20013 uit Hoofdstuk I beperkt tot maximum 4 injecties. | | | | | | | |
| g) Après une bonne réponse thérapeutique au cours des premiers cycles de traitement au Lu-177-PSMA, le Lu-177-PSMA peut être redémarrée en cas de progression du PSA suivant une période stable d'au moins 6 mois après la dernière injection de Lu-177-PSMA. | | | | | | g) Na een goede therapeutische respons tijdens de eerste cycli met Lu-177-PSMA therapie kan in geval van PSA-progressie na een stabiele periode van minstens 6 maanden na de laatste Lu-177-PSMA injectie terug opgestart worden met Lu-177-PSMA. | | | | | | | |
|  | | | | | |  | | | | | | | |
| Dénomination / Benaming (Demandeur/Aanvrager) | | | | | | | | | | | | | |
| Cat. | | | Code | Conditionnements | Verpakkingen | | | | Obs  Opm | Prix  Prijs  ***ex-usine / buiten bedrijf*** | Base de remb  Basis v tegem  ***ex-usine / buiten bedrijf*** | I | II |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 177-LU-PSMA I&T (AZ GROENINGE KORTRIJK) | | | Algemeen Ziekenhuis Groeninge | |  | | | | ATC: | | |
|  | ***0749-350*** | ***1 doses solution injectable, 1 dose*** | | ***1 doses oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-T9 **\*** | 0749-350 | 1 administration, 1 dose | | 1 toediening, 1 dosis | |  |  | 7500,0000 | |  |  |
| Ri-T9 **\*\*** | 0749-361 | 1 administration, 1 dose | | 1 toediening, 1 dosis | |  |  | 7500,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 177-LU-PSMA I&T (BORDET) | | | Association hospitalière de Bruxelles-Centre hospitalier Universitaire Jules Bordet | |  | | | | ATC: | | |
|  | ***0749-372*** | ***1 doses solution injectable, 1 dose*** | | ***1 doses oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-T9 **\*** | 0749-372 | 1 administration, 1 dose | | 1 toediening, 1 dosis | |  |  | 7500,0000 | |  |  |
| Ri-T9 **\*\*** | 0749-383 | 1 administration, 1 dose | | 1 toediening, 1 dosis | |  |  | 7500,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 177-LU-PSMA I&T (UZ BRUSSEL) | | | Vrije Universiteit Brussel | |  | | | | ATC: | | |
|  | ***0749-593*** | ***1 doses solution injectable, 1 dose*** | | ***1 doses oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-T9 **\*** | 0749-593 | 1 administration, 1 dose | | 1 toediening, 1 dosis | |  |  | 7500,0000 | |  |  |
| Ri-T9 **\*\*** | 0749-604 | 1 administration, 1 dose | | 1 toediening, 1 dosis | |  |  | 7500,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 177-LU-PSMA I&T (UZ GENT) | | | Universitair Ziekenhuis Gent | |  | | | | ATC: | | |
|  | ***0749-490*** | ***1 doses solution injectable, 1 dose*** | | ***1 doses oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-T9 **\*** | 0749-490 | 1 administration, 1 dose | | 1 toediening, 1 dosis | |  |  | 7500,0000 | |  |  |
| Ri-T9 **\*\*** | 0749-501 | 1 administration, 1 dose | | 1 toediening, 1 dosis | |  |  | 7500,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 177-LU-PSMA I&T (UZ LEUVEN) | | | Katholieke Universiteit te Leuven | |  | | | | ATC: | | |
|  | ***0749-615*** | ***1 doses solution injectable, 1 dose*** | | ***1 doses oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-T9 **\*** | 0749-615 | 1 administration, 1 dose | | 1 toediening, 1 dosis | |  |  | 7500,0000 | |  |  |
| Ri-T9 **\*\*** | 0749-626 | 1 administration, 1 dose | | 1 toediening, 1 dosis | |  |  | 7500,0000 | |  |  |
|  |  |  | |  | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | | |  | | | | | |
| **Paragraphe 20010** | | | | **Paragraaf 20010** | | | | | |
| Produits radiopharmaceutiques à base de 177-Lu-DOTATATE - catégorie de remboursement Ri-T9 | | | | Radiofarmaceutische producten op basis van 177-Lu-DOTATATE - vergoedingscategorie Ri-T9 | | | | | |
| a) L’autorisation qui a été délivrée pour le produit pharmaceutique à base de lutetium (177Lu)-oxodotreotide figurant dans le présent paragraphe avant l’entrée en vigueur de la présente réglementation, conserve sa validité dans sa catégorie de remboursement jusqu’à la fin de la période d’autorisation qui y est mentionnée | | | | a) De machtiging die werd uitgereikt voor het farmaceutische product op basis van lutetium (177Lu)-oxodotreotide beschreven in deze paragraaf vóór de inwerkingtreding van de huidige reglementering, behoudt zijn geldigheid in zijn vergoedingscategorie tot het einde van de toelatingsperiode die daar vermeld werd | | | | | |
|  | | | |  | | | | | |
| Dénomination / Benaming (Demandeur/Aanvrager) | | | | | | | | | |
| Cat. | Code | Conditionnements | Verpakkingen | | Obs  Opm | Prix  Prijs  ***ex-usine / buiten bedrijf*** | Base de remb  Basis v tegem  ***ex-usine / buiten bedrijf*** | I | II |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 177-LU-DOTATATE (BORDET) | | | Association hospitalière de Bruxelles-Centre hospitalier Universitaire Jules Bordet | |  | | | | ATC: | | |
|  | ***0749-534*** | ***1 doses solution injectable, 1 dose*** | | ***1 doses oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-T9 **\*** | 0749-534 | 1 administration, 1 dose | | 1 toediening, 1 dosis | |  |  | 7500,0000 | |  |  |
| Ri-T9 **\*\*** | 0749-545 | 1 administration, 1 dose | | 1 toediening, 1 dosis | |  |  | 7500,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 177-LU-DOTATATE (UZ LEUVEN) | | | Katholieke Universiteit te Leuven | |  | | | | ATC: | | |
|  | ***0749-571*** | ***1 doses solution injectable, 1 dose*** | | ***1 doses oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-T9 **\*** | 0749-571 | 1 administration, 1 dose | | 1 toediening, 1 dosis | |  |  | 7500,0000 | |  |  |
| Ri-T9 **\*\*** | 0749-582 | 1 administration, 1 dose | | 1 toediening, 1 dosis | |  |  | 7500,0000 | |  |  |
|  |  |  | |  | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | | | | |  | | | | | | | |
| **Paragraphe 20011** | | | | | | **Paragraaf 20011** | | | | | | | |
| produits radiopharmaceutiques basés sur le lutetium (177-Lu)-oxodotreotide catégorie de remboursement Ri-T9 - domaine d'application thérapeutique. | | | | | | Radiofarmaceutische producten op basis van lutetium (177-Lu)-oxodotreotide, vergoedingscategorie Ri-T9 - therapeutisch toepassingsgebied. | | | | | | | |
| a) Le produit radiopharmaceutique à base de lutetium (177-Lu)-oxodotreotide est remboursable si il est administrée par un médecin spécialiste en médecine nucléaire autorisé par l'AFCN pour l'administration du lutetium (177-Lu)-oxodotreotide (thérapie aux radionucléides) avec hospitalisation à l'hôpital, pour le traitement d’un bénéficiaire atteint d’un cancer en progression (sur base clinique, biochimique et/ou d’imagerie) et qui démontre une captation des ligands aux récepteurs à la somatostatine (p.ex. 68-Ga-DOTATATE, 68-Ga-DOTANOC, …) sur la base d'un examen d'imagerie PET/CT pré-thérapeutique. | | | | | | a) Het radiofarmaceutisch product op basis van lutetium (177-Lu)-oxodotreotide komt in aanmerking voor vergoeding indien het wordt toegediend door een arts-specialist erkend in de nucleaire geneeskunde, vergund door het FANC voor de toediening van lutetium (177-Lu)-oxodotreotide (radionuclidetherapie) met hospitalisatie in het desbetreffende ziekenhuis, voor de behandeling van een rechthebbende met progressieve kanker (klinisch, biochemisch en/of op beeldvorming), en die opname van PET radioliganden voor de somatostatinereceptor (bv. 68-Ga-DOTATATE, 68-Ga-DOTANOC, ...) aantoont op basis van een pre-therapeutische PET/CT scan. | | | | | | | |
| b) Au début du traitement par lutetium (177-Lu)-oxodotreotide , le bénéficiaire doit répondre à chacun des critères suivants: | | | | | | b) Bij aanvang van de behandeling met lutetium (177-Lu)-oxodotreotide moet de rechthebbende aan elk van de volgende criteria voldoen: | | | | | | | |
|  | - Tumeur neuroendocrine métastatique et/ou localement avancée, non-résécable (de manière curative) du système digestif, du pancréas, carcinoid typique ou atypique du poumon, d'origine de la crête neurale (y compris phéochromocytome et paragangliome) ou d'origine primaire inconnue ("CUP-NET"). | | | | |  | - Metastatisch en/of lokaal gevorderde, inoperabel (i.e. niet curatief operabel) neuro-endocriene tumor van het spijsverteringstelsel, pancreas, typisch carcinoid of atypisch carcinoid van de long, van neurale lijst origine (oa. feochromocytoom en paraganglioom) of van ongekende primaire oorsprong ("CUP-NET"). | | | | | | |
|  | - L'indice Ki-67 est < 55 % et la tumeur n'est pas un carcinome neuroendocrine (NEC). | | | | |  | - De Ki-67 index is < 55% en de tumor betreft geen neuro-endocrien carcinoom (NEC). | | | | | | |
|  | - Le bénéficiaire a une maladie évolutive sous analogues de la somatostatine (ASS) non radioactifs (lorsqu'ils sont indiqués en soins primaires), sur la base d'un ou plusieurs éléments énumérés ci-dessous : | | | | |  | - De rechthebbende heeft een progressieve ziekte onder niet-radioactieve somatostatine analogen (SSA) (wanneer deze in eerste lijn geïndiceerd zijn), gebaseerd op één of meerdere elementen hieronder vermeld: | | | | | | |
|  | | • Augmentation des plaintes et/ou des symptômes causés par la tumeur et/ou les métastases | | | |  | | • Toename van klachten en/of symptomen veroorzaakt door de tumor en/of de metastasen | | | | | |
|  | | • Progression biochimique, avec augmentation des marqueurs tumoraux et/ou une sécrétion hormonale | | | |  | | • Biochemische progressie, met oplopen van tumormerkers en/of hormonale secretie | | | | | |
|  | | • Progression en imagerie, soit par des techniques morphologiques (CT, IRM) soit par imagerie moléculaire (ex : PET des récepteurs à la somatostatine, 18-F-FDG PET) | | | |  | | • Progressie op beeldvorming, hetzij via morfologische technieken (CT, MRI), hetzij via moleculaire beeldvorming (oa. somatostatine receptor PET, 18-F-FDG PET) | | | | | |
|  | - En utilisant un ligand pour le récepteur de la somatostatine, l'imagerie PET/CT montre une surexpression des récepteurs à la somatostatine sur toutes les lésions cliniquement pertinentes, avec au moins une captation plus intense que celle du foie dans les lésions cliniquement pertinentes qui sont suffisamment grandes pour une caractérisation scintigraphique | | | | |  | - Met gebruik van een ligand voor de somatostatine receptor wordt er via PET/CT beeldvorming overexpressie van de somatostatine receptor aangetoond op alle klinisch relevante letsels, met minstens meer captatie dan de lever in de klinisch relevante letsels die voldoende groot zijn voor accurate scintigrafische karakterisatie. | | | | | | |
|  | - Espérance de vie d'au moins 6 mois | | | | |  | - Levensverwachting van minimum 6 maanden | | | | | | |
|  | - Fonction des organes suffisante : | | | | |  | - Voldoende orgaanfunctie: | | | | | | |
|  | | • Clairance rénale (filtration glomérulaire ; GFR) : > of = 40 ml/min/1,73 m² | | | |  | | • Renale klaring (glomérulaire filtratie; GFR): > of = 40 ml/min/1.73 m2 | | | | | |
|  | | • Réserve hématologique suffisante | | | |  | | • Voldoende hematologische reserve | | | | | |
|  | | • Bilirubine < of = 3 fois la limite supérieure de la plage normale (sauf syndrome de Gilbert) | | | |  | | • Bilirubine < of = 3 maal de bovengrens van het normale bereik (tenzij syndroom van Gilbert). | | | | | |
|  | | • Albumine sérique > of = 30 g/L ou temps de prothrombine normal | | | |  | | • Serum albumine > of = 30 g/L of normale prothrombine tijd. | | | | | |
|  | | • Pas d'insuffisance cardiaque congestive non contrôlée (NYHA III ou IV) | | | |  | | • Geen ongecontroleerd congestief hartfalen (NYHA III of IV) | | | | | |
|  | - Pas de grossesse ni de lactation active | | | | |  | - Geen zwangerschap noch actieve lactatie. | | | | | | |
| c) Le remboursement ne peut être accordé que si le lutetium (177-Lu)-oxodotreotide synthétisé est libéré par un radiopharmacien agréé par l'AFCN autorisé à libérer le lutetium (177-Lu)-oxodotreotide (thérapie aux radionucléides). | | | | | | c) De vergoeding kan slechts worden toegestaan als de gesynthetiseerde lutetium (177-Lu)-oxodotreotide wordt vrijgegeven door een door het FANC erkende radiofarmaceut die bevoegd is voor de vrijgave van lutetium (177-Lu)-oxodotreotide (radionuclidetherapie). | | | | | | | |
| d) Parallèlement, le médecin spécialiste mentionne dans le dossier: | | | | | | d) De arts-specialist vermeldt gelijktijdig in het dossier: | | | | | | | |
|  | - les éléments liés à l'état du bénéficiaire; | | | | |  | - de elementen die betrekking hebben op de toestand van de rechthebbende; | | | | | | |
|  | - une documentation claire indiquant que le bénéficiaire a été informé par les médecins concernés des risques potentiels associés ; | | | | |  | - duidelijke documentatie dat de rechthebbende geïnformeerd werd door de betrokken artsen over de mogelijke risico's die verbonden zijn aan de behandeling ; | | | | | | |
|  | - d’attester de disposer du rapport de la consultation oncologique multidisciplinaire (COM) (au moins constituée d’un médecin spécialiste en médecine nucléaire, un oncologue médical ou un médecin spécialiste en gastro-entérologie porteur de la qualification professionnelle particulière en oncologie ou un médecin spécialiste en pneumologie porteur de la qualification professionnelle particulière en oncologie et un chirurgien) autorisant le traitement qui est appliqué; | | | | |  | - te bevestigen over het rapport van het multidisciplinair oncologisch consult (MOC) (minimaal bestaande uit een arts-specialist in de nucleaire geneeskunde, een medisch oncoloog of gastro-enteroloog met een bijzondere beroepsbekwaamheid in de oncologie of een pneumoloog met een bijzondere bekwaamheid in de oncologie en een chirurg) te beschikken dat het akkoord geeft voor de behandeling die wordt toegepast; | | | | | | |
|  | - de confirmer que l’établissement où le bénéficiaire est traité, peut disposer des services d’un expert agréé en radiophysique médicale et un expert agréé en contrôle physique ; | | | | |  | - te bevestigen dat de instelling waar de rechthebbende behandeld wordt, kan beschikken over de diensten van een erkende deskundige in de medische stralingsfysica en een deskundige erkend in de fysische controle; | | | | | | |
|  | - de s’engager à tenir à la disposition du médecin-conseil les éléments de preuve qui attestent de la situation décrite; | | | | |  | - zich te verbinden om ten behoeve van de adviserend arts de bewijsstukken ter beschikking te houden die de gegevens bevestigen; | | | | | | |
|  | - de s’engager à évaluer l’état du bénéficiaire avant chaque injection afin d’évaluer si la poursuite du traitement est médicalement justifiée; au moins cliniquement et biochimiquement, éventuellement avec imagerie; | | | | |  | - zich te verbinden om voor elke injectie de toestand van de rechthebbende te beoordelen opdat de voortzetting van de behandeling medisch gerechtvaardigd is, minstens klinisch en biochemisch, eventueel met beeldvorming; | | | | | | |
|  | - de s'engager à prolonger l'intervalle entre les cycles de traitement en cas de réduction cliniquement significative des plaquettes et/ou des leucocytes à l’exception des lymphocytes | | | | |  | - zich te verbinden om het interval tussen de cycli te verlengen in geval van klinisch relevante daling van de bloedplaatjes en/of de witte bloedcellen (met uitzondering van de lymfocyten). | | | | | | |
| e) Le nombre d'injections remboursables tient compte de la réponse du bénéficiaire au lutetium (177-Lu)-oxodotreotide, administré en injection toutes les 7 à 16 semaines, avec un maximum de 4 injections par période de traitement. | | | | | | e) Het aantal vergoede injecties houdt rekening met het antwoord van de rechthebbende op lutetium (177-Lu)-oxodotreotide, toegediend via injectie om de 7 à 16 weken, met een maximum van 4 injecties per behandelingsperiode. | | | | | | | |
| f) Après une bonne réponse thérapeutique au cours des premiers cycles de traitement au lutetium (177-Lu)-oxodotreotide, le lutetium (177-Lu)-oxodotreotide peut être redémarré en cas de progression suivant une période stable d'au moins 6 mois après la dernière injection de lutetium (177-Lu)-oxodotreotide. | | | | | | f) Na een goed therapeutisch effect na de eerste cycli lutetium (177-Lu)-oxodotreotide, kan lutetium (177-Lu)-oxodotreotide opnieuw worden toegediend in geval van progressie na een stabiele ziekte periode van minstens 6 maanden na de laatste lutetium (177-Lu)-oxodotreotide injectie. | | | | | | | |
| g) Le remboursement simultané de lutetium (177-Lu)-oxodotreotide et de spécialités à base d’Everolimus ou Sunitinib n’est pas autorisé. Exceptionnellement, le remboursement simultané est autorisé chez un patient présentant un insulinome métastatique. | | | | | | g) De gelijktijdige vergoeding van (177-Lu)-oxodotreotide en specialiteiten op basis van Everolimus of op basis van Sunitinib is niet toegestaan. Bij wijze van uitzondering is zulke combinatie wel vergoedbaar bij een patiënt met gemetastaseerd insulinoom. | | | | | | | |
|  | | | | | |  | | | | | | | |
| Dénomination / Benaming (Demandeur/Aanvrager) | | | | | | | | | | | | | |
| Cat. | | | Code | Conditionnements | Verpakkingen | | | | Obs  Opm | Prix  Prijs  ***ex-usine / buiten bedrijf*** | Base de remb  Basis v tegem  ***ex-usine / buiten bedrijf*** | I | II |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 177-LU-DOTATATE (AZ GROENINGE KORTRIJK) | | | Algemeen Ziekenhuis Groeninge | |  | | | | ATC: | | |
|  | ***0749-674*** | ***1 doses solution injectable, 1 dose*** | | ***1 doses oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-T9 **\*** | 0749-674 | 1 administration, 1 dose | | 1 toediening, 1 dosis | |  |  | 7500,0000 | |  |  |
| Ri-T9 **\*\*** | 0749-685 | 1 administration, 1 dose | | 1 toediening, 1 dosis | |  |  | 7500,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 177-LU-DOTATATE (BORDET) | | | Association hospitalière de Bruxelles-Centre hospitalier Universitaire Jules Bordet | |  | | | | ATC: | | |
|  | ***0749-711*** | ***1 doses solution injectable, 1 dose*** | | ***1 doses oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-T9 **\*** | 0749-711 | 1 administration, 1 dose | | 1 toediening, 1 dosis | |  |  | 7500,0000 | |  |  |
| Ri-T9 **\*\*** | 0749-722 | 1 administration, 1 dose | | 1 toediening, 1 dosis | |  |  | 7500,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 177-LU-DOTATATE (UZ GENT) | | | Universitair Ziekenhuis Gent | |  | | | | ATC: | | |
|  | ***0758-796*** | ***1 doses solution injectable, 1 dose*** | | ***1 doses oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-T9 **\*** | 0758-796 | 1 administration, 1 dose | | 1 toediening, 1 dosis | |  |  | 7500,0000 | |  |  |
| Ri-T9 **\*\*** | 0758-800 | 1 administration, 1 dose | | 1 toediening, 1 dosis | |  |  | 7500,0000 | |  |  |
|  |  |  | |  | |  |  |  | |  |  |
| 177-LU-DOTATATE (UZ LEUVEN) | | | Katholieke Universiteit te Leuven | |  | | | | ATC: | | |
|  | ***0749-696*** | ***1 doses solution injectable, 1 dose*** | | ***1 doses oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-T9 **\*** | 0749-696 | 1 administration, 1 dose | | 1 toediening, 1 dosis | |  |  | 7500,0000 | |  |  |
| Ri-T9 **\*\*** | 0749-700 | 1 administration, 1 dose | | 1 toediening, 1 dosis | |  |  | 7500,0000 | |  |  |
|  |  |  | |  | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | | | | |  | | | | | | | |
| **Paragraphe 20012** | | | | | | **Paragraaf 20012** | | | | | | | |
| Spécialités radiopharmaceutiques basés sur le lutetium (177Lu)-oxodotreotide, catégorie de remboursement Ri-T10 - domaine d'application thérapeutique. | | | | | | Radiofarmaceutische specialiteiten op basis lutetium (177Lu)-oxodotreotide, vergoedingscategorie Ri-T10- therapeutisch toepassingsgebied. | | | | | | | |
| a) La spécialité radiopharmaceutique à base de lutetium (177Lu)-oxodotreotide est remboursable si elle est administrée par un médecin spécialiste en médecine nucléaire autorisé par l'AFCN pour l'administration du lutetium (177Lu)-oxodotreotide (thérapie aux radionucléides) avec hospitalisation à l'hôpital, pour le traitement d’un bénéficiaire atteint d’un cancer en progression (sur base clinique, biochimique et/ou d’imagerie) et qui démontre une captation des ligands aux récepteurs à la somatostatine (p.ex. 68Ga-DOTATATE, 68Ga-DOTANOC, …) sur la base d'un examen d'imagerie PET/CT pré-thérapeutique. | | | | | | a) De radiofarmaceutische specialiteit op basis van lutetium (177Lu)-oxodotreotide komt in aanmerking voor vergoeding indien het wordt toegediend door een arts-specialist erkend in de nucleaire geneeskunde, vergund door het FANC voor de toediening van lutetium (177Lu)-oxodotreotide (radionuclidetherapie) met hospitalisatie in het desbetreffende ziekenhuis, voor de behandeling van een rechthebbende met progressieve kanker (klinisch, biochemisch en/of op beeldvorming), en die opname van PET radioliganden voor de somatostatinereceptor (bv. 68Ga-DOTATATE, 68Ga-DOTANOC, ...) aantoont op basis van een pre-therapeutische PET/CT scan. | | | | | | | |
| b) Au début du traitement par la spécialité radiopharmaceutique à base de lutetium (177Lu)-oxodotreotide, le bénéficiaire doit répondre à chacun des critères suivants : | | | | | | b) Bij aanvang van de behandeling met de radiofarmaceutische specialiteit op basis van lutetium (177Lu)-oxodotreotide moet de rechthebbende aan elk van de volgende criteria voldoen: | | | | | | | |
|  | - Tumeur neuroendocrine gastroentéropancréatique (TNE-GEP) inopérable ou métastatique, progressive, bien différenciée (G1 et G2) et exprimant des récepteurs de somatostatine. | | | | |  | - niet-reseceerbare of gemetastaseerde, progressieve, goed gedifferentieerde (G1 en G2), somatostatinereceptor-positieve gastro-entero-pancreatische neuro-endocriene tumor (GEP-NET’s) | | | | | | |
|  | - L'indice Ki-67 est < 55 % et la tumeur n'est pas un carcinome neuroendocrine (NEC). | | | | |  | - De Ki-67 index is < 55% en de tumor betreft geen neuro-endocrien carcinoom (NEC). | | | | | | |
|  | - Le bénéficiaire a une maladie évolutive sous analogues de la somatostatine (ASS) non radioactifs (lorsqu'ils sont indiqués en soins primaires), sur la base d'un ou plusieurs éléments énumérés ci-dessous : | | | | |  | - De rechthebbende heeft een progressieve ziekte onder niet-radioactieve somatostatine analogen (SSA) (wanneer deze in eerste lijn geïndiceerd zijn), gebaseerd op één of meerdere elementen hieronder vermeld: | | | | | | |
|  | | • Augmentation des plaintes et/ou des symptômes causés par la tumeur et/ou les métastases | | | |  | | • Toename van klachten en/of symptomen veroorzaakt door de tumor en/of de metastasen | | | | | |
|  | | • Progression biochimique, avec augmentation des marqueurs tumoraux et/ou une sécrétion hormonale | | | |  | | • Biochemische progressie, met oplopen van tumormerkers en/of hormonale secretie | | | | | |
|  | | • Progression en imagerie, soit par des techniques morphologiques (CT, IRM) soit par imagerie moléculaire (ex : PET des récepteurs à la somatostatine, 18F-FDG PET) | | | |  | | • Progressie op beeldvorming, hetzij via morfologische technieken (CT, MRI), hetzij via moleculaire beeldvorming (oa. somatostatine receptor PET, 18F-FDG PET) | | | | | |
|  | - En utilisant un ligand pour le récepteur de la somatostatine, l'imagerie PET/CT montre une surexpression des récepteurs à la somatostatine sur toutes les lésions cliniquement pertinentes, avec au moins une captation plus intense que celle du foie dans les lésions cliniquement pertinentes qui sont suffisamment grandes pour une caractérisation scintigraphique | | | | |  | - Met gebruik van een ligand voor de somatostatine receptor wordt er via PET/CT beeldvorming overexpressie van de somatostatine receptor aangetoond op alle klinisch relevante letsels, met minstens meer captatie dan de lever in de klinisch relevante letsels die voldoende groot zijn voor accurate scintigrafische karakterisatie. | | | | | | |
|  | - Espérance de vie d'au moins 6 mois | | | | |  | - Levensverwachting van minimum 6 maanden | | | | | | |
|  | - Fonction des organes suffisante : | | | | |  | - Voldoende orgaanfunctie: | | | | | | |
|  | | • Clairance rénale (filtration glomérulaire ; GFR) : > of = 40 ml/min/1,73 m² | | | |  | | • Renale klaring (glomérulaire filtratie; GFR): > of = 40 ml/min/1.73 m2 | | | | | |
|  | | • Réserve hématologique suffisante | | | |  | | • Voldoende hematologische reserve | | | | | |
|  | | • Bilirubine < of = 3 fois la limite supérieure de la plage normale (sauf syndrome de Gilbert) | | | |  | | • Bilirubine < of = 3 maal de bovengrens van het normale bereik (tenzij syndroom van Gilbert). | | | | | |
|  | | • Albumine sérique > of = 30 g/L ou temps de prothrombine normal | | | |  | | • Serum albumine > of = 30 g/L of normale prothrombine tijd. | | | | | |
|  | | • Pas d'insuffisance cardiaque congestive non contrôlée (NYHA III ou IV) | | | |  | | • Geen ongecontroleerd congestief hartfalen (NYHA III of IV) | | | | | |
|  | - Pas de grossesse ni de lactation active | | | | |  | - Geen zwangerschap noch actieve lactatie. | | | | | | |
| c) Parallèlement, le médecin spécialiste mentionne dans le dossier: | | | | | | c) De arts-specialist vermeldt gelijktijdig in het dossier: | | | | | | | |
|  | - les éléments liés à l'état du bénéficiaire; | | | | |  | - de elementen die betrekking hebben op de toestand van de rechthebbende; | | | | | | |
|  | - une documentation claire indiquant que le bénéficiaire a été informé par les médecins concernés des risques potentiels associés ; | | | | |  | - duidelijke documentatie dat de rechthebbende geïnformeerd werd door de betrokken artsen over de mogelijke risico's die verbonden zijn aan de behandeling ; | | | | | | |
|  | - qu’il atteste disposer du rapport de la consultation oncologique multidisciplinaire (COM) (au moins constituée d’un médecin spécialiste en médecine nucléaire, un oncologue médical ou un gastro-entérologue porteur de la qualification professionnelle particulière en oncologie et un chirurgien) autorisant le traitement qui est appliqué; | | | | |  | - dat hij bevestigt dat hij over het rapport van het multidisciplinair oncologisch consult (MOC) (minimaal bestaande uit een arts-specialist in de nucleaire geneeskunde, een medisch oncoloog of gastro-enteroloog met een bijzondere beroepsbekwaamheid in de oncologie en een chirurg) beschikt dat het akkoord geeft voor de behandeling die wordt toegepast; | | | | | | |
|  | - qu’il confirme que l’établissement où le bénéficiaire est traité, peut disposer des services d’un expert agréé en radiophysique médicale et un expert agréé en contrôle physique; | | | | |  | - dat hij bevestigt dat de instelling waar de rechthebbende behandeld wordt, kan beschikken over de diensten van een erkende deskundige in de medische stralingsfysica en een deskundige erkend in de fysische controle; | | | | | | |
|  | - qu’il s’engage à tenir à la disposition du médecin-conseil les éléments de preuve qui attestent de la situation décrite; | | | | |  | - dat hij zich ertoe verbindt om ten behoeve van de adviserend-arts de bewijsstukken ter beschikking te houden die de gegevens bevestigen; | | | | | | |
|  | - qu’il s’engage à évaluer l’état du bénéficiaire avant chaque injection afin d’évaluer si la poursuite du traitement est médicalement justifiée; au moins cliniquement et biochimiquement, éventuellement avec imagerie; | | | | |  | - dat hij zich ertoe verbindt om voor elke injectie de toestand van de rechthebbende te beoordelen opdat de voortzetting van de behandeling medisch gerechtvaardigd is, minstens klinisch en biochemisch, eventueel met beeldvorming; | | | | | | |
|  | - qu'il s'engage à prolonger l'intervalle entre les cycles de traitement en cas de réduction cliniquement significative des plaquettes et/ou des leucocytes à l’exception des lymphocytes | | | | |  | - dat hij zich ertoe verbindt om het interval tussen de cycli te verlengen in geval van klinisch relevante daling van de bloedplaatjes en/of de witte bloedcellen (met uitzondering van de lymfocyten). | | | | | | |
| d) La posologie recommandée chez l’ adulte est de 4 perfusions avec une intervalle entre chaque administration de 8 semaines. | | | | | | d) Het aanbevolen behandelingsschema bij een volwassene bestaat uit 4 toedieningen met een interval van 8 weken tussen elke toediening. | | | | | | | |
|  | Le nombre de flacons remboursables est limitée à 3 dans la vie du bénéficiaire. Le coût du 4ième flacon de la spécialité radiopharmaceutique lutetium (177Lu)-oxodotreotide est complètement à charge du titulaire de l’enregistrement | | | | |  | Het aantal vergoedbare flacons is beperkt tot 3 in het leven van de rechthebbende. De kost van de 4de flacon van het radiofarmaceutisch specialiteit lutetium (177Lu)-oxodotreotide valt volledig ten laste van de vergunninghouder. | | | | | | |
| e) Le remboursement simultané de la spécialité radiopharmaceutique à base de lutetium (177Lu)-oxodotreotide et de spécialités à base d’Everolimus ou Sunitinib n’est pas autorisé. Exceptionnellement, le remboursement simultané est autorisé chez un bénéficiare présentant un insulinome métastatique. | | | | | | e) De gelijktijdige vergoeding van radiofarmaceutische specialiteit op basis van lutetium (177Lu)-oxodotreotide en specialiteiten op basis van Everolimus of op basis van Sunitinib is niet toegestaan. Bij wijze van uitzondering is zulke combinatie wel vergoedbaar bij een rechthebbende met gemetastaseerd insulinoom. | | | | | | | |
|  | | | | | |  | | | | | | | |
| Dénomination / Benaming (Demandeur/Aanvrager) | | | | | | | | | | | | | |
| Cat. | | | Code | Conditionnements | Verpakkingen | | | | Obs  Opm | Prix  Prijs  ***ex-usine / buiten bedrijf*** | Base de remb  Basis v tegem  ***ex-usine / buiten bedrijf*** | I | II |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| LUTATHERA 370 MBq/ml | | | NOVARTIS PHARMA | |  | | | | ATC: | | |
|  | ***0749-733*** | ***1 doses solution injectable, 1 dose*** | | ***1 doses oplossing voor injectie, 1 dosis*** | |  | ***19568,78*** |  | |  |  |
| Ri-T10 **\*** | 0749-733 | 1 administration, 1 dose | | 1 toediening, 1 dosis | |  |  | 18500,0000 | |  |  |
| Ri-T10 **\*\*** | 0749-744 | 1 administration, 1 dose | | 1 toediening, 1 dosis | |  |  | 18500,0000 | |  |  |
|  |  |  | |  | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | | | | | | |  | | | | | | | | | |
| **Paragraphe 20013** | | | | | | | | **Paragraaf 20013** | | | | | | | | | |
| Spécialités radiopharmaceutiques à base de lutétium (177Lu)-PSMA-617 – catégorie de remboursement Ri-T11 – domine d’application thérapeutique. | | | | | | | | Radiofarmaceutische specialiteiten op basis van lutetium (177Lu)-PSMA-617 - vergoedingscategorie Ri-T11 – therapeutisch toepassingsgebied. | | | | | | | | | |
| a) La spécialité radiopharmaceutique à base de lutétium (177Lu)-PSMA-617 est remboursable si elle est administrée par un médecin spécialiste en médecine nucléaire agréé par l'AFCN pour l'administration du lutétium (177Lu)-PSMA (thérapie aux radionucléides) avec hospitalisation à l'hôpital, pour le traitement d'un bénéficiaire adulte atteint d'un cancer métastatique de la prostate résistant à la castration (mCRPC) dont la maladie est en progression. | | | | | | | | a) De radiofarmaceutische specialiteit op basis van lutetium (177Lu)-PSMA-617 komt in aanmerking voor vergoeding indien het wordt toegediend door een arts-specialist erkend in de nucleaire geneeskunde, vergund door het FANC voor de toediening van lutetium (177Lu)-PSMA (radionuclidetherapie) met hospitalisatie in het desbetreffende ziekenhuis, voor de behandeling van een volwassen rechthebbende met gemetastaseerde castratieresistente prostaatkanker (mCRPC) met progressieve ziekte. | | | | | | | | | |
|  | Le bénéficiaire répond à chacun des des critères suivants: | | | | | | |  | De rechthebbende beantwoordt aan elk van de volgende criteria: | | | | | | | | |
|  | | - Taux sérique de testostérone de castration < 50 ng/dL ou < 1.7 nmol/L. | | | | | |  | | - Serum castratiespiegels van testosteron < 50 ng/dL of < 1.7 nmol/L. | | | | | | | |
|  | | - A été prétraité avec au moins une thérapie anti-androgénique de 2e génération (ARPI) et au moins une chimiothérapie à base de taxane, sauf si le bénéficiaire est inéligible à ces traitements. | | | | | |  | | - Voorbehandeling met minstens één 2de generatie antiandrogeen therapie (ARPI) en met minstens 1 taxaan-gebaseerde chemotherapie, tenzij de rechthebbende niet in aanmerking komt voor deze behandelingen. | | | | | | | |
|  | | - La majorité des métastases démontre une captation des ligands au PSMA sur la base d'un examen d'imagerie pré-thérapeutique. | | | | | |  | | - De meerderheid van de uitzaaiingen vertoont uptake van liganden bij het PSMA op basis van beeldvormend onderzoek voorafgaand aan de therapie. | | | | | | | |
|  | | - Présente au moins 1 des signes suivants de progression de la maladie : | | | | | |  | | - Vertoont minstens 1 van de volgende tekens van ziekteprogressie : | | | | | | | |
|  | | | • Trois augmentations consécutives du PSA sérique, à intervalle de 7 jours, dont au moins deux avec un PSA sérique > 2 ng/ml et représentant une augmentation d’au moins 50% par rapport au nadir de PSA. | | | | |  | | | • Drie opeenvolgende PSA stijgingen, met elk 1 week tussen, waarvan minstens 2 maal een PSA spiegel van > 2 ng/ml die tegelijkertijd een stijging met 50% ten opzichte van de nadir PSA vertegenwoordigt. | | | | | | |
|  | | | • Progression des lésions osseuses (apparition d’une nouvelle métastase osseuse ou de 2 lésions osseuses complémentaires sur scintigraphie osseuse). | | | | |  | | | • Progressie van botletsels (ontstaan van een nieuwe botmetastase of van 2 bijkomende botletsels op botscintigrafie). | | | | | | |
|  | | | • Progression des lésions des tissus mous selon les critères RECIST (Response Evaluation Criteria in Solid Tumours) : augmentation de la somme des diamètres des lésions cibles d’au moins 20% et d’au moins 5 mm (les métastases lymphatiques < 2 cm n’entrent pas en ligne de compte). | | | | |  | | | • Progressie van weke delenletsels volgens de RECIST (Response Evaluation Criteria in Solid Tumours) criteria : een toename van minstens 20% en van minstens 5 mm van de som van de diameters van de meetbare letsels (lymfekliermetastasen van < 2 cm komen niet in aanmerking). | | | | | | |
|  | | | • Apparition d’une ou plusieurs métastases viscérales ou des tissus mous (y compris les ganglions lymphatiques). | | | | |  | | | • Verschijnen van 1 of meer nieuwe viscerale of weke delen (inclusief lymfeklier) metastase.). | | | | | | |
|  | | - Espérance de vie d'au moins 6 mois ; | | | | | |  | | - Levensverwachting van minimum 6 maanden ; | | | | | | | |
|  | | - Le bénéficiaire est et restera également traité par castration médicamenteuse (uniquement en absence de castration chirurgicale). | | | | | |  | | - De rechthebbende is en blijft eveneens behandeld met een medicamenteuze castratie (alleen bij afwezigheid van een chirurgische castratie) | | | | | | | |
|  | | - Au début du traitement par Pluvicto, le bénéficiaire doit en plus répondre à chacun des critères suivants : | | | | | |  | | - Bij aanvang van de behandeling met Pluvicto moet de rechthebbende eveneens aan elk van de volgende criteria voldoen: | | | | | | | |
|  | | | • Score de performance ECOG de 0, 1 ou 2, | | | | |  | | | • ECOG-performantiescore van 0, 1 of 2, | | | | | | |
|  | | | • Fonction des organes suffisante : | | | | |  | | | • Voldoende orgaanfunctie : | | | | | | |
|  | | | | - Créatinine sérique ≤ 1,5 fois la limite supérieure de la plage normale ou clairance rénale 50mL/min, | | | |  | | | | - Serum creatinine ≤ 1,5 maal de bovengrens van het normale bereik of creatinineklaring ≥ 50mL/min, | | | | | |
|  | | | | - Bilirubine ≤ 3 fois la limite supérieure de la plage normale (sauf syndrome de Gilbert), | | | |  | | | | - Totale bilirubine ≤ 1,5 maal de bovengrens van het normale bereik (tenzij syndroom van Gilbert), | | | | | |
|  | | | | - ALT ou AST ≤ 3 fois la limite supérieure de la plage normale (≥ 5 pour les patients avec maladie hépatique), | | | |  | | | | - ALT of AST ≤ 3,0 maal de bovengrens van het normale bereik (≤ 5,0 voor patiënten met leverziekte), | | | | | |
|  | | | | - Albumine sérique ≥ 30g/L ou temps de prothrombine normal, | | | |  | | | | - Serum albumine ≥ 30g/L of normale prothrombinetijd, | | | | | |
|  | | | | - Réserve hématologique suffisant. | | | |  | | | | - Voldoende beenmergreserve. | | | | | |
| b) Parallèlement, le médecin spécialiste mentionne dans le dossier : | | | | | | | | b) De arts-specialist vermeldt gelijktijdig in het dossier : | | | | | | | | | |
|  | - Les éléments liés à l'état du bénéficiaire ; | | | | | | |  | - De elementen die betrekking hebben op de toestand van de rechthebbende; | | | | | | | | |
|  | - D’attester de disposer du rapport de la consultation oncologique multidisciplinaire (COM) (au moins constituée d'un médecin spécialiste en médecine nucléaire, un oncologue médical, un radiothérapeute et un urologue) autorisant le traitement qui est appliqué ; | | | | | | |  | - Te bevestigen over het rapport van het multidisciplinair oncologisch consult (MOC) (minimaal bestaande uit een arts-specialist in nucleaire geneeskunde, een medisch oncoloog, een radiotherapeut en een uroloog) te beschikken dat het akkoord geeft voor de behandeling die wordt toegepast ; | | | | | | | | |
|  | - De confirmer que l'établissement où le bénéficiaire est traité, peut disposer des services d'un expert agréé en radiophysique médicale et d’un expert agréé en contrôle physique ; | | | | | | |  | - Te bevestigen dat de instelling waar de rechthebbende behandeld wordt, kan beschikken over de diensten van een erkende deskundige in de medische stralingsfysica en een deskundige erkend in de fysische controle; | | | | | | | | |
|  | - De s'engager à tenir à la disposition du médecin-conseil les éléments de preuve qui attestent de la situation décrite ; | | | | | | |  | - Zich ertoe te verbinden om ten behoeve van de adviserend arts de bewijsstukken ter beschikking te houden die de gegevens bevestigen ; | | | | | | | | |
|  | - De s'engager à évaluer l'état du patient avant chaque injection afin d’évaluer si la poursuite du traitement est médicalement justifiée. Cette évaluation se fera e.a. en examinant l'expression des récepteurs PSMA par imagerie après 2 ou 3 injections ; | | | | | | |  | - Zich ertoe te verbinden om voor elke injectie de toestand van de rechthebbende te beoordelen opdat de voortzetting van de behandeling medisch gerechtvaardigd is. Deze evaluatie zal o.a. gebeuren a.h.v. de PSMA receptor expressie op beeldvorming na 2 of 3 injecties ; | | | | | | | | |
|  | - De s'engager à interrompre l'administration d’un nouveau cycle de traitement : | | | | | | |  | - Zich ertoe te verbindt om de nieuwe therapietoediening te staken : | | | | | | | | |
|  | | • Lorsque le PSA après une diminution précédente augmente par rapport au nadir d'au moins 25% (relativement) et d'au moins 2 ng/ml en valeur absolue, et que cette augmentation est confirmée par un deuxième examen au moins 3 semaines plus tard. | | | | | |  | | • Wanneer de PSA na een eerdere daling toeneemt t.a.v. het nadir met minstens 25% (relatief) én minstens 2 ng/ml in absolute waarde, en deze toename bevestigd wordt door een tweede onderzoek minstens 3 weken later. | | | | | | | |
|  | | • Si, au cours des 12 premières semaines de traitement, il n'y a pas eu de diminution antérieure de la valeur de base du PSA, la valeur de base du PSA devient le point de référence pour la même augmentation relative et absolue. | | | | | |  | | • Indien er gedurende de eerste 12 weken van de behandeling geen voorafgaandelijke PSA-daling is opgetreden t.a.v. de baseline PSA-waarde wordt de baseline PSA-waarde het referentiepunt voor dezelfde relatieve én absolute toename. | | | | | | | |
|  | - De s'engager à prolonger l'intervalle entre les cycles de traitement en cas de réduction significative des plaquettes ou des leucocytes. | | | | | | |  | - Zich ertoe te verbinden om het therapie-interval te verlengen bij een relevante verlaging van de bloedplaatjes of de leukocyten. | | | | | | | | |
|  | - De s'engager à arrêter le traitement remboursé si un traitement par chimiothérapie ou par radiothérapie externe hemibody est instauré; | | | | | | |  | - Zich ertoe te verbinden om de vergoede behandeling te stoppen wanneer een behandeling met chemotherapie of met externe hemibody radiotherapie wordt ingesteld; | | | | | | | | |
| c) La posologie recommandée chez le bénéficiaire adulte est de 6 infusions avec une intervalle entre chaque administration de 6 semaines. | | | | | | | | c) Het aanbevolen behandelingsschema bij een volwassen rechthebbende bestaat uit 6 toedieningen met een interval van 6 weken tussen elke toediening. | | | | | | | | | |
|  | - Le nombre d’injections remboursables tient compte de la réponse du bénéficiaire au Pluvicto, avec un maximum 4 injections par période de traitement. | | | | | | |  | - Het aantal vergoedbare injecties houdt rekening met de respons van de rechthebbende op Pluvicto, met een maximum van 4 injecties per behandelingscyclus. | | | | | | | | |
|  | - Le coût d’une 5ieme et 6ième flacon de la spécialité radiopharmaceutique Pluvicto, après confirmation d’une réponse clinique favorable, est complètement à charge du titulaire de l’enregistrement. | | | | | | |  | - De kost van een 5de en 6de flacon van de radiofarmaceutische specialiteit Pluvicto, na bevestiging van een gunstige klinische respons, valt volledig ten laste van de vergunningshouder. | | | | | | | | |
| d) Le remboursement simultané de PLUVICTO avec les spécialités XOFIGO, JEVTANA et des spécialités à base de docetaxel n'est jamais autorisé. | | | | | | | | d) De gelijktijdige vergoeding van PLUVICTO met de specialiteiten XOFIGO, JEVTANA en specialiteiten op basis van docetaxel is nooit toegestaan. | | | | | | | | | |
|  | | | | | | | |  | | | | | | | | | |
| Dénomination / Benaming (Demandeur/Aanvrager) | | | | | | | | | | | | | | | | | |
| Cat. | | | | | Code | Conditionnements | Verpakkingen | | | | | | Obs  Opm | Prix  Prijs  ***ex-usine / buiten bedrijf*** | Base de remb  Basis v tegem  ***ex-usine / buiten bedrijf*** | I | II |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| PLUVICTO 1000 MBq/mL | | | NOVARTIS PHARMA | |  | | | | ATC: V10XX05 | | |
|  | ***0749-954*** | ***1 doses solution injectable, 1 dose*** | | ***1 doses oplossing voor injectie, 1 dosis*** | |  | ***20000,00*** |  | |  |  |
| Ri-T11 **\*** | 0749-954 | 1 administration, 1 dose | | 1 toediening, 1 dosis | |  |  | 19175,0000 | |  |  |
| Ri-T11 **\*\*** | 0749-965 | 1 administration, 1 dose | | 1 toediening, 1 dosis | |  |  | 19175,0000 | |  |  |
|  |  |  | |  | |  |  |  | |  |  |

|  |  |  |
| --- | --- | --- |
|  |  | |
| II | II | |
| **HOOFDSTUK II** | | **CHAPITRE II** |
|  | |  |
| 1. **Toepassingsmodaliteiten** | | **A. Modalités d’application** |
|  | |  |
| De tegemoetkoming van de ziekte- en invaliditeitsverzekering wordt toegestaan in de kosten van de diagnostisch in vivo aangewende radiofarmaceutische producten voor zover het product opgenomen is op de lijst die volgt en voor zover het gebruik bij de begunstigde, in voorkomend geval, voldoet aan de bijkomende vergoedingsvoorwaarden zoals bepaald in de lijst. | | L’intervention de l’assurance maladie-invalidité est accordée dans le coût des produits radio-pharmaceutiques utilisés à titre diagnostique in vivo pour autant que le produit soit inscrit sur la liste qui suit et pour autant que l’utilisation chez le bénéficiaire remplit, le cas échéant, les conditions de remboursement supplémentaires, comme stipulé dans la liste. |
|  | |  |
| De verzekeringstegemoetkoming bestaat uit een forfaitair bedrag per onderzoek, vastgesteld volgens de hierna vermelde vergoedingscategorieën (Ri-Dn). | | L’intervention de l’assurance consiste en un montant forfaitaire par examen , fixée forfaitairement selon les catégories de remboursement mentionnées ci-après (Ri-Dn). |
|  | |  |
| 1. **Lijst van de diagnostisch aangewende radiofarmaceutische producten** | | **B. Liste des produits radio-pharmaceutiques utilisés à titre diagnostique** |
|  | |  |
| § 1 de radiofarmaca, de radionuclidengeneratoren en de radionuclideuitgangstoffen | | § 1 les médicaments radio-pharmaceutiques, les générateurs de radionucléides et les précurseurs de radionucléides |
|  | |  |

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Paragraphe 10001** | | | | **Paragraaf 10001** | | | | | |
| Produits radio-pharmaceutiques à base de radionucléides émetteurs de positons, catégorie de remboursement Ri-D7 - domaine d’application diagnostique: TEP scan | | | | Radiofarmaceutische producten op basis van positronen-emitterende radionucliden, vergoedingscategorie Ri-D7 - toepassingsgebied diagnostiek: PET scan | | | | | |
| Les produits inscrits dans ce paragraphe sont remboursables dans la catégorie de remboursement Ri-D7 s’ils sont utilisés pour effectuer une tomographie à positrons prévue sous les n° s 442750-442761 de la nomenclature. | | | | De producten ingeschreven in deze paragraaf zijn vergoedbaar in de vergoedingscategorie Ri-D7 indien ze gebruikt worden om een positronentomografie tot stand te die voorzien is onder nrs. 442750-442761 van de nomenclatuur. | | | | | |
|  | | | |  | | | | | |
| Dénomination / Benaming (Demandeur/Aanvrager) | | | | | | | | | |
| Cat. | Code | Conditionnements | Verpakkingen | | Obs  Opm | Prix  Prijs  ***ex-usine / buiten bedrijf*** | Base de remb  Basis v tegem  ***ex-usine / buiten bedrijf*** | I | II |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 18F-JK-PSMA-7 (UZ Leuven) | | | Katholieke Universiteit te Leuven | |  | | | | ATC: V09IX04 | | |
|  | ***0749-814*** | ***1 doses solution injectable, 1 dose*** | | ***1 doses oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D7 **\*** | 0749-814 | 1 administration, 1 dose | | 1 toediening, 1 dosis | |  |  |  | |  |  |
| Ri-D7 **\*\*** | 0749-825 | 1 administration, 1 dose | | 1 toediening, 1 dosis | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| AXUMIN 1600 MBq/mL 16000 MBq 10 mL | | | BLUE EARTH DIAGNOSTICS | |  | | | | ATC: V09IX12 | | |
|  | ***0749-232*** | ***1 flacon injectable 10 mL solution injectable, 1 dose*** | | ***1 injectieflacon 10 mL oplossing voor injectie, 1 dosis*** | |  | ***1000,00*** |  | |  |  |
| Ri-D7 **\*** | 0749-232 | 1 administration 10 mL solution injectable, 1 dose | | 1 toediening 10 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |
| Ri-D7 **\*\*** | 0749-243 | 1 administration 10 mL solution injectable, 1 dose | | 1 toediening 10 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| AXUMIN 1600 MBq/mL 16000 MBq 15 mL | | | BLUE EARTH DIAGNOSTICS | |  | | | | ATC: V09IX12 | | |
|  | ***0749-232*** | ***1 flacon injectable 15 mL solution injectable, 1 dose*** | | ***1 injectieflacon 15 mL oplossing voor injectie, 1 dosis*** | |  | ***1000,00*** |  | |  |  |
| Ri-D7 **\*** | 0749-232 | 1 administration 15 mL solution injectable, 1 dose | | 1 toediening 15 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |
| Ri-D7 **\*\*** | 0749-243 | 1 administration 15 mL solution injectable, 1 dose | | 1 toediening 15 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| AXUMIN 3200 MBq/mL 32000 MBq 10 mL | | | BLUE EARTH DIAGNOSTICS | |  | | | | ATC: V09IX12 | | |
|  | ***0749-232*** | ***1 flacon injectable 10 mL solution injectable, 1 dose*** | | ***1 injectieflacon 10 mL oplossing voor injectie, 1 dosis*** | |  | ***1000,00*** |  | |  |  |
| Ri-D7 **\*** | 0749-232 | 1 administration 10 mL solution injectable, 1 dose | | 1 toediening 10 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |
| Ri-D7 **\*\*** | 0749-243 | 1 administration 10 mL solution injectable, 1 dose | | 1 toediening 10 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| AXUMIN 3200 MBq/mL 32000 MBq 15 mL | | | BLUE EARTH DIAGNOSTICS | |  | | | | ATC: V09IX12 | | |
|  | ***0749-232*** | ***1 flacon injectable 15 mL solution injectable, 1 dose*** | | ***1 injectieflacon 15 mL oplossing voor injectie, 1 dosis*** | |  | ***1000,00*** |  | |  |  |
| Ri-D7 **\*** | 0749-232 | 1 administration 15 mL solution injectable, 1 dose | | 1 toediening 15 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |
| Ri-D7 **\*\*** | 0749-243 | 1 administration 15 mL solution injectable, 1 dose | | 1 toediening 15 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| C-11-ACETATE (UCL) | | | UNIVERSITE CATHOLIQUE DE LOUVAIN UCL | |  | | | | ATC: | | |
|  | ***0746-454*** | ***1 solution injectable, 1 dose*** | | ***1 oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D7 **\*** | 0746-454 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |
| Ri-D7 **\*\*** | 0746-465 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| C-11-CHOLINE (ULB) | | | Université Libre de Bruxelles | |  | | | | ATC: | | |
|  | ***0746-270*** | ***1 solution injectable, 1 dose*** | | ***1 oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D7 **\*** | 0746-270 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |
| Ri-D7 **\*\*** | 0746-281 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| C-11-CHOLINE (UZ LEUVEN) | | | Katholieke Universiteit te Leuven | |  | | | | ATC: | | |
|  | ***0746-756*** | ***1 solution injectable, 1 dose*** | | ***1 oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D7 **\*** | 0746-756 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |
| Ri-D7 **\*\*** | 0746-760 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| C-11-METHIONINE (UCL) | | | UNIVERSITE CATHOLIQUE DE LOUVAIN UCL | |  | | | | ATC: | | |
|  | ***0746-491*** | ***1 solution injectable, 1 dose*** | | ***1 oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D7 **\*** | 0746-491 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |
| Ri-D7 **\*\*** | 0746-502 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| C-11-METHIONINE (ULB) | | | Université Libre de Bruxelles | |  | | | | ATC: | | |
|  | ***0746-196*** | ***1 solution injectable, 1 dose*** | | ***1 oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D7 **\*** | 0746-196 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |
| Ri-D7 **\*\*** | 0746-200 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| C-11-METHIONINE (UZ LEUVEN) | | | Katholieke Universiteit te Leuven | |  | | | | ATC: | | |
|  | ***0746-793*** | ***1 solution injectable, 1 dose*** | | ***1 oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D7 **\*** | 0746-793 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |
| Ri-D7 **\*\*** | 0746-804 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| C-11-PIB (UCL) | | | UNIVERSITE CATHOLIQUE DE LOUVAIN UCL | |  | | | | ATC: | | |
|  | ***0749-910*** | ***1 solution injectable, 1 dose*** | | ***1 oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D7 **\*** | 0749-910 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |
| Ri-D7 **\*\*** | 0749-921 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| C-11-PIB (UZ LEUVEN) | | | Katholieke Universiteit te Leuven | |  | | | | ATC: | | |
|  | ***0746-771*** | ***1 solution injectable, 1 dose*** | | ***1 oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D7 **\*** | 0746-771 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |
| Ri-D7 **\*\*** | 0746-782 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| C-11-PIB (UZA) | | | Universitair Ziekenhuis Antwerpen | |  | | | | ATC: | | |
|  | ***0749-055*** | ***1 solution injectable, 1 dose*** | | ***1 oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D7 **\*** | 0749-055 | 1 administration, 1 dose | | 1 toediening, 1 dosis | |  |  |  | |  |  |
| Ri-D7 **\*\*** | 0749-066 | 1 administration, 1 dose | | 1 toediening, 1 dosis | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| C-11-RACLOPRIDE (UZ GENT) | | | Universitair Ziekenhuis Gent | |  | | | | ATC: | | |
|  | ***0746-830*** | ***1 solution injectable, 1 dose*** | | ***1 oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D7 **\*** | 0746-830 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |
| Ri-D7 **\*\*** | 0746-841 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| C-11-RACLOPRIDE (UZ LEUVEN) | | | Katholieke Universiteit te Leuven | |  | | | | ATC: | | |
|  | ***0746-815*** | ***1 solution injectable, 1 dose*** | | ***1 oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D7 **\*** | 0746-815 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |
| Ri-D7 **\*\*** | 0746-826 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| C-11-RACLOPRIDE (UZA) | | | Universitair Ziekenhuis Antwerpen | |  | | | | ATC: | | |
|  | ***0749-136*** | ***1 doses solution injectable, 1 dose*** | | ***1 doses oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D7 **\*** | 0749-136 | 1 administration, 1 dose | | 1 toediening, 1 dosis | |  |  |  | |  |  |
| Ri-D7 **\*\*** | 0749-140 | 1 administration, 1 dose | | 1 toediening, 1 dosis | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| F-18-CHOLINE (UCL) | | | UNIVERSITE CATHOLIQUE DE LOUVAIN UCL | |  | | | | ATC: | | |
|  | ***0746-410*** | ***1 solution injectable, 1 dose*** | | ***1 oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D7 **\*** | 0746-410 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |
| Ri-D7 **\*\*** | 0746-421 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| F-18-CHOLINE (ULg) | | | UNIVERSITE DE LIEGE | |  | | | | ATC: | | |
|  | ***0746-594*** | ***1 solution injectable, 1 dose*** | | ***1 oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D7 **\*** | 0746-594 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |
| Ri-D7 **\*\*** | 0746-605 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| F-18-CHOLINE (UZ GENT) | | | Universitair Ziekenhuis Gent | |  | | | | ATC: | | |
|  | ***0746-874*** | ***1 solution injectable, 1 dose*** | | ***1 oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D7 **\*** | 0746-874 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |
| Ri-D7 **\*\*** | 0746-885 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| F-18-CHOLINE (UZ LEUVEN) | | | Katholieke Universiteit te Leuven | |  | | | | ATC: | | |
|  | ***0745-953*** | ***1 solution injectable, 1 dose*** | | ***1 oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D7 **\*** | 0745-953 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |
| Ri-D7 **\*\*** | 0745-964 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| F-18-DCFPyL (ULB) | | | Université Libre de Bruxelles | |  | | | | ATC: | | |
|  | ***0748-856*** | ***1 solution injectable, 1 dose*** | | ***1 oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D7 **\*** | 0748-856 | 1 administration 16 mL solution injectable, 1 dose | | 1 toediening 16 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |
| Ri-D7 **\*\*** | 0748-860 | 1 administration 16 mL solution injectable, 1 dose | | 1 toediening 16 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| F-18-FDG (ULB) | | | Université Libre de Bruxelles | |  | | | | ATC: V09IX04 | | |
|  | ***0746-395*** | ***1 solution injectable, 1 dose*** | | ***1 oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D7 **\*** | 0746-395 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |
| Ri-D7 **\*\*** | 0746-406 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| F-18-FDG (UZ BRUSSEL) | | | Vrije Universiteit Brussel | |  | | | | ATC: V09IX04 | | |
|  | ***0746-675*** | ***1 solution injectable, 1 dose*** | | ***1 oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D7 **\*** | 0746-675 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |
| Ri-D7 **\*\*** | 0746-686 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| F-18-FDG (UZ GENT) | | | Universitair Ziekenhuis Gent | |  | | | | ATC: V09IX04 | | |
|  | ***0746-712*** | ***1 solution injectable, 1 dose*** | | ***1 oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D7 **\*** | 0746-712 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |
| Ri-D7 **\*\*** | 0746-723 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| F-18-FDG (UZA) | | | Universitair Ziekenhuis Antwerpen | |  | | | | ATC: V09IX04 | | |
|  | ***0746-255*** | ***1 solution injectable, 1 dose*** | | ***1 oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D7 **\*** | 0746-255 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |
| Ri-D7 **\*\*** | 0746-266 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| F-18-FET (UZ BRUSSEL) | | | Vrije Universiteit Brussel | |  | | | | ATC: | | |
|  | ***0746-336*** | ***1 solution injectable, 1 dose*** | | ***1 oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D7 **\*** | 0746-336 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |
| Ri-D7 **\*\*** | 0746-340 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| F-18-FET (UZ GENT) | | | Universitair Ziekenhuis Gent | |  | | | | ATC: | | |
|  | ***0746-373*** | ***1 solution injectable, 1 dose*** | | ***1 oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D7 **\*** | 0746-373 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |
| Ri-D7 **\*\*** | 0746-384 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| F-18-FET (UZ LEUVEN) | | | Katholieke Universiteit te Leuven | |  | | | | ATC: | | |
|  | ***0746-535*** | ***1 solution injectable, 1 dose*** | | ***1 oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D7 **\*** | 0746-535 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |
| Ri-D7 **\*\*** | 0746-546 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| F-18-FET (UZA) | | | Universitair Ziekenhuis Antwerpen | |  | | | | ATC: | | |
|  | ***0746-233*** | ***1 solution injectable, 1 dose*** | | ***1 oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D7 **\*** | 0746-233 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |
| Ri-D7 **\*\*** | 0746-244 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| F-18-FLORBETAPIR (UZA) | | | Universitair Ziekenhuis Antwerpen | |  | | | | ATC: | | |
|  | ***0748-451*** | ***1 flacon injectable 15 ml solution injectable, 1 dose*** | | ***1 injectieflacon 15 ml oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D7 **\*** | 0748-451 | 1 administration 15 mL solution injectable, 1 dose | | 1 toediening 15 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |
| Ri-D7 **\*\*** | 0748-462 | 1 administration 15 mL solution injectable, 1 dose | | 1 toediening 15 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| F-18-FLT (UCL) | | | UNIVERSITE CATHOLIQUE DE LOUVAIN UCL | |  | | | | ATC: | | |
|  | ***0746-432*** | ***1 solution injectable, 1 dose*** | | ***1 oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D7 **\*** | 0746-432 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |
| Ri-D7 **\*\*** | 0746-443 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| F-18-FLT (ULg) | | | UNIVERSITE DE LIEGE | |  | | | | ATC: | | |
|  | ***0746-572*** | ***1 solution injectable, 1 dose*** | | ***1 oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D7 **\*** | 0746-572 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |
| Ri-D7 **\*\*** | 0746-583 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| F-18-FLUOROCHOLINE (ULB) | | | Université Libre de Bruxelles | |  | | | | ATC: | | |
|  | ***0746-292*** | ***1 solution injectable, 1 dose*** | | ***1 oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D7 **\*** | 0746-292 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |
| Ri-D7 **\*\*** | 0746-303 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| F-18-FLUORODOPA (ULg) | | | UNIVERSITE DE LIEGE | |  | | | | ATC: V09IX05 | | |
|  | ***0746-616*** | ***1 solution injectable, 1 dose*** | | ***1 oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D7 **\*** | 0746-616 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |
| Ri-D7 **\*\*** | 0746-620 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| F-18-FLUORURE (ULB) | | | Université Libre de Bruxelles | |  | | | | ATC: V09IX06 | | |
|  | ***0746-314*** | ***1 solution injectable, 1 dose*** | | ***1 oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D7 **\*** | 0746-314 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |
| Ri-D7 **\*\*** | 0746-325 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| F-18-FMISO (ULg) | | | UNIVERSITE DE LIEGE | |  | | | | ATC: | | |
|  | ***0746-550*** | ***1 solution injectable, 1 dose*** | | ***1 oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D7 **\*** | 0746-550 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |
| Ri-D7 **\*\*** | 0746-561 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| F-18-NAF (ULg) | | | UNIVERSITE DE LIEGE | |  | | | | ATC: V09IX06 | | |
|  | ***0746-653*** | ***1 solution injectable, 1 dose*** | | ***1 oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D7 **\*** | 0746-653 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |
| Ri-D7 **\*\*** | 0746-664 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| F-18-NAV-4694 (UZ Leuven) | | | Katholieke Universiteit te Leuven | |  | | | | ATC: | | |
|  | ***0749-431*** | ***1 solution injectable, 1 dose*** | | ***1 oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D7 **\*** | 0749-431 | 1 administration, 1 dose | | 1 toediening, 1 dosis | |  |  |  | |  |  |
| Ri-D7 **\*\*** | 0749-442 | 1 administration, 1 dose | | 1 toediening, 1 dosis | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| F-18-PSMA-1007 (UZ-KU LEUVEN) | | | Katholieke Universiteit te Leuven | |  | | | | ATC: | | |
|  | ***0748-915*** | ***1 doses solution injectable, 1 dose*** | | ***1 doses oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D7 **\*** | 0748-915 | 1 administration, 1 dose | | 1 toediening, 1 dosis | |  |  |  | |  |  |
| Ri-D7 **\*\*** | 0748-926 | 1 administration, 1 dose | | 1 toediening, 1 dosis | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| F-18-PSMA-1007 (UZA) | | | Universitair Ziekenhuis Antwerpen | |  | | | | ATC: | | |
|  | ***0749-195*** | ***1 doses solution injectable, 1 dose*** | | ***1 doses oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D7 **\*** | 0749-195 | 1 administration, 1 dose | | 1 toediening, 1 dosis | |  |  |  | |  |  |
| Ri-D7 **\*\*** | 0749-206 | 1 administration, 1 dose | | 1 toediening, 1 dosis | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| F-18-PSMA-11 (UZ GENT) | | | Universitair Ziekenhuis Gent | |  | | | | ATC: | | |
|  | ***0749-335*** | ***1 doses solution injectable, 1 dose*** | | ***1 doses oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D7 **\*** | 0749-335 | 1 administration, 1 dose | | 1 toediening, 1 dosis | |  |  |  | |  |  |
| Ri-D7 **\*\*** | 0749-346 | 1 administration, 1 dose | | 1 toediening, 1 dosis | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| F-18-PSMA-7 (UZ BRUSSEL) | | | Vrije Universiteit Brussel | |  | | | | ATC: V09IX04 | | |
|  | ***0749-755*** | ***1 doses solution injectable, 1 dose*** | | ***1 doses oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D7 **\*** | 0749-755 | 1 administration, 1 dose | | 1 toediening, 1 dosis | |  |  |  | |  |  |
| Ri-D7 **\*\*** | 0749-766 | 1 administration, 1 dose | | 1 toediening, 1 dosis | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| F-18-TYROSINE (ULg) | | | UNIVERSITE DE LIEGE | |  | | | | ATC: | | |
|  | ***0746-631*** | ***1 solution injectable, 1 dose*** | | ***1 oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D7 **\*** | 0746-631 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |
| Ri-D7 **\*\*** | 0746-642 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| FLUDESOXYGLUCOSE (18F) IBA 185 Mbq/ml | | | IBA PHARMA | |  | | | | ATC: V09IX04 | | |
|  | ***0747-552*** | ***1 flacon injectable 10 ml solution injectable, 1850 MBq*** | | ***1 injectieflacon 10 ml oplossing voor injectie, 1850 MBq*** | |  |  |  | |  |  |
| Ri-D7 **\*** | 0747-552 | 1 administration 10 mL solution injectable, 1850 MBq | | 1 toediening 10 mL oplossing voor injectie, 1850 MBq | |  |  |  | |  |  |
| Ri-D7 **\*\*** | 0747-563 | 1 administration 10 mL solution injectable, 1850 MBq | | 1 toediening 10 mL oplossing voor injectie, 1850 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| FLUORODOPA (18F) CIS BIO INTERNATIONAL 90 MBq/ml | | | CIS BIO INTERNATIONAL SAS | |  | | | | ATC: V09IX05 | | |
|  | ***0746-211*** | ***1 solution injectable, 200 MBq*** | | ***1 oplossing voor injectie, 200 MBq*** | |  | ***731,26*** |  | |  |  |
| Ri-D7 **\*** | 0746-211 | 1 administration 1 mL solution injectable, 200 MBq | | 1 toediening 1 mL oplossing voor injectie, 200 MBq | |  |  |  | |  |  |
| Ri-D7 **\*\*** | 0746-222 | 1 administration 1 mL solution injectable, 200 MBq | | 1 toediening 1 mL oplossing voor injectie, 200 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| FLUORODOPA (18F) CIS BIO INTERNATIONAL 90 MBq/ml | | | CIS BIO INTERNATIONAL SAS | |  | | | | ATC: V09IX05 | | |
|  | ***0746-211*** | ***1 solution injectable, 400 MBq*** | | ***1 oplossing voor injectie, 400 MBq*** | |  | ***1336,21*** |  | |  |  |
| Ri-D7 **\*** | 0746-211 | 1 administration 1 mL solution injectable, 400 MBq | | 1 toediening 1 mL oplossing voor injectie, 400 MBq | |  |  |  | |  |  |
| Ri-D7 **\*\*** | 0746-222 | 1 administration 1 mL solution injectable, 400 MBq | | 1 toediening 1 mL oplossing voor injectie, 400 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| GA-68 DOTATATE (UZ GENT) | | | Universitair Ziekenhuis Gent | |  | | | | ATC: | | |
|  | ***0749-851*** | ***1 doses solution injectable, 1 dose*** | | ***1 doses oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D7 **\*** | 0749-851 | 1 administration, 1 dose | | 1 toediening, 1 dosis | |  |  |  | |  |  |
| Ri-D7 **\*\*** | 0749-862 | 1 administration, 1 dose | | 1 toediening, 1 dosis | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| GA-68-DOTANOC | | | Katholieke Universiteit te Leuven | |  | | | | ATC: | | |
|  | ***0748-075*** | ***1 flacon injectable 16 ml solution injectable, 1 dose*** | | ***1 injectieflacon 16 ml oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D7 **\*** | 0748-075 | 1 administration 16 mL solution injectable, 1 dose | | 1 toediening 16 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |
| Ri-D7 **\*\*** | 0748-086 | 1 administration 16 mL solution injectable, 1 dose | | 1 toediening 16 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| GA-68-DOTANOC (CHU DE LIEGE) | | | CHU DE LIEGE | |  | | | | ATC: | | |
|  | ***0747-935*** | ***1 flacon injectable 8 ml solution injectable, 1 dose*** | | ***1 injectieflacon 8 ml oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D7 **\*** | 0747-935 | 1 administration 8 mL solution injectable, 1 dose | | 1 toediening 8 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |
| Ri-D7 **\*\*** | 0747-946 | 1 administration 8 mL solution injectable, 1 dose | | 1 toediening 8 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| GA-68-DOTANOC (UZ BRUSSEL) | | | Vrije Universiteit Brussel | |  | | | | ATC: | | |
|  | ***0748-812*** | ***1 flacon injectable 8 mL solution injectable, 1 dose*** | | ***1 injectieflacon 8 mL oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D7 **\*** | 0748-812 | 1 administration 8 mL solution injectable, 1 dose | | 1 toediening 8 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |
| Ri-D7 **\*\*** | 0748-823 | 1 administration 8 mL solution injectable, 1 dose | | 1 toediening 8 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| GA-68-DOTANOC (UZA) | | | Universitair Ziekenhuis Antwerpen | |  | | | | ATC: | | |
|  | ***0748-495*** | ***1 flacon injectable 15 ml solution injectable, 1 dose*** | | ***1 injectieflacon 15 ml oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D7 **\*** | 0748-495 | 1 administration 15 mL solution injectable, 1 dose | | 1 toediening 15 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |
| Ri-D7 **\*\*** | 0748-506 | 1 administration 15 mL solution injectable, 1 dose | | 1 toediening 15 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| GA-68-DOTATATE | | | Katholieke Universiteit te Leuven | |  | | | | ATC: | | |
|  | ***0748-112*** | ***1 flacon injectable 15 ml solution injectable, 1 dose*** | | ***1 injectieflacon 15 ml oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D7 **\*** | 0748-112 | 1 administration 15 mL solution injectable, 1 dose | | 1 toediening 15 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |
| Ri-D7 **\*\*** | 0748-123 | 1 administration 15 mL solution injectable, 1 dose | | 1 toediening 15 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| GA-68-DOTATATE | | | Association hospitalière de Bruxelles-Centre hospitalier Universitaire Jules Bordet | |  | | | | ATC: | | |
|  | ***0748-230*** | ***1 flacon injectable 15 ml solution injectable, 1 dose*** | | ***1 injectieflacon 15 ml oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D7 **\*** | 0748-230 | 1 administration 15 mL solution injectable, 1 dose | | 1 toediening 15 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |
| Ri-D7 **\*\*** | 0748-241 | 1 administration 15 mL solution injectable, 1 dose | | 1 toediening 15 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| GA-68-DOTATATE (AZ GROENINGE KORTRIJK) | | | Algemeen Ziekenhuis Groeninge | |  | | | | ATC: | | |
|  | ***0748-694*** | ***1 flacon injectable 10 mL solution injectable, 1 dose*** | | ***1 injectieflacon 10 mL oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D7 **\*** | 0748-694 | 1 administration 10 mL solution injectable, 1 dose | | 1 toediening 10 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |
| Ri-D7 **\*\*** | 0748-705 | 1 administration 10 mL solution injectable, 1 dose | | 1 toediening 10 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| GA-68-DOTATATE (CHU DE LIEGE) | | | CHU DE LIEGE | |  | | | | ATC: | | |
|  | ***0747-972*** | ***1 flacon injectable 8 ml solution injectable, 1 dose*** | | ***1 injectieflacon 8 ml oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D7 **\*** | 0747-972 | 1 administration 8 mL solution injectable, 1 dose | | 1 toediening 8 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |
| Ri-D7 **\*\*** | 0747-983 | 1 administration 8 mL solution injectable, 1 dose | | 1 toediening 8 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| GA-68-DOTATATE (UCL) | | | UNIVERSITE CATHOLIQUE DE LOUVAIN UCL | |  | | | | ATC: | | |
|  | ***0748-414*** | ***1 flacon injectable 15 ml solution injectable, 1 dose*** | | ***1 injectieflacon 15 ml oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D7 **\*** | 0748-414 | 1 administration 15 mL solution injectable, 1 dose | | 1 toediening 15 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |
| Ri-D7 **\*\*** | 0748-425 | 1 administration 15 mL solution injectable, 1 dose | | 1 toediening 15 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| GA-68-PSMA-HBED-CC | | | Katholieke Universiteit te Leuven | |  | | | | ATC: | | |
|  | ***0748-193*** | ***1 flacon injectable 15 ml solution injectable, 1 dose*** | | ***1 injectieflacon 15 ml oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D7 **\*** | 0748-193 | 1 administration 15 mL solution injectable, 1 dose | | 1 toediening 15 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |
| Ri-D7 **\*\*** | 0748-204 | 1 administration 15 mL solution injectable, 1 dose | | 1 toediening 15 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| GA-68-PSMA-HBED-CC (AZ GROENINGE KORTRIJK) | | | Algemeen Ziekenhuis Groeninge | |  | | | | ATC: | | |
|  | ***0748-635*** | ***1 flacon injectable 10 mL solution injectable, 1 dose*** | | ***1 injectieflacon 10 mL oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D7 **\*** | 0748-635 | 1 administration 10 mL solution injectable, 1 dose | | 1 toediening 10 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |
| Ri-D7 **\*\*** | 0748-646 | 1 administration 10 mL solution injectable, 1 dose | | 1 toediening 10 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| GA-68-PSMA-HBED-CC (BORDET) | | | Association hospitalière de Bruxelles-Centre hospitalier Universitaire Jules Bordet | |  | | | | ATC: | | |
|  | ***0748-355*** | ***1 flacon injectable 20 ml solution injectable, 1 dose*** | | ***1 injectieflacon 20 ml oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D7 **\*** | 0748-355 | 1 administration 20 mL solution injectable, 1 dose | | 1 toediening 20 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |
| Ri-D7 **\*\*** | 0748-366 | 1 administration 20 mL solution injectable, 1 dose | | 1 toediening 20 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| GA-68-PSMA-HBED-CC (CHR NAMUR) | | | CHR NAMUR | |  | | | | ATC: | | |
|  | ***0749-092*** | ***1 flacon injectable 20 mL solution injectable, 1 dose*** | | ***1 injectieflacon 20 mL oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D7 **\*** | 0749-092 | 1 administration 20 mL solution injectable, 1 dose | | 1 toediening 20 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |
| Ri-D7 **\*\*** | 0749-103 | 1 administration 20 mL solution injectable, 1 dose | | 1 toediening 20 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| GA-68-PSMA-HBED-CC (CHU DE LIEGE) | | | CHU DE LIEGE | |  | | | | ATC: | | |
|  | ***0748-031*** | ***1 flacon injectable 8 ml solution injectable, 8 ml*** | | ***1 injectieflacon 8 ml oplossing voor injectie, 8 ml*** | |  |  |  | |  |  |
| Ri-D7 **\*** | 0748-031 | 1 administration 8 mL solution injectable, 1 dose | | 1 toediening 8 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |
| Ri-D7 **\*\*** | 0748-042 | 1 administration 8 mL solution injectable, 1 dose | | 1 toediening 8 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| GA-68-PSMA-HBED-CC (GRAND HOPITAL DE CHARLEROI) | | | GRAND HOPITAL DE CHARLEROI (GHdC) | |  | | | | ATC: | | |
|  | ***0748-952*** | ***1 solution injectable, 1 dose*** | | ***1 oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D7 **\*** | 0748-952 | 1 administration, 1 dose | | 1 toediening, 1 dosis | |  |  |  | |  |  |
| Ri-D7 **\*\*** | 0748-963 | 1 administration, 1 dose | | 1 toediening, 1 dosis | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| GA-68-PSMA-HBED-CC (UCL) | | | UNIVERSITE CATHOLIQUE DE LOUVAIN UCL | |  | | | | ATC: | | |
|  | ***0748-274*** | ***1 flacon injectable 20 ml solution injectable, 1 dose*** | | ***1 injectieflacon 20 ml oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D7 **\*** | 0748-274 | 1 administration 20 mL solution injectable, 1 dose | | 1 toediening 20 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |
| Ri-D7 **\*\*** | 0748-285 | 1 administration 20 mL solution injectable, 1 dose | | 1 toediening 20 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| GA-68-PSMA-HBED-CC (UZ BRUSSEL) | | | Vrije Universiteit Brussel | |  | | | | ATC: | | |
|  | ***0748-775*** | ***1 flacon injectable 8 mL solution injectable, 1 dose*** | | ***1 injectieflacon 8 mL oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D7 **\*** | 0748-775 | 1 administration 8 mL solution injectable, 1 dose | | 1 toediening 8 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |
| Ri-D7 **\*\*** | 0748-786 | 1 administration 8 mL solution injectable, 1 dose | | 1 toediening 8 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| GA-68-PSMA-HBED-CC (UZ GENT) | | | Universitair Ziekenhuis Gent | |  | | | | ATC: | | |
|  | ***0749-011*** | ***1 solution injectable, 1 dose*** | | ***1 oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D7 **\*** | 0749-011 | 1 administration, 1 dose | | 1 toediening, 1 dosis | |  |  |  | |  |  |
| Ri-D7 **\*\*** | 0749-022 | 1 administration, 1 dose | | 1 toediening, 1 dosis | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| GA-68-PSMA-HBED-CC (UZA) | | | Universitair Ziekenhuis Antwerpen | |  | | | | ATC: | | |
|  | ***0748-311*** | ***1 flacon injectable 10 ml solution injectable, 1 dose*** | | ***1 injectieflacon 10 ml oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D7 **\*** | 0748-311 | 1 administration 10 mL solution injectable, 1 dose | | 1 toediening 10 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |
| Ri-D7 **\*\*** | 0748-322 | 1 administration 10 mL solution injectable, 1 dose | | 1 toediening 10 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| GLUCOGAST 1850 MBq/ml (UZ-KU LEUVEN) | | | Katholieke Universiteit te Leuven | |  | | | | ATC: V09IX04 | | |
|  | ***0747-552*** | ***1 flacon injectable 20 mL solution injectable, 1850 MBq/mL*** | | ***1 injectieflacon 20 mL oplossing voor injectie, 1850 MBq/mL*** | |  | ***205,00*** |  | |  |  |
| Ri-D7 **\*** | 0747-552 | 1 administration 20 mL solution injectable, 1850 MBq/mL | | 1 toediening 20 mL oplossing voor injectie, 1850 MBq/mL | |  |  |  | |  |  |
| Ri-D7 **\*\*** | 0747-563 | 1 administration 20 mL solution injectable, 1850 MBq/mL | | 1 toediening 20 mL oplossing voor injectie, 1850 MBq/mL | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| GLUCOTRACE | | | NUCLEIS SA | |  | | | | ATC: V09IX04 | | |
|  | ***0746-852*** | ***1 solution injectable, 185 MBq*** | | ***1 oplossing voor injectie, 185 MBq*** | |  | ***205,00*** |  | |  |  |
| Ri-D7 **\*** | 0746-852 | 1 administration 1 mL solution injectable, 185 MBq | | 1 toediening 1 mL oplossing voor injectie, 185 MBq | |  |  |  | |  |  |
| Ri-D7 **\*** | 0746-852 | 1 administration 1 mL solution injectable, 185 MBq | | 1 toediening 1 mL oplossing voor injectie, 185 MBq | |  |  |  | |  |  |
| Ri-D7 **\*\*** | 0746-863 | 1 administration 1 mL solution injectable, 185 MBq | | 1 toediening 1 mL oplossing voor injectie, 185 MBq | |  |  |  | |  |  |
| Ri-D7 **\*\*** | 0746-863 | 1 administration 1 mL solution injectable, 185 MBq | | 1 toediening 1 mL oplossing voor injectie, 185 MBq | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| N-13-NH3 (ULB) | | | Université Libre de Bruxelles | |  | | | | ATC: | | |
|  | ***0746-351*** | ***1 solution injectable, 1 dose*** | | ***1 oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D7 **\*** | 0746-351 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |
| Ri-D7 **\*\*** | 0746-362 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| O-15-EAU (ULB) | | | Université Libre de Bruxelles | |  | | | | ATC: | | |
|  | ***0746-513*** | ***1 solution injectable, 1 dose*** | | ***1 oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D7 **\*** | 0746-513 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |
| Ri-D7 **\*\*** | 0746-524 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| O-15-WATER (UZ LEUVEN) | | | Katholieke Universiteit te Leuven | |  | | | | ATC: | | |
|  | ***0747-876*** | ***1 solution injectable, 1 dose*** | | ***1 oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D7 **\*** | 0747-876 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |
| Ri-D7 **\*\*** | 0747-880 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  |  | |  |  |
|  |  |  | |  | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | | |  | | | | | |
| **Paragraphe 10002** | | | | **Paragraaf 10002** | | | | | |
| Produits radio-pharmaceutiques à base de radionucléides émetteurs de positons, catégorie de remboursement Ri-D9 - domaine d’application diagnostique: TEP scan | | | | Radiofarmaceutische producten op basis van positronen-emitterende radionucliden, vergoedingscategorie Ri-D9 - toepassingsgebied diagnostiek: PET scan | | | | | |
| Les produits inscrits dans ce paragraphe sont remboursables dans la catégorie de remboursement Ri-D9 s’ils sont utilisés pour effectuer une tomographie à positrons prévue sous les n° s 442971 – 442982, 442676 – 442680, 442691 – 442702, 442713 – 442724, 442735 – 442746 de la nomenclature. | | | | De producten ingeschreven in deze paragraaf zijn vergoedbaar in de vergoedingscategorie Ri-D9 indien ze gebruikt worden om een positronentomografie tot stand te brengen die voorzien is onder nrs. 442971 – 442982, 442676 – 442680, 442691 – 442702, 442713 – 442724, 442735 – 442746 van de nomenclatuur. | | | | | |
|  | | | |  | | | | | |
| Dénomination / Benaming (Demandeur/Aanvrager) | | | | | | | | | |
| Cat. | Code | Conditionnements | Verpakkingen | | Obs  Opm | Prix  Prijs  ***ex-usine / buiten bedrijf*** | Base de remb  Basis v tegem  ***ex-usine / buiten bedrijf*** | I | II |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 18F-JK-PSMA-7 (UZ Leuven) | | | Katholieke Universiteit te Leuven | |  | | | | ATC: V09IX04 | | |
|  | ***0749-836*** | ***1 doses solution injectable, 1 dose*** | | ***1 doses oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D9 **\*** | 0749-836 | 1 administration, 1 dose | | 1 toediening, 1 dosis | |  |  | 60,0000 | |  |  |
| Ri-D9 **\*\*** | 0749-840 | 1 administration, 1 dose | | 1 toediening, 1 dosis | |  |  | 60,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| AXUMIN 1600 MBq/mL 16000 MBq 10 mL | | | BLUE EARTH DIAGNOSTICS | |  | | | | ATC: V09IX12 | | |
|  | ***0749-254*** | ***1 flacon injectable 10 mL solution injectable, 1 dose*** | | ***1 injectieflacon 10 mL oplossing voor injectie, 1 dosis*** | |  | ***1000,00*** |  | |  |  |
| Ri-D9 **\*** | 0749-254 | 1 administration 10 mL solution injectable, 1 dose | | 1 toediening 10 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |
| Ri-D9 **\*\*** | 0749-265 | 1 administration 10 mL solution injectable, 1 dose | | 1 toediening 10 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| AXUMIN 1600 MBq/mL 16000 MBq 15 mL | | | BLUE EARTH DIAGNOSTICS | |  | | | | ATC: V09IX12 | | |
|  | ***0749-254*** | ***1 flacon injectable 15 mL solution injectable, 1 dose*** | | ***1 injectieflacon 15 mL oplossing voor injectie, 1 dosis*** | |  | ***1000,00*** |  | |  |  |
| Ri-D9 **\*** | 0749-254 | 1 administration 15 mL solution injectable, 1 dose | | 1 toediening 15 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |
| Ri-D9 **\*\*** | 0749-265 | 1 administration 15 mL solution injectable, 1 dose | | 1 toediening 15 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| AXUMIN 3200 MBq/mL 32000 MBq 10 mL | | | BLUE EARTH DIAGNOSTICS | |  | | | | ATC: V09IX12 | | |
|  | ***0749-254*** | ***1 flacon injectable 10 mL solution injectable, 1 dose*** | | ***1 injectieflacon 10 mL oplossing voor injectie, 1 dosis*** | |  | ***1000,00*** |  | |  |  |
| Ri-D9 **\*** | 0749-254 | 1 administration 10 mL solution injectable, 1 dose | | 1 toediening 10 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |
| Ri-D9 **\*\*** | 0749-265 | 1 administration 10 mL solution injectable, 1 dose | | 1 toediening 10 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| AXUMIN 3200 MBq/mL 32000 MBq 15 mL | | | BLUE EARTH DIAGNOSTICS | |  | | | | ATC: V09IX12 | | |
|  | ***0749-254*** | ***1 flacon injectable 15 mL solution injectable, 1 dose*** | | ***1 injectieflacon 15 mL oplossing voor injectie, 1 dosis*** | |  | ***1000,00*** |  | |  |  |
| Ri-D9 **\*** | 0749-254 | 1 administration 15 mL solution injectable, 1 dose | | 1 toediening 15 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |
| Ri-D9 **\*\*** | 0749-265 | 1 administration 15 mL solution injectable, 1 dose | | 1 toediening 15 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| C-11-ACETATE (UCL) | | | UNIVERSITE CATHOLIQUE DE LOUVAIN UCL | |  | | | | ATC: | | |
|  | ***0747-412*** | ***1 solution injectable, 1 dose*** | | ***1 oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D9 **\*** | 0747-412 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |
| Ri-D9 **\*\*** | 0747-423 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| C-11-CHOLINE (ULB) | | | Université Libre de Bruxelles | |  | | | | ATC: | | |
|  | ***0746-911*** | ***1 solution injectable, 1 dose*** | | ***1 oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D9 **\*** | 0746-911 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |
| Ri-D9 **\*\*** | 0746-922 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| C-11-CHOLINE (UZ LEUVEN) | | | Katholieke Universiteit te Leuven | |  | | | | ATC: | | |
|  | ***0747-795*** | ***1 solution injectable, 1 dose*** | | ***1 oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D9 **\*** | 0747-795 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |
| Ri-D9 **\*\*** | 0747-806 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| C-11-METHIONINE (UCL) | | | UNIVERSITE CATHOLIQUE DE LOUVAIN UCL | |  | | | | ATC: | | |
|  | ***0747-390*** | ***1 solution injectable, 1 dose*** | | ***1 oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D9 **\*** | 0747-390 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |
| Ri-D9 **\*\*** | 0747-401 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| C-11-METHIONINE (ULB) | | | Université Libre de Bruxelles | |  | | | | ATC: | | |
|  | ***0747-515*** | ***1 solution injectable, 1 dose*** | | ***1 oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D9 **\*** | 0747-515 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |
| Ri-D9 **\*\*** | 0747-526 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| C-11-METHIONINE (UZ LEUVEN) | | | Katholieke Universiteit te Leuven | |  | | | | ATC: | | |
|  | ***0747-110*** | ***1 solution injectable, 1 dose*** | | ***1 oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D9 **\*** | 0747-110 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |
| Ri-D9 **\*\*** | 0747-121 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| C-11-PIB (UCL) | | | UNIVERSITE CATHOLIQUE DE LOUVAIN UCL | |  | | | | ATC: | | |
|  | ***0749-932*** | ***1 solution injectable, 1 dose*** | | ***1 oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D9 **\*** | 0749-932 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |
| Ri-D9 **\*\*** | 0749-943 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| C-11-PIB (UZ LEUVEN) | | | Katholieke Universiteit te Leuven | |  | | | | ATC: | | |
|  | ***0747-132*** | ***1 solution injectable, 1 dose*** | | ***1 oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D9 **\*** | 0747-132 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |
| Ri-D9 **\*\*** | 0747-143 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| C-11-PIB (UZA) | | | Universitair Ziekenhuis Antwerpen | |  | | | | ATC: | | |
|  | ***0749-070*** | ***1 solution injectable, 1 dose*** | | ***1 oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D9 **\*** | 0749-070 | 1 administration, 1 dose | | 1 toediening, 1 dosis | |  |  | 60,0000 | |  |  |
| Ri-D9 **\*\*** | 0749-081 | 1 administration, 1 dose | | 1 toediening, 1 dosis | |  |  | 60,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| C-11-RACLOPRIDE (UZ GENT) | | | Universitair Ziekenhuis Gent | |  | | | | ATC: | | |
|  | ***0747-073*** | ***1 solution injectable, 1 dose*** | | ***1 oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D9 **\*** | 0747-073 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |
| Ri-D9 **\*\*** | 0747-084 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| C-11-RACLOPRIDE (UZ LEUVEN) | | | Katholieke Universiteit te Leuven | |  | | | | ATC: | | |
|  | ***0746-896*** | ***1 solution injectable, 1 dose*** | | ***1 oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D9 **\*** | 0746-896 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |
| Ri-D9 **\*\*** | 0746-900 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| C-11-RACLOPRIDE (UZA) | | | Universitair Ziekenhuis Antwerpen | |  | | | | ATC: | | |
|  | ***0749-151*** | ***1 doses solution injectable, 1 dose*** | | ***1 doses oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D9 **\*** | 0749-151 | 1 administration, 1 dose | | 1 toediening, 1 dosis | |  |  | 60,0000 | |  |  |
| Ri-D9 **\*\*** | 0749-162 | 1 administration, 1 dose | | 1 toediening, 1 dosis | |  |  | 60,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| F-18-CHOLINE (UCL) | | | UNIVERSITE CATHOLIQUE DE LOUVAIN UCL | |  | | | | ATC: | | |
|  | ***0747-471*** | ***1 solution injectable, 1 dose*** | | ***1 oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D9 **\*** | 0747-471 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |
| Ri-D9 **\*\*** | 0747-482 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| F-18-CHOLINE (ULg) | | | UNIVERSITE DE LIEGE | |  | | | | ATC: | | |
|  | ***0747-316*** | ***1 solution injectable, 1 dose*** | | ***1 oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D9 **\*** | 0747-316 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |
| Ri-D9 **\*\*** | 0747-320 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| F-18-CHOLINE (UZ GENT) | | | Universitair Ziekenhuis Gent | |  | | | | ATC: | | |
|  | ***0747-213*** | ***1 solution injectable, 1 dose*** | | ***1 oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D9 **\*** | 0747-213 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |
| Ri-D9 **\*\*** | 0747-224 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| F-18-CHOLINE (UZ LEUVEN) | | | Katholieke Universiteit te Leuven | |  | | | | ATC: | | |
|  | ***0747-036*** | ***1 solution injectable, 1 dose*** | | ***1 oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D9 **\*** | 0747-036 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |
| Ri-D9 **\*\*** | 0747-040 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| F-18-DCFPyL (ULB) | | | Université Libre de Bruxelles | |  | | | | ATC: | | |
|  | ***0748-893*** | ***1 solution injectable, 1 dose*** | | ***1 oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D9 **\*** | 0748-893 | 1 administration 16 mL solution injectable, 1 dose | | 1 toediening 16 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |
| Ri-D9 **\*\*** | 0748-904 | 1 administration 16 mL solution injectable, 1 dose | | 1 toediening 16 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| F-18-FDG (ULB) | | | Université Libre de Bruxelles | |  | | | | ATC: V09IX04 | | |
|  | ***0747-751*** | ***1 solution injectable, 1 dose*** | | ***1 oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D9 **\*** | 0747-751 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |
| Ri-D9 **\*\*** | 0747-762 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| F-18-FDG (UZ BRUSSEL) | | | Vrije Universiteit Brussel | |  | | | | ATC: V09IX04 | | |
|  | ***0746-970*** | ***1 solution injectable, 1 dose*** | | ***1 oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D9 **\*** | 0746-970 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |
| Ri-D9 **\*\*** | 0746-981 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| F-18-FDG (UZ GENT) | | | Universitair Ziekenhuis Gent | |  | | | | ATC: V09IX04 | | |
|  | ***0747-014*** | ***1 solution injectable, 1 dose*** | | ***1 oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D9 **\*** | 0747-014 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |
| Ri-D9 **\*\*** | 0747-025 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| F-18-FDG (UZA) | | | Universitair Ziekenhuis Antwerpen | |  | | | | ATC: V09IX04 | | |
|  | ***0747-810*** | ***1 solution injectable, 1 dose*** | | ***1 oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D9 **\*** | 0747-810 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |
| Ri-D9 **\*\*** | 0747-821 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| F-18-FET (UZ BRUSSEL) | | | Vrije Universiteit Brussel | |  | | | | ATC: | | |
|  | ***0747-095*** | ***1 solution injectable, 1 dose*** | | ***1 oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D9 **\*** | 0747-095 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |
| Ri-D9 **\*\*** | 0747-106 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| F-18-FET (UZ GENT) | | | Universitair Ziekenhuis Gent | |  | | | | ATC: | | |
|  | ***0747-250*** | ***1 solution injectable, 1 dose*** | | ***1 oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D9 **\*** | 0747-250 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |
| Ri-D9 **\*\*** | 0747-261 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| F-18-FET (UZ LEUVEN) | | | Katholieke Universiteit te Leuven | |  | | | | ATC: | | |
|  | ***0746-992*** | ***1 solution injectable, 1 dose*** | | ***1 oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D9 **\*** | 0746-992 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |
| Ri-D9 **\*\*** | 0747-003 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| F-18-FET (UZA) | | | Universitair Ziekenhuis Antwerpen | |  | | | | ATC: | | |
|  | ***0747-655*** | ***1 solution injectable, 1 dose*** | | ***1 oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D9 **\*** | 0747-655 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |
| Ri-D9 **\*\*** | 0747-666 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| F-18-FLORBETAPIR (UZA) | | | Universitair Ziekenhuis Antwerpen | |  | | | | ATC: | | |
|  | ***0748-473*** | ***1 flacon injectable 15 ml solution injectable, 1 dose*** | | ***1 injectieflacon 15 ml oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D9 **\*** | 0748-473 | 1 administration 15 mL solution injectable, 1 dose | | 1 toediening 15 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |
| Ri-D9 **\*\*** | 0748-484 | 1 administration 15 mL solution injectable, 1 dose | | 1 toediening 15 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| F-18-FLT (UCL) | | | UNIVERSITE CATHOLIQUE DE LOUVAIN UCL | |  | | | | ATC: | | |
|  | ***0747-456*** | ***1 solution injectable, 1 dose*** | | ***1 oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D9 **\*** | 0747-456 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |
| Ri-D9 **\*\*** | 0747-460 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| F-18-FLT (ULg) | | | UNIVERSITE DE LIEGE | |  | | | | ATC: | | |
|  | ***0747-611*** | ***1 solution injectable, 1 dose*** | | ***1 oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D9 **\*** | 0747-611 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |
| Ri-D9 **\*\*** | 0747-622 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| F-18-FLUOROCHOLINE (ULB) | | | Université Libre de Bruxelles | |  | | | | ATC: | | |
|  | ***0747-051*** | ***1 solution injectable, 1 dose*** | | ***1 oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D9 **\*** | 0747-051 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |
| Ri-D9 **\*\*** | 0747-062 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| F-18-FLUORODOPA (ULg) | | | UNIVERSITE DE LIEGE | |  | | | | ATC: V09IX05 | | |
|  | ***0747-331*** | ***1 solution injectable, 1 dose*** | | ***1 oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D9 **\*** | 0747-331 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |
| Ri-D9 **\*\*** | 0747-342 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| F-18-FLUORURE (ULB) | | | Université Libre de Bruxelles | |  | | | | ATC: V09IX06 | | |
|  | ***0747-294*** | ***1 solution injectable, 1 dose*** | | ***1 oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D9 **\*** | 0747-294 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |
| Ri-D9 **\*\*** | 0747-305 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| F-18-FMISO (ULg) | | | UNIVERSITE DE LIEGE | |  | | | | ATC: | | |
|  | ***0747-272*** | ***1 solution injectable, 1 dose*** | | ***1 oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D9 **\*** | 0747-272 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |
| Ri-D9 **\*\*** | 0747-283 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| F-18-NAF (ULg) | | | UNIVERSITE DE LIEGE | |  | | | | ATC: V09IX06 | | |
|  | ***0747-375*** | ***1 solution injectable, 1 dose*** | | ***1 oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D9 **\*** | 0747-375 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |
| Ri-D9 **\*\*** | 0747-386 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| F-18-NAV-4694 (UZ Leuven) | | | Katholieke Universiteit te Leuven | |  | | | | ATC: | | |
|  | ***0749-453*** | ***1 solution injectable, 1 dose*** | | ***1 oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D9 **\*** | 0749-453 | 1 administration, 1 dose | | 1 toediening, 1 dosis | |  |  | 60,0000 | |  |  |
| Ri-D9 **\*\*** | 0749-464 | 1 administration, 1 dose | | 1 toediening, 1 dosis | |  |  | 60,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| F-18-PSMA-1007 (UZ-KU LEUVEN) | | | Katholieke Universiteit te Leuven | |  | | | | ATC: | | |
|  | ***0748-930*** | ***1 doses solution injectable, 1 dose*** | | ***1 doses oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D9 **\*** | 0748-930 | 1 administration, 1 dose | | 1 toediening, 1 dosis | |  |  | 60,0000 | |  |  |
| Ri-D9 **\*\*** | 0748-941 | 1 administration, 1 dose | | 1 toediening, 1 dosis | |  |  | 60,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| F-18-PSMA-1007 (UZA) | | | Universitair Ziekenhuis Antwerpen | |  | | | | ATC: | | |
|  | ***0749-210*** | ***1 doses solution injectable, 1 dose*** | | ***1 doses oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D9 **\*** | 0749-210 | 1 administration, 1 dose | | 1 toediening, 1 dosis | |  |  | 60,0000 | |  |  |
| Ri-D9 **\*\*** | 0749-221 | 1 administration, 1 dose | | 1 toediening, 1 dosis | |  |  | 60,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| F-18-PSMA-11 (UZ GENT) | | | Universitair Ziekenhuis Gent | |  | | | | ATC: | | |
|  | ***0749-313*** | ***1 doses solution injectable, 1 dose*** | | ***1 doses oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D9 **\*** | 0749-313 | 1 administration, 1 dose | | 1 toediening, 1 dosis | |  |  | 60,0000 | |  |  |
| Ri-D9 **\*\*** | 0749-324 | 1 administration, 1 dose | | 1 toediening, 1 dosis | |  |  | 60,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| F-18-PSMA-7 (UZ BRUSSEL) | | | Vrije Universiteit Brussel | |  | | | | ATC: V09IX04 | | |
|  | ***0749-792*** | ***1 doses solution injectable, 1 dose*** | | ***1 doses oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D9 **\*** | 0749-792 | 1 administration, 1 dose | | 1 toediening, 1 dosis | |  |  | 60,0000 | |  |  |
| Ri-D9 **\*\*** | 0749-803 | 1 administration, 1 dose | | 1 toediening, 1 dosis | |  |  | 60,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| F-18-TYROSINE (ULg) | | | UNIVERSITE DE LIEGE | |  | | | | ATC: | | |
|  | ***0747-353*** | ***1 solution injectable, 1 dose*** | | ***1 oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D9 **\*** | 0747-353 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |
| Ri-D9 **\*\*** | 0747-364 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| FLUDESOXYGLUCOSE (18F) IBA 185 Mbq/ml | | | IBA PHARMA | |  | | | | ATC: V09IX04 | | |
|  | ***0747-574*** | ***1 flacon injectable 10 ml solution injectable, 1850 MBq*** | | ***1 injectieflacon 10 ml oplossing voor injectie, 1850 MBq*** | |  |  |  | |  |  |
| Ri-D9 **\*** | 0747-574 | 1 administration 10 mL solution injectable, 1850 MBq | | 1 toediening 10 mL oplossing voor injectie, 1850 MBq | |  |  | 60,0000 | |  |  |
| Ri-D9 **\*\*** | 0747-585 | 1 administration 10 mL solution injectable, 1850 MBq | | 1 toediening 10 mL oplossing voor injectie, 1850 MBq | |  |  | 60,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| FLUORODOPA (18F) CIS BIO INTERNATIONAL 90 MBq/ml | | | CIS BIO INTERNATIONAL SAS | |  | | | | ATC: V09IX05 | | |
|  | ***0746-476*** | ***1 solution injectable, 200 MBq*** | | ***1 oplossing voor injectie, 200 MBq*** | |  | ***731,26*** |  | |  |  |
| Ri-D9 **\*** | 0746-476 | 1 administration 1 mL solution injectable, 200 MBq | | 1 toediening 1 mL oplossing voor injectie, 200 MBq | |  |  | 60,0000 | |  |  |
| Ri-D9 **\*\*** | 0746-480 | 1 administration 1 mL solution injectable, 200 MBq | | 1 toediening 1 mL oplossing voor injectie, 200 MBq | |  |  | 60,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| FLUORODOPA (18F) CIS BIO INTERNATIONAL 90 MBq/ml | | | CIS BIO INTERNATIONAL SAS | |  | | | | ATC: V09IX05 | | |
|  | ***0746-476*** | ***1 solution injectable, 400 MBq*** | | ***1 oplossing voor injectie, 400 MBq*** | |  | ***1336,21*** |  | |  |  |
| Ri-D9 **\*** | 0746-476 | 1 administration 1 mL solution injectable, 400 MBq | | 1 toediening 1 mL oplossing voor injectie, 400 MBq | |  |  | 60,0000 | |  |  |
| Ri-D9 **\*\*** | 0746-480 | 1 administration 1 mL solution injectable, 400 MBq | | 1 toediening 1 mL oplossing voor injectie, 400 MBq | |  |  | 60,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| GA-68 DOTATATE (UZ GENT) | | | Universitair Ziekenhuis Gent | |  | | | | ATC: | | |
|  | ***0749-873*** | ***1 doses solution injectable, 1 dose*** | | ***1 doses oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D9 **\*** | 0749-873 | 1 administration, 1 dose | | 1 toediening, 1 dosis | |  |  | 60,0000 | |  |  |
| Ri-D9 **\*\*** | 0749-884 | 1 administration, 1 dose | | 1 toediening, 1 dosis | |  |  | 60,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| GA-68-DOTANOC | | | Katholieke Universiteit te Leuven | |  | | | | ATC: | | |
|  | ***0748-090*** | ***1 flacon injectable 16 ml solution injectable, 1 dose*** | | ***1 injectieflacon 16 ml oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D9 **\*** | 0748-090 | 1 administration 16 mL solution injectable, 1 dose | | 1 toediening 16 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |
| Ri-D9 **\*\*** | 0748-101 | 1 administration 16 mL solution injectable, 1 dose | | 1 toediening 16 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| GA-68-DOTANOC (CHU DE LIEGE) | | | CHU DE LIEGE | |  | | | | ATC: | | |
|  | ***0747-950*** | ***1 flacon injectable 8 ml solution injectable, 1 dose*** | | ***1 injectieflacon 8 ml oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D9 **\*** | 0747-950 | 1 administration 8 mL solution injectable, 1 dose | | 1 toediening 8 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |
| Ri-D9 **\*\*** | 0747-961 | 1 administration 8 mL solution injectable, 1 dose | | 1 toediening 8 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| GA-68-DOTANOC (UZ BRUSSEL) | | | Vrije Universiteit Brussel | |  | | | | ATC: | | |
|  | ***0748-834*** | ***1 flacon injectable 8 mL solution injectable, 1 dose*** | | ***1 injectieflacon 8 mL oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D9 **\*** | 0748-834 | 1 administration 8 mL solution injectable, 1 dose | | 1 toediening 8 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |
| Ri-D9 **\*\*** | 0748-845 | 1 administration 8 mL solution injectable, 1 dose | | 1 toediening 8 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| GA-68-DOTANOC (UZA) | | | Universitair Ziekenhuis Antwerpen | |  | | | | ATC: | | |
|  | ***0748-510*** | ***1 flacon injectable 15 ml solution injectable, 1 dose*** | | ***1 injectieflacon 15 ml oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D9 **\*** | 0748-510 | 1 administration 15 mL solution injectable, 1 dose | | 1 toediening 15 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |
| Ri-D9 **\*\*** | 0748-521 | 1 administration 15 mL solution injectable, 1 dose | | 1 toediening 15 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| GA-68-DOTATATE | | | Katholieke Universiteit te Leuven | |  | | | | ATC: | | |
|  | ***0748-171*** | ***1 flacon injectable 15 ml solution injectable, 1 dose*** | | ***1 injectieflacon 15 ml oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D9 **\*** | 0748-171 | 1 administration 15 mL solution injectable, 1 dose | | 1 toediening 15 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |
| Ri-D9 **\*\*** | 0748-182 | 1 administration 15 mL solution injectable, 1 dose | | 1 toediening 15 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| GA-68-DOTATATE | | | Association hospitalière de Bruxelles-Centre hospitalier Universitaire Jules Bordet | |  | | | | ATC: | | |
|  | ***0748-252*** | ***1 flacon injectable 15 ml solution injectable, 1 dose*** | | ***1 injectieflacon 15 ml oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D9 **\*** | 0748-252 | 1 administration 15 mL solution injectable, 1 dose | | 1 toediening 15 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |
| Ri-D9 **\*\*** | 0748-263 | 1 administration 15 mL solution injectable, 1 dose | | 1 toediening 15 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| GA-68-DOTATATE (AZ GROENINGE KORTRIJK) | | | Algemeen Ziekenhuis Groeninge | |  | | | | ATC: | | |
|  | ***0748-716*** | ***1 flacon injectable 10 mL solution injectable, 1 dose*** | | ***1 injectieflacon 10 mL oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D9 **\*** | 0748-716 | 1 administration 10 mL solution injectable, 1 dose | | 1 toediening 10 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |
| Ri-D9 **\*\*** | 0748-720 | 1 administration 10 mL solution injectable, 1 dose | | 1 toediening 10 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| GA-68-DOTATATE (CHU DE LIEGE) | | | CHU DE LIEGE | |  | | | | ATC: | | |
|  | ***0747-994*** | ***1 flacon injectable 8 ml solution injectable, 1 dose*** | | ***1 injectieflacon 8 ml oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D9 **\*** | 0747-994 | 1 administration 8 mL solution injectable, 1 dose | | 1 toediening 8 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |
| Ri-D9 **\*\*** | 0748-005 | 1 administration 8 mL solution injectable, 1 dose | | 1 toediening 8 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| GA-68-DOTATATE (UCL) | | | UNIVERSITE CATHOLIQUE DE LOUVAIN UCL | |  | | | | ATC: | | |
|  | ***0748-436*** | ***1 flacon injectable 15 ml solution injectable, 1 dose*** | | ***1 injectieflacon 15 ml oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D9 **\*** | 0748-436 | 1 administration 15 mL solution injectable, 1 dose | | 1 toediening 15 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |
| Ri-D9 **\*\*** | 0748-440 | 1 administration 15 mL solution injectable, 1 dose | | 1 toediening 15 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| GA-68-PSMA-HBED-CC | | | Katholieke Universiteit te Leuven | |  | | | | ATC: | | |
|  | ***0748-215*** | ***1 flacon injectable 15 ml solution injectable, 1 dose*** | | ***1 injectieflacon 15 ml oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D9 **\*** | 0748-215 | 1 administration 15 mL solution injectable, 1 dose | | 1 toediening 15 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |
| Ri-D9 **\*\*** | 0748-226 | 1 administration 15 mL solution injectable, 1 dose | | 1 toediening 15 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| GA-68-PSMA-HBED-CC (AZ GROENINGE KORTRIJK) | | | Algemeen Ziekenhuis Groeninge | |  | | | | ATC: | | |
|  | ***0748-650*** | ***1 flacon injectable 10 mL solution injectable, 1 dose*** | | ***1 injectieflacon 10 mL oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D9 **\*** | 0748-650 | 1 administration 10 mL solution injectable, 1 dose | | 1 toediening 10 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |
| Ri-D9 **\*\*** | 0748-661 | 1 administration 10 mL solution injectable, 1 dose | | 1 toediening 10 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| GA-68-PSMA-HBED-CC (BORDET) | | | Association hospitalière de Bruxelles-Centre hospitalier Universitaire Jules Bordet | |  | | | | ATC: | | |
|  | ***0748-370*** | ***1 flacon injectable 20 ml solution injectable, 1 dose*** | | ***1 injectieflacon 20 ml oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D9 **\*** | 0748-370 | 1 administration 20 mL solution injectable, 1 dose | | 1 toediening 20 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |
| Ri-D9 **\*\*** | 0748-381 | 1 administration 20 mL solution injectable, 1 dose | | 1 toediening 20 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| GA-68-PSMA-HBED-CC (CHR NAMUR) | | | CHR NAMUR | |  | | | | ATC: | | |
|  | ***0749-114*** | ***1 flacon injectable 20 mL solution injectable, 1 dose*** | | ***1 injectieflacon 20 mL oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D9 **\*** | 0749-114 | 1 administration 20 mL solution injectable, 1 dose | | 1 toediening 20 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |
| Ri-D9 **\*\*** | 0749-125 | 1 administration 20 mL solution injectable, 1 dose | | 1 toediening 20 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| GA-68-PSMA-HBED-CC (CHU DE LIEGE) | | | CHU DE LIEGE | |  | | | | ATC: | | |
|  | ***0748-053*** | ***1 flacon injectable 8 ml solution injectable, 8 ml*** | | ***1 injectieflacon 8 ml oplossing voor injectie, 8 ml*** | |  |  |  | |  |  |
| Ri-D9 **\*** | 0748-053 | 1 administration 8 mL solution injectable, 1 dose | | 1 toediening 8 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |
| Ri-D9 **\*\*** | 0748-064 | 1 administration 8 mL solution injectable, 1 dose | | 1 toediening 8 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| GA-68-PSMA-HBED-CC (GRAND HOPITAL DE CHARLEROI) | | | GRAND HOPITAL DE CHARLEROI (GHdC) | |  | | | | ATC: | | |
|  | ***0748-974*** | ***1 solution injectable, 1 dose*** | | ***1 oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D9 **\*** | 0748-974 | 1 administration, 1 dose | | 1 toediening, 1 dosis | |  |  | 60,0000 | |  |  |
| Ri-D9 **\*\*** | 0748-985 | 1 administration, 1 dose | | 1 toediening, 1 dosis | |  |  | 60,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| GA-68-PSMA-HBED-CC (UCL) | | | UNIVERSITE CATHOLIQUE DE LOUVAIN UCL | |  | | | | ATC: | | |
|  | ***0748-296*** | ***1 flacon injectable 20 ml solution injectable, 1 dose*** | | ***1 injectieflacon 20 ml oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D9 **\*** | 0748-296 | 1 administration 20 mL solution injectable, 1 dose | | 1 toediening 20 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |
| Ri-D9 **\*\*** | 0748-300 | 1 administration 20 mL solution injectable, 1 dose | | 1 toediening 20 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| GA-68-PSMA-HBED-CC (UZ BRUSSEL) | | | Vrije Universiteit Brussel | |  | | | | ATC: | | |
|  | ***0748-790*** | ***1 flacon injectable 8 mL solution injectable, 1 dose*** | | ***1 injectieflacon 8 mL oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D9 **\*** | 0748-790 | 1 administration 8 mL solution injectable, 1 dose | | 1 toediening 8 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |
| Ri-D9 **\*\*** | 0748-801 | 1 administration 8 mL solution injectable, 1 dose | | 1 toediening 8 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| GA-68-PSMA-HBED-CC (UZ GENT) | | | Universitair Ziekenhuis Gent | |  | | | | ATC: | | |
|  | ***0749-276*** | ***1 solution injectable, 1 dose*** | | ***1 oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D9 **\*** | 0749-276 | 1 administration, 1 dose | | 1 toediening, 1 dosis | |  |  | 60,0000 | |  |  |
| Ri-D9 **\*\*** | 0749-280 | 1 administration, 1 dose | | 1 toediening, 1 dosis | |  |  | 60,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| GA-68-PSMA-HBED-CC (UZA) | | | Universitair Ziekenhuis Antwerpen | |  | | | | ATC: | | |
|  | ***0748-333*** | ***1 flacon injectable 10 ml solution injectable, 1 dose*** | | ***1 injectieflacon 10 ml oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D9 **\*** | 0748-333 | 1 administration 10 mL solution injectable, 1 dose | | 1 toediening 10 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |
| Ri-D9 **\*\*** | 0748-344 | 1 administration 10 mL solution injectable, 1 dose | | 1 toediening 10 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| GLUCOGAST 1850 MBq/ml (UZ-KU LEUVEN) | | | Katholieke Universiteit te Leuven | |  | | | | ATC: V09IX04 | | |
|  | ***0747-574*** | ***1 flacon injectable 20 mL solution injectable, 1850 MBq/mL*** | | ***1 injectieflacon 20 mL oplossing voor injectie, 1850 MBq/mL*** | |  | ***205,00*** |  | |  |  |
| Ri-D9 **\*** | 0747-574 | 1 administration 20 mL solution injectable, 1850 MBq/mL | | 1 toediening 20 mL oplossing voor injectie, 1850 MBq/mL | |  |  | 60,0000 | |  |  |
| Ri-D9 **\*\*** | 0747-585 | 1 administration 20 mL solution injectable, 1850 MBq/mL | | 1 toediening 20 mL oplossing voor injectie, 1850 MBq/mL | |  |  | 60,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| GLUCOTRACE | | | NUCLEIS SA | |  | | | | ATC: V09IX04 | | |
|  | ***0747-191*** | ***1 solution injectable, 185 MBq*** | | ***1 oplossing voor injectie, 185 MBq*** | |  | ***205,00*** |  | |  |  |
| Ri-D9 **\*** | 0747-191 | 1 administration 1 mL solution injectable, 185 MBq | | 1 toediening 1 mL oplossing voor injectie, 185 MBq | |  |  | 60,0000 | |  |  |
| Ri-D9 **\*\*** | 0747-202 | 1 administration 1 mL solution injectable, 185 MBq | | 1 toediening 1 mL oplossing voor injectie, 185 MBq | |  |  | 60,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| N-13-NH3 (ULB) | | | Université Libre de Bruxelles | |  | | | | ATC: | | |
|  | ***0747-530*** | ***1 solution injectable, 1 dose*** | | ***1 oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D9 **\*** | 0747-530 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |
| Ri-D9 **\*\*** | 0747-541 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| O-15-EAU (ULB) | | | Université Libre de Bruxelles | |  | | | | ATC: | | |
|  | ***0747-434*** | ***1 solution injectable, 1 dose*** | | ***1 oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D9 **\*** | 0747-434 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |
| Ri-D9 **\*\*** | 0747-445 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| O-15-WATER (UZ LEUVEN) | | | Katholieke Universiteit te Leuven | |  | | | | ATC: | | |
|  | ***0747-891*** | ***1 solution injectable, 1 dose*** | | ***1 oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D9 **\*** | 0747-891 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |
| Ri-D9 **\*\*** | 0747-902 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  | 60,0000 | |  |  |
|  |  |  | |  | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | | |  | | | | | |
| **Paragraphe 10003** | | | | **Paragraaf 10003** | | | | | |
| Produits radio-pharmaceutiques à base de technetium (Tc-99m) pertechnétate - catégorie de remboursement Ri-D5 | | | | Radiofarmaceutische producten op basis van technetium (Tc-99m) pertechnetaat - vergoedingscategorie Ri-D5 | | | | | |
|  | | | |  | | | | | |
| Dénomination / Benaming (Demandeur/Aanvrager) | | | | | | | | | |
| Cat. | Code | Conditionnements | Verpakkingen | | Obs  Opm | Prix  Prijs  ***ex-usine / buiten bedrijf*** | Base de remb  Basis v tegem  ***ex-usine / buiten bedrijf*** | I | II |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| TEKCIS | | | CIS BIO INTERNATIONAL SAS | |  | | | | ATC: V09FX01 | | |
|  | ***0745-231*** | ***1 container 1 générateur de radionuclide, 2 GBq*** | | ***1 container 1 radionuclide generator, 2 GBq*** | |  | ***608,00*** |  | |  |  |
| Ri-D5 **\*** | 0745-231 | 1 administration 1 mL solution injectable, 2 GBq | | 1 toediening 1 mL oplossing voor injectie, 2 GBq | |  |  | 18,5900 | |  |  |
| Ri-D5 **\*\*** | 0745-242 | 1 administration 1 mL solution injectable, 2 GBq | | 1 toediening 1 mL oplossing voor injectie, 2 GBq | |  |  | 18,5900 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| TEKCIS | | | CIS BIO INTERNATIONAL SAS | |  | | | | ATC: V09FX01 | | |
|  | ***0745-231*** | ***1 container 1 générateur de radionuclide, 12 GBq*** | | ***1 container 1 radionuclide generator, 12 GBq*** | |  | ***1225,00*** |  | |  |  |
| Ri-D5 **\*** | 0745-231 | 1 administration 1 mL solution injectable, 12 GBq | | 1 toediening 1 mL oplossing voor injectie, 12 GBq | |  |  | 18,5900 | |  |  |
| Ri-D5 **\*\*** | 0745-242 | 1 administration 1 mL solution injectable, 12 GBq | | 1 toediening 1 mL oplossing voor injectie, 12 GBq | |  |  | 18,5900 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| TEKCIS | | | CIS BIO INTERNATIONAL SAS | |  | | | | ATC: V09FX01 | | |
|  | ***0745-231*** | ***1 container 1 générateur de radionuclide, 16 GBq*** | | ***1 container 1 radionuclide generator, 16 GBq*** | |  | ***1480,00*** |  | |  |  |
| Ri-D5 **\*** | 0745-231 | 1 administration 1 mL solution injectable, 16 GBq | | 1 toediening 1 mL oplossing voor injectie, 16 GBq | |  |  | 18,5900 | |  |  |
| Ri-D5 **\*\*** | 0745-242 | 1 administration 1 mL solution injectable, 16 GBq | | 1 toediening 1 mL oplossing voor injectie, 16 GBq | |  |  | 18,5900 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| TEKCIS | | | CIS BIO INTERNATIONAL SAS | |  | | | | ATC: V09FX01 | | |
|  | ***0745-231*** | ***1 container 1 générateur de radionuclide, 20 GBq*** | | ***1 container 1 radionuclide generator, 20 GBq*** | |  | ***1620,00*** |  | |  |  |
| Ri-D5 **\*** | 0745-231 | 1 administration 1 mL solution injectable, 20 GBq | | 1 toediening 1 mL oplossing voor injectie, 20 GBq | |  |  | 18,5900 | |  |  |
| Ri-D5 **\*\*** | 0745-242 | 1 administration 1 mL solution injectable, 20 GBq | | 1 toediening 1 mL oplossing voor injectie, 20 GBq | |  |  | 18,5900 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| TEKCIS | | | CIS BIO INTERNATIONAL SAS | |  | | | | ATC: V09FX01 | | |
|  | ***0745-231*** | ***1 container 1 générateur de radionuclide, 6 GBq*** | | ***1 container 1 radionuclide generator, 6 GBq*** | |  | ***789,00*** |  | |  |  |
| Ri-D5 **\*** | 0745-231 | 1 administration 1 mL solution injectable, 6 GBq | | 1 toediening 1 mL oplossing voor injectie, 6 GBq | |  |  | 18,5900 | |  |  |
| Ri-D5 **\*\*** | 0745-242 | 1 administration 1 mL solution injectable, 6 GBq | | 1 toediening 1 mL oplossing voor injectie, 6 GBq | |  |  | 18,5900 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| TEKCIS | | | CIS BIO INTERNATIONAL SAS | |  | | | | ATC: V09FX01 | | |
|  | ***0745-231*** | ***1 container 1 générateur de radionuclide, 8 GBq*** | | ***1 container 1 radionuclide generator, 8 GBq*** | |  | ***905,00*** |  | |  |  |
| Ri-D5 **\*** | 0745-231 | 1 administration 1 mL solution injectable, 8 GBq | | 1 toediening 1 mL oplossing voor injectie, 8 GBq | |  |  | 18,5900 | |  |  |
| Ri-D5 **\*\*** | 0745-242 | 1 administration 1 mL solution injectable, 8 GBq | | 1 toediening 1 mL oplossing voor injectie, 8 GBq | |  |  | 18,5900 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| TEKCIS | | | CIS BIO INTERNATIONAL SAS | |  | | | | ATC: V09FX01 | | |
|  | ***0745-231*** | ***1 container 1 générateur de radionuclide, 4 GBq*** | | ***1 container 1 radionuclide generator, 4 GBq*** | |  | ***702,00*** |  | |  |  |
| Ri-D5 **\*** | 0745-231 | 1 administration 1 mL solution injectable, 4 GBq | | 1 toediening 1 mL oplossing voor injectie, 4 GBq | |  |  | 18,5900 | |  |  |
| Ri-D5 **\*\*** | 0745-242 | 1 administration 1 mL solution injectable, 4 GBq | | 1 toediening 1 mL oplossing voor injectie, 4 GBq | |  |  | 18,5900 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| TEKCIS | | | CIS BIO INTERNATIONAL SAS | |  | | | | ATC: V09FX01 | | |
|  | ***0745-231*** | ***1 container 1 générateur de radionuclide, 10 GBq*** | | ***1 container 1 radionuclide generator, 10 GBq*** | |  | ***1013,00*** |  | |  |  |
| Ri-D5 **\*** | 0745-231 | 1 administration 1 mL solution injectable, 10 GBq | | 1 toediening 1 mL oplossing voor injectie, 10 GBq | |  |  | 18,5900 | |  |  |
| Ri-D5 **\*\*** | 0745-242 | 1 administration 1 mL solution injectable, 10 GBq | | 1 toediening 1 mL oplossing voor injectie, 10 GBq | |  |  | 18,5900 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ULTRATECHNEKOW FM | | | CURIUM BELGIUM BV | |  | | | | ATC: V09FX01 | | |
|  | ***0745-231*** | ***1 container 1 générateur de radionuclide, 34,4 GBq*** | | ***1 container 1 radionuclide generator, 34,4 GBq*** | |  | ***2510,00*** |  | |  |  |
| Ri-D5 **\*** | 0745-231 | 1 administration 1 mL solution injectable, 34,4 GBq | | 1 toediening 1 mL oplossing voor injectie, 34,4 GBq | |  |  | 18,5900 | |  |  |
| Ri-D5 **\*\*** | 0745-242 | 1 administration 1 mL solution injectable, 34,4 GBq | | 1 toediening 1 mL oplossing voor injectie, 34,4 GBq | |  |  | 18,5900 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ULTRATECHNEKOW FM | | | CURIUM BELGIUM BV | |  | | | | ATC: V09FX01 | | |
|  | ***0745-231*** | ***1 container 1 générateur de radionuclide, 2,15 GBq*** | | ***1 container 1 radionuclide generator, 2,15 GBq*** | |  | ***710,00*** |  | |  |  |
| Ri-D5 **\*** | 0745-231 | 1 administration 1 mL solution injectable, 2,15 GBq | | 1 toediening 1 mL oplossing voor injectie, 2,15 GBq | |  |  | 18,5900 | |  |  |
| Ri-D5 **\*\*** | 0745-242 | 1 administration 1 mL solution injectable, 2,15 GBq | | 1 toediening 1 mL oplossing voor injectie, 2,15 GBq | |  |  | 18,5900 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ULTRATECHNEKOW FM | | | CURIUM BELGIUM BV | |  | | | | ATC: V09FX01 | | |
|  | ***0745-231*** | ***1 container 1 générateur de radionuclide, 4,3 GBq*** | | ***1 container 1 radionuclide generator, 4,3 GBq*** | |  | ***830,00*** |  | |  |  |
| Ri-D5 **\*** | 0745-231 | 1 administration 1 mL solution injectable, 4,3 GBq | | 1 toediening 1 mL oplossing voor injectie, 4,3 GBq | |  |  | 18,5900 | |  |  |
| Ri-D5 **\*\*** | 0745-242 | 1 administration 1 mL solution injectable, 4,3 GBq | | 1 toediening 1 mL oplossing voor injectie, 4,3 GBq | |  |  | 18,5900 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ULTRATECHNEKOW FM | | | CURIUM BELGIUM BV | |  | | | | ATC: V09FX01 | | |
|  | ***0745-231*** | ***1 container 1 générateur de radionuclide, 43 GBq*** | | ***1 container 1 radionuclide generator, 43 GBq*** | |  | ***2990,00*** |  | |  |  |
| Ri-D5 **\*** | 0745-231 | 1 administration 1 mL solution injectable, 43 GBq | | 1 toediening 1 mL oplossing voor injectie, 43 GBq | |  |  | 18,5900 | |  |  |
| Ri-D5 **\*\*** | 0745-242 | 1 administration 1 mL solution injectable, 43 GBq | | 1 toediening 1 mL oplossing voor injectie, 43 GBq | |  |  | 18,5900 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ULTRATECHNEKOW FM | | | CURIUM BELGIUM BV | |  | | | | ATC: V09FX01 | | |
|  | ***0745-231*** | ***1 container 1 générateur de radionuclide, 17,2 GBq*** | | ***1 container 1 radionuclide generator, 17,2 GBq*** | |  | ***1550,00*** |  | |  |  |
| Ri-D5 **\*** | 0745-231 | 1 administration 1 mL solution injectable, 17,2 GBq | | 1 toediening 1 mL oplossing voor injectie, 17,2 GBq | |  |  | 18,5900 | |  |  |
| Ri-D5 **\*\*** | 0745-242 | 1 administration 1 mL solution injectable, 17,2 GBq | | 1 toediening 1 mL oplossing voor injectie, 17,2 GBq | |  |  | 18,5900 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ULTRATECHNEKOW FM | | | CURIUM BELGIUM BV | |  | | | | ATC: V09FX01 | | |
|  | ***0745-231*** | ***1 container 1 générateur de radionuclide, 12,9 GBq*** | | ***1 container 1 radionuclide generator, 12,9 GBq*** | |  | ***1310,00*** |  | |  |  |
| Ri-D5 **\*** | 0745-231 | 1 administration 1 mL solution injectable, 12,9 GBq | | 1 toediening 1 mL oplossing voor injectie, 12,9 GBq | |  |  | 18,5900 | |  |  |
| Ri-D5 **\*\*** | 0745-242 | 1 administration 1 mL solution injectable, 12,9 GBq | | 1 toediening 1 mL oplossing voor injectie, 12,9 GBq | |  |  | 18,5900 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ULTRATECHNEKOW FM | | | CURIUM BELGIUM BV | |  | | | | ATC: V09FX01 | | |
|  | ***0745-231*** | ***1 container 1 générateur de radionuclide, 21,5 GBq*** | | ***1 container 1 radionuclide generator, 21,5 GBq*** | |  | ***1790,00*** |  | |  |  |
| Ri-D5 **\*** | 0745-231 | 1 administration 1 mL solution injectable, 21,5 GBq | | 1 toediening 1 mL oplossing voor injectie, 21,5 GBq | |  |  | 18,5900 | |  |  |
| Ri-D5 **\*\*** | 0745-242 | 1 administration 1 mL solution injectable, 21,5 GBq | | 1 toediening 1 mL oplossing voor injectie, 21,5 GBq | |  |  | 18,5900 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ULTRATECHNEKOW FM | | | CURIUM BELGIUM BV | |  | | | | ATC: V09FX01 | | |
|  | ***0745-231*** | ***1 container 1 générateur de radionuclide, 25,8 GBq*** | | ***1 container 1 radionuclide generator, 25,8 GBq*** | |  | ***2030,00*** |  | |  |  |
| Ri-D5 **\*** | 0745-231 | 1 administration 1 mL solution injectable, 25,8 GBq | | 1 toediening 1 mL oplossing voor injectie, 25,8 GBq | |  |  | 18,5900 | |  |  |
| Ri-D5 **\*\*** | 0745-242 | 1 administration 1 mL solution injectable, 25,8 GBq | | 1 toediening 1 mL oplossing voor injectie, 25,8 GBq | |  |  | 18,5900 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ULTRATECHNEKOW FM | | | CURIUM BELGIUM BV | |  | | | | ATC: V09FX01 | | |
|  | ***0745-231*** | ***1 container 1 générateur de radionuclide, 30,1 GBq*** | | ***1 container 1 radionuclide generator, 30,1 GBq*** | |  | ***2270,00*** |  | |  |  |
| Ri-D5 **\*** | 0745-231 | 1 administration 1 mL solution injectable, 30,1 GBq | | 1 toediening 1 mL oplossing voor injectie, 30,1 GBq | |  |  | 18,5900 | |  |  |
| Ri-D5 **\*\*** | 0745-242 | 1 administration 1 mL solution injectable, 30,1 GBq | | 1 toediening 1 mL oplossing voor injectie, 30,1 GBq | |  |  | 18,5900 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ULTRATECHNEKOW FM | | | CURIUM BELGIUM BV | |  | | | | ATC: V09FX01 | | |
|  | ***0745-231*** | ***1 container 1 générateur de radionuclide, 10,75 GBq*** | | ***1 container 1 radionuclide generator, 10,75 GBq*** | |  | ***1190,00*** |  | |  |  |
| Ri-D5 **\*** | 0745-231 | 1 administration 1 mL solution injectable, 10,75 GBq | | 1 toediening 1 mL oplossing voor injectie, 10,75 GBq | |  |  | 18,5900 | |  |  |
| Ri-D5 **\*\*** | 0745-242 | 1 administration 1 mL solution injectable, 10,75 GBq | | 1 toediening 1 mL oplossing voor injectie, 10,75 GBq | |  |  | 18,5900 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ULTRATECHNEKOW FM | | | CURIUM BELGIUM BV | |  | | | | ATC: V09FX01 | | |
|  | ***0745-231*** | ***1 container 1 générateur de radionuclide, 6,45 GBq*** | | ***1 container 1 radionuclide generator, 6,45 GBq*** | |  | ***950,00*** |  | |  |  |
| Ri-D5 **\*** | 0745-231 | 1 administration 1 mL solution injectable, 6,45 GBq | | 1 toediening 1 mL oplossing voor injectie, 6,45 GBq | |  |  | 18,5900 | |  |  |
| Ri-D5 **\*\*** | 0745-242 | 1 administration 1 mL solution injectable, 6,45 GBq | | 1 toediening 1 mL oplossing voor injectie, 6,45 GBq | |  |  | 18,5900 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ULTRATECHNEKOW FM | | | CURIUM BELGIUM BV | |  | | | | ATC: V09FX01 | | |
|  | ***0745-231*** | ***1 container 1 générateur de radionuclide, 8,6 GBq*** | | ***1 container 1 radionuclide generator, 8,6 GBq*** | |  | ***1070,00*** |  | |  |  |
| Ri-D5 **\*** | 0745-231 | 1 administration 1 mL solution injectable, 8,6 GBq | | 1 toediening 1 mL oplossing voor injectie, 8,6 GBq | |  |  | 18,5900 | |  |  |
| Ri-D5 **\*\*** | 0745-242 | 1 administration 1 mL solution injectable, 8,6 GBq | | 1 toediening 1 mL oplossing voor injectie, 8,6 GBq | |  |  | 18,5900 | |  |  |
|  |  |  | |  | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | | |  | | | | | |
| **Paragraphe 10004** | | | | **Paragraaf 10004** | | | | | |
| Produits radio-pharmaceutiques à base de pentétate d'indium (In-111) - catégorie de remboursement Ri-D7 - domaine d’application diagnostique: neuro | | | | Radiofarmaceutische producten op basis van indium (In-111) pentetaat - vergoedingscategorie Ri-D7 – toepassingsgebied diagnostiek: neuro | | | | | |
|  | | | |  | | | | | |
| Dénomination / Benaming (Demandeur/Aanvrager) | | | | | | | | | |
| Cat. | Code | Conditionnements | Verpakkingen | | Obs  Opm | Prix  Prijs  ***ex-usine / buiten bedrijf*** | Base de remb  Basis v tegem  ***ex-usine / buiten bedrijf*** | I | II |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| INDIUM (IN-111) DTPA CURIUM 37 MBq/ml | | | CURIUM BELGIUM BV | |  | | | | ATC: V09AX01 | | |
|  | ***0745-253*** | ***1 flacon injectable 1 ml solution injectable, 37 MBq*** | | ***1 injectieflacon 1 ml oplossing voor injectie, 37 MBq*** | |  | ***448,50*** |  | |  |  |
| Ri-D7 **\*** | 0745-253 | 1 administration 1 mL solution injectable, 37 MBq | | 1 toediening 1 mL oplossing voor injectie, 37 MBq | |  |  | 70,0000 | |  |  |
| Ri-D7 **\*\*** | 0745-264 | 1 administration 1 mL solution injectable, 37 MBq | | 1 toediening 1 mL oplossing voor injectie, 37 MBq | |  |  | 70,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| INDIUM (IN-111) DTPA CURIUM 37 MBq/ml | | | CURIUM BELGIUM BV | |  | | | | ATC: V09AX01 | | |
|  | ***0745-253*** | ***1 flacon injectable 0,5 ml solution injectable, 18,5 MBq*** | | ***1 injectieflacon 0,5 ml oplossing voor injectie, 18,5 MBq*** | |  | ***348,75*** |  | |  |  |
| Ri-D7 **\*** | 0745-253 | 1 administration 0,5 mL solution injectable, 18,5 MBq | | 1 toediening 0,5 mL oplossing voor injectie, 18,5 MBq | |  |  | 70,0000 | |  |  |
| Ri-D7 **\*\*** | 0745-264 | 1 administration 0,5 mL solution injectable, 18,5 MBq | | 1 toediening 0,5 mL oplossing voor injectie, 18,5 MBq | |  |  | 70,0000 | |  |  |
|  |  |  | |  | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | | |  | | | | | |
| **Paragraphe 10005** | | | | **Paragraaf 10005** | | | | | |
| Produits radio-pharmaceutiques à base de pentétate d'indium (In-111) - catégorie de remboursement Ri-D7 - domaine d’application diagnostique: gastro-intestinal | | | | Radiofarmaceutische producten op basis van indium (In-111) pentetaat - vergoedingscategorie Ri-D7 – toepassingsgebied diagnostiek: gastro-intestinaal | | | | | |
|  | | | |  | | | | | |
| Dénomination / Benaming (Demandeur/Aanvrager) | | | | | | | | | |
| Cat. | Code | Conditionnements | Verpakkingen | | Obs  Opm | Prix  Prijs  ***ex-usine / buiten bedrijf*** | Base de remb  Basis v tegem  ***ex-usine / buiten bedrijf*** | I | II |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| INDIUM (IN-111) DTPA CURIUM 37 MBq/ml | | | CURIUM BELGIUM BV | |  | | | | ATC: V09AX01 | | |
|  | ***0745-275*** | ***1 flacon injectable 1 ml solution injectable, 37 MBq*** | | ***1 injectieflacon 1 ml oplossing voor injectie, 37 MBq*** | |  | ***448,50*** |  | |  |  |
| Ri-D7 **\*** | 0745-275 | 1 administration 1 mL solution injectable, 37 MBq | | 1 toediening 1 mL oplossing voor injectie, 37 MBq | |  |  | 70,0000 | |  |  |
| Ri-D7 **\*\*** | 0745-286 | 1 administration 1 mL solution injectable, 37 MBq | | 1 toediening 1 mL oplossing voor injectie, 37 MBq | |  |  | 70,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| INDIUM (IN-111) DTPA CURIUM 37 MBq/ml | | | CURIUM BELGIUM BV | |  | | | | ATC: V09AX01 | | |
|  | ***0745-275*** | ***1 flacon injectable 0,5 ml solution injectable, 18,5 MBq*** | | ***1 injectieflacon 0,5 ml oplossing voor injectie, 18,5 MBq*** | |  | ***348,75*** |  | |  |  |
| Ri-D7 **\*** | 0745-275 | 1 administration 0,5 mL solution injectable, 18,5 MBq | | 1 toediening 0,5 mL oplossing voor injectie, 18,5 MBq | |  |  | 70,0000 | |  |  |
| Ri-D7 **\*\*** | 0745-286 | 1 administration 0,5 mL solution injectable, 18,5 MBq | | 1 toediening 0,5 mL oplossing voor injectie, 18,5 MBq | |  |  | 70,0000 | |  |  |
|  |  |  | |  | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | | |  | | | | | |
| **Paragraphe 10006** | | | | **Paragraaf 10006** | | | | | |
| § 10006 est supprimé au 01/03/2024. | | | | § 10006 is geschrapt op 01/03/2024. | | | | | |
|  | | | |  | | | | | |
| **Paragraphe 10007** | | | | **Paragraaf 10007** | | | | | |
| Produits radio-pharmaceutiques à base de krypton (Kr-81m) gaz - catégorie de remboursement Ri-D5 - domaine d’application diagnostique: poumons | | | | Radiofarmaceutische producten op basis van krypton (Kr-81m) gas - vergoedingscategorie Ri-D5 – toepassingsgebied diagnostiek: longen | | | | | |
|  | | | |  | | | | | |
| Dénomination / Benaming (Demandeur/Aanvrager) | | | | | | | | | |
| Cat. | Code | Conditionnements | Verpakkingen | | Obs  Opm | Prix  Prijs  ***ex-usine / buiten bedrijf*** | Base de remb  Basis v tegem  ***ex-usine / buiten bedrijf*** | I | II |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| KRYPTOSCAN | | | CURIUM BELGIUM BV | |  | | | | ATC: V09EX01 | | |
|  | ***0745-312*** | ***1 container 1 générateur de radionuclide, 222 MBq*** | | ***1 container 1 radionuclide generator, 222 MBq*** | |  | ***765,87*** |  | |  |  |
| Ri-D5 **\*** | 0745-312 | 1 administration 1 gaz pour inhalation, 222 MBq | | 1 toediening 1 inhalatiegas, 222 MBq | |  |  | 18,5900 | |  |  |
| Ri-D5 **\*\*** | 0745-323 | 1 administration 1 gaz pour inhalation, 222 MBq | | 1 toediening 1 inhalatiegas, 222 MBq | |  |  | 18,5900 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| KRYPTOSCAN | | | CURIUM BELGIUM BV | |  | | | | ATC: V09EX01 | | |
|  | ***0745-312*** | ***1 container 1 générateur de radionuclide, 74 MBq*** | | ***1 container 1 radionuclide generator, 74 MBq*** | |  | ***560,94*** |  | |  |  |
| Ri-D5 **\*** | 0745-312 | 1 administration 1 gaz pour inhalation, 74 MBq | | 1 toediening 1 inhalatiegas, 74 MBq | |  |  | 18,5900 | |  |  |
| Ri-D5 **\*\*** | 0745-323 | 1 administration 1 gaz pour inhalation, 74 MBq | | 1 toediening 1 inhalatiegas, 74 MBq | |  |  | 18,5900 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| KRYPTOSCAN | | | CURIUM BELGIUM BV | |  | | | | ATC: V09EX01 | | |
|  | ***0745-312*** | ***1 container 1 générateur de radionuclide, 444 MBq*** | | ***1 container 1 radionuclide generator, 444 MBq*** | |  | ***1084,65*** |  | |  |  |
| Ri-D5 **\*** | 0745-312 | 1 administration 1 gaz pour inhalation, 444 MBq | | 1 toediening 1 inhalatiegas, 444 MBq | |  |  | 18,5900 | |  |  |
| Ri-D5 **\*\*** | 0745-323 | 1 administration 1 gaz pour inhalation, 444 MBq | | 1 toediening 1 inhalatiegas, 444 MBq | |  |  | 18,5900 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| KRYPTOSCAN | | | CURIUM BELGIUM BV | |  | | | | ATC: V09EX01 | | |
|  | ***0745-312*** | ***1 container 1 générateur de radionuclide, 111 MBq*** | | ***1 container 1 radionuclide generator, 111 MBq*** | |  | ***612,17*** |  | |  |  |
| Ri-D5 **\*** | 0745-312 | 1 administration 1 gaz pour inhalation, 111 MBq | | 1 toediening 1 inhalatiegas, 111 MBq | |  |  | 18,5900 | |  |  |
| Ri-D5 **\*\*** | 0745-323 | 1 administration 1 gaz pour inhalation, 111 MBq | | 1 toediening 1 inhalatiegas, 111 MBq | |  |  | 18,5900 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| KRYPTOSCAN | | | CURIUM BELGIUM BV | |  | | | | ATC: V09EX01 | | |
|  | ***0745-312*** | ***1 container 1 générateur de radionuclide, 148 MBq*** | | ***1 container 1 radionuclide generator, 148 MBq*** | |  | ***663,41*** |  | |  |  |
| Ri-D5 **\*** | 0745-312 | 1 administration 1 gaz pour inhalation, 148 MBq | | 1 toediening 1 inhalatiegas, 148 MBq | |  |  | 18,5900 | |  |  |
| Ri-D5 **\*\*** | 0745-323 | 1 administration 1 gaz pour inhalation, 148 MBq | | 1 toediening 1 inhalatiegas, 148 MBq | |  |  | 18,5900 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| KRYPTOSCAN | | | CURIUM BELGIUM BV | |  | | | | ATC: V09EX01 | | |
|  | ***0745-312*** | ***1 container 1 générateur de radionuclide, 629 MBq*** | | ***1 container 1 radionuclide generator, 629 MBq*** | |  | ***1346,51*** |  | |  |  |
| Ri-D5 **\*** | 0745-312 | 1 administration 1 gaz pour inhalation, 629 MBq | | 1 toediening 1 inhalatiegas, 629 MBq | |  |  | 18,5900 | |  |  |
| Ri-D5 **\*\*** | 0745-323 | 1 administration 1 gaz pour inhalation, 629 MBq | | 1 toediening 1 inhalatiegas, 629 MBq | |  |  | 18,5900 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| KRYPTOSCAN | | | CURIUM BELGIUM BV | |  | | | | ATC: V09EX01 | | |
|  | ***0745-312*** | ***1 container 1 générateur de radionuclide, 185 MBq*** | | ***1 container 1 radionuclide generator, 185 MBq*** | |  | ***714,64*** |  | |  |  |
| Ri-D5 **\*** | 0745-312 | 1 administration 1 gaz pour inhalation, 185 MBq | | 1 toediening 1 inhalatiegas, 185 MBq | |  |  | 18,5900 | |  |  |
| Ri-D5 **\*\*** | 0745-323 | 1 administration 1 gaz pour inhalation, 185 MBq | | 1 toediening 1 inhalatiegas, 185 MBq | |  |  | 18,5900 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| KRYPTOSCAN | | | CURIUM BELGIUM BV | |  | | | | ATC: V09EX01 | | |
|  | ***0745-312*** | ***1 container 1 générateur de radionuclide, 259 MBq*** | | ***1 container 1 radionuclide generator, 259 MBq*** | |  | ***822,80*** |  | |  |  |
| Ri-D5 **\*** | 0745-312 | 1 administration 1 gaz pour inhalation, 259 MBq | | 1 toediening 1 inhalatiegas, 259 MBq | |  |  | 18,5900 | |  |  |
| Ri-D5 **\*\*** | 0745-323 | 1 administration 1 gaz pour inhalation, 259 MBq | | 1 toediening 1 inhalatiegas, 259 MBq | |  |  | 18,5900 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| KRYPTOSCAN | | | CURIUM BELGIUM BV | |  | | | | ATC: V09EX01 | | |
|  | ***0745-312*** | ***1 container 1 générateur de radionuclide, 296 MBq*** | | ***1 container 1 radionuclide generator, 296 MBq*** | |  | ***874,03*** |  | |  |  |
| Ri-D5 **\*** | 0745-312 | 1 administration 1 gaz pour inhalation, 296 MBq | | 1 toediening 1 inhalatiegas, 296 MBq | |  |  | 18,5900 | |  |  |
| Ri-D5 **\*\*** | 0745-323 | 1 administration 1 gaz pour inhalation, 296 MBq | | 1 toediening 1 inhalatiegas, 296 MBq | |  |  | 18,5900 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| KRYPTOSCAN | | | CURIUM BELGIUM BV | |  | | | | ATC: V09EX01 | | |
|  | ***0745-312*** | ***1 container 1 générateur de radionuclide, 481 MBq*** | | ***1 container 1 radionuclide generator, 481 MBq*** | |  | ***1135,88*** |  | |  |  |
| Ri-D5 **\*** | 0745-312 | 1 administration 1 gaz pour inhalation, 481 MBq | | 1 toediening 1 inhalatiegas, 481 MBq | |  |  | 18,5900 | |  |  |
| Ri-D5 **\*\*** | 0745-323 | 1 administration 1 gaz pour inhalation, 481 MBq | | 1 toediening 1 inhalatiegas, 481 MBq | |  |  | 18,5900 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| KRYPTOSCAN | | | CURIUM BELGIUM BV | |  | | | | ATC: V09EX01 | | |
|  | ***0745-312*** | ***1 container 1 générateur de radionuclide, 555 MBq*** | | ***1 container 1 radionuclide generator, 555 MBq*** | |  | ***1238,35*** |  | |  |  |
| Ri-D5 **\*** | 0745-312 | 1 administration 1 gaz pour inhalation, 555 MBq | | 1 toediening 1 inhalatiegas, 555 MBq | |  |  | 18,5900 | |  |  |
| Ri-D5 **\*\*** | 0745-323 | 1 administration 1 gaz pour inhalation, 555 MBq | | 1 toediening 1 inhalatiegas, 555 MBq | |  |  | 18,5900 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| KRYPTOSCAN | | | CURIUM BELGIUM BV | |  | | | | ATC: V09EX01 | | |
|  | ***0745-312*** | ***1 container 1 générateur de radionuclide, 592 MBq*** | | ***1 container 1 radionuclide generator, 592 MBq*** | |  | ***1289,58*** |  | |  |  |
| Ri-D5 **\*** | 0745-312 | 1 administration 1 gaz pour inhalation, 592 MBq | | 1 toediening 1 inhalatiegas, 592 MBq | |  |  | 18,5900 | |  |  |
| Ri-D5 **\*\*** | 0745-323 | 1 administration 1 gaz pour inhalation, 592 MBq | | 1 toediening 1 inhalatiegas, 592 MBq | |  |  | 18,5900 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| KRYPTOSCAN | | | CURIUM BELGIUM BV | |  | | | | ATC: V09EX01 | | |
|  | ***0745-312*** | ***1 container 1 générateur de radionuclide, 333 MBq*** | | ***1 container 1 radionuclide generator, 333 MBq*** | |  | ***925,26*** |  | |  |  |
| Ri-D5 **\*** | 0745-312 | 1 administration 1 gaz pour inhalation, 333 MBq | | 1 toediening 1 inhalatiegas, 333 MBq | |  |  | 18,5900 | |  |  |
| Ri-D5 **\*\*** | 0745-323 | 1 administration 1 gaz pour inhalation, 333 MBq | | 1 toediening 1 inhalatiegas, 333 MBq | |  |  | 18,5900 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| KRYPTOSCAN | | | CURIUM BELGIUM BV | |  | | | | ATC: V09EX01 | | |
|  | ***0745-312*** | ***1 container 1 générateur de radionuclide, 370 MBq*** | | ***1 container 1 radionuclide generator, 370 MBq*** | |  | ***976,49*** |  | |  |  |
| Ri-D5 **\*** | 0745-312 | 1 administration 1 gaz pour inhalation, 370 MBq | | 1 toediening 1 inhalatiegas, 370 MBq | |  |  | 18,5900 | |  |  |
| Ri-D5 **\*\*** | 0745-323 | 1 administration 1 gaz pour inhalation, 370 MBq | | 1 toediening 1 inhalatiegas, 370 MBq | |  |  | 18,5900 | |  |  |
|  |  |  | |  | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | | |  | | | | | |
| **Paragraphe 10008** | | | | **Paragraaf 10008** | | | | | |
| Produits radio-pharmaceutiques à base d’ iodure (I-123) de sodium - catégorie de remboursement Ri-D2 - domaine d’application diagnostique: glande thyroïde | | | | Radiofarmaceutische producten op basis van natriumjodide (I-123) - vergoedingscategorie Ri-D2 – toepassingsgebied diagnostiek: schildklier | | | | | |
| Les produits inscrits dans ce paragraphe sont remboursables dans la catégorie de remboursement Ri-D2 s’ils sont utilisés dans des cas où une exploration de la thyroïde n'a, au cours d'une séance précédente, pas fourni de renseignements suffisants et qu'un examen complémentaire à l'I 123 est dès lors nécessaire. | | | | De producten ingeschreven in deze paragraaf zijn vergoedbaar in de vergoedingscategorie Ri-D2 indien ze aangewend worden in gevallen waar een exploratie van de schildklier in een vorige vacatie onvoldoende inlichtingen bezorgde zodat een aanvullend onderzoek met I 123 aangewezen is. | | | | | |
|  | | | |  | | | | | |
| Dénomination / Benaming (Demandeur/Aanvrager) | | | | | | | | | |
| Cat. | Code | Conditionnements | Verpakkingen | | Obs  Opm | Prix  Prijs  ***ex-usine / buiten bedrijf*** | Base de remb  Basis v tegem  ***ex-usine / buiten bedrijf*** | I | II |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (123I) CURIUM 37 MBq/ml | | | CURIUM BELGIUM BV | |  | | | | ATC: V09FX02 | | |
|  | ***0745-334*** | ***1 flacon injectable 2 ml solution injectable, 74 MBq*** | | ***1 injectieflacon 2 ml oplossing voor injectie, 74 MBq*** | |  | ***260,00*** |  | |  |  |
| Ri-D2 **\*** | 0745-334 | 1 administration 2 mL solution injectable, 74 MBq | | 1 toediening 2 mL oplossing voor injectie, 74 MBq | |  |  | 49,5800 | |  |  |
| Ri-D2 **\*\*** | 0745-345 | 1 administration 2 mL solution injectable, 74 MBq | | 1 toediening 2 mL oplossing voor injectie, 74 MBq | |  |  | 49,5800 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (123I) CURIUM 37 MBq/ml | | | CURIUM BELGIUM BV | |  | | | | ATC: V09FX02 | | |
|  | ***0745-334*** | ***1 flacon injectable 5 ml solution injectable, 185 MBq*** | | ***1 injectieflacon 5 ml oplossing voor injectie, 185 MBq*** | |  | ***460,00*** |  | |  |  |
| Ri-D2 **\*** | 0745-334 | 1 administration 5 mL solution injectable, 185 MBq | | 1 toediening 5 mL oplossing voor injectie, 185 MBq | |  |  | 49,5800 | |  |  |
| Ri-D2 **\*\*** | 0745-345 | 1 administration 5 mL solution injectable, 185 MBq | | 1 toediening 5 mL oplossing voor injectie, 185 MBq | |  |  | 49,5800 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (123I) CURIUM 37 MBq/ml | | | CURIUM BELGIUM BV | |  | | | | ATC: V09FX02 | | |
|  | ***0745-334*** | ***1 flacon injectable 10 ml solution injectable, 370 MBq*** | | ***1 injectieflacon 10 ml oplossing voor injectie, 370 MBq*** | |  | ***460,00*** |  | |  |  |
| Ri-D2 **\*** | 0745-334 | 1 administration 10 mL solution injectable, 370 MBq | | 1 toediening 10 mL oplossing voor injectie, 370 MBq | |  |  | 49,5800 | |  |  |
| Ri-D2 **\*\*** | 0745-345 | 1 administration 10 mL solution injectable, 370 MBq | | 1 toediening 10 mL oplossing voor injectie, 370 MBq | |  |  | 49,5800 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (123I) CURIUM 37 MBq/ml | | | CURIUM BELGIUM BV | |  | | | | ATC: V09FX02 | | |
|  | ***0745-334*** | ***1 flacon injectable 1 ml solution injectable, 37 MBq*** | | ***1 injectieflacon 1 ml oplossing voor injectie, 37 MBq*** | |  | ***205,00*** |  | |  |  |
| Ri-D2 **\*** | 0745-334 | 1 administration 1 mL solution injectable, 37 MBq | | 1 toediening 1 mL oplossing voor injectie, 37 MBq | |  |  | 49,5800 | |  |  |
| Ri-D2 **\*\*** | 0745-345 | 1 administration 1 mL solution injectable, 37 MBq | | 1 toediening 1 mL oplossing voor injectie, 37 MBq | |  |  | 49,5800 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (123I) GE HEALTHCARE | | | GE HEALTHCARE | |  | | | | ATC: V09FX02 | | |
|  | ***0745-334*** | ***5 gélules, 3,7 MBq*** | | ***5 capsules, hard, 3,7 MBq*** | |  | ***325,00*** |  | |  |  |
| Ri-D2 **\*** | 0745-334 | 1 administration, 3,7 MBq | | 1 toediening, 3,7 MBq | |  |  | 49,5800 | |  |  |
| Ri-D2 **\*\*** | 0745-345 | 1 administration, 3,7 MBq | | 1 toediening, 3,7 MBq | |  |  | 49,5800 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (123I) GE HEALTHCARE | | | GE HEALTHCARE | |  | | | | ATC: V09FX02 | | |
|  | ***0745-334*** | ***6 gélules, 7,4 MBq*** | | ***6 capsules, hard, 7,4 MBq*** | |  | ***445,00*** |  | |  |  |
| Ri-D2 **\*** | 0745-334 | 1 administration, 7,4 MBq | | 1 toediening, 7,4 MBq | |  |  | 49,5800 | |  |  |
| Ri-D2 **\*\*** | 0745-345 | 1 administration, 7,4 MBq | | 1 toediening, 7,4 MBq | |  |  | 49,5800 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (123I) GE HEALTHCARE | | | GE HEALTHCARE | |  | | | | ATC: V09FX02 | | |
|  | ***0745-334*** | ***7 gélules, 11,1 MBq*** | | ***7 capsules, hard, 11,1 MBq*** | |  | ***515,00*** |  | |  |  |
| Ri-D2 **\*** | 0745-334 | 1 administration, 11,1 MBq | | 1 toediening, 11,1 MBq | |  |  | 49,5800 | |  |  |
| Ri-D2 **\*\*** | 0745-345 | 1 administration, 11,1 MBq | | 1 toediening, 11,1 MBq | |  |  | 49,5800 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (123I) GE HEALTHCARE | | | GE HEALTHCARE | |  | | | | ATC: V09FX02 | | |
|  | ***0745-334*** | ***1 gélule, 18,5 MBq*** | | ***1 capsule, hard, 18,5 MBq*** | |  | ***165,00*** |  | |  |  |
| Ri-D2 **\*** | 0745-334 | 1 administration, 18,5 MBq | | 1 toediening, 18,5 MBq | |  |  | 49,5800 | |  |  |
| Ri-D2 **\*\*** | 0745-345 | 1 administration, 18,5 MBq | | 1 toediening, 18,5 MBq | |  |  | 49,5800 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (123I) GE HEALTHCARE | | | GE HEALTHCARE | |  | | | | ATC: V09FX02 | | |
|  | ***0745-334*** | ***2 gélules, 18,5 MBq*** | | ***2 capsules, hard, 18,5 MBq*** | |  | ***230,00*** |  | |  |  |
| Ri-D2 **\*** | 0745-334 | 1 administration, 18,5 MBq | | 1 toediening, 18,5 MBq | |  |  | 49,5800 | |  |  |
| Ri-D2 **\*\*** | 0745-345 | 1 administration, 18,5 MBq | | 1 toediening, 18,5 MBq | |  |  | 49,5800 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (123I) GE HEALTHCARE | | | GE HEALTHCARE | |  | | | | ATC: V09FX02 | | |
|  | ***0745-334*** | ***3 gélules, 18,5 MBq*** | | ***3 capsules, hard, 18,5 MBq*** | |  | ***295,00*** |  | |  |  |
| Ri-D2 **\*** | 0745-334 | 1 administration, 18,5 MBq | | 1 toediening, 18,5 MBq | |  |  | 49,5800 | |  |  |
| Ri-D2 **\*\*** | 0745-345 | 1 administration, 18,5 MBq | | 1 toediening, 18,5 MBq | |  |  | 49,5800 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (123I) GE HEALTHCARE | | | GE HEALTHCARE | |  | | | | ATC: V09FX02 | | |
|  | ***0745-334*** | ***4 gélules, 18,5 MBq*** | | ***4 capsules, hard, 18,5 MBq*** | |  | ***360,00*** |  | |  |  |
| Ri-D2 **\*** | 0745-334 | 1 administration, 18,5 MBq | | 1 toediening, 18,5 MBq | |  |  | 49,5800 | |  |  |
| Ri-D2 **\*\*** | 0745-345 | 1 administration, 18,5 MBq | | 1 toediening, 18,5 MBq | |  |  | 49,5800 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (123I) GE HEALTHCARE | | | GE HEALTHCARE | |  | | | | ATC: V09FX02 | | |
|  | ***0745-334*** | ***1 gélule, 3,7 MBq*** | | ***1 capsule, hard, 3,7 MBq*** | |  | ***105,00*** |  | |  |  |
| Ri-D2 **\*** | 0745-334 | 1 administration, 3,7 MBq | | 1 toediening, 3,7 MBq | |  |  | 49,5800 | |  |  |
| Ri-D2 **\*\*** | 0745-345 | 1 administration, 3,7 MBq | | 1 toediening, 3,7 MBq | |  |  | 49,5800 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (123I) GE HEALTHCARE | | | GE HEALTHCARE | |  | | | | ATC: V09FX02 | | |
|  | ***0745-334*** | ***7 gélules, 3,7 MBq*** | | ***7 capsules, hard, 3,7 MBq*** | |  | ***445,00*** |  | |  |  |
| Ri-D2 **\*** | 0745-334 | 1 administration, 3,7 MBq | | 1 toediening, 3,7 MBq | |  |  | 49,5800 | |  |  |
| Ri-D2 **\*\*** | 0745-345 | 1 administration, 3,7 MBq | | 1 toediening, 3,7 MBq | |  |  | 49,5800 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (123I) GE HEALTHCARE | | | GE HEALTHCARE | |  | | | | ATC: V09FX02 | | |
|  | ***0745-334*** | ***3 gélules, 11,1 MBq*** | | ***3 capsules, hard, 11,1 MBq*** | |  | ***255,00*** |  | |  |  |
| Ri-D2 **\*** | 0745-334 | 1 administration, 11,1 MBq | | 1 toediening, 11,1 MBq | |  |  | 49,5800 | |  |  |
| Ri-D2 **\*\*** | 0745-345 | 1 administration, 11,1 MBq | | 1 toediening, 11,1 MBq | |  |  | 49,5800 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (123I) GE HEALTHCARE | | | GE HEALTHCARE | |  | | | | ATC: V09FX02 | | |
|  | ***0745-334*** | ***6 gélules, 18,5 MBq*** | | ***6 capsules, hard, 18,5 MBq*** | |  | ***490,00*** |  | |  |  |
| Ri-D2 **\*** | 0745-334 | 1 administration, 18,5 MBq | | 1 toediening, 18,5 MBq | |  |  | 49,5800 | |  |  |
| Ri-D2 **\*\*** | 0745-345 | 1 administration, 18,5 MBq | | 1 toediening, 18,5 MBq | |  |  | 49,5800 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (123I) GE HEALTHCARE | | | GE HEALTHCARE | |  | | | | ATC: V09FX02 | | |
|  | ***0745-334*** | ***6 gélules, 3,7 MBq*** | | ***6 capsules, hard, 3,7 MBq*** | |  | ***380,00*** |  | |  |  |
| Ri-D2 **\*** | 0745-334 | 1 administration, 3,7 MBq | | 1 toediening, 3,7 MBq | |  |  | 49,5800 | |  |  |
| Ri-D2 **\*\*** | 0745-345 | 1 administration, 3,7 MBq | | 1 toediening, 3,7 MBq | |  |  | 49,5800 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (123I) GE HEALTHCARE | | | GE HEALTHCARE | |  | | | | ATC: V09FX02 | | |
|  | ***0745-334*** | ***2 gélules, 11,1 MBq*** | | ***2 capsules, hard, 11,1 MBq*** | |  | ***200,00*** |  | |  |  |
| Ri-D2 **\*** | 0745-334 | 1 administration, 11,1 MBq | | 1 toediening, 11,1 MBq | |  |  | 49,5800 | |  |  |
| Ri-D2 **\*\*** | 0745-345 | 1 administration, 11,1 MBq | | 1 toediening, 11,1 MBq | |  |  | 49,5800 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (123I) GE HEALTHCARE | | | GE HEALTHCARE | |  | | | | ATC: V09FX02 | | |
|  | ***0745-334*** | ***6 gélules, 11,1 MBq*** | | ***6 capsules, hard, 11,1 MBq*** | |  | ***450,00*** |  | |  |  |
| Ri-D2 **\*** | 0745-334 | 1 administration, 11,1 MBq | | 1 toediening, 11,1 MBq | |  |  | 49,5800 | |  |  |
| Ri-D2 **\*\*** | 0745-345 | 1 administration, 11,1 MBq | | 1 toediening, 11,1 MBq | |  |  | 49,5800 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (123I) GE HEALTHCARE | | | GE HEALTHCARE | |  | | | | ATC: V09FX02 | | |
|  | ***0745-334*** | ***5 gélules, 18,5 MBq*** | | ***5 capsules, hard, 18,5 MBq*** | |  | ***425,00*** |  | |  |  |
| Ri-D2 **\*** | 0745-334 | 1 administration, 18,5 MBq | | 1 toediening, 18,5 MBq | |  |  | 49,5800 | |  |  |
| Ri-D2 **\*\*** | 0745-345 | 1 administration, 18,5 MBq | | 1 toediening, 18,5 MBq | |  |  | 49,5800 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (123I) GE HEALTHCARE | | | GE HEALTHCARE | |  | | | | ATC: V09FX02 | | |
|  | ***0745-334*** | ***7 gélules, 18,5 MBq*** | | ***7 capsules, hard, 18,5 MBq*** | |  | ***555,00*** |  | |  |  |
| Ri-D2 **\*** | 0745-334 | 1 administration, 18,5 MBq | | 1 toediening, 18,5 MBq | |  |  | 49,5800 | |  |  |
| Ri-D2 **\*\*** | 0745-345 | 1 administration, 18,5 MBq | | 1 toediening, 18,5 MBq | |  |  | 49,5800 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (123I) GE HEALTHCARE | | | GE HEALTHCARE | |  | | | | ATC: V09FX02 | | |
|  | ***0745-334*** | ***2 gélules, 37 MBq*** | | ***2 capsules, hard, 37 MBq*** | |  | ***315,00*** |  | |  |  |
| Ri-D2 **\*** | 0745-334 | 1 administration, 37 MBq | | 1 toediening, 37 MBq | |  |  | 49,5800 | |  |  |
| Ri-D2 **\*\*** | 0745-345 | 1 administration, 37 MBq | | 1 toediening, 37 MBq | |  |  | 49,5800 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (123I) GE HEALTHCARE | | | GE HEALTHCARE | |  | | | | ATC: V09FX02 | | |
|  | ***0745-334*** | ***3 gélules, 3,7 MBq*** | | ***3 capsules, hard, 3,7 MBq*** | |  | ***215,00*** |  | |  |  |
| Ri-D2 **\*** | 0745-334 | 1 administration, 3,7 MBq | | 1 toediening, 3,7 MBq | |  |  | 49,5800 | |  |  |
| Ri-D2 **\*\*** | 0745-345 | 1 administration, 3,7 MBq | | 1 toediening, 3,7 MBq | |  |  | 49,5800 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (123I) GE HEALTHCARE | | | GE HEALTHCARE | |  | | | | ATC: V09FX02 | | |
|  | ***0745-334*** | ***4 gélules, 3,7 MBq*** | | ***4 capsules, hard, 3,7 MBq*** | |  | ***270,00*** |  | |  |  |
| Ri-D2 **\*** | 0745-334 | 1 administration, 3,7 MBq | | 1 toediening, 3,7 MBq | |  |  | 49,5800 | |  |  |
| Ri-D2 **\*\*** | 0745-345 | 1 administration, 3,7 MBq | | 1 toediening, 3,7 MBq | |  |  | 49,5800 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (123I) GE HEALTHCARE | | | GE HEALTHCARE | |  | | | | ATC: V09FX02 | | |
|  | ***0745-334*** | ***4 gélules, 7,4 MBq*** | | ***4 capsules, hard, 7,4 MBq*** | |  | ***315,00*** |  | |  |  |
| Ri-D2 **\*** | 0745-334 | 1 administration, 7,4 MBq | | 1 toediening, 7,4 MBq | |  |  | 49,5800 | |  |  |
| Ri-D2 **\*\*** | 0745-345 | 1 administration, 7,4 MBq | | 1 toediening, 7,4 MBq | |  |  | 49,5800 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (123I) GE HEALTHCARE | | | GE HEALTHCARE | |  | | | | ATC: V09FX02 | | |
|  | ***0745-334*** | ***5 gélules, 7,4 MBq*** | | ***5 capsules, hard, 7,4 MBq*** | |  | ***380,00*** |  | |  |  |
| Ri-D2 **\*** | 0745-334 | 1 administration, 7,4 MBq | | 1 toediening, 7,4 MBq | |  |  | 49,5800 | |  |  |
| Ri-D2 **\*\*** | 0745-345 | 1 administration, 7,4 MBq | | 1 toediening, 7,4 MBq | |  |  | 49,5800 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (123I) GE HEALTHCARE | | | GE HEALTHCARE | |  | | | | ATC: V09FX02 | | |
|  | ***0745-334*** | ***4 gélules, 37 MBq*** | | ***4 capsules, hard, 37 MBq*** | |  | ***495,00*** |  | |  |  |
| Ri-D2 **\*** | 0745-334 | 1 administration, 37 MBq | | 1 toediening, 37 MBq | |  |  | 49,5800 | |  |  |
| Ri-D2 **\*\*** | 0745-345 | 1 administration, 37 MBq | | 1 toediening, 37 MBq | |  |  | 49,5800 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (123I) GE HEALTHCARE | | | GE HEALTHCARE | |  | | | | ATC: V09FX02 | | |
|  | ***0745-334*** | ***5 gélules, 37 MBq*** | | ***5 capsules, hard, 37 MBq*** | |  | ***585,00*** |  | |  |  |
| Ri-D2 **\*** | 0745-334 | 1 administration, 37 MBq | | 1 toediening, 37 MBq | |  |  | 49,5800 | |  |  |
| Ri-D2 **\*\*** | 0745-345 | 1 administration, 37 MBq | | 1 toediening, 37 MBq | |  |  | 49,5800 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (123I) GE HEALTHCARE | | | GE HEALTHCARE | |  | | | | ATC: V09FX02 | | |
|  | ***0745-334*** | ***7 gélules, 37 MBq*** | | ***7 capsules, hard, 37 MBq*** | |  | ***765,00*** |  | |  |  |
| Ri-D2 **\*** | 0745-334 | 1 administration, 37 MBq | | 1 toediening, 37 MBq | |  |  | 49,5800 | |  |  |
| Ri-D2 **\*\*** | 0745-345 | 1 administration, 37 MBq | | 1 toediening, 37 MBq | |  |  | 49,5800 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (123I) GE HEALTHCARE | | | GE HEALTHCARE | |  | | | | ATC: V09FX02 | | |
|  | ***0745-334*** | ***2 gélules, 3,7 MBq*** | | ***2 capsules, hard, 3,7 MBq*** | |  | ***160,00*** |  | |  |  |
| Ri-D2 **\*** | 0745-334 | 1 administration, 3,7 MBq | | 1 toediening, 3,7 MBq | |  |  | 49,5800 | |  |  |
| Ri-D2 **\*\*** | 0745-345 | 1 administration, 3,7 MBq | | 1 toediening, 3,7 MBq | |  |  | 49,5800 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (123I) GE HEALTHCARE | | | GE HEALTHCARE | |  | | | | ATC: V09FX02 | | |
|  | ***0745-334*** | ***2 gélules, 7,4 MBq*** | | ***2 capsules, hard, 7,4 MBq*** | |  | ***185,00*** |  | |  |  |
| Ri-D2 **\*** | 0745-334 | 1 administration, 7,4 MBq | | 1 toediening, 7,4 MBq | |  |  | 49,5800 | |  |  |
| Ri-D2 **\*\*** | 0745-345 | 1 administration, 7,4 MBq | | 1 toediening, 7,4 MBq | |  |  | 49,5800 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (123I) GE HEALTHCARE | | | GE HEALTHCARE | |  | | | | ATC: V09FX02 | | |
|  | ***0745-334*** | ***3 gélules, 7,4 MBq*** | | ***3 capsules, hard, 7,4 MBq*** | |  | ***250,00*** |  | |  |  |
| Ri-D2 **\*** | 0745-334 | 1 administration, 7,4 MBq | | 1 toediening, 7,4 MBq | |  |  | 49,5800 | |  |  |
| Ri-D2 **\*\*** | 0745-345 | 1 administration, 7,4 MBq | | 1 toediening, 7,4 MBq | |  |  | 49,5800 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (123I) GE HEALTHCARE | | | GE HEALTHCARE | |  | | | | ATC: V09FX02 | | |
|  | ***0745-334*** | ***7 gélules, 7,4 MBq*** | | ***7 capsules, hard, 7,4 MBq*** | |  | ***510,00*** |  | |  |  |
| Ri-D2 **\*** | 0745-334 | 1 administration, 7,4 MBq | | 1 toediening, 7,4 MBq | |  |  | 49,5800 | |  |  |
| Ri-D2 **\*\*** | 0745-345 | 1 administration, 7,4 MBq | | 1 toediening, 7,4 MBq | |  |  | 49,5800 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (123I) GE HEALTHCARE | | | GE HEALTHCARE | |  | | | | ATC: V09FX02 | | |
|  | ***0745-334*** | ***6 gélules, 37 MBq*** | | ***6 capsules, hard, 37 MBq*** | |  | ***675,00*** |  | |  |  |
| Ri-D2 **\*** | 0745-334 | 1 administration, 37 MBq | | 1 toediening, 37 MBq | |  |  | 49,5800 | |  |  |
| Ri-D2 **\*\*** | 0745-345 | 1 administration, 37 MBq | | 1 toediening, 37 MBq | |  |  | 49,5800 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (123I) GE HEALTHCARE | | | GE HEALTHCARE | |  | | | | ATC: V09FX02 | | |
|  | ***0745-334*** | ***1 gélule, 7,4 MBq*** | | ***1 capsule, hard, 7,4 MBq*** | |  | ***120,00*** |  | |  |  |
| Ri-D2 **\*** | 0745-334 | 1 administration, 7,4 MBq | | 1 toediening, 7,4 MBq | |  |  | 49,5800 | |  |  |
| Ri-D2 **\*\*** | 0745-345 | 1 administration, 7,4 MBq | | 1 toediening, 7,4 MBq | |  |  | 49,5800 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (123I) GE HEALTHCARE | | | GE HEALTHCARE | |  | | | | ATC: V09FX02 | | |
|  | ***0745-334*** | ***1 gélule, 11,1 MBq*** | | ***1 capsule, hard, 11,1 MBq*** | |  | ***135,00*** |  | |  |  |
| Ri-D2 **\*** | 0745-334 | 1 administration, 11,1 MBq | | 1 toediening, 11,1 MBq | |  |  | 49,5800 | |  |  |
| Ri-D2 **\*\*** | 0745-345 | 1 administration, 11,1 MBq | | 1 toediening, 11,1 MBq | |  |  | 49,5800 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (123I) GE HEALTHCARE | | | GE HEALTHCARE | |  | | | | ATC: V09FX02 | | |
|  | ***0745-334*** | ***4 gélules, 11,1 MBq*** | | ***4 capsules, hard, 11,1 MBq*** | |  | ***320,00*** |  | |  |  |
| Ri-D2 **\*** | 0745-334 | 1 administration, 11,1 MBq | | 1 toediening, 11,1 MBq | |  |  | 49,5800 | |  |  |
| Ri-D2 **\*\*** | 0745-345 | 1 administration, 11,1 MBq | | 1 toediening, 11,1 MBq | |  |  | 49,5800 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (123I) GE HEALTHCARE | | | GE HEALTHCARE | |  | | | | ATC: V09FX02 | | |
|  | ***0745-334*** | ***5 gélules, 11,1 MBq*** | | ***5 capsules, hard, 11,1 MBq*** | |  | ***385,00*** |  | |  |  |
| Ri-D2 **\*** | 0745-334 | 1 administration, 11,1 MBq | | 1 toediening, 11,1 MBq | |  |  | 49,5800 | |  |  |
| Ri-D2 **\*\*** | 0745-345 | 1 administration, 11,1 MBq | | 1 toediening, 11,1 MBq | |  |  | 49,5800 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (123I) GE HEALTHCARE | | | GE HEALTHCARE | |  | | | | ATC: V09FX02 | | |
|  | ***0745-334*** | ***1 gélule, 37 MBq*** | | ***1 capsule, hard, 37 MBq*** | |  | ***185,00*** |  | |  |  |
| Ri-D2 **\*** | 0745-334 | 1 administration, 37 MBq | | 1 toediening, 37 MBq | |  |  | 49,5800 | |  |  |
| Ri-D2 **\*\*** | 0745-345 | 1 administration, 37 MBq | | 1 toediening, 37 MBq | |  |  | 49,5800 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (123I) GE HEALTHCARE | | | GE HEALTHCARE | |  | | | | ATC: V09FX02 | | |
|  | ***0745-334*** | ***3 gélules, 37 MBq*** | | ***3 capsules, hard, 37 MBq*** | |  | ***405,00*** |  | |  |  |
| Ri-D2 **\*** | 0745-334 | 1 administration, 37 MBq | | 1 toediening, 37 MBq | |  |  | 49,5800 | |  |  |
| Ri-D2 **\*\*** | 0745-345 | 1 administration, 37 MBq | | 1 toediening, 37 MBq | |  |  | 49,5800 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (123I) GE HEALTHCARE 37 MBq/ml | | | GE HEALTHCARE | |  | | | | ATC: V09FX02 | | |
|  | ***0745-334*** | ***1 flacon injectable 2 ml solution injectable, 74 MBq*** | | ***1 injectieflacon 2 ml oplossing voor injectie, 74 MBq*** | |  | ***251,00*** |  | |  |  |
| Ri-D2 **\*** | 0745-334 | 1 administration 2 mL solution injectable, 74 MBq | | 1 toediening 2 mL oplossing voor injectie, 74 MBq | |  |  | 49,5800 | |  |  |
| Ri-D2 **\*\*** | 0745-345 | 1 administration 2 mL solution injectable, 74 MBq | | 1 toediening 2 mL oplossing voor injectie, 74 MBq | |  |  | 49,5800 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (123I) GE HEALTHCARE 37 MBq/ml | | | GE HEALTHCARE | |  | | | | ATC: V09FX02 | | |
|  | ***0745-334*** | ***1 flacon injectable 6 ml solution injectable, 222 MBq*** | | ***1 injectieflacon 6 ml oplossing voor injectie, 222 MBq*** | |  | ***499,00*** |  | |  |  |
| Ri-D2 **\*** | 0745-334 | 1 administration 6 mL solution injectable, 222 MBq | | 1 toediening 6 mL oplossing voor injectie, 222 MBq | |  |  | 49,5800 | |  |  |
| Ri-D2 **\*\*** | 0745-345 | 1 administration 6 mL solution injectable, 222 MBq | | 1 toediening 6 mL oplossing voor injectie, 222 MBq | |  |  | 49,5800 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (123I) GE HEALTHCARE 37 MBq/ml | | | GE HEALTHCARE | |  | | | | ATC: V09FX02 | | |
|  | ***0745-334*** | ***1 flacon injectable 8 ml solution injectable, 296 MBq*** | | ***1 injectieflacon 8 ml oplossing voor injectie, 296 MBq*** | |  | ***623,00*** |  | |  |  |
| Ri-D2 **\*** | 0745-334 | 1 administration 8 mL solution injectable, 296 MBq | | 1 toediening 8 mL oplossing voor injectie, 296 MBq | |  |  | 49,5800 | |  |  |
| Ri-D2 **\*\*** | 0745-345 | 1 administration 8 mL solution injectable, 296 MBq | | 1 toediening 8 mL oplossing voor injectie, 296 MBq | |  |  | 49,5800 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (123I) GE HEALTHCARE 37 MBq/ml | | | GE HEALTHCARE | |  | | | | ATC: V09FX02 | | |
|  | ***0745-334*** | ***1 flacon injectable 3 ml solution injectable, 111 MBq*** | | ***1 injectieflacon 3 ml oplossing voor injectie, 111 MBq*** | |  | ***313,00*** |  | |  |  |
| Ri-D2 **\*** | 0745-334 | 1 administration 3 mL solution injectable, 111 MBq | | 1 toediening 3 mL oplossing voor injectie, 111 MBq | |  |  | 49,5800 | |  |  |
| Ri-D2 **\*\*** | 0745-345 | 1 administration 3 mL solution injectable, 111 MBq | | 1 toediening 3 mL oplossing voor injectie, 111 MBq | |  |  | 49,5800 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (123I) GE HEALTHCARE 37 MBq/ml | | | GE HEALTHCARE | |  | | | | ATC: V09FX02 | | |
|  | ***0745-334*** | ***1 flacon injectable 9 ml solution injectable, 333 MBq*** | | ***1 injectieflacon 9 ml oplossing voor injectie, 333 MBq*** | |  | ***685,00*** |  | |  |  |
| Ri-D2 **\*** | 0745-334 | 1 administration 9 mL solution injectable, 333 MBq | | 1 toediening 9 mL oplossing voor injectie, 333 MBq | |  |  | 49,5800 | |  |  |
| Ri-D2 **\*\*** | 0745-345 | 1 administration 9 mL solution injectable, 333 MBq | | 1 toediening 9 mL oplossing voor injectie, 333 MBq | |  |  | 49,5800 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (123I) GE HEALTHCARE 37 MBq/ml | | | GE HEALTHCARE | |  | | | | ATC: V09FX02 | | |
|  | ***0745-334*** | ***1 flacon injectable 10 ml solution injectable, 370 MBq*** | | ***1 injectieflacon 10 ml oplossing voor injectie, 370 MBq*** | |  | ***747,00*** |  | |  |  |
| Ri-D2 **\*** | 0745-334 | 1 administration 10 mL solution injectable, 370 MBq | | 1 toediening 10 mL oplossing voor injectie, 370 MBq | |  |  | 49,5800 | |  |  |
| Ri-D2 **\*\*** | 0745-345 | 1 administration 10 mL solution injectable, 370 MBq | | 1 toediening 10 mL oplossing voor injectie, 370 MBq | |  |  | 49,5800 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (123I) GE HEALTHCARE 37 MBq/ml | | | GE HEALTHCARE | |  | | | | ATC: V09FX02 | | |
|  | ***0745-334*** | ***1 flacon injectable 1 ml solution injectable, 37 MBq*** | | ***1 injectieflacon 1 ml oplossing voor injectie, 37 MBq*** | |  | ***189,00*** |  | |  |  |
| Ri-D2 **\*** | 0745-334 | 1 administration 1 mL solution injectable, 37 MBq | | 1 toediening 1 mL oplossing voor injectie, 37 MBq | |  |  | 49,5800 | |  |  |
| Ri-D2 **\*\*** | 0745-345 | 1 administration 1 mL solution injectable, 37 MBq | | 1 toediening 1 mL oplossing voor injectie, 37 MBq | |  |  | 49,5800 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (123I) GE HEALTHCARE 37 MBq/ml | | | GE HEALTHCARE | |  | | | | ATC: V09FX02 | | |
|  | ***0745-334*** | ***1 flacon injectable 7 ml solution injectable, 259 MBq*** | | ***1 injectieflacon 7 ml oplossing voor injectie, 259 MBq*** | |  | ***561,00*** |  | |  |  |
| Ri-D2 **\*** | 0745-334 | 1 administration 7 mL solution injectable, 259 MBq | | 1 toediening 7 mL oplossing voor injectie, 259 MBq | |  |  | 49,5800 | |  |  |
| Ri-D2 **\*\*** | 0745-345 | 1 administration 7 mL solution injectable, 259 MBq | | 1 toediening 7 mL oplossing voor injectie, 259 MBq | |  |  | 49,5800 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (123I) GE HEALTHCARE 37 MBq/ml | | | GE HEALTHCARE | |  | | | | ATC: V09FX02 | | |
|  | ***0745-334*** | ***1 flacon injectable 4 ml solution injectable, 148 MBq*** | | ***1 injectieflacon 4 ml oplossing voor injectie, 148 MBq*** | |  | ***375,00*** |  | |  |  |
| Ri-D2 **\*** | 0745-334 | 1 administration 4 mL solution injectable, 148 MBq | | 1 toediening 4 mL oplossing voor injectie, 148 MBq | |  |  | 49,5800 | |  |  |
| Ri-D2 **\*\*** | 0745-345 | 1 administration 4 mL solution injectable, 148 MBq | | 1 toediening 4 mL oplossing voor injectie, 148 MBq | |  |  | 49,5800 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (123I) GE HEALTHCARE 37 MBq/ml | | | GE HEALTHCARE | |  | | | | ATC: V09FX02 | | |
|  | ***0745-334*** | ***1 flacon injectable 5 ml solution injectable, 185 MBq*** | | ***1 injectieflacon 5 ml oplossing voor injectie, 185 MBq*** | |  | ***437,00*** |  | |  |  |
| Ri-D2 **\*** | 0745-334 | 1 administration 5 mL solution injectable, 185 MBq | | 1 toediening 5 mL oplossing voor injectie, 185 MBq | |  |  | 49,5800 | |  |  |
| Ri-D2 **\*\*** | 0745-345 | 1 administration 5 mL solution injectable, 185 MBq | | 1 toediening 5 mL oplossing voor injectie, 185 MBq | |  |  | 49,5800 | |  |  |
|  |  |  | |  | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | | |  | | | | | |
| **Paragraphe 10009** | | | | **Paragraaf 10009** | | | | | |
| Produits radio-pharmaceutiques à base d’ iodure (I-131) de sodium -catégorie de remboursement Ri-D4 - domaine d’application diagnostique : glande thyroïde | | | | Radiofarmaceutische producten op basis van natriumjodide (I-131) - vergoedingscategorie Ri-D4 – toepassingsgebied diagnostiek: schildklier | | | | | |
|  | | | |  | | | | | |
| Dénomination / Benaming (Demandeur/Aanvrager) | | | | | | | | | |
| Cat. | Code | Conditionnements | Verpakkingen | | Obs  Opm | Prix  Prijs  ***ex-usine / buiten bedrijf*** | Base de remb  Basis v tegem  ***ex-usine / buiten bedrijf*** | I | II |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (131 I) GE HEALTHCARE | | | GE HEALTHCARE | |  | | | | ATC: V09FX03 | | |
|  | ***0747-773*** | ***185 MBq solution injectable, 185 MBq*** | | ***185 MBq oplossing voor injectie, 185 MBq*** | |  | ***300,00*** |  | |  |  |
| Ri-D4 **\*** | 0747-773 | 1 administration, 185 MBq | | 1 toediening, 185 MBq | |  |  | 4,9600 | |  |  |
| Ri-D4 **\*\*** | 0747-784 | 1 administration, 185 MBq | | 1 toediening, 185 MBq | |  |  | 4,9600 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (131 I) GE HEALTHCARE | | | GE HEALTHCARE | |  | | | | ATC: V09FX03 | | |
|  | ***0747-773*** | ***740 MBq solution injectable, 740 MBq*** | | ***740 MBq oplossing voor injectie, 740 MBq*** | |  | ***340,00*** |  | |  |  |
| Ri-D4 **\*** | 0747-773 | 1 administration, 740 MBq | | 1 toediening, 740 MBq | |  |  | 4,9600 | |  |  |
| Ri-D4 **\*\*** | 0747-784 | 1 administration, 740 MBq | | 1 toediening, 740 MBq | |  |  | 4,9600 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (131 I) GE HEALTHCARE | | | GE HEALTHCARE | |  | | | | ATC: V09FX03 | | |
|  | ***0747-773*** | ***74 MBq solution injectable, 74 MBq*** | | ***74 MBq oplossing voor injectie, 74 MBq*** | |  | ***280,00*** |  | |  |  |
| Ri-D4 **\*** | 0747-773 | 1 administration, 74 MBq | | 1 toediening, 74 MBq | |  |  | 4,9600 | |  |  |
| Ri-D4 **\*\*** | 0747-784 | 1 administration, 74 MBq | | 1 toediening, 74 MBq | |  |  | 4,9600 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (131 I) GE HEALTHCARE | | | GE HEALTHCARE | |  | | | | ATC: V09FX03 | | |
|  | ***0747-773*** | ***370 MBq solution injectable, 370 MBq*** | | ***370 MBq oplossing voor injectie, 370 MBq*** | |  | ***320,00*** |  | |  |  |
| Ri-D4 **\*** | 0747-773 | 1 administration, 370 MBq | | 1 toediening, 370 MBq | |  |  | 4,9600 | |  |  |
| Ri-D4 **\*\*** | 0747-784 | 1 administration, 370 MBq | | 1 toediening, 370 MBq | |  |  | 4,9600 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (131 I) GE HEALTHCARE | | | GE HEALTHCARE | |  | | | | ATC: V09FX03 | | |
|  | ***0747-773*** | ***37 MBq solution injectable, 37 MBq*** | | ***37 MBq oplossing voor injectie, 37 MBq*** | |  | ***260,00*** |  | |  |  |
| Ri-D4 **\*** | 0747-773 | 1 administration, 37 MBq | | 1 toediening, 37 MBq | |  |  | 4,9600 | |  |  |
| Ri-D4 **\*\*** | 0747-784 | 1 administration, 37 MBq | | 1 toediening, 37 MBq | |  |  | 4,9600 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (131 I) GE HEALTHCARE | | | GE HEALTHCARE | |  | | | | ATC: V09FX03 | | |
|  | ***0747-773*** | ***1850 MBq solution injectable, 1850 MBq*** | | ***1850 MBq oplossing voor injectie, 1850 MBq*** | |  | ***360,00*** |  | |  |  |
| Ri-D4 **\*** | 0747-773 | 1 administration, 1850 MBq | | 1 toediening, 1850 MBq | |  |  | 4,9600 | |  |  |
| Ri-D4 **\*\*** | 0747-784 | 1 administration, 1850 MBq | | 1 toediening, 1850 MBq | |  |  | 4,9600 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (131 I) GE HEALTHCARE | | | GE HEALTHCARE | |  | | | | ATC: V09FX03 | | |
|  | ***0747-773*** | ***3700 MBq solution injectable, 3700 MBq*** | | ***3700 MBq oplossing voor injectie, 3700 MBq*** | |  | ***380,00*** |  | |  |  |
| Ri-D4 **\*** | 0747-773 | 1 administration, 3700 MBq | | 1 toediening, 3700 MBq | |  |  | 4,9600 | |  |  |
| Ri-D4 **\*\*** | 0747-784 | 1 administration, 3700 MBq | | 1 toediening, 3700 MBq | |  |  | 4,9600 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (131 I) GE HEALTHCARE | | | GE HEALTHCARE | |  | | | | ATC: V09FX03 | | |
|  | ***0747-773*** | ***5550 MBq solution injectable, 5550 MBq*** | | ***5550 MBq oplossing voor injectie, 5550 MBq*** | |  | ***400,00*** |  | |  |  |
| Ri-D4 **\*** | 0747-773 | 1 administration, 5550 MBq | | 1 toediening, 5550 MBq | |  |  | 4,9600 | |  |  |
| Ri-D4 **\*\*** | 0747-784 | 1 administration, 5550 MBq | | 1 toediening, 5550 MBq | |  |  | 4,9600 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 111 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0747-773*** | ***1 gélule, 111 MBq*** | | ***1 capsule, hard, 111 MBq*** | |  | ***172,00*** |  | |  |  |
| Ri-D4 **\*** | 0747-773 | 1 administration, 111 MBq | | 1 toediening, 111 MBq | |  |  | 4,9600 | |  |  |
| Ri-D4 **\*\*** | 0747-784 | 1 administration, 111 MBq | | 1 toediening, 111 MBq | |  |  | 4,9600 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 148 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0747-773*** | ***1 gélule, 148 MBq*** | | ***1 capsule, hard, 148 MBq*** | |  | ***176,00*** |  | |  |  |
| Ri-D4 **\*** | 0747-773 | 1 administration, 148 MBq | | 1 toediening, 148 MBq | |  |  | 4,9600 | |  |  |
| Ri-D4 **\*\*** | 0747-784 | 1 administration, 148 MBq | | 1 toediening, 148 MBq | |  |  | 4,9600 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 185 MBq | | | CURIUM BELGIUM BV | | (voir aussi chapitre: I / zie ook hoofdstuk: I) | | | | ATC: V10XA01 | | |
|  | ***0747-773*** | ***1 gélule, 185 MBq*** | | ***1 capsule, hard, 185 MBq*** | |  | ***180,00*** |  | |  |  |
| Ri-D4 **\*** | 0747-773 | 1 administration, 185 MBq | | 1 toediening, 185 MBq | |  |  | 4,9600 | |  |  |
| Ri-D4 **\*\*** | 0747-784 | 1 administration, 185 MBq | | 1 toediening, 185 MBq | |  |  | 4,9600 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 37 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0747-773*** | ***1 gélule, 37 MBq*** | | ***1 capsule, hard, 37 MBq*** | |  | ***164,00*** |  | |  |  |
| Ri-D4 **\*** | 0747-773 | 1 administration, 37 MBq | | 1 toediening, 37 MBq | |  |  | 4,9600 | |  |  |
| Ri-D4 **\*\*** | 0747-784 | 1 administration, 37 MBq | | 1 toediening, 37 MBq | |  |  | 4,9600 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SODIUM IODIDE (I-131) CAPSULE T CURIUM 74 MBq | | | CURIUM BELGIUM BV | |  | | | | ATC: V10XA01 | | |
|  | ***0747-773*** | ***1 gélule, 74 MBq*** | | ***1 capsule, hard, 74 MBq*** | |  | ***168,00*** |  | |  |  |
| Ri-D4 **\*** | 0747-773 | 1 administration, 74 MBq | | 1 toediening, 74 MBq | |  |  | 4,9600 | |  |  |
| Ri-D4 **\*\*** | 0747-784 | 1 administration, 74 MBq | | 1 toediening, 74 MBq | |  |  | 4,9600 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| THERACAP 111 MBq | | | GE HEALTHCARE | |  | | | | ATC: V10XA01 | | |
|  | ***0747-773*** | ***1 gélule, 111 MBq*** | | ***1 capsule, hard, 111 MBq*** | |  | ***162,00*** |  | |  |  |
| Ri-D4 **\*** | 0747-773 | 1 administration, 111 MBq | | 1 toediening, 111 MBq | |  |  | 4,9600 | |  |  |
| Ri-D4 **\*\*** | 0747-784 | 1 administration, 111 MBq | | 1 toediening, 111 MBq | |  |  | 4,9600 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| THERACAP 148 MBq | | | GE HEALTHCARE | |  | | | | ATC: V10XA01 | | |
|  | ***0747-773*** | ***1 gélule, 148 MBq*** | | ***1 capsule, hard, 148 MBq*** | |  | ***164,00*** |  | |  |  |
| Ri-D4 **\*** | 0747-773 | 1 administration, 148 MBq | | 1 toediening, 148 MBq | |  |  | 4,9600 | |  |  |
| Ri-D4 **\*\*** | 0747-784 | 1 administration, 148 MBq | | 1 toediening, 148 MBq | |  |  | 4,9600 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| THERACAP 185 MBq | | | GE HEALTHCARE | | (voir aussi chapitre: I / zie ook hoofdstuk: I) | | | | ATC: V10XA01 | | |
|  | ***0747-773*** | ***1 gélule, 185 MBq*** | | ***1 capsule, hard, 185 MBq*** | |  | ***166,00*** |  | |  |  |
| Ri-D4 **\*** | 0747-773 | 1 administration, 185 MBq | | 1 toediening, 185 MBq | |  |  | 4,9600 | |  |  |
| Ri-D4 **\*\*** | 0747-784 | 1 administration, 185 MBq | | 1 toediening, 185 MBq | |  |  | 4,9600 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| THERACAP 37 MBq | | | GE HEALTHCARE | |  | | | | ATC: V10XA01 | | |
|  | ***0747-773*** | ***1 gélule, 37 MBq*** | | ***1 capsule, hard, 37 MBq*** | |  | ***158,00*** |  | |  |  |
| Ri-D4 **\*** | 0747-773 | 1 administration, 37 MBq | | 1 toediening, 37 MBq | |  |  | 4,9600 | |  |  |
| Ri-D4 **\*\*** | 0747-784 | 1 administration, 37 MBq | | 1 toediening, 37 MBq | |  |  | 4,9600 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| THERACAP 74 MBq | | | GE HEALTHCARE | |  | | | | ATC: V10XA01 | | |
|  | ***0747-773*** | ***1 gélule, 74 MBq*** | | ***1 capsule, hard, 74 MBq*** | |  | ***160,00*** |  | |  |  |
| Ri-D4 **\*** | 0747-773 | 1 administration, 74 MBq | | 1 toediening, 74 MBq | |  |  | 4,9600 | |  |  |
| Ri-D4 **\*\*** | 0747-784 | 1 administration, 74 MBq | | 1 toediening, 74 MBq | |  |  | 4,9600 | |  |  |
|  |  |  | |  | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | | |  | | | | | |
| **Paragraphe 10010** | | | | **Paragraaf 10010** | | | | | |
| Produits radio-pharmaceutiques à base de chlorure de thalleux (Tl-201) - catégorie de remboursement Ri-D7 | | | | Radiofarmaceutische producten op basis van thallous (Tl-201)- chloride - vergoedingscategorie Ri-D7 | | | | | |
|  | | | |  | | | | | |
| Dénomination / Benaming (Demandeur/Aanvrager) | | | | | | | | | |
| Cat. | Code | Conditionnements | Verpakkingen | | Obs  Opm | Prix  Prijs  ***ex-usine / buiten bedrijf*** | Base de remb  Basis v tegem  ***ex-usine / buiten bedrijf*** | I | II |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| THALLIUM (201TL) -CHLORIDE TL-201-S-1 | | | CIS BIO INTERNATIONAL SAS | |  | | | | ATC: V09GX01 | | |
|  | ***0745-371*** | ***1 flacon injectable 12 ml solution injectable, 444 MBq*** | | ***1 injectieflacon 12 ml oplossing voor injectie, 444 MBq*** | |  | ***1177,10*** |  | |  |  |
| Ri-D7 **\*** | 0745-371 | 1 administration 12 mL solution injectable, 444 MBq | | 1 toediening 12 mL oplossing voor injectie, 444 MBq | |  |  | 70,0000 | |  |  |
| Ri-D7 **\*\*** | 0745-382 | 1 administration 12 mL solution injectable, 444 MBq | | 1 toediening 12 mL oplossing voor injectie, 444 MBq | |  |  | 70,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| THALLIUM (201TL) -CHLORIDE TL-201-S-1 | | | CIS BIO INTERNATIONAL SAS | |  | | | | ATC: V09GX01 | | |
|  | ***0745-371*** | ***1 flacon injectable 13 ml solution injectable, 481 MBq*** | | ***1 injectieflacon 13 ml oplossing voor injectie, 481 MBq*** | |  | ***1274,10*** |  | |  |  |
| Ri-D7 **\*** | 0745-371 | 1 administration 13 mL solution injectable, 481 MBq | | 1 toediening 13 mL oplossing voor injectie, 481 MBq | |  |  | 70,0000 | |  |  |
| Ri-D7 **\*\*** | 0745-382 | 1 administration 13 mL solution injectable, 481 MBq | | 1 toediening 13 mL oplossing voor injectie, 481 MBq | |  |  | 70,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| THALLIUM (201TL) -CHLORIDE TL-201-S-1 | | | CIS BIO INTERNATIONAL SAS | |  | | | | ATC: V09GX01 | | |
|  | ***0745-371*** | ***1 flacon injectable 11 ml solution injectable, 407 MBq*** | | ***1 injectieflacon 11 ml oplossing voor injectie, 407 MBq*** | |  | ***1077,10*** |  | |  |  |
| Ri-D7 **\*** | 0745-371 | 1 administration 11 mL solution injectable, 407 MBq | | 1 toediening 11 mL oplossing voor injectie, 407 MBq | |  |  | 70,0000 | |  |  |
| Ri-D7 **\*\*** | 0745-382 | 1 administration 11 mL solution injectable, 407 MBq | | 1 toediening 11 mL oplossing voor injectie, 407 MBq | |  |  | 70,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| THALLIUM (201TL) -CHLORIDE TL-201-S-1 | | | CIS BIO INTERNATIONAL SAS | |  | | | | ATC: V09GX01 | | |
|  | ***0745-371*** | ***1 flacon injectable 14 ml solution injectable, 518 MBq*** | | ***1 injectieflacon 14 ml oplossing voor injectie, 518 MBq*** | |  | ***1371,70*** |  | |  |  |
| Ri-D7 **\*** | 0745-371 | 1 administration 14 mL solution injectable, 518 MBq | | 1 toediening 14 mL oplossing voor injectie, 518 MBq | |  |  | 70,0000 | |  |  |
| Ri-D7 **\*\*** | 0745-382 | 1 administration 14 mL solution injectable, 518 MBq | | 1 toediening 14 mL oplossing voor injectie, 518 MBq | |  |  | 70,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| THALLIUM (201TL) -CHLORIDE TL-201-S-1 | | | CIS BIO INTERNATIONAL SAS | |  | | | | ATC: V09GX01 | | |
|  | ***0745-371*** | ***1 flacon injectable 9 ml solution injectable, 333 MBq*** | | ***1 injectieflacon 9 ml oplossing voor injectie, 333 MBq*** | |  | ***904,30*** |  | |  |  |
| Ri-D7 **\*** | 0745-371 | 1 administration 9 mL solution injectable, 333 MBq | | 1 toediening 9 mL oplossing voor injectie, 333 MBq | |  |  | 70,0000 | |  |  |
| Ri-D7 **\*\*** | 0745-382 | 1 administration 9 mL solution injectable, 333 MBq | | 1 toediening 9 mL oplossing voor injectie, 333 MBq | |  |  | 70,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| THALLIUM (201TL) -CHLORIDE TL-201-S-1 | | | CIS BIO INTERNATIONAL SAS | |  | | | | ATC: V09GX01 | | |
|  | ***0745-371*** | ***1 flacon injectable 10 ml solution injectable, 370 MBq*** | | ***1 injectieflacon 10 ml oplossing voor injectie, 370 MBq*** | |  | ***979,90*** |  | |  |  |
| Ri-D7 **\*** | 0745-371 | 1 administration 10 mL solution injectable, 370 MBq | | 1 toediening 10 mL oplossing voor injectie, 370 MBq | |  |  | 70,0000 | |  |  |
| Ri-D7 **\*\*** | 0745-382 | 1 administration 10 mL solution injectable, 370 MBq | | 1 toediening 10 mL oplossing voor injectie, 370 MBq | |  |  | 70,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| THALLIUM (201TL) -CHLORIDE TL-201-S-1 | | | CIS BIO INTERNATIONAL SAS | |  | | | | ATC: V09GX01 | | |
|  | ***0745-371*** | ***1 flacon injectable 7 ml solution injectable, 259 MBq*** | | ***1 injectieflacon 7 ml oplossing voor injectie, 259 MBq*** | |  | ***703,20*** |  | |  |  |
| Ri-D7 **\*** | 0745-371 | 1 administration 7 mL solution injectable, 259 MBq | | 1 toediening 7 mL oplossing voor injectie, 259 MBq | |  |  | 70,0000 | |  |  |
| Ri-D7 **\*\*** | 0745-382 | 1 administration 7 mL solution injectable, 259 MBq | | 1 toediening 7 mL oplossing voor injectie, 259 MBq | |  |  | 70,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| THALLIUM (201TL) -CHLORIDE TL-201-S-1 | | | CIS BIO INTERNATIONAL SAS | |  | | | | ATC: V09GX01 | | |
|  | ***0745-371*** | ***1 flacon injectable 8 ml solution injectable, 296 MBq*** | | ***1 injectieflacon 8 ml oplossing voor injectie, 296 MBq*** | |  | ***802,70*** |  | |  |  |
| Ri-D7 **\*** | 0745-371 | 1 administration 8 mL solution injectable, 296 MBq | | 1 toediening 8 mL oplossing voor injectie, 296 MBq | |  |  | 70,0000 | |  |  |
| Ri-D7 **\*\*** | 0745-382 | 1 administration 8 mL solution injectable, 296 MBq | | 1 toediening 8 mL oplossing voor injectie, 296 MBq | |  |  | 70,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| THALLIUM (201TL)-CHLORIDE TL-201-S-1 | | | CIS BIO INTERNATIONAL SAS | |  | | | | ATC: V09GX01 | | |
|  | ***0745-371*** | ***1 flacon injectable 15 ml solution injectable, 555 MBq*** | | ***1 injectieflacon 15 ml oplossing voor injectie, 555 MBq*** | |  | ***1447,40*** |  | |  |  |
| Ri-D7 **\*** | 0745-371 | 1 administration 15 mL solution injectable, 555 MBq | | 1 toediening 15 mL oplossing voor injectie, 555 MBq | |  |  | 70,0000 | |  |  |
| Ri-D7 **\*\*** | 0745-382 | 1 administration 15 mL solution injectable, 555 MBq | | 1 toediening 15 mL oplossing voor injectie, 555 MBq | |  |  | 70,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| THALLIUM (201TL)-CHLORIDE TL-201-S-1 | | | CIS BIO INTERNATIONAL SAS | |  | | | | ATC: V09GX01 | | |
|  | ***0745-371*** | ***1 flacon injectable 1 ml solution injectable, 37 MBq*** | | ***1 injectieflacon 1 ml oplossing voor injectie, 37 MBq*** | |  | ***155,90*** |  | |  |  |
| Ri-D7 **\*** | 0745-371 | 1 administration 1 mL solution injectable, 37 MBq | | 1 toediening 1 mL oplossing voor injectie, 37 MBq | |  |  | 70,0000 | |  |  |
| Ri-D7 **\*\*** | 0745-382 | 1 administration 1 mL solution injectable, 37 MBq | | 1 toediening 1 mL oplossing voor injectie, 37 MBq | |  |  | 70,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| THALLIUM (201TL)-CHLORIDE TL-201-S-1 | | | CIS BIO INTERNATIONAL SAS | |  | | | | ATC: V09GX01 | | |
|  | ***0745-371*** | ***1 flacon injectable 6 ml solution injectable, 222 MBq*** | | ***1 injectieflacon 6 ml oplossing voor injectie, 222 MBq*** | |  | ***601,60*** |  | |  |  |
| Ri-D7 **\*** | 0745-371 | 1 administration 6 mL solution injectable, 222 MBq | | 1 toediening 6 mL oplossing voor injectie, 222 MBq | |  |  | 70,0000 | |  |  |
| Ri-D7 **\*\*** | 0745-382 | 1 administration 6 mL solution injectable, 222 MBq | | 1 toediening 6 mL oplossing voor injectie, 222 MBq | |  |  | 70,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| THALLIUM (201TL)-CHLORIDE TL-201-S-1 | | | CIS BIO INTERNATIONAL SAS | |  | | | | ATC: V09GX01 | | |
|  | ***0745-371*** | ***1 flacon injectable 3 ml solution injectable, 111 MBq*** | | ***1 injectieflacon 3 ml oplossing voor injectie, 111 MBq*** | |  | ***333,20*** |  | |  |  |
| Ri-D7 **\*** | 0745-371 | 1 administration 3 mL solution injectable, 111 MBq | | 1 toediening 3 mL oplossing voor injectie, 111 MBq | |  |  | 70,0000 | |  |  |
| Ri-D7 **\*\*** | 0745-382 | 1 administration 3 mL solution injectable, 111 MBq | | 1 toediening 3 mL oplossing voor injectie, 111 MBq | |  |  | 70,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| THALLIUM (201TL)-CHLORIDE TL-201-S-1 | | | CIS BIO INTERNATIONAL SAS | |  | | | | ATC: V09GX01 | | |
|  | ***0745-371*** | ***1 flacon injectable 4 ml solution injectable, 148 MBq*** | | ***1 injectieflacon 4 ml oplossing voor injectie, 148 MBq*** | |  | ***444,00*** |  | |  |  |
| Ri-D7 **\*** | 0745-371 | 1 administration 4 mL solution injectable, 148 MBq | | 1 toediening 4 mL oplossing voor injectie, 148 MBq | |  |  | 70,0000 | |  |  |
| Ri-D7 **\*\*** | 0745-382 | 1 administration 4 mL solution injectable, 148 MBq | | 1 toediening 4 mL oplossing voor injectie, 148 MBq | |  |  | 70,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| THALLIUM (201TL)-CHLORIDE TL-201-S-1 | | | CIS BIO INTERNATIONAL SAS | |  | | | | ATC: V09GX01 | | |
|  | ***0745-371*** | ***1 flacon injectable 5 ml solution injectable, 185 MBq*** | | ***1 injectieflacon 5 ml oplossing voor injectie, 185 MBq*** | |  | ***501,80*** |  | |  |  |
| Ri-D7 **\*** | 0745-371 | 1 administration 5 mL solution injectable, 185 MBq | | 1 toediening 5 mL oplossing voor injectie, 185 MBq | |  |  | 70,0000 | |  |  |
| Ri-D7 **\*\*** | 0745-382 | 1 administration 5 mL solution injectable, 185 MBq | | 1 toediening 5 mL oplossing voor injectie, 185 MBq | |  |  | 70,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| THALLIUM (201TL)-CHLORIDE TL-201-S-1 | | | CIS BIO INTERNATIONAL SAS | |  | | | | ATC: V09GX01 | | |
|  | ***0745-371*** | ***1 flacon injectable 2 ml solution injectable, 74 MBq*** | | ***1 injectieflacon 2 ml oplossing voor injectie, 74 MBq*** | |  | ***235,80*** |  | |  |  |
| Ri-D7 **\*** | 0745-371 | 1 administration 2 mL solution injectable, 74 MBq | | 1 toediening 2 mL oplossing voor injectie, 74 MBq | |  |  | 70,0000 | |  |  |
| Ri-D7 **\*\*** | 0745-382 | 1 administration 2 mL solution injectable, 74 MBq | | 1 toediening 2 mL oplossing voor injectie, 74 MBq | |  |  | 70,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| THALLOUS CHLORIDE (201 TL) CURIUM 37 MBq/ml | | | CURIUM BELGIUM BV | |  | | | | ATC: V09GX01 | | |
|  | ***0745-371*** | ***1 flacon injectable 1,7 ml solution injectable, 63 MBq*** | | ***1 injectieflacon 1,7 ml oplossing voor injectie, 63 MBq*** | |  | ***195,00*** |  | |  |  |
| Ri-D7 **\*** | 0745-371 | 1 administration 1,7 mL solution injectable, 63 MBq | | 1 toediening 1,7 mL oplossing voor injectie, 63 MBq | |  |  | 70,0000 | |  |  |
| Ri-D7 **\*\*** | 0745-382 | 1 administration 1,7 mL solution injectable, 63 MBq | | 1 toediening 1,7 mL oplossing voor injectie, 63 MBq | |  |  | 70,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| THALLOUS CHLORIDE (201 TL) CURIUM 37 MBq/ml | | | CURIUM BELGIUM BV | |  | | | | ATC: V09GX01 | | |
|  | ***0745-371*** | ***1 flacon injectable 2,3 ml solution injectable, 85 MBq*** | | ***1 injectieflacon 2,3 ml oplossing voor injectie, 85 MBq*** | |  | ***200,00*** |  | |  |  |
| Ri-D7 **\*** | 0745-371 | 1 administration 2,3 mL solution injectable, 85 MBq | | 1 toediening 2,3 mL oplossing voor injectie, 85 MBq | |  |  | 70,0000 | |  |  |
| Ri-D7 **\*\*** | 0745-382 | 1 administration 2,3 mL solution injectable, 85 MBq | | 1 toediening 2,3 mL oplossing voor injectie, 85 MBq | |  |  | 70,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| THALLOUS CHLORIDE (201 TL) CURIUM 37 MBq/ml | | | CURIUM BELGIUM BV | |  | | | | ATC: V09GX01 | | |
|  | ***0745-371*** | ***1 flacon injectable 5,8 ml solution injectable, 213 MBq*** | | ***1 injectieflacon 5,8 ml oplossing voor injectie, 213 MBq*** | |  | ***355,00*** |  | |  |  |
| Ri-D7 **\*** | 0745-371 | 1 administration 5,8 mL solution injectable, 213 MBq | | 1 toediening 5,8 mL oplossing voor injectie, 213 MBq | |  |  | 70,0000 | |  |  |
| Ri-D7 **\*\*** | 0745-382 | 1 administration 5,8 mL solution injectable, 213 MBq | | 1 toediening 5,8 mL oplossing voor injectie, 213 MBq | |  |  | 70,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| THALLOUS CHLORIDE (201 TL) CURIUM 37 MBq/ml | | | CURIUM BELGIUM BV | |  | | | | ATC: V09GX01 | | |
|  | ***0745-371*** | ***1 flacon injectable 10 ml solution injectable, 370 MBq*** | | ***1 injectieflacon 10 ml oplossing voor injectie, 370 MBq*** | |  | ***485,00*** |  | |  |  |
| Ri-D7 **\*** | 0745-371 | 1 administration 10 mL solution injectable, 370 MBq | | 1 toediening 10 mL oplossing voor injectie, 370 MBq | |  |  | 70,0000 | |  |  |
| Ri-D7 **\*\*** | 0745-382 | 1 administration 10 mL solution injectable, 370 MBq | | 1 toediening 10 mL oplossing voor injectie, 370 MBq | |  |  | 70,0000 | |  |  |
|  |  |  | |  | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | | |  | | | | | |
| **Paragraphe 10011** | | | | **Paragraaf 10011** | | | | | |
| § 10011 est supprimé au 01/01/2021. | | | | § 10011 is geschrapt op 01/01/2021. | | | | | |
|  | | | |  | | | | | |
| **Paragraphe 10012** | | | | **Paragraaf 10012** | | | | | |
| Produits radio-pharmaceutiques à base de citrate de gallium (Ga-67) - catégorie de remboursement Ri-D7 | | | | Radiofarmaceutische producten op basis van gallium (Ga-67) citraat - vergoedingscategorie Ri-D7 | | | | | |
|  | | | |  | | | | | |
| Dénomination / Benaming (Demandeur/Aanvrager) | | | | | | | | | |
| Cat. | Code | Conditionnements | Verpakkingen | | Obs  Opm | Prix  Prijs  ***ex-usine / buiten bedrijf*** | Base de remb  Basis v tegem  ***ex-usine / buiten bedrijf*** | I | II |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| GALLIUM [67 GA] CITRAAT CURIUM 37 MBq/ml | | | CURIUM BELGIUM BV | |  | | | | ATC: V09HX01 | | |
|  | ***0745-415*** | ***1 flacon injectable 2,2 ml solution injectable, 82 MBq*** | | ***1 injectieflacon 2,2 ml oplossing voor injectie, 82 MBq*** | |  | ***280,00*** |  | |  |  |
| Ri-D7 **\*** | 0745-415 | 1 administration 2,2 mL solution injectable, 82 MBq | | 1 toediening 2,2 mL oplossing voor injectie, 82 MBq | |  |  | 70,0000 | |  |  |
| Ri-D7 **\*\*** | 0745-426 | 1 administration 2,2 mL solution injectable, 82 MBq | | 1 toediening 2,2 mL oplossing voor injectie, 82 MBq | |  |  | 70,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| GALLIUM [67 GA] CITRAAT CURIUM 37 MBq/ml | | | CURIUM BELGIUM BV | |  | | | | ATC: V09HX01 | | |
|  | ***0745-415*** | ***1 flacon injectable 3,3 ml solution injectable, 123 MBq*** | | ***1 injectieflacon 3,3 ml oplossing voor injectie, 123 MBq*** | |  | ***322,00*** |  | |  |  |
| Ri-D7 **\*** | 0745-415 | 1 administration 3,3 mL solution injectable, 123 MBq | | 1 toediening 3,3 mL oplossing voor injectie, 123 MBq | |  |  | 70,0000 | |  |  |
| Ri-D7 **\*\*** | 0745-426 | 1 administration 3,3 mL solution injectable, 123 MBq | | 1 toediening 3,3 mL oplossing voor injectie, 123 MBq | |  |  | 70,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| GALLIUM [67 GA] CITRAAT CURIUM 37 MBq/ml | | | CURIUM BELGIUM BV | |  | | | | ATC: V09HX01 | | |
|  | ***0745-415*** | ***1 flacon injectable 5,5 ml solution injectable, 205 MBq*** | | ***1 injectieflacon 5,5 ml oplossing voor injectie, 205 MBq*** | |  | ***459,00*** |  | |  |  |
| Ri-D7 **\*** | 0745-415 | 1 administration 5,5 mL solution injectable, 205 MBq | | 1 toediening 5,5 mL oplossing voor injectie, 205 MBq | |  |  | 70,0000 | |  |  |
| Ri-D7 **\*\*** | 0745-426 | 1 administration 5,5 mL solution injectable, 205 MBq | | 1 toediening 5,5 mL oplossing voor injectie, 205 MBq | |  |  | 70,0000 | |  |  |
|  |  |  | |  | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | | |  | | | | | |
| **Paragraphe 10013** | | | | **Paragraaf 10013** | | | | | |
| Produits radio-pharmaceutiques à base de chlorure d'indium (In-111) - catégorie de remboursement Ri-D7 - domaine d’application diagnostique: sang | | | | Radiofarmaceutische producten op basis van indium (In-111)-chloride - vergoedingscategorie Ri-D7 – toepassingsgebied diagnostiek: bloed | | | | | |
|  | | | |  | | | | | |
| Dénomination / Benaming (Demandeur/Aanvrager) | | | | | | | | | |
| Cat. | Code | Conditionnements | Verpakkingen | | Obs  Opm | Prix  Prijs  ***ex-usine / buiten bedrijf*** | Base de remb  Basis v tegem  ***ex-usine / buiten bedrijf*** | I | II |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| INDIUM (IN-111) CHLORIDE CURIUM 370 MBq/ml | | | CURIUM BELGIUM BV | |  | | | | ATC: V09IB | | |
|  | ***0747-692*** | ***1 flacon injectable 0,5 ml précurseurs radiopharmaceutiques, 185 MBq*** | | ***1 injectieflacon 0,5 ml radiofarmaceutische uitgangsstof, 185 MBq*** | |  | ***690,00*** |  | |  |  |
| Ri-D7 **\*** | 0747-692 | 1 administration 0,5 mL solution injectable, 185 MBq | | 1 toediening 0,5 mL oplossing voor injectie, 185 MBq | |  |  | 70,0000 | |  |  |
| Ri-D7 **\*\*** | 0747-703 | 1 administration 0,5 mL solution injectable, 185 MBq | | 1 toediening 0,5 mL oplossing voor injectie, 185 MBq | |  |  | 70,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| INDIUM (IN-111) CHLORIDE CURIUM 370 MBq/ml | | | CURIUM BELGIUM BV | |  | | | | ATC: V09IB | | |
|  | ***0747-692*** | ***1 flacon injectable 0,3 ml précurseurs radiopharmaceutiques, 111 MBq*** | | ***1 injectieflacon 0,3 ml radiofarmaceutische uitgangsstof, 111 MBq*** | |  | ***637,50*** |  | |  |  |
| Ri-D7 **\*** | 0747-692 | 1 administration 0,3 mL solution injectable, 111 MBq | | 1 toediening 0,3 mL oplossing voor injectie, 111 MBq | |  |  | 70,0000 | |  |  |
| Ri-D7 **\*\*** | 0747-703 | 1 administration 0,3 mL solution injectable, 111 MBq | | 1 toediening 0,3 mL oplossing voor injectie, 111 MBq | |  |  | 70,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| INDIUM (IN-111) CHLORIDE CURIUM 370 MBq/ml | | | CURIUM BELGIUM BV | |  | | | | ATC: V09IB | | |
|  | ***0747-692*** | ***1 flacon injectable 1 ml précurseur radiopharmaceutique, 370 MBq*** | | ***1 injectieflacon 1 ml radiofarmaceutische uitgangsstof, 370 MBq*** | |  | ***742,50*** |  | |  |  |
| Ri-D7 **\*** | 0747-692 | 1 administration 1 mL solution injectable, 370 MBq | | 1 toediening 1 mL oplossing voor injectie, 370 MBq | |  |  | 70,0000 | |  |  |
| Ri-D7 **\*\*** | 0747-703 | 1 administration 1 mL solution injectable, 370 MBq | | 1 toediening 1 mL oplossing voor injectie, 370 MBq | |  |  | 70,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| INDIUM (IN-111) CHLORIDE CURIUM 370 MBq/ml | | | CURIUM BELGIUM BV | |  | | | | ATC: V09IB | | |
|  | ***0747-692*** | ***1 flacon injectable 1,5 ml précurseurs radiopharmaceutiques, 555 MBq*** | | ***1 injectieflacon 1,5 ml radiofarmaceutische uitgangsstof, 555 MBq*** | |  | ***793,00*** |  | |  |  |
| Ri-D7 **\*** | 0747-692 | 1 administration 1,5 mL solution injectable, 555 MBq | | 1 toediening 1,5 mL oplossing voor injectie, 555 MBq | |  |  | 70,0000 | |  |  |
| Ri-D7 **\*\*** | 0747-703 | 1 administration 1,5 mL solution injectable, 555 MBq | | 1 toediening 1,5 mL oplossing voor injectie, 555 MBq | |  |  | 70,0000 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| INDIUM (IN-111) CHLORIDE CURIUM 370MBq/ml | | | CURIUM BELGIUM BV | |  | | | | ATC: V09IB | | |
|  | ***0747-692*** | ***1 flacon injectable 2 ml précurseurs radiopharmaceutiques, 740 MBq*** | | ***1 injectieflacon 2 ml radiofarmaceutische uitgangsstof, 740 MBq*** | |  | ***845,50*** |  | |  |  |
| Ri-D7 **\*** | 0747-692 | 1 administration 2 mL solution injectable, 740 MBq | | 1 toediening 2 mL oplossing voor injectie, 740 MBq | |  |  | 70,0000 | |  |  |
| Ri-D7 **\*\*** | 0747-703 | 1 administration 2 mL solution injectable, 740 MBq | | 1 toediening 2 mL oplossing voor injectie, 740 MBq | |  |  | 70,0000 | |  |  |
|  |  |  | |  | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | | |  | | | | | |
| **Paragraphe 10014** | | | | **Paragraaf 10014** | | | | | |
| Produits radio-pharmaceutiques à base d’ oxine d'indium (In-111) - catégorie de remboursement Ri-D7 - domaine d’application diagnostique : sang | | | | Radiofarmaceutische producten op basis van indium (In-111)-oxine - vergoedingscategorie Ri-D7 – toepassingsgebied diagnostiek: bloed | | | | | |
|  | | | |  | | | | | |
| Dénomination / Benaming (Demandeur/Aanvrager) | | | | | | | | | |
| Cat. | Code | Conditionnements | Verpakkingen | | Obs  Opm | Prix  Prijs  ***ex-usine / buiten bedrijf*** | Base de remb  Basis v tegem  ***ex-usine / buiten bedrijf*** | I | II |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| INDIUM (IN-111) OXINATE CURIUM 37 Mbq/ml | | | CURIUM BELGIUM BV | |  | | | | ATC: V09IB | | |
|  | ***0745-452*** | ***1 flacon injectable 1 ml précurseur radiopharmaceutique, 37 MBq*** | | ***1 injectieflacon 1 ml radiofarmaceutische uitgangsstof, 37 MBq*** | |  | ***291,00*** |  | |  |  |
| Ri-D7 **\*** | 0745-452 | 1 administration 1 mL solution injectable, 37 MBq | | 1 toediening 1 mL oplossing voor injectie, 37 MBq | |  |  | 70,0000 | |  |  |
| Ri-D7 **\*\*** | 0745-463 | 1 administration 1 mL solution injectable, 37 MBq | | 1 toediening 1 mL oplossing voor injectie, 37 MBq | |  |  | 70,0000 | |  |  |
|  |  |  | |  | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | | | |  | | | | | | |
| **Paragraphe 10015** | | | | | **Paragraaf 10015** | | | | | | |
| Produits radio-pharmaceutiques à base de fluor (F-18) catégorie de remboursement Ri-D12 - domaine d’application diagnostique: neuro | | | | | Radiofarmaceutische producten op basis van fluor (F-18) vergoedingscategorie Ri-D12 – toepassingsgebied diagnostiek : neuro | | | | | | |
| Les produits inscrits dans ce paragraphe sont remboursables dans la catégorie de remboursement Ri-D12 s’ils sont utilisés pour effectuer un examen de positrontomographie, lorsque toutes les conditions suivantes sont remplies simultanément: | | | | | De producten ingeschreven in deze paragraaf zijn vergoedbaar in de vergoedingscategorie Ri-D12 indien ze aangewend worden voor een positrontomografie onder de volgende voorwaarden simultaan voldaan: | | | | | | |
|  | 1. l’examen n’a encore jamais été remboursé chez le bénéficiaire concerné; | | | |  | 1. het onderzoek is nog nooit terugbetaald geweest bij de betrokken rechthebbende; | | | | | |
|  | 2. l’examen concerne un bénéficiaire adulte et est destiné à établir un diagnostic différentiel entre tremblement essentiel et syndromes parkinsoniens et/ou démence de type Lewy bodies; | | | |  | 2. het onderzoek betreft een volwassen rechthebende en is bestemd om een differentiële diagnose te maken tussen essentiële tremor en parkinsonsyndromen en/of dementie type Lewy bodies; | | | | | |
|  | 3. un médecin spécialiste en neurologie, psychiatrie ou en neuropsychiatrie a attesté que l’anamnèse et l’examen clinique ne sont pas suffisamment contributifs pour établir ce diagnostic différentiel; | | | |  | 3. de arts gespecialiseerd in neurologie, psychiatrie of neuropsychiatrie attesteert dat de anamnese en het klinisch onderzoek niet voldoende bijdragen tot deze differentiële diagnose; | | | | | |
|  | 4. l’activité maximale remboursable est 110 MBq. | | | |  | 4. de maximale terugbetaalbare activiteit is 110 MBq. | | | | | |
|  | 5. le remboursement n’est pas cumulable avec le remboursement de [123I]FP-CIT SPECT à vie | | | |  | 5. terugbetaling niet cumuleerbaar met [123I]FP-CIT SPECT voor het leven | | | | | |
| A cet effet, et dans la mesure où cette démarche n’a pas encore été accomplie au moment de la facture, il y a lieu de joindre à la facture intégrée individuelle du bénéficiaire concerné un rapport médical circonstancié rédigé confidentiellement à l’intention du médecin-conseil de l’organisme assureur par le médecin spécialiste en neurologie ou en neuropsychiatrie, qui confirme que toutes les conditions mentionnées ci-dessus sont rencontrées. | | | | | Hiertoe, en in de mate dat dit nog niet is gebeurd op het ogenblik van facturatie, is er reden om aan de factuur van de individuele rechthebbende ten behoeve van de adviserend-arts van het verzekeringsorganisme door de arts gespecialiseerd in neurologie of neuropsychiatrie, een omstandig vertrouwelijk medisch rapport toe te voegen dat bevestigt dat aan alle hiervoor opgesomde voorwaarden is voldaan. | | | | | | |
|  | | | | |  | | | | | | |
| Dénomination / Benaming (Demandeur/Aanvrager) | | | | | | | | | | | |
| Cat. | | Code | Conditionnements | Verpakkingen | | | Obs  Opm | Prix  Prijs  ***ex-usine / buiten bedrijf*** | Base de remb  Basis v tegem  ***ex-usine / buiten bedrijf*** | I | II |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| F-18-PE2I (UZ Leuven) | | | Katholieke Universiteit te Leuven | |  | | | | ATC: | | |
|  | ***0749-475*** | ***1 solution injectable*** | | ***1 oplossing voor injectie*** | |  | ***550,00*** |  | |  |  |
| Ri-D12 **\*** | 0749-475 | 1 administration 25 mL solution injectable, 1 dose | | 1 toediening 25 mL oplossing voor injectie, 1 dosis | |  |  | 487,2600 | |  |  |
| Ri-D12 **\*\*** | 0749-486 | 1 administration 25 mL solution injectable, 1 dose | | 1 toediening 25 mL oplossing voor injectie, 1 dosis | |  |  | 487,2600 | |  |  |
|  |  |  | |  | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | | |  | | | | | |
| **Paragraphe 10016** | | | | **Paragraaf 10016** | | | | | |
| Produits radio-pharmaceutiques à base de fluor (F-18) octréotide catégorie de remboursement Ri-D13 - domaine d’application diagnostique: tumeur | | | | Radiofarmaceutische producten op basis van fluor (F-18) octreotide vergoedingscategorie Ri-D13 – toepassingsgebied diagnostiek: tumor | | | | | |
| Les produits inscrits dans ce paragraphe sont remboursables dans la catégorie de remboursement Ri-D13 s’ils sont utilisés pour la localisation visuelle de tumeurs exprimant des récepteurs à la somatostatine au moyen d’une tomographie à positrons telle que prévue au n° 442971 – 442982 de la nomenclature. | | | | De producten ingeschreven in deze paragraaf zijn vergoedbaar in de vergoedingscategorie Ri-D13 indien ze aangewend worden voor de visuele plaatsbepaling van somatostatinereceptor (SSTR) exprimerende tumoren door middel van een positronentomografie zoals voorzien is onder nr. 442971 – 442982 van de nomenclatuur. | | | | | |
|  | | | |  | | | | | |
| Dénomination / Benaming (Demandeur/Aanvrager) | | | | | | | | | |
| Cat. | Code | Conditionnements | Verpakkingen | | Obs  Opm | Prix  Prijs  ***ex-usine / buiten bedrijf*** | Base de remb  Basis v tegem  ***ex-usine / buiten bedrijf*** | I | II |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 18F-OCTREOTIDE (UZ LEUVEN) | | | Katholieke Universiteit te Leuven | |  | | | | ATC: | | |
|  | ***0749-976*** | ***1 flacon 25 mL solution injectable, 1 dose*** | | ***1 fles 25 mL oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D13 **\*** | 0749-976 | 1 administration 25 mL solution injectable, 1 dose | | 1 toediening 25 mL oplossing voor injectie, 1 dosis | |  |  | 410,0000 | |  |  |
| Ri-D13 **\*\*** | 0749-980 | 1 administration 25 mL solution injectable, 1 dose | | 1 toediening 25 mL oplossing voor injectie, 1 dosis | |  |  | 410,0000 | |  |  |
|  |  |  | |  | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | | |  | | | | | |
| **Paragraphe 20001** | | | | **Paragraaf 20001** | | | | | |
| Eléments sanguins figurés ou protéines plasmatiques du patient, à marquer extracorporellement par des molécules inorganiques - catégorie de remboursement Ri-D10 | | | | Gefigureerde bloedelementen of plasmaprotëinen van de patiënt ter extracorporeale merking met anorganische molekulen - vergoedingscategorie Ri-D10 | | | | | |
|  | | | |  | | | | | |
| Dénomination / Benaming (Demandeur/Aanvrager) | | | | | | | | | |
| Cat. | Code | Conditionnements | Verpakkingen | | Obs  Opm | Prix  Prijs  ***ex-usine / buiten bedrijf*** | Base de remb  Basis v tegem  ***ex-usine / buiten bedrijf*** | I | II |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| BLOEDELEMENTEN ELEMENTS SANGUINS | | | HOSPITALS ALL | |  | | | | ATC: | | |
|  | ***0745-474*** | ***1 solution injectable, 1 dose*** | | ***1 oplossing voor injectie, 1 dosis*** | |  |  |  | |  |  |
| Ri-D10 **\*** | 0745-474 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  | 6,2000 | |  |  |
| Ri-D10 **\*\*** | 0745-485 | 1 administration 1 mL solution injectable, 1 dose | | 1 toediening 1 mL oplossing voor injectie, 1 dosis | |  |  | 6,2000 | |  |  |
|  |  |  | |  | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | | |  | | | | | |
| **Paragraphe 20002** | | | | **Paragraaf 20002** | | | | | |
| Produits radio-pharmaceutiques à base d’ examétazine -catégorie de remboursement Ri-D11 - domaine d’application diagnostique: neuro | | | | Radiofarmaceutische producten op basis van exametazine -vergoedingscategorie Ri-D11 – toepassingsgebied diagnostiek: neuro | | | | | |
|  | | | |  | | | | | |
| Dénomination / Benaming (Demandeur/Aanvrager) | | | | | | | | | |
| Cat. | Code | Conditionnements | Verpakkingen | | Obs  Opm | Prix  Prijs  ***ex-usine / buiten bedrijf*** | Base de remb  Basis v tegem  ***ex-usine / buiten bedrijf*** | I | II |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| STABILISED CERETEC | | | GE HEALTHCARE | |  | | | | ATC: V09AA01 | | |
|  | ***0745-496*** | ***1 flacon injectable 0,5 mg poudre pour solution injectable, 0,5 mg*** | | ***1 injectieflacon 0,5 mg poeder voor oplossing voor injectie, 0,5 mg*** | |  | ***794,00*** |  | |  |  |
| Ri-D11 **\*** | 0745-496 | 1 administration 0,5 mg solution injectable, 0,5 mg | | 1 toediening 0,5 mg oplossing voor injectie, 0,5 mg | |  |  | 18,5900 | |  |  |
| Ri-D11 **\*\*** | 0745-500 | 1 administration 0,5 mg solution injectable, 0,5 mg | | 1 toediening 0,5 mg oplossing voor injectie, 0,5 mg | |  |  | 18,5900 | |  |  |
|  |  |  | |  | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | | |  | | | | | |
| **Paragraphe 20003** | | | | **Paragraaf 20003** | | | | | |
| Produits radio-pharmaceutiques à base d’ examétazine -catégorie de remboursement Ri-D11 - domaine d’application diagnostique: sang | | | | Radiofarmaceutische producten op basis van exametazine -vergoedingscategorie Ri-D11 – toepassingsgebied diagnostiek: bloed | | | | | |
|  | | | |  | | | | | |
| Dénomination / Benaming (Demandeur/Aanvrager) | | | | | | | | | |
| Cat. | Code | Conditionnements | Verpakkingen | | Obs  Opm | Prix  Prijs  ***ex-usine / buiten bedrijf*** | Base de remb  Basis v tegem  ***ex-usine / buiten bedrijf*** | I | II |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| STABILISED CERETEC | | | GE HEALTHCARE | |  | | | | ATC: V09AA01 | | |
|  | ***0745-511*** | ***1 flacon injectable 0,5 mg poudre pour solution injectable, 0,5 mg*** | | ***1 injectieflacon 0,5 mg poeder voor oplossing voor injectie, 0,5 mg*** | |  | ***794,00*** |  | |  |  |
| Ri-D11 **\*** | 0745-511 | 1 administration 0,5 mg solution injectable, 0,5 mg | | 1 toediening 0,5 mg oplossing voor injectie, 0,5 mg | |  |  | 18,5900 | |  |  |
| Ri-D11 **\*\*** | 0745-522 | 1 administration 0,5 mg solution injectable, 0,5 mg | | 1 toediening 0,5 mg oplossing voor injectie, 0,5 mg | |  |  | 18,5900 | |  |  |
|  |  |  | |  | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | | |  | | | | | |
| **Paragraphe 20004** | | | | **Paragraaf 20004** | | | | | |
| Produits radio-pharmaceutiques à base de bicisate - catégorie de remboursement Ri-D11 - domaine d’application diagnostique: neuro | | | | Radiofarmaceutische producten op basis van bicisaat - vergoedingscategorie Ri-D11 – toepassingsgebied diagnostiek: neuro | | | | | |
|  | | | |  | | | | | |
| Dénomination / Benaming (Demandeur/Aanvrager) | | | | | | | | | |
| Cat. | Code | Conditionnements | Verpakkingen | | Obs  Opm | Prix  Prijs  ***ex-usine / buiten bedrijf*** | Base de remb  Basis v tegem  ***ex-usine / buiten bedrijf*** | I | II |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| NEUROLITE | | | CIS BIO INTERNATIONAL SAS | |  | | | | ATC: V09AA02 | | |
|  | ***0745-533*** | ***1 flacon injectable 1 solvant pour solution injectable, 900 µg*** | | ***1 injectieflacon 1 oplosmiddel voor oplossing voor injectie, 900 µg*** | |  | ***191,37*** |  | |  |  |
| Ri-D11 **\*** | 0745-533 | 1 administration 900 mL solution injectable, 900 µg | | 1 toediening 900 mL oplossing voor injectie, 900 µg | |  |  | 18,5900 | |  |  |
| Ri-D11 **\*\*** | 0745-544 | 1 administration 900 mL solution injectable, 900 µg | | 1 toediening 900 mL oplossing voor injectie, 900 µg | |  |  | 18,5900 | |  |  |
|  |  |  | |  | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | | |  | | | | | |
| **Paragraphe 20005** | | | | **Paragraaf 20005** | | | | | |
| Produits radio-pharmaceutiques à base de pyrophosphate de sodium - catégorie de remboursement Ri-D11 - domaine d’application diagnostique: sang | | | | Radiofarmaceutische producten op basis van natriumpyrofosfaat - vergoedingscategorie Ri-D11 – toepassingsgebied diagnostiek: bloed | | | | | |
|  | | | |  | | | | | |
| Dénomination / Benaming (Demandeur/Aanvrager) | | | | | | | | | |
| Cat. | Code | Conditionnements | Verpakkingen | | Obs  Opm | Prix  Prijs  ***ex-usine / buiten bedrijf*** | Base de remb  Basis v tegem  ***ex-usine / buiten bedrijf*** | I | II |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ANGIOCIS | | | CIS BIO INTERNATIONAL SAS | |  | | | | ATC: V09GA06 | | |
|  | ***0745-555*** | ***5 flacons injectables 20 mg poudre pour solution injectable, 20,12 mg*** | | ***5 injectieflacons 20 mg poeder voor oplossing voor injectie, 20,12 mg*** | |  | ***300,00*** |  | |  |  |
| Ri-D11 **\*** | 0745-555 | 1 administration 20 mg solution injectable, 20,12 mg | | 1 toediening 20 mg oplossing voor injectie, 20,12 mg | |  |  | 18,5900 | |  |  |
| Ri-D11 **\*\*** | 0745-566 | 1 administration 20 mg solution injectable, 20,12 mg | | 1 toediening 20 mg oplossing voor injectie, 20,12 mg | |  |  | 18,5900 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| TECHNESCAN PYP | | | CURIUM BELGIUM BV | |  | | | | ATC: V09GA06 | | |
|  | ***0745-555*** | ***5 flacons injectables 11,9 mg poudre pour solution injectable, 11,9 mg*** | | ***5 injectieflacons 11,9 mg poeder voor oplossing voor injectie, 11,9 mg*** | |  | ***210,00*** |  | |  |  |
| Ri-D11 **\*** | 0745-555 | 1 administration 11,9 mg solution injectable, 11,9 mg | | 1 toediening 11,9 mg oplossing voor injectie, 11,9 mg | |  |  | 18,5900 | |  |  |
| Ri-D11 **\*\*** | 0745-566 | 1 administration 11,9 mg solution injectable, 11,9 mg | | 1 toediening 11,9 mg oplossing voor injectie, 11,9 mg | |  |  | 18,5900 | |  |  |
|  |  |  | |  | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | | |  | | | | | |
| **Paragraphe 20006** | | | | **Paragraaf 20006** | | | | | |
| Produits radio-pharmaceutiques à base d’ oxydronate de sodium - catégorie de remboursement Ri-D11 - domaine d’application diagnostique: squelette | | | | Radiofarmaceutische producten op basis van natriumoxidronaat - vergoedingscategorie Ri-D11 – toepassingsgebied diagnostiek: skelet | | | | | |
|  | | | |  | | | | | |
| Dénomination / Benaming (Demandeur/Aanvrager) | | | | | | | | | |
| Cat. | Code | Conditionnements | Verpakkingen | | Obs  Opm | Prix  Prijs  ***ex-usine / buiten bedrijf*** | Base de remb  Basis v tegem  ***ex-usine / buiten bedrijf*** | I | II |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| OSTEOCIS | | | CIS BIO INTERNATIONAL SAS | |  | | | | ATC: V09BA01 | | |
|  | ***0745-570*** | ***5 flacons injectables 3 mg poudre pour solution injectable, 3 mg*** | | ***5 injectieflacons 3 mg poeder voor oplossing voor injectie, 3 mg*** | |  | ***309,00*** |  | |  |  |
| Ri-D11 **\*** | 0745-570 | 1 administration 3 mg solution injectable, 3 mg | | 1 toediening 3 mg oplossing voor injectie, 3 mg | |  |  | 18,5900 | |  |  |
| Ri-D11 **\*\*** | 0745-581 | 1 administration 3 mg solution injectable, 3 mg | | 1 toediening 3 mg oplossing voor injectie, 3 mg | |  |  | 18,5900 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| TECHNESCAN HDP | | | CURIUM BELGIUM BV | |  | | | | ATC: V09BA01 | | |
|  | ***0745-570*** | ***5 flacons injectables 3 mg poudre pour solution injectable, 3 mg*** | | ***5 injectieflacons 3 mg poeder voor oplossing voor injectie, 3 mg*** | |  | ***210,00*** |  | |  |  |
| Ri-D11 **\*** | 0745-570 | 1 administration 3 mg solution injectable, 3 mg | | 1 toediening 3 mg oplossing voor injectie, 3 mg | |  |  | 18,5900 | |  |  |
| Ri-D11 **\*\*** | 0745-581 | 1 administration 3 mg solution injectable, 3 mg | | 1 toediening 3 mg oplossing voor injectie, 3 mg | |  |  | 18,5900 | |  |  |
|  |  |  | |  | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | | |  | | | | | |
| **Paragraphe 20007** | | | | **Paragraaf 20007** | | | | | |
| Produits radio-pharmaceutiques à base d’ oxydronate de sodium - catégorie de remboursement Ri-D11 - domaine d’application diagnostique: poumons-ventilation | | | | Radiofarmaceutische producten op basis van natriumoxidronaat - vergoedingscategorie Ri-D11 – toepassingsgebied diagnostiek: longen-ventilatie | | | | | |
|  | | | |  | | | | | |
| Dénomination / Benaming (Demandeur/Aanvrager) | | | | | | | | | |
| Cat. | Code | Conditionnements | Verpakkingen | | Obs  Opm | Prix  Prijs  ***ex-usine / buiten bedrijf*** | Base de remb  Basis v tegem  ***ex-usine / buiten bedrijf*** | I | II |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| TECHNESCAN HDP | | | CURIUM BELGIUM BV | |  | | | | ATC: V09BA01 | | |
|  | ***0745-592*** | ***5 flacons injectables 3 mg poudre pour solution injectable, 3 mg*** | | ***5 injectieflacons 3 mg poeder voor oplossing voor injectie, 3 mg*** | |  | ***210,00*** |  | |  |  |
| Ri-D11 **\*** | 0745-592 | 1 administration 3 mg solution injectable, 3 mg | | 1 toediening 3 mg oplossing voor injectie, 3 mg | |  |  | 18,5900 | |  |  |
| Ri-D11 **\*\*** | 0745-603 | 1 administration 3 mg solution injectable, 3 mg | | 1 toediening 3 mg oplossing voor injectie, 3 mg | |  |  | 18,5900 | |  |  |
|  |  |  | |  | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | | |  | | | | | |
| **Paragraphe 20008** | | | | **Paragraaf 20008** | | | | | |
| § 20008 est supprimé au 01/08/2020. | | | | § 20008 is geschrapt op 01/08/2020. | | | | | |
|  | | | |  | | | | | |
| **Paragraphe 20009** | | | | **Paragraaf 20009** | | | | | |
| Produits radio-pharmaceutiques à base de pentétate de calcium trisodique - catégorie de remboursement Ri-D11 - domaine d’application diagnostique: reins | | | | Radiofarmaceutische producten op basis van calciumtrinatriumpentetaat - vergoedingscategorie Ri-D11 – toepassingsgebied diagnostiek: nieren | | | | | |
|  | | | |  | | | | | |
| Dénomination / Benaming (Demandeur/Aanvrager) | | | | | | | | | |
| Cat. | Code | Conditionnements | Verpakkingen | | Obs  Opm | Prix  Prijs  ***ex-usine / buiten bedrijf*** | Base de remb  Basis v tegem  ***ex-usine / buiten bedrijf*** | I | II |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| TECHNESCAN DTPA | | | CURIUM BELGIUM BV | |  | | | | ATC: V09CA01 | | |
|  | ***0745-636*** | ***5 flacons injectables 25 mg poudre pour solution injectable, 25 mg*** | | ***5 injectieflacons 25 mg poeder voor oplossing voor injectie, 25 mg*** | |  | ***210,00*** |  | |  |  |
| Ri-D11 **\*** | 0745-636 | 1 administration 25 mg solution injectable, 25 mg | | 1 toediening 25 mg oplossing voor injectie, 25 mg | |  |  | 18,5900 | |  |  |
| Ri-D11 **\*\*** | 0745-640 | 1 administration 25 mg solution injectable, 25 mg | | 1 toediening 25 mg oplossing voor injectie, 25 mg | |  |  | 18,5900 | |  |  |
|  |  |  | |  | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | | |  | | | | | |
| **Paragraphe 20010** | | | | **Paragraaf 20010** | | | | | |
| Produits radio-pharmaceutiques à base de pentétate de calcium trisodique - catégorie de remboursement Ri-D11 - domaine d’application diagnostique: poumons-ventilation | | | | Radiofarmaceutische producten op basis van calciumtrinatriumpentetaat - vergoedingscategorie Ri-D11 – toepassingsgebied diagnostiek: longen-ventilatie | | | | | |
|  | | | |  | | | | | |
| Dénomination / Benaming (Demandeur/Aanvrager) | | | | | | | | | |
| Cat. | Code | Conditionnements | Verpakkingen | | Obs  Opm | Prix  Prijs  ***ex-usine / buiten bedrijf*** | Base de remb  Basis v tegem  ***ex-usine / buiten bedrijf*** | I | II |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| TECHNESCAN DTPA | | | CURIUM BELGIUM BV | |  | | | | ATC: V09CA01 | | |
|  | ***0745-651*** | ***5 flacons injectables 25 mg poudre pour solution injectable, 25 mg*** | | ***5 injectieflacons 25 mg poeder voor oplossing voor injectie, 25 mg*** | |  | ***210,00*** |  | |  |  |
| Ri-D11 **\*** | 0745-651 | 1 administration 25 mg solution injectable, 25 mg | | 1 toediening 25 mg oplossing voor injectie, 25 mg | |  |  | 18,5900 | |  |  |
| Ri-D11 **\*\*** | 0745-662 | 1 administration 25 mg solution injectable, 25 mg | | 1 toediening 25 mg oplossing voor injectie, 25 mg | |  |  | 18,5900 | |  |  |
|  |  |  | |  | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | | |  | | | | | |
| **Paragraphe 20011** | | | | **Paragraaf 20011** | | | | | |
| Produits radio-pharmaceutiques à base d’ acide dimercaptosuccinique - catégorie de remboursement Ri-D11 - domaine d’application diagnostique: reins | | | | Radiofarmaceutische producten op basis van dimercaptobarnsteenzuur - vergoedingscategorie Ri-D11 – toepassingsgebied diagnostique: nieren | | | | | |
|  | | | |  | | | | | |
| Dénomination / Benaming (Demandeur/Aanvrager) | | | | | | | | | |
| Cat. | Code | Conditionnements | Verpakkingen | | Obs  Opm | Prix  Prijs  ***ex-usine / buiten bedrijf*** | Base de remb  Basis v tegem  ***ex-usine / buiten bedrijf*** | I | II |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| TECHESCAN DMSA | | | CURIUM BELGIUM BV | |  | | | | ATC: V09CA02 | | |
|  | ***0745-673*** | ***5 flacons injectables 1,2 mg poudre pour solution injectable, 1,2 mg*** | | ***5 injectieflacons 1,2 mg poeder voor oplossing voor injectie, 1,2 mg*** | |  | ***210,00*** |  | |  |  |
| Ri-D11 **\*** | 0745-673 | 1 administration 1,2 mg solution injectable, 1,2 mg | | 1 toediening 1,2 mg oplossing voor injectie, 1,2 mg | |  |  | 18,5900 | |  |  |
| Ri-D11 **\*\*** | 0745-684 | 1 administration 1,2 mg solution injectable, 1,2 mg | | 1 toediening 1,2 mg oplossing voor injectie, 1,2 mg | |  |  | 18,5900 | |  |  |
|  |  |  | |  | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | | |  | | | | | |
| **Paragraphe 20012** | | | | **Paragraaf 20012** | | | | | |
| Produits radio-pharmaceutiques à base de mercaptoacétyltriglycine ou dérivé – catégorie de remboursement Ri-D11 – domaine d’application diagnostique: reins | | | | Radiofarmaceutische producten op mercaptoacetyltriglycine of derivaat – vergoedingscategorie Ri-D11 – toepassingsgebied diagnostiek: nieren | | | | | |
|  | | | |  | | | | | |
| Dénomination / Benaming (Demandeur/Aanvrager) | | | | | | | | | |
| Cat. | Code | Conditionnements | Verpakkingen | | Obs  Opm | Prix  Prijs  ***ex-usine / buiten bedrijf*** | Base de remb  Basis v tegem  ***ex-usine / buiten bedrijf*** | I | II |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| NephroMAG | | | ROTOP PHARMAKA GmbH | |  | | | | ATC: V09CA03 | | |
|  | ***0745-695*** | ***5 flacons injectables 0,2 mg poudre pour solution injectable, 0,2 mg*** | | ***5 injectieflacons 0,2 mg poeder voor oplossing voor injectie, 0,2 mg*** | |  | ***450,00*** |  | |  |  |
| Ri-D11 **\*** | 0745-695 | 1 administration 0,2 mg solution injectable, 0,2 mg | | 1 toediening 0,2 mg oplossing voor injectie, 0,2 mg | |  |  | 18,5900 | |  |  |
| Ri-D11 **\*\*** | 0745-706 | 1 administration 0,2 mg solution injectable, 0,2 mg | | 1 toediening 0,2 mg oplossing voor injectie, 0,2 mg | |  |  | 18,5900 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| TECHNESCAN MAG3 | | | CURIUM BELGIUM BV | |  | | | | ATC: V09CA03 | | |
|  | ***0745-695*** | ***5 flacons injectables 1 mg poudre pour solution injectable, 1 mg*** | | ***5 injectieflacons 1 mg poeder voor oplossing voor injectie, 1 mg*** | |  | ***560,00*** |  | |  |  |
| Ri-D11 **\*** | 0745-695 | 1 administration 1 mg solution injectable, 1 mg | | 1 toediening 1 mg oplossing voor injectie, 1 mg | |  |  | 18,5900 | |  |  |
| Ri-D11 **\*\*** | 0745-706 | 1 administration 1 mg solution injectable, 1 mg | | 1 toediening 1 mg oplossing voor injectie, 1 mg | |  |  | 18,5900 | |  |  |
|  |  |  | |  | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | | |  | | | | | |
| **Paragraphe 20013** | | | | **Paragraaf 20013** | | | | | |
| Produits radio-pharmaceutiques à base d’ ethylène dicystéïne - catégorie de remboursement Ri-D11 - domaine d’application diagnostique: reins | | | | Radiofarmaceutische producten op basis van etheendicysteïne - vergoedingscategorie Ri-D11 – toepassingsgebied diagnostiek: nieren | | | | | |
|  | | | |  | | | | | |
| Dénomination / Benaming (Demandeur/Aanvrager) | | | | | | | | | |
| Cat. | Code | Conditionnements | Verpakkingen | | Obs  Opm | Prix  Prijs  ***ex-usine / buiten bedrijf*** | Base de remb  Basis v tegem  ***ex-usine / buiten bedrijf*** | I | II |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| EDICIS | | | CIS BIO INTERNATIONAL SAS | |  | | | | ATC: V09CA06 | | |
|  | ***0745-710*** | ***4 flacons injectables 2 mg poudre pour solution injectable, 2 mg*** | | ***4 injectieflacons 2 mg poeder voor oplossing voor injectie, 2 mg*** | |  | ***300,00*** |  | |  |  |
| Ri-D11 **\*** | 0745-710 | 1 administration 2 mg solution injectable, 2 mg | | 1 toediening 2 mg oplossing voor injectie, 2 mg | |  |  | 18,5900 | |  |  |
| Ri-D11 **\*\*** | 0745-721 | 1 administration 2 mg solution injectable, 2 mg | | 1 toediening 2 mg oplossing voor injectie, 2 mg | |  |  | 18,5900 | |  |  |
|  |  |  | |  | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | | |  | | | | | |
| **Paragraphe 20014** | | | | **Paragraaf 20014** | | | | | |
| § 20014 est supprimé au 01/06/2023. | | | | § 20014 is geschrapt op 01/06/2023. | | | | | |
|  | | | |  | | | | | |
| **Paragraphe 20015** | | | | **Paragraaf 20015** | | | | | |
| § 20015 est supprimé au 01/06/2023. | | | | § 20015 is geschrapt op 01/06/2023. | | | | | |
|  | | | |  | | | | | |
| **Paragraphe 20016** | | | | **Paragraaf 20016** | | | | | |
| Produits radio-pharmaceutiques à base de phytate de sodium - catégorie de remboursement Ri-D11 - domaine d’application diagnostique: foie | | | | Radiofarmaceutische producten op basis van natriumfytaat - vergoedingscategorie Ri-D11 – toepassingsgebied diagnostiek: lever | | | | | |
|  | | | |  | | | | | |
| Dénomination / Benaming (Demandeur/Aanvrager) | | | | | | | | | |
| Cat. | Code | Conditionnements | Verpakkingen | | Obs  Opm | Prix  Prijs  ***ex-usine / buiten bedrijf*** | Base de remb  Basis v tegem  ***ex-usine / buiten bedrijf*** | I | II |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| PHYTACIS | | | CIS BIO INTERNATIONAL SAS | |  | | | | ATC: V09DB07 | | |
|  | ***0745-776*** | ***5 flacons injectables 20 mg poudre pour solution injectable*** | | ***5 injectieflacons 20 mg poeder voor oplossing voor injectie*** | |  | ***210,10*** |  | |  |  |
| Ri-D11 **\*** | 0745-776 | 1 administration 20 mg solution injectable, 20 mg | | 1 toediening 20 mg oplossing voor injectie, 20 mg | |  |  | 18,5900 | |  |  |
| Ri-D11 **\*\*** | 0745-780 | 1 administration 20 mg solution injectable, 20 mg | | 1 toediening 20 mg oplossing voor injectie, 20 mg | |  |  | 18,5900 | |  |  |
|  |  |  | |  | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | | |  | | | | | |
| **Paragraphe 20017** | | | | **Paragraaf 20017** | | | | | |
| § 20017 est supprimé au 01/01/2021. | | | | § 20017 is geschrapt op 01/01/2021. | | | | | |
|  | | | |  | | | | | |
| **Paragraphe 20018** | | | | **Paragraaf 20018** | | | | | |
| Produits radio-pharmaceutiques à base d’ albumine humaine, macro-aggrégats - catégorie de remboursement Ri-D11 - domaine d’application diagnostique: shunt | | | | Radiofarmaceutische producten op basis van humaan albumine macroaggregaten - vergoedingscategorie Ri-D11 – toepassingsgebied diagnostiek: shunt | | | | | |
|  | | | |  | | | | | |
| Dénomination / Benaming (Demandeur/Aanvrager) | | | | | | | | | |
| Cat. | Code | Conditionnements | Verpakkingen | | Obs  Opm | Prix  Prijs  ***ex-usine / buiten bedrijf*** | Base de remb  Basis v tegem  ***ex-usine / buiten bedrijf*** | I | II |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| PULMOCIS 2MG Kit for radiopharmaceutical preparation | | | CIS BIO INTERNATIONAL SAS | |  | | | | ATC: V09EB01 | | |
|  | ***0745-813*** | ***5 flacons injectables 2 mg poudre pour solution injectable, 2 mg*** | | ***5 injectieflacons 2 mg poeder voor oplossing voor injectie, 2 mg*** | |  | ***495,00*** |  | |  |  |
| Ri-D11 **\*** | 0745-813 | 1 administration 2 mg solution injectable, 2 mg | | 1 toediening 2 mg oplossing voor injectie, 2 mg | |  |  | 18,5900 | |  |  |
| Ri-D11 **\*\*** | 0745-824 | 1 administration 2 mg solution injectable, 2 mg | | 1 toediening 2 mg oplossing voor injectie, 2 mg | |  |  | 18,5900 | |  |  |
|  |  |  | |  | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | | |  | | | | | |
| **Paragraphe 20019** | | | | **Paragraaf 20019** | | | | | |
| Produits radio-pharmaceutiques à base d’ albumine humaine, macro-aggrégats - catégorie de remboursement Ri-D11 - domaine d’application diagnostique: gastro-intestinal | | | | Radiofarmaceutische producten op basis van humaan albumine macroaggregaten - vergoedingscategorie Ri-D11 – toepassingsgebied diagnostiek: gastro-intestinaal | | | | | |
|  | | | |  | | | | | |
| Dénomination / Benaming (Demandeur/Aanvrager) | | | | | | | | | |
| Cat. | Code | Conditionnements | Verpakkingen | | Obs  Opm | Prix  Prijs  ***ex-usine / buiten bedrijf*** | Base de remb  Basis v tegem  ***ex-usine / buiten bedrijf*** | I | II |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| PULMOCIS 2MG Kit for radiopharmaceutical preparation | | | CIS BIO INTERNATIONAL SAS | |  | | | | ATC: V09EB01 | | |
|  | ***0745-835*** | ***5 flacons injectables 2 mg poudre pour solution injectable, 2 mg*** | | ***5 injectieflacons 2 mg poeder voor oplossing voor injectie, 2 mg*** | |  | ***495,00*** |  | |  |  |
| Ri-D11 **\*** | 0745-835 | 1 administration 2 mg solution injectable, 2 mg | | 1 toediening 2 mg oplossing voor injectie, 2 mg | |  |  | 18,5900 | |  |  |
| Ri-D11 **\*\*** | 0745-846 | 1 administration 2 mg solution injectable, 2 mg | | 1 toediening 2 mg oplossing voor injectie, 2 mg | |  |  | 18,5900 | |  |  |
|  |  |  | |  | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | | |  | | | | | |
| **< Paragraphe 20020** | | | | **Paragraaf 20020** | | | | | |
| Produits radio-pharmaceutiques à base d’ albumine humaine, macro-aggrégats - catégorie de remboursement Ri-D11 - domaine d’application diagnostique: poumons-perfusion | | | | Radiofarmaceutische producten op basis van humaan albumine macroaggregaten - vergoedingscategorie Ri-D11 – toepassingsgebied diagnostiek: longen-perfusie | | | | | |
|  | | | |  | | | | | |
| Dénomination / Benaming (Demandeur/Aanvrager) | | | | | | | | | |
| Cat. | Code | Conditionnements | Verpakkingen | | Obs  Opm | Prix  Prijs  ***ex-usine / buiten bedrijf*** | Base de remb  Basis v tegem  ***ex-usine / buiten bedrijf*** | I | II |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| PULMOCIS 2MG Kit for radiopharmaceutical preparation | | | CIS BIO INTERNATIONAL SAS | |  | | | | ATC: V09EB01 | | |
|  | ***0745-850*** | ***5 flacons injectables 2 mg poudre pour solution injectable, 2 mg*** | | ***5 injectieflacons 2 mg poeder voor oplossing voor injectie, 2 mg*** | |  | ***495,00*** |  | |  |  |
| Ri-D11 **\*** | 0745-850 | 1 administration 2 mg solution injectable, 2 mg | | 1 toediening 2 mg oplossing voor injectie, 2 mg | |  |  | 18,5900 | |  |  |
| Ri-D11 **\*\*** | 0745-861 | 1 administration 2 mg solution injectable, 2 mg | | 1 toediening 2 mg oplossing voor injectie, 2 mg | |  |  | 18,5900 | |  |  |
|  |  |  | |  | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | | |  | | | | | |
| **Paragraphe 20021** | | | | **Paragraaf 20021** | | | | | |
| Produits radio-pharmaceutiques à base de tétrafluorate de tetrakis(2-methoxy isobutyl isonitrile) cuivre (I) / chlorure stanneux / chlorhydrate de cystéine - catégorie de remboursement Ri-D11 - domaine d’application diagnostique: coeur | | | | Radiofarmaceutische producten op basis van tetrakis (2-methoxy-isobutylisonitrile) tetrafluorboraat koper (I) / tinchloride / cysteïnehydrochloride - vergoedingscategorie Ri-D11 – toepassingsgebied diagnostiek: hart | | | | | |
|  | | | |  | | | | | |
| Dénomination / Benaming (Demandeur/Aanvrager) | | | | | | | | | |
| Cat. | Code | Conditionnements | Verpakkingen | | Obs  Opm | Prix  Prijs  ***ex-usine / buiten bedrijf*** | Base de remb  Basis v tegem  ***ex-usine / buiten bedrijf*** | I | II |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| STAMICIS | | | CIS BIO INTERNATIONAL SAS | |  | | | | ATC: V09GA01 | | |
|  | ***0745-872*** | ***5 flacons injectables 1 mg poudre pour solution injectable, 1 mg*** | | ***5 injectieflacons 1 mg poeder voor oplossing voor injectie, 1 mg*** | |  | ***550,00*** |  | |  |  |
| Ri-D11 **\*** | 0745-872 | 1 administration 1 mg solution injectable, 1 mg | | 1 toediening 1 mg oplossing voor injectie, 1 mg | |  |  | 18,5900 | |  |  |
| Ri-D11 **\*\*** | 0745-883 | 1 administration 1 mg solution injectable, 1 mg | | 1 toediening 1 mg oplossing voor injectie, 1 mg | |  |  | 18,5900 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| TECHNESCAN SESTAMIBI | | | CURIUM BELGIUM BV | |  | | | | ATC: V09GA01 | | |
|  | ***0745-872*** | ***5 flacons injectables 1 mg poudre pour solution injectable*** | | ***5 injectieflacons 1 mg poeder voor oplossing voor injectie*** | |  | ***660,00*** |  | |  |  |
| Ri-D11 **\*** | 0745-872 | 1 administration 1 mg solution injectable, 1 mg | | 1 toediening 1 mg oplossing voor injectie, 1 mg | |  |  | 18,5900 | |  |  |
| Ri-D11 **\*\*** | 0745-883 | 1 administration 1 mg solution injectable, 1 mg | | 1 toediening 1 mg oplossing voor injectie, 1 mg | |  |  | 18,5900 | |  |  |
|  |  |  | |  | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | | |  | | | | | |
| **Paragraphe 20022** | | | | **Paragraaf 20022** | | | | | |
| Produits radio-pharmaceutiques à base de tétrafluorate de tetrakis(2-methoxy isobutyl isonitrile) cuivre (I) / chlorure stanneux / chlorhydrate de cystéine - catégorie de remboursement Ri-D11 - domaine d’application diagnostique: tumeur | | | | Radiofarmaceutische producten op basis van tetrakis (2-methoxy-isobutylisonitrile) tetrafluorboraat koper (I) / tinchloride / cysteïnehydrochloride - vergoedingscategorie Ri-D11 – toepassingsgebied diagnostiek: tumor | | | | | |
|  | | | |  | | | | | |
| Dénomination / Benaming (Demandeur/Aanvrager) | | | | | | | | | |
| Cat. | Code | Conditionnements | Verpakkingen | | Obs  Opm | Prix  Prijs  ***ex-usine / buiten bedrijf*** | Base de remb  Basis v tegem  ***ex-usine / buiten bedrijf*** | I | II |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| STAMICIS | | | CIS BIO INTERNATIONAL SAS | |  | | | | ATC: V09GA01 | | |
|  | ***0745-894*** | ***5 flacons injectables 1 mg poudre pour solution injectable, 1 mg*** | | ***5 injectieflacons 1 mg poeder voor oplossing voor injectie, 1 mg*** | |  | ***550,00*** |  | |  |  |
| Ri-D11 **\*** | 0745-894 | 1 administration 1 mg solution injectable, 1 mg | | 1 toediening 1 mg oplossing voor injectie, 1 mg | |  |  | 18,5900 | |  |  |
| Ri-D11 **\*\*** | 0745-905 | 1 administration 1 mg solution injectable, 1 mg | | 1 toediening 1 mg oplossing voor injectie, 1 mg | |  |  | 18,5900 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| TECHNESCAN SESTAMIBI | | | CURIUM BELGIUM BV | |  | | | | ATC: V09GA01 | | |
|  | ***0745-894*** | ***5 flacons injectables 1 mg poudre pour solution injectable*** | | ***5 injectieflacons 1 mg poeder voor oplossing voor injectie*** | |  | ***660,00*** |  | |  |  |
| Ri-D11 **\*** | 0745-894 | 1 administration 1 mg solution injectable, 1 mg | | 1 toediening 1 mg oplossing voor injectie, 1 mg | |  |  | 18,5900 | |  |  |
| Ri-D11 **\*\*** | 0745-905 | 1 administration 1 mg solution injectable, 1 mg | | 1 toediening 1 mg oplossing voor injectie, 1 mg | |  |  | 18,5900 | |  |  |
|  |  |  | |  | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | | |  | | | | | |
| **Paragraphe 20023** | | | | **Paragraaf 20023** | | | | | |
| Produits radio-pharmaceutiques à base de tétrofosmin -catégorie de remboursement Ri-D11 - domaine d’application diagnostique: coeur | | | | Radiofarmaceutische producten op basis van tetrofosmine - vergoedingscategorie Ri-D11 – toepassingsgebied diagnostiek: hart | | | | | |
|  | | | |  | | | | | |
| Dénomination / Benaming (Demandeur/Aanvrager) | | | | | | | | | |
| Cat. | Code | Conditionnements | Verpakkingen | | Obs  Opm | Prix  Prijs  ***ex-usine / buiten bedrijf*** | Base de remb  Basis v tegem  ***ex-usine / buiten bedrijf*** | I | II |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| MYOVIEW 230 µg | | | GE HEALTHCARE | |  | | | | ATC: V09GA02 | | |
|  | ***0745-916*** | ***5 flacons injectables 230 µg poudre pour solution injectable, 230 µg*** | | ***5 injectieflacons 230 µg poeder voor oplossing voor injectie, 230 µg*** | |  | ***694,00*** |  | |  |  |
| Ri-D11 **\*** | 0745-916 | 1 administration 230 µg solution injectable, 230 µg | | 1 toediening 230 µg oplossing voor injectie, 230 µg | |  |  | 18,5900 | |  |  |
| Ri-D11 **\*\*** | 0745-920 | 1 administration 230 µg solution injectable, 230 µg | | 1 toediening 230 µg oplossing voor injectie, 230 µg | |  |  | 18,5900 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| TETROFOSMIN ROTOP 230 µg | | | ROTOP PHARMAKA GmbH | |  | | | | ATC: V09GA02 | | |
|  | ***0745-916*** | ***5 flacons injectables 230 µg poudre pour solution injectable, 230 µg*** | | ***5 injectieflacons 230 µg poeder voor oplossing voor injectie, 230 µg*** | |  | ***873,71*** |  | |  |  |
| Ri-D11 **\*** | 0745-916 | 1 administration 230 µg solution injectable, 230 µg | | 1 toedining 230 µg oplossing voor injectie, 230 µg | |  |  | 18,5900 | |  |  |
| Ri-D11 **\*\*** | 0745-920 | 1 administration 230 µg solution injectable, 230 µg | | 1 toedining 230 µg oplossing voor injectie, 230 µg | |  |  | 18,5900 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| TETROFOSMIN ROTOP 230 µg | | | ROTOP PHARMAKA GmbH | |  | | | | ATC: V09GA02 | | |
|  | ***0745-916*** | ***2 flacons injectables 230 µg poudre pour solution injectable, 230 µg*** | | ***2 injectieflacons 230 µg poeder voor oplossing voor injectie, 230 µg*** | |  | ***436,86*** |  | |  |  |
| Ri-D11 **\*** | 0745-916 | 1 administration 230 µg solution injectable, 230 µg | | 1 toedining 230 µg oplossing voor injectie, 230 µg | |  |  | 18,5900 | |  |  |
| Ri-D11 **\*\*** | 0745-920 | 1 administration 230 µg solution injectable, 230 µg | | 1 toedining 230 µg oplossing voor injectie, 230 µg | |  |  | 18,5900 | |  |  |
|  |  |  | |  | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | | |  | | | | | |
| **Paragraphe 20024** | | | | **Paragraaf 20024** | | | | | |
| Produits radio-pharmaceutiques à base de tétrofosmin - catégorie de remboursement Ri-D11 - domaine d’application diagnostique: tumeur | | | | Radiofarmaceutische producten op basis van tetrofosmine - vergoedingscategorie Ri-D11 – toepassingsgebied diagnostiek: tumor | | | | | |
|  | | | |  | | | | | |
| Dénomination / Benaming (Demandeur/Aanvrager) | | | | | | | | | |
| Cat. | Code | Conditionnements | Verpakkingen | | Obs  Opm | Prix  Prijs  ***ex-usine / buiten bedrijf*** | Base de remb  Basis v tegem  ***ex-usine / buiten bedrijf*** | I | II |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| MYOVIEW 230 µg | | | GE HEALTHCARE | |  | | | | ATC: V09GA02 | | |
|  | ***0745-931*** | ***5 flacons injectables 230 µg poudre pour solution injectable, 230 µg*** | | ***5 injectieflacons 230 µg poeder voor oplossing voor injectie, 230 µg*** | |  | ***694,00*** |  | |  |  |
| Ri-D11 **\*** | 0745-931 | 1 administration 230 µg solution injectable, 230 µg | | 1 toediening 230 µg oplossing voor injectie, 230 µg | |  |  | 18,5900 | |  |  |
| Ri-D11 **\*\*** | 0745-942 | 1 administration 230 µg solution injectable, 230 µg | | 1 toediening 230 µg oplossing voor injectie, 230 µg | |  |  | 18,5900 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| TETROFOSMIN ROTOP 230 µg | | | ROTOP PHARMAKA GmbH | |  | | | | ATC: V09GA02 | | |
|  | ***0745-931*** | ***5 flacons injectables 230 µg poudre pour solution injectable, 230 µg*** | | ***5 injectieflacons 230 µg poeder voor oplossing voor injectie, 230 µg*** | |  | ***873,71*** |  | |  |  |
| Ri-D11 **\*** | 0745-931 | 1 administration 230 µg solution injectable, 230 µg | | 1 toedining 230 µg oplossing voor injectie, 230 µg | |  |  | 18,5900 | |  |  |
| Ri-D11 **\*\*** | 0745-942 | 1 administration 230 µg solution injectable, 230 µg | | 1 toedining 230 µg oplossing voor injectie, 230 µg | |  |  | 18,5900 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| TETROFOSMIN ROTOP 230 µg | | | ROTOP PHARMAKA GmbH | |  | | | | ATC: V09GA02 | | |
|  | ***0745-931*** | ***2 flacons injectables 230 µg poudre pour solution injectable, 230 µg*** | | ***2 injectieflacons 230 µg poeder voor oplossing voor injectie, 230 µg*** | |  | ***436,86*** |  | |  |  |
| Ri-D11 **\*** | 0745-931 | 1 administration 230 µg solution injectable, 230 µg | | 1 toedining 230 µg oplossing voor injectie, 230 µg | |  |  | 18,5900 | |  |  |
| Ri-D11 **\*\*** | 0745-942 | 1 administration 230 µg solution injectable, 230 µg | | 1 toedining 230 µg oplossing voor injectie, 230 µg | |  |  | 18,5900 | |  |  |
|  |  |  | |  | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | | |  | | | | | |
| **Paragraphe 20025** | | | | **Paragraaf 20025** | | | | | |
| Produits radio-pharmaceutiques à base de besilesomab - catégorie de remboursement Ri-D11 - domaine d’application diagnostique: infection | | | | Radiofarmaceutische producten op basis van besilesomab - vergoedingscategorie Ri-D11 – toepassingsgebied diagnostiek: infectie | | | | | |
|  | | | |  | | | | | |
| Dénomination / Benaming (Demandeur/Aanvrager) | | | | | | | | | |
| Cat. | Code | Conditionnements | Verpakkingen | | Obs  Opm | Prix  Prijs  ***ex-usine / buiten bedrijf*** | Base de remb  Basis v tegem  ***ex-usine / buiten bedrijf*** | I | II |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SCINTIMUN | | | CIS BIO INTERNATIONAL SAS | |  | | | | ATC: V09HA03 | | |
|  | ***0745-975*** | ***2 flacons injectables 1 mg poudre pour solution injectable, 1 mg*** | | ***2 injectieflacons 1 mg poeder voor oplossing voor injectie, 1 mg*** | |  | ***700,00*** |  | |  |  |
| Ri-D11 **\*** | 0745-975 | 1 administration 2 mL solution injectable, 1 mg | | 1 toediening 2 mL oplossing voor injectie, 1 mg | |  |  | 18,5900 | |  |  |
| Ri-D11 **\*\*** | 0745-986 | 1 administration 2 mL solution injectable, 1 mg | | 1 toediening 2 mL oplossing voor injectie, 1 mg | |  |  | 18,5900 | |  |  |
|  |  |  | |  | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | | |  | | | | | |
| **Paragraphe 20026** | | | | **Paragraaf 20026** | | | | | |
| Produits radio-pharmaceutiques à base de besilesomab -catégorie de remboursement Ri-D11 - domaine d’application diagnostique: squelette | | | | Radiofarmaceutische producten op besilesomab -vergoedingscategorie Ri-D11 – toepassingsgebied diagnostiek: skelet | | | | | |
|  | | | |  | | | | | |
| Dénomination / Benaming (Demandeur/Aanvrager) | | | | | | | | | |
| Cat. | Code | Conditionnements | Verpakkingen | | Obs  Opm | Prix  Prijs  ***ex-usine / buiten bedrijf*** | Base de remb  Basis v tegem  ***ex-usine / buiten bedrijf*** | I | II |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SCINTIMUN | | | CIS BIO INTERNATIONAL SAS | |  | | | | ATC: V09HA03 | | |
|  | ***0745-990*** | ***2 flacons injectables 1 mg poudre pour solution injectable, 1 mg*** | | ***2 injectieflacons 1 mg poeder voor oplossing voor injectie, 1 mg*** | |  | ***700,00*** |  | |  |  |
| Ri-D11 **\*** | 0745-990 | 1 administration 2 mL solution injectable, 1 mg | | 1 toediening 2 mL oplossing voor injectie, 1 mg | |  |  | 18,5900 | |  |  |
| Ri-D11 **\*\*** | 0746-001 | 1 administration 2 mL solution injectable, 1 mg | | 1 toediening 2 mL oplossing voor injectie, 1 mg | |  |  | 18,5900 | |  |  |
|  |  |  | |  | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | | |  | | | | | |
| **Paragraphe 20027** | | | | **Paragraaf 20027** | | | | | |
| Radiofarmaceutische producten op basis van Technetium (Tc-99m) gemerkt koolstof- vergoedingscategorie Ri-D11 -toepassingsgebied diagnostiek: longen - ventilatie. | | | | Produits radio-pharmaceutiques à base de carbone marqué par Technetium (Tc-99m) - catégorie de remboursement Ri-D11 - domaine d’application diagnostique: poumons-ventilation. | | | | | |
|  | | | |  | | | | | |
| Dénomination / Benaming (Demandeur/Aanvrager) | | | | | | | | | |
| Cat. | Code | Conditionnements | Verpakkingen | | Obs  Opm | Prix  Prijs  ***ex-usine / buiten bedrijf*** | Base de remb  Basis v tegem  ***ex-usine / buiten bedrijf*** | I | II |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| PULMOTEC | | | CYCLOMEDICA BENELUX | |  | | | | ATC: V09EA02 | | |
|  | ***0749-394*** | ***5 x 10 creusets de graphite 135 µl pour la préparation de Technegas pour inhalation*** | | ***5 x 10 grafietkroesjes 135 µl voor de bereiding van inhalatiesuspensie Techengas*** | |  | ***2100,00*** |  | |  |  |
| Ri-D11 **\*** | 0749-394 | 1 administration 10 poudre pour inhalation, 1,34 g | | 1 toediening 10 inhalatiepoeder, 1,34 g | |  |  | 18,5900 | |  |  |
| Ri-D11 **\*\*** | 0749-405 | 1 administration 10 poudre pour inhalation, 1,34 g | | 1 toediening 10 inhalatiepoeder, 1,34 g | |  |  | 18,5900 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| PULMOTEC | | | CYCLOMEDICA BENELUX | |  | | | | ATC: V09EA02 | | |
|  | ***0749-394*** | ***5 x 10 creusets de graphite 300 µl pour la préparation de Technegas pour inhalation*** | | ***5 x 10 grafietkroesjes 300 µl voor de bereiding van inhalatiesuspensie Techengas*** | |  | ***2100,00*** |  | |  |  |
| Ri-D11 **\*** | 0749-394 | 1 administration 10 poudre pour inhalation, 1,34 g | | 1 toediening 10 inhalatiepoeder, 1,34 g | |  |  | 18,5900 | |  |  |
| Ri-D11 **\*\*** | 0749-405 | 1 administration 10 poudre pour inhalation, 1,34 g | | 1 toediening 10 inhalatiepoeder, 1,34 g | |  |  | 18,5900 | |  |  |
|  |  |  | |  | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | | | |  | | | | | | |
| **Paragraphe 30001** | | | | | **Paragraaf 30001** | | | | | | |
| Produits radio-pharmaceutiques à base de loflupane (I-123) catégorie de remboursement Ri-D3 - domaine d’application diagnostique: neuro | | | | | Radiofarmaceutische producten op basis van joflupaan (I-123) vergoedingscategorie Ri-D3 – toepassingsgebied diagnostiek : neuro | | | | | | |
| Les produits inscrits dans ce paragraphe sont remboursables dans la catégorie de remboursement Ri-D3 s’ils sont utilisés pour effectuer un examen de tomoscintigraphie d’émission monophotonique à l’aide d’une gammacaméra munie d’un collimateur haute résolution calibrée en utilisant le pic d’absorption totale de 159 keV, lorsque cet examen a été prescrit par un médecin spécialiste en neurologie ou en neuropsychiatrie pour réaliser la détection d’une perte de terminaisons neuronales dopaminergiques fonctionnelles dans le striatum de patients présentant un syndrome parkinsonien cliniquement douteux, lorsque toutes les conditions suivantes sont remplies simultanément: | | | | | De producten ingeschreven in deze paragraaf zijn vergoedbaar in de vergoedingscategorie Ri-D3 indien ze aangewend worden om een single photon emission tomoscintigrafie uit te voeren met behulp van een gammacamera voorzien van een hogeresolutiecollimator, gecalibreerd door gebruikt te maken van de totale absorptiepiek van 159 keV, als dit onderzoek is voorgeschreven geweest door een arts gespecialiseerd in neurologie of in neuropsychiatrie, om een verlies van functionele dopaminerge neuronale uiteinden in het striatum bij patiënten met een klinisch onzeker parkinsonsyndroom te detecteren als alle volgende criteria gelijktijdig worden vervuld: | | | | | | |
|  | 1. l’examen n’a encore jamais été remboursé chez le patient concerné; | | | |  | 1. het onderzoek is nog nooit terugbetaald geweest bij de betrokken patiënt; | | | | | |
|  | 2. l’examen concerne un patient adulte et est destiné à établir un diagnostic différentiel entre tremblement essentiel et syndromes parkinsoniens; | | | |  | 2. het onderzoek betreft een volwassen patiënt en is bestemd om een differentiële diagnose te maken tussen essentiële tremor en parkinsonsyndromen; | | | | | |
|  | 3. un médecin spécialiste en neurologie ou en neuropsychiatrie a attesté que l’anamnèse et l’examen clinique ne sont pas suffisamment contributifs pour établir ce diagnostic différentiel; | | | |  | 3. de arts gespecialiseerd in neurologie of neuropsychiatrie attesteert dat de anamnese en het klinisch onderzoek niet voldoende bijdragen tot deze differentiële diagnose; | | | | | |
|  | 4. la dose maximale remboursable est 185 MBq. | | | |  | 4. de maximale terugbetaalbare dosis is 185 MBq. | | | | | |
| A cet effet, et dans la mesure où cette démarche n’a pas encore été accomplie au moment de la facture, il y a lieu de joindre à la facture intégrée individuelle du patient concerné un rapport médical circonstancié rédigé confidentiellement à l’intention du médecin-conseil de l’organisme assureur par le médecin spécialiste en neurologie ou en neuropsychiatrie, qui confirme que toutes les conditions mentionnées ci-dessus sont rencontrées. | | | | | Hiertoe, en in de mate dat dit nog niet is gebeurd op het ogenblik van facturatie, is er reden om aan de factuur van de individuele patiënt ten behoeve van de adviserend-arts van het verzekeringsorganisme door de arts gespecialiseerd in neurologie of neuropsychiatrie, een omstandig vertrouwelijk medisch rapport toe te voegen dat bevestigt dat aan alle hiervoor opgesomde voorwaarden is voldaan. | | | | | | |
|  | | | | |  | | | | | | |
| Dénomination / Benaming (Demandeur/Aanvrager) | | | | | | | | | | | |
| Cat. | | Code | Conditionnements | Verpakkingen | | | Obs  Opm | Prix  Prijs  ***ex-usine / buiten bedrijf*** | Base de remb  Basis v tegem  ***ex-usine / buiten bedrijf*** | I | II |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| DATSCAN 74 MBq/ml | | | GE HEALTHCARE | |  | | | | ATC: V09AB03 | | |
|  | ***0746-012*** | ***1 flacon injectable 2,5 ml solution injectable, 185 MBq*** | | ***1 injectieflacon 2,5 ml oplossing voor injectie, 185 MBq*** | |  | ***755,00*** |  | |  |  |
| Ri-D3 **\*** | 0746-012 | 1 administration 2,5 mL solution injectable, 185 MBq | | 1 toediening 2,5 mL oplossing voor injectie, 185 MBq | |  |  | 749,1100 | |  |  |
| Ri-D3 **\*\*** | 0746-023 | 1 administration 2,5 mL solution injectable, 185 MBq | | 1 toediening 2,5 mL oplossing voor injectie, 185 MBq | |  |  | 749,1100 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| JOFLUPAN (I-123) ROTOP | | | ROTOP PHARMAKA GmbH | |  | | | | ATC: V09AB03 | | |
|  | ***0746-012*** | ***1 flacon injectable 2,5 mL solution injectable, 185 MBq*** | | ***1 injectieflacon 2,5 mL oplossing voor injectie, 185 MBq*** | |  | ***755,00*** |  | |  |  |
| Ri-D3 **\*** | 0746-012 | 1 administration 2,5 mL solution injectable, 185 MBq | | 1 toediening 2,5 mL oplossing voor injectie, 185 MBq | |  |  | 749,1100 | |  |  |
| Ri-D3 **\*\*** | 0746-023 | 1 administration 2,5 mL solution injectable, 185 MBq | | 1 toediening 2,5 mL oplossing voor injectie, 185 MBq | |  |  | 749,1100 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| STRIASCAN 74 MBq/ml | | | CIS BIO INTERNATIONAL SAS | |  | | | | ATC: V09AB03 | | |
|  | ***0746-012*** | ***1 flacon injectable 5 mL solution injectable, 74 MBq/mL*** | | ***1 injectieflacon 5 mL oplossing voor injectie, 74 MBq/mL*** | |  | ***1100,00*** |  | |  |  |
| Ri-D3 **\*** | 0746-012 | 1 administration 5 mL solution injectable, 74 MBq/mL | | 1 toediening 5 mL oplossing voor injectie, 74 MBq/mL | |  |  | 749,1100 | |  |  |
| Ri-D3 **\*\*** | 0746-023 | 1 administration 5 mL solution injectable, 74 MBq/mL | | 1 toediening 5 mL oplossing voor injectie, 74 MBq/mL | |  |  | 749,1100 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| STRIASCAN 74 MBq/ml | | | CIS BIO INTERNATIONAL SAS | |  | | | | ATC: V09AB03 | | |
|  | ***0746-012*** | ***1 flacon injectable 2,5 mL solution injectable, 74 MBq/mL*** | | ***1 injectieflacon 2,5 mL oplossing voor injectie, 74 MBq/mL*** | |  | ***755,00*** |  | |  |  |
| Ri-D3 **\*** | 0746-012 | 1 administration 2,5 mL solution injectable, 74 MBq/mL | | 1 toediening 2,5 mL oplossing voor injectie, 74 MBq/mL | |  |  | 749,1100 | |  |  |
| Ri-D3 **\*\*** | 0746-023 | 1 administration 2,5 mL solution injectable, 74 MBq/mL | | 1 toediening 2,5 mL oplossing voor injectie, 74 MBq/mL | |  |  | 749,1100 | |  |  |
|  |  |  | |  | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | | |  | | | | | |
| **Paragraphe 30002** | | | | **Paragraaf 30002** | | | | | |
| § 30002 est supprimé au 01/01/2021. | | | | § 30002 is geschrapt op 01/01/2021. | | | | | |
|  | | | |  | | | | | |
| **Paragraphe 30003** | | | | **Paragraaf 30003** | | | | | |
| Produits radio-pharmaceutiques à base d’ acide tauroselcholique (Se-75) - catégorie de remboursement Ri-D1 - domaine d’application diagnostique: gastro-intestinal | | | | Radiofarmaceutische producten op basis van tauroselcholinezuur (Se-75) - vergoedingscategorie Ri-D1 – toepassingsgebied diagnostiek: gastro-intestinaal | | | | | |
|  | | | |  | | | | | |
| Dénomination / Benaming (Demandeur/Aanvrager) | | | | | | | | | |
| Cat. | Code | Conditionnements | Verpakkingen | | Obs  Opm | Prix  Prijs  ***ex-usine / buiten bedrijf*** | Base de remb  Basis v tegem  ***ex-usine / buiten bedrijf*** | I | II |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SEHCAT 370 kBq | | | GE HEALTHCARE | |  | | | | ATC: V09DX01 | | |
|  | ***0746-056*** | ***1 gélule, 370 kBq*** | | ***1 capsule, hard, 370 kBq*** | |  | ***415,00*** |  | |  |  |
| Ri-D1 **\*** | 0746-056 | 1 administration, 370 kBq | | 1 toediening, 370 kBq | |  |  | 29,7500 | |  |  |
| Ri-D1 **\*\*** | 0746-060 | 1 administration, 370 kBq | | 1 toediening, 370 kBq | |  |  | 29,7500 | |  |  |
|  |  |  | |  | |  |  |  | |  |  |

|  |  |
| --- | --- |
|  |  |
| **Paragraphe 30004** | **Paragraaf 30004** |
| Produits radio-pharmaceutiques à base d’ indium (In-111) pentetréotide catégorie de remboursement Ri-D8 - domaine d’application diagnostique: tumeur | Radiofarmaceutische producten op basis van indium (In-111) pentetreotide vergoedingscategorie Ri-D8 – toepassingsgebied diagnostiek: tumor |
| Les produits inscrits dans ce paragraphe sont remboursables dans la catégorie de remboursement Ri-D8 s’ils sont utilisés pour la localisation visuelle de tumeurs neuroendocrines gastro-entéro-pancréatiques et de tumeurs carcinoïdes par tomographie par émission monophotonique (SPECT) chez des patients chez qui on suspecte fortement ce diagnostic sur base d’examens biologiques et/ou radiologiques ou chez qui le diagnostic a déjà été fait et qui sont soumis à un suivi annuel. | De producten ingeschreven in deze paragraaf zijn vergoedbaar in de vergoedingscategorie Ri-D8 indien ze aangewend worden voor de visuele plaatsbepaling door middel van emissietomografie (SPECT) van gastro-entero-pancreatische neuroendocriene tumoren en carcinoïdtumoren bij patiënten bij wie de diagnose sterk wordt vermoed op basis van biologische onderzoeken en/of diagnostische beeldvorming of bij wie de diagnose al werd gesteld en die een jaarlijkse follow-up ondergaan. |
| Normalement, seul un remboursement pour un conditionnement par an peut être autorisé. Dans le cas où le patient a subi une intervention chirurgicale pour cette affection, un deuxième conditionnement peut être remboursé, dans les 6 mois suivant l’intervention chirurgicale. | Normaal kan er maar een vergoeding voor één verpakking per jaar worden toegestaan. In geval de patiënt een chirurgische ingreep heeft ondergaan voor deze aandoening, kan er een 2de verpakking vergoed worden, binnen de 6 maanden na de chirurgische ingreep. |
| Le remboursement est subordonné à la remise au pharmacien hospitalier concerné du formulaire de demande, dont le modèle est repris à l’annexe A du présent paragraphe, complété et signé par le médecin spécialiste responsable du traitement , qui est agréé en oncologie médicale, ou en médecine interne ou en chirurgie. | De vergoeding hangt af van de aflevering aan de betrokkene ziekenhuisapotheker van het aanvraagformulier, waarvan het model in bijlage A van de huidige paragraaf is overgenomen, ingevuld en ondertekend door de geneesheer-specialist verantwoordelijk voor de behandeling en die erkend is in de medische oncologie of in de interne geneeskunde of in de heelkunde. |
| En complétant de la sorte les rubriques ad hoc de ce formulaire, le médecin spécialiste dont il est question ci-dessus s’engage également à conserver les documents exigés dans son dossier. | Door aldus het formulier volledig in te vullen in de ad hoc rubrieken, engageert de geneesheer-specialist van wie hierboven sprake is, gelijktijdig om in zijn dossier de vereiste documenten bij te houden. |
| Le formulaire A doit être tenu à la disposition du médecin conseil. | Het formulier A moet ter beschikking gehouden worden van de geneesheer-adviseur. |

**ANNEXE A: modèle de formulaire de demande destiné au pharmacien hospitalier**

Formulaire de demande destiné au pharmacien hospitalier comme condition nécessaire pour la facturation de la spécialité OCTREOSCAN (§ 30004 du chapitre II de l’Arrêté Royal du 22 mai 2014).

**I - Identification du bénéficiaire (nom, prénom, numéro d’affiliation à l’organisme assureur) :**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

**II - Eléments à attester par un médecin spécialiste en oncologie médicale, ou en médecine interne ou en chirurgie :**

Je soussigné, docteur en médecine, spécialiste

⊔ en oncologie médicale

(ou)

⊔ en médecine interne

(ou)

⊔ en chirurgie

certifie que toutes les conditions figurant au § 30004 du chapitre IV de l’AR du 22 mai 2014 pour le remboursement de l’administration d’OCTREOSCAN chez ce (cette) patient(e) sont satisfaites, étant donné que cette administration a été faite pour la situation attestée au point III ci-dessous :

**III - Situation du (de la) patient(e) qui doit subir une SPECTomographie avec OCTREOSCAN (cochez les cases appropriées) :**

⊔ J’atteste qu’il s’agit d’un(e) patient(e) chez qui il existe une forte suspicion qu’il/elle:

⊔ présente une tumeur carcinoïde

(ou)

⊔ présente une tumeur neuro-endocrine de ⊔ l’estomac, ⊔ l’intestin ou ⊔ du pancréas

Je dispose dans mon dossier des protocoles et des résultats des examens qui ont conduit à la suspicion de ce diagnostic

⊔ J’atteste qu’il s’agit d’un suivi annuel d’un(e) patient(e) dont la maladie a déjà été diagnostiquée et qui :

⊔ n’a jamais subi un examen avec OCTREOSCAN auparavant

⊔ a déjà subi un examen avec OCTREOSCAN le ⊔⊔/⊔⊔/⊔⊔⊔⊔

Je dispose dans mon dossier des protocoles et des résultats des examens qui on été effectuées l’an dernier.

⊔ J’atteste que ce/cette patient(e) a subi une intervention chirurgicale pour son/sa tumeur carcinoïde ou neuro-endocrine ou une (des) métastase(s) de celle-ci le ⊔⊔/⊔⊔/⊔⊔⊔⊔. Un examen de suivi supplémentaire dans les 6 mois suivants l’intervention est nécessaire chez ce (cette) patient(e).

Je dispose dans mon dossier du protocole de l’intervention chirurgicale.

**IV - Identification du médecin spécialiste en oncologie médicale ou en médecine interne ou en chirurgie. (nom, prénom, adres, numéro INAMI)**;

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (nom) |

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (prénom) |

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1 | - |  |  |  |  |  | - |  |  | - |  |  |  | (n° INAMI) |

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | / |  |  | / |  |  |  |  | (date) |

|  |  |  |  |
| --- | --- | --- | --- |
|  | (cachet) | .......................................... | (signature du médecin) |

**BIJLAGE A: model van aanvraagformulier bestemd voor de ziekenhuisapotheker:**

Aanvraagformulier bestemd voor de ziekenhuisapotheker als noodzakelijke voorwaarde voor facturatie van de specialiteit OCTREOSCAN (§ 30004 van hoofdstuk II van het Koninklijk Besluit van 22 mei 2014).

**I - Identificatie van de begunstigde (naam, voornaam, inschrijvingsnummer bij de verzekeringsinstelling) :**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

**II - Elementen te bevestigen door een geneesheer-specialist in de medische oncologie of in de interne geneeskunde of in de heelkunde:**

Ik ondergetekende, dokter in de geneeskunde, specialist

⊔ in de medische oncologie

(of)

⊔ in de interne geneeskunde

(of)

⊔ in de heelkunde

verklaar dat de voorwaarden gesteld in § 30004 van hoofdstuk II van het KB van 22 mei 2014 voor de terugbetaling van de toediening van OCTREOSCAN bij deze patiënt(e) alle voldaan zijn, gezien deze toediening werd uitgevoerd voor de situatie geattesteerd in het punt III hieronder :

**III -Toestand van de patiënt die een SPECTomografie met OCTREOSCAN moet ondergaan (vul de passende vakjes in) :**

⊔ Ik verklaar dat het om een patiënt(e) gaat bij wie een sterk vermoeden bestaat dat hij/zij :

⊔ een carcinoïde tumor vertoont

(of)

⊔ een neuro-endocriene tumor van ⊔ de maag, ⊔ de darm of ⊔de pancreas vertoont

Ik beschik in mijn dossier over de protocollen en resultaten van de onderzoeken die tot het vermoeden van deze diagnose geleid hebben

⊔ Ik verklaar dat het om een jaarlijks follow-up onderzoek gaat bij een patiënt(e) van wie de ziekte al gediagnosticeerd werd en die:

⊔ nooit eerder een onderzoek met OCTREOSCAN heeft ondergaan

⊔ reeds een onderzoek met OCTREOSCAN op ⊔⊔/⊔⊔/⊔⊔⊔⊔ heeft ondergaan

Ik beschik in mijn dossier over de protocollen en resultaten van de onderzoeken die het laatste jaar werden uitgevoerd.

⊔ Ik verklaar dat deze patiënt een chirurgische ingreep heeft ondergaan voor zijn/haar carcinoïde tumor of neuro-endocriene tumor of voor metastase(n) daarvan op ⊔⊔/⊔⊔/⊔⊔⊔⊔. Een extra follow-up onderzoek binnen de 6 maanden van de ingreep is bij deze patiënt noodzakelijk.

Ik beschik in mijn dossier over het protocol van de chirurgische ingreep.

**IV - Identificatie van de geneesheer-specialist in medische oncologie of in de interne geneeskunde of in de heelkunde. (naam, voornaam, adres, RIZIV nummer)**;

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (naam) |

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (voornaam) |

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1 | - |  |  |  |  |  | - |  |  | - |  |  |  | (n° RIZIV) |

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | / |  |  | / |  |  |  |  | (datum) |

|  |  |  |  |
| --- | --- | --- | --- |
|  | (stempel) | .......................................... | (handtekening van de geneesheer) |

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | | |  | | | | | |
| Dénomination / Benaming (Demandeur/Aanvrager) | | | | | | | | | |
| Cat. | Code | Conditionnements | Verpakkingen | | Obs  Opm | Prix  Prijs  ***ex-usine / buiten bedrijf*** | Base de remb  Basis v tegem  ***ex-usine / buiten bedrijf*** | I | II |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| OCTREOSCAN | | | CURIUM BELGIUM BV | |  | | | | ATC: V09IB01 | | |
|  | ***0746-071*** | ***1 flacon injectable 1 trousse pour préparation radiopharmaceutique, 122 MBq*** | | ***1 injectieflacon 1 kit voor radiofarmaceutisch preparaat, 122 MBq*** | |  | ***679,75*** |  | |  |  |
| Ri-D8 **\*** | 0746-071 | 1 administration 1 solution injectable, 122 MBq | | 1 toediening 1 oplossing voor injectie, 122 MBq | |  |  | 720,5400 | |  |  |
| Ri-D8 **\*\*** | 0746-082 | 1 administration 1 solution injectable, 122 MBq | | 1 toediening 1 oplossing voor injectie, 122 MBq | |  |  | 720,5400 | |  |  |
|  |  |  | |  | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | | |  | | | | | |
| **Paragraphe 30005** | | | | **Paragraaf 30005** | | | | | |
| Produits radio-pharmaceutiques à base de iobengane (I-123) - catégorie de remboursement Ri-D1 - domaine d’application diagnostique: glande surrénale | | | | Radiofarmaceutische producten op basis van iobenguaan (I-123) - vergoedingscategorie Ri-D1 – toepassingsgebied diagnostiek: bijnier | | | | | |
|  | | | |  | | | | | |
| Dénomination / Benaming (Demandeur/Aanvrager) | | | | | | | | | |
| Cat. | Code | Conditionnements | Verpakkingen | | Obs  Opm | Prix  Prijs  ***ex-usine / buiten bedrijf*** | Base de remb  Basis v tegem  ***ex-usine / buiten bedrijf*** | I | II |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ADREVIEW 74 MBq/ml | | | GE HEALTHCARE | |  | | | | ATC: V09IX01 | | |
|  | ***0746-093*** | ***1 flacon injectable 1 ml solution injectable, 74 MBq*** | | ***1 injectieflacon 1 ml oplossing voor injectie, 74 MBq*** | |  | ***330,00*** |  | |  |  |
| Ri-D1 **\*** | 0746-093 | 1 administration 1 mL solution injectable, 74 MBq | | 1 toediening 1 mL oplossing voor injectie, 74 MBq | |  |  | 29,7500 | |  |  |
| Ri-D1 **\*\*** | 0746-104 | 1 administration 1 mL solution injectable, 74 MBq | | 1 toediening 1 mL oplossing voor injectie, 74 MBq | |  |  | 29,7500 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ADREVIEW 74 MBq/ml | | | GE HEALTHCARE | |  | | | | ATC: V09IX01 | | |
|  | ***0746-093*** | ***1 flacon injectable 3 ml solution injectable, 222 MBq*** | | ***1 injectieflacon 3 ml oplossing voor injectie, 222 MBq*** | |  | ***545,00*** |  | |  |  |
| Ri-D1 **\*** | 0746-093 | 1 administration 3 mL solution injectable, 222 MBq | | 1 toediening 3 mL oplossing voor injectie, 222 MBq | |  |  | 29,7500 | |  |  |
| Ri-D1 **\*\*** | 0746-104 | 1 administration 3 mL solution injectable, 222 MBq | | 1 toediening 3 mL oplossing voor injectie, 222 MBq | |  |  | 29,7500 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ADREVIEW 74 MBq/ml | | | GE HEALTHCARE | |  | | | | ATC: V09IX01 | | |
|  | ***0746-093*** | ***1 flacon injectable 3,5 ml solution injectable, 259 MBq*** | | ***1 injectieflacon 3,5 ml oplossing voor injectie, 259 MBq*** | |  | ***610,00*** |  | |  |  |
| Ri-D1 **\*** | 0746-093 | 1 administration 3,5 mL solution injectable, 259 MBq | | 1 toediening 3,5 mL oplossing voor injectie, 259 MBq | |  |  | 29,7500 | |  |  |
| Ri-D1 **\*\*** | 0746-104 | 1 administration 3,5 mL solution injectable, 259 MBq | | 1 toediening 3,5 mL oplossing voor injectie, 259 MBq | |  |  | 29,7500 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ADREVIEW 74 MBq/ml | | | GE HEALTHCARE | |  | | | | ATC: V09IX01 | | |
|  | ***0746-093*** | ***1 flacon injectable 4 ml solution injectable, 296 MBq*** | | ***1 injectieflacon 4 ml oplossing voor injectie, 296 MBq*** | |  | ***675,00*** |  | |  |  |
| Ri-D1 **\*** | 0746-093 | 1 administration 4 mL solution injectable, 296 MBq | | 1 toediening 4 mL oplossing voor injectie, 296 MBq | |  |  | 29,7500 | |  |  |
| Ri-D1 **\*\*** | 0746-104 | 1 administration 4 mL solution injectable, 296 MBq | | 1 toediening 4 mL oplossing voor injectie, 296 MBq | |  |  | 29,7500 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ADREVIEW 74 MBq/ml | | | GE HEALTHCARE | |  | | | | ATC: V09IX01 | | |
|  | ***0746-093*** | ***1 flacon injectable 4,5 ml solution injectable, 333 MBq*** | | ***1 injectieflacon 4,5 ml oplossing voor injectie, 333 MBq*** | |  | ***740,00*** |  | |  |  |
| Ri-D1 **\*** | 0746-093 | 1 administration 4,5 mL solution injectable, 333 MBq | | 1 toediening 4,5 mL oplossing voor injectie, 333 MBq | |  |  | 29,7500 | |  |  |
| Ri-D1 **\*\*** | 0746-104 | 1 administration 4,5 mL solution injectable, 333 MBq | | 1 toediening 4,5 mL oplossing voor injectie, 333 MBq | |  |  | 29,7500 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ADREVIEW 74 MBq/ml | | | GE HEALTHCARE | |  | | | | ATC: V09IX01 | | |
|  | ***0746-093*** | ***1 flacon injectable 5 ml solution injectable, 370 MBq*** | | ***1 injectieflacon 5 ml oplossing voor injectie, 370 MBq*** | |  | ***805,00*** |  | |  |  |
| Ri-D1 **\*** | 0746-093 | 1 administration 5 mL solution injectable, 370 MBq | | 1 toediening 5 mL oplossing voor injectie, 370 MBq | |  |  | 29,7500 | |  |  |
| Ri-D1 **\*\*** | 0746-104 | 1 administration 5 mL solution injectable, 370 MBq | | 1 toediening 5 mL oplossing voor injectie, 370 MBq | |  |  | 29,7500 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ADREVIEW 74 MBq/ml | | | GE HEALTHCARE | |  | | | | ATC: V09IX01 | | |
|  | ***0746-093*** | ***1 flacon injectable 2,5 ml solution injectable, 185 MBq*** | | ***1 injectieflacon 2,5 ml oplossing voor injectie, 185 MBq*** | |  | ***480,00*** |  | |  |  |
| Ri-D1 **\*** | 0746-093 | 1 administration 2,5 mL solution injectable, 185 MBq | | 1 toediening 2,5 mL oplossing voor injectie, 185 MBq | |  |  | 29,7500 | |  |  |
| Ri-D1 **\*\*** | 0746-104 | 1 administration 2,5 mL solution injectable, 185 MBq | | 1 toediening 2,5 mL oplossing voor injectie, 185 MBq | |  |  | 29,7500 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ADREVIEW 74 MBq/ml | | | GE HEALTHCARE | |  | | | | ATC: V09IX01 | | |
|  | ***0746-093*** | ***1 flacon injectable 1,5 ml solution injectable, 111 MBq*** | | ***1 injectieflacon 1,5 ml oplossing voor injectie, 111 MBq*** | |  | ***350,00*** |  | |  |  |
| Ri-D1 **\*** | 0746-093 | 1 administration 1,5 mL solution injectable, 111 MBq | | 1 toediening 1,5 mL oplossing voor injectie, 111 MBq | |  |  | 29,7500 | |  |  |
| Ri-D1 **\*\*** | 0746-104 | 1 administration 1,5 mL solution injectable, 111 MBq | | 1 toediening 1,5 mL oplossing voor injectie, 111 MBq | |  |  | 29,7500 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ADREVIEW 74 MBq/ml | | | GE HEALTHCARE | |  | | | | ATC: V09IX01 | | |
|  | ***0746-093*** | ***1 flacon injectable 2 ml solution injectable, 148 MBq*** | | ***1 injectieflacon 2 ml oplossing voor injectie, 148 MBq*** | |  | ***415,00*** |  | |  |  |
| Ri-D1 **\*** | 0746-093 | 1 administration 2 mL solution injectable, 148 MBq | | 1 toediening 2 mL oplossing voor injectie, 148 MBq | |  |  | 29,7500 | |  |  |
| Ri-D1 **\*\*** | 0746-104 | 1 administration 2 mL solution injectable, 148 MBq | | 1 toediening 2 mL oplossing voor injectie, 148 MBq | |  |  | 29,7500 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ADREVIEW 74 MBq/ml | | | GE HEALTHCARE | |  | | | | ATC: V09IX01 | | |
|  | ***0746-093*** | ***1 flacon injectable 0,5 ml solution injectable, 37 MBq*** | | ***1 injectieflacon 0,5 ml oplossing voor injectie, 37 MBq*** | |  | ***310,00*** |  | |  |  |
| Ri-D1 **\*** | 0746-093 | 1 administration 0,5 mL solution injectable, 37 MBq | | 1 toediening 0,5 mL oplossing voor injectie, 37 MBq | |  |  | 29,7500 | |  |  |
| Ri-D1 **\*\*** | 0746-104 | 1 administration 0,5 mL solution injectable, 37 MBq | | 1 toediening 0,5 mL oplossing voor injectie, 37 MBq | |  |  | 29,7500 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| MIBG-I-123 74 MBq/ml | | | CURIUM BELGIUM BV | |  | | | | ATC: V09IX01 | | |
|  | ***0746-093*** | ***1 flacon injectable 5 ml solution injectable, 370 MBq*** | | ***1 injectieflacon 5 ml oplossing voor injectie, 370 MBq*** | |  | ***841,32*** |  | |  |  |
| Ri-D1 **\*** | 0746-093 | 1 administration 5 mL solution injectable, 370 MBq | | 1 toediening 5 mL oplossing voor injectie, 370 MBq | |  |  | 29,7500 | |  |  |
| Ri-D1 **\*\*** | 0746-104 | 1 administration 5 mL solution injectable, 370 MBq | | 1 toediening 5 mL oplossing voor injectie, 370 MBq | |  |  | 29,7500 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| MIBG-I-123 74 MBq/ml | | | CURIUM BELGIUM BV | |  | | | | ATC: V09IX01 | | |
|  | ***0746-093*** | ***1 flacon injectable 2 ml solution injectable, 148 MBq*** | | ***1 injectieflacon 2 ml oplossing voor injectie, 148 MBq*** | |  | ***491,76*** |  | |  |  |
| Ri-D1 **\*** | 0746-093 | 1 administration 2 mL solution injectable, 148 MBq | | 1 toediening 2 mL oplossing voor injectie, 148 MBq | |  |  | 29,7500 | |  |  |
| Ri-D1 **\*\*** | 0746-104 | 1 administration 2 mL solution injectable, 148 MBq | | 1 toediening 2 mL oplossing voor injectie, 148 MBq | |  |  | 29,7500 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| MIBG-I-123 74 MBq/ml | | | CURIUM BELGIUM BV | |  | | | | ATC: V09IX01 | | |
|  | ***0746-093*** | ***1 flacon injectable 3 ml solution injectable, 222 MBq*** | | ***1 injectieflacon 3 ml oplossing voor injectie, 222 MBq*** | |  | ***707,64*** |  | |  |  |
| Ri-D1 **\*** | 0746-093 | 1 administration 3 mL solution injectable, 222 MBq | | 1 toediening 3 mL oplossing voor injectie, 222 MBq | |  |  | 29,7500 | |  |  |
| Ri-D1 **\*\*** | 0746-104 | 1 administration 3 mL solution injectable, 222 MBq | | 1 toediening 3 mL oplossing voor injectie, 222 MBq | |  |  | 29,7500 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| MIBG-I-123 74 MBq/ml | | | CURIUM BELGIUM BV | |  | | | | ATC: V09IX01 | | |
|  | ***0746-093*** | ***1 flacon injectable 1 ml solution injectable, 74 MBq*** | | ***1 injectieflacon 1 ml oplossing voor injectie, 74 MBq*** | |  | ***275,88*** |  | |  |  |
| Ri-D1 **\*** | 0746-093 | 1 administration 1 mL solution injectable, 74 MBq | | 1 toediening 1 mL oplossing voor injectie, 74 MBq | |  |  | 29,7500 | |  |  |
| Ri-D1 **\*\*** | 0746-104 | 1 administration 1 mL solution injectable, 74 MBq | | 1 toediening 1 mL oplossing voor injectie, 74 MBq | |  |  | 29,7500 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| MIBG-I-123 74 MBq/ml | | | CURIUM BELGIUM BV | |  | | | | ATC: V09IX01 | | |
|  | ***0746-093*** | ***1 flacon injectable 4 ml solution injectable, 296 MBq*** | | ***1 injectieflacon 4 ml oplossing voor injectie, 296 MBq*** | |  | ***763,80*** |  | |  |  |
| Ri-D1 **\*** | 0746-093 | 1 administration 4 mL solution injectable, 296 MBq | | 1 toediening 4 mL oplossing voor injectie, 296 MBq | |  |  | 29,7500 | |  |  |
| Ri-D1 **\*\*** | 0746-104 | 1 administration 4 mL solution injectable, 296 MBq | | 1 toediening 4 mL oplossing voor injectie, 296 MBq | |  |  | 29,7500 | |  |  |
|  |  |  | |  | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | | |  | | | | | |
| **Paragraphe 30006** | | | | **Paragraaf 30006** | | | | | |
| Produits radio-pharmaceutiques à base de Iobengane (I-123) - catégorie de remboursement Ri-D1 - domaine d’application diagnostique: tumeur | | | | Radiofarmaceutische producten op basis van iobenguaan (I-123) - vergoedingscategorie Ri-D1 – toepassingsgebied diagnostiek: tumor | | | | | |
|  | | | |  | | | | | |
| Dénomination / Benaming (Demandeur/Aanvrager) | | | | | | | | | |
| Cat. | Code | Conditionnements | Verpakkingen | | Obs  Opm | Prix  Prijs  ***ex-usine / buiten bedrijf*** | Base de remb  Basis v tegem  ***ex-usine / buiten bedrijf*** | I | II |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ADREVIEW 74 MBq/ml | | | GE HEALTHCARE | |  | | | | ATC: V09IX01 | | |
|  | ***0747-736*** | ***1 flacon injectable 1 ml solution injectable, 74 MBq*** | | ***1 injectieflacon 1 ml oplossing voor injectie, 74 MBq*** | |  | ***330,00*** |  | |  |  |
| Ri-D1 **\*** | 0747-736 | 1 administration 1 mL solution injectable, 74 MBq | | 1 toediening 1 mL oplossing voor injectie, 74 MBq | |  |  | 29,7500 | |  |  |
| Ri-D1 **\*\*** | 0747-740 | 1 administration 1 mL solution injectable, 74 MBq | | 1 toediening 1 mL oplossing voor injectie, 74 MBq | |  |  | 29,7500 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ADREVIEW 74 MBq/ml | | | GE HEALTHCARE | |  | | | | ATC: V09IX01 | | |
|  | ***0747-736*** | ***1 flacon injectable 3 ml solution injectable, 222 MBq*** | | ***1 injectieflacon 3 ml oplossing voor injectie, 222 MBq*** | |  | ***545,00*** |  | |  |  |
| Ri-D1 **\*** | 0747-736 | 1 administration 3 mL solution injectable, 222 MBq | | 1 toediening 3 mL oplossing voor injectie, 222 MBq | |  |  | 29,7500 | |  |  |
| Ri-D1 **\*\*** | 0747-740 | 1 administration 3 mL solution injectable, 222 MBq | | 1 toediening 3 mL oplossing voor injectie, 222 MBq | |  |  | 29,7500 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ADREVIEW 74 MBq/ml | | | GE HEALTHCARE | |  | | | | ATC: V09IX01 | | |
|  | ***0747-736*** | ***1 flacon injectable 3,5 ml solution injectable, 259 MBq*** | | ***1 injectieflacon 3,5 ml oplossing voor injectie, 259 MBq*** | |  | ***610,00*** |  | |  |  |
| Ri-D1 **\*** | 0747-736 | 1 administration 3,5 mL solution injectable, 259 MBq | | 1 toediening 3,5 mL oplossing voor injectie, 259 MBq | |  |  | 29,7500 | |  |  |
| Ri-D1 **\*\*** | 0747-740 | 1 administration 3,5 mL solution injectable, 259 MBq | | 1 toediening 3,5 mL oplossing voor injectie, 259 MBq | |  |  | 29,7500 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ADREVIEW 74 MBq/ml | | | GE HEALTHCARE | |  | | | | ATC: V09IX01 | | |
|  | ***0747-736*** | ***1 flacon injectable 4 ml solution injectable, 296 MBq*** | | ***1 injectieflacon 4 ml oplossing voor injectie, 296 MBq*** | |  | ***675,00*** |  | |  |  |
| Ri-D1 **\*** | 0747-736 | 1 administration 4 mL solution injectable, 296 MBq | | 1 toediening 4 mL oplossing voor injectie, 296 MBq | |  |  | 29,7500 | |  |  |
| Ri-D1 **\*\*** | 0747-740 | 1 administration 4 mL solution injectable, 296 MBq | | 1 toediening 4 mL oplossing voor injectie, 296 MBq | |  |  | 29,7500 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ADREVIEW 74 MBq/ml | | | GE HEALTHCARE | |  | | | | ATC: V09IX01 | | |
|  | ***0747-736*** | ***1 flacon injectable 4,5 ml solution injectable, 333 MBq*** | | ***1 injectieflacon 4,5 ml oplossing voor injectie, 333 MBq*** | |  | ***740,00*** |  | |  |  |
| Ri-D1 **\*** | 0747-736 | 1 administration 4,5 mL solution injectable, 333 MBq | | 1 toediening 4,5 mL oplossing voor injectie, 333 MBq | |  |  | 29,7500 | |  |  |
| Ri-D1 **\*\*** | 0747-740 | 1 administration 4,5 mL solution injectable, 333 MBq | | 1 toediening 4,5 mL oplossing voor injectie, 333 MBq | |  |  | 29,7500 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ADREVIEW 74 MBq/ml | | | GE HEALTHCARE | |  | | | | ATC: V09IX01 | | |
|  | ***0747-736*** | ***1 flacon injectable 5 ml solution injectable, 370 MBq*** | | ***1 injectieflacon 5 ml oplossing voor injectie, 370 MBq*** | |  | ***805,00*** |  | |  |  |
| Ri-D1 **\*** | 0747-736 | 1 administration 5 mL solution injectable, 370 MBq | | 1 toediening 5 mL oplossing voor injectie, 370 MBq | |  |  | 29,7500 | |  |  |
| Ri-D1 **\*\*** | 0747-740 | 1 administration 5 mL solution injectable, 370 MBq | | 1 toediening 5 mL oplossing voor injectie, 370 MBq | |  |  | 29,7500 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ADREVIEW 74 MBq/ml | | | GE HEALTHCARE | |  | | | | ATC: V09IX01 | | |
|  | ***0747-736*** | ***1 flacon injectable 2,5 ml solution injectable, 185 MBq*** | | ***1 injectieflacon 2,5 ml oplossing voor injectie, 185 MBq*** | |  | ***480,00*** |  | |  |  |
| Ri-D1 **\*** | 0747-736 | 1 administration 2,5 mL solution injectable, 185 MBq | | 1 toediening 2,5 mL oplossing voor injectie, 185 MBq | |  |  | 29,7500 | |  |  |
| Ri-D1 **\*\*** | 0747-740 | 1 administration 2,5 mL solution injectable, 185 MBq | | 1 toediening 2,5 mL oplossing voor injectie, 185 MBq | |  |  | 29,7500 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ADREVIEW 74 MBq/ml | | | GE HEALTHCARE | |  | | | | ATC: V09IX01 | | |
|  | ***0747-736*** | ***1 flacon injectable 1,5 ml solution injectable, 111 MBq*** | | ***1 injectieflacon 1,5 ml oplossing voor injectie, 111 MBq*** | |  | ***350,00*** |  | |  |  |
| Ri-D1 **\*** | 0747-736 | 1 administration 1,5 mL solution injectable, 111 MBq | | 1 toediening 1,5 mL oplossing voor injectie, 111 MBq | |  |  | 29,7500 | |  |  |
| Ri-D1 **\*\*** | 0747-740 | 1 administration 1,5 mL solution injectable, 111 MBq | | 1 toediening 1,5 mL oplossing voor injectie, 111 MBq | |  |  | 29,7500 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ADREVIEW 74 MBq/ml | | | GE HEALTHCARE | |  | | | | ATC: V09IX01 | | |
|  | ***0747-736*** | ***1 flacon injectable 2 ml solution injectable, 148 MBq*** | | ***1 injectieflacon 2 ml oplossing voor injectie, 148 MBq*** | |  | ***415,00*** |  | |  |  |
| Ri-D1 **\*** | 0747-736 | 1 administration 2 mL solution injectable, 148 MBq | | 1 toediening 2 mL oplossing voor injectie, 148 MBq | |  |  | 29,7500 | |  |  |
| Ri-D1 **\*\*** | 0747-740 | 1 administration 2 mL solution injectable, 148 MBq | | 1 toediening 2 mL oplossing voor injectie, 148 MBq | |  |  | 29,7500 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ADREVIEW 74 MBq/ml | | | GE HEALTHCARE | |  | | | | ATC: V09IX01 | | |
|  | ***0747-736*** | ***1 flacon injectable 0,5 ml solution injectable, 37 MBq*** | | ***1 injectieflacon 0,5 ml oplossing voor injectie, 37 MBq*** | |  | ***310,00*** |  | |  |  |
| Ri-D1 **\*** | 0747-736 | 1 administration 0,5 mL solution injectable, 37 MBq | | 1 toediening 0,5 mL oplossing voor injectie, 37 MBq | |  |  | 29,7500 | |  |  |
| Ri-D1 **\*\*** | 0747-740 | 1 administration 0,5 mL solution injectable, 37 MBq | | 1 toediening 0,5 mL oplossing voor injectie, 37 MBq | |  |  | 29,7500 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| MIBG-I-123 74 MBq/ml | | | CURIUM BELGIUM BV | |  | | | | ATC: V09IX01 | | |
|  | ***0747-736*** | ***1 flacon injectable 5 ml solution injectable, 370 MBq*** | | ***1 injectieflacon 5 ml oplossing voor injectie, 370 MBq*** | |  | ***841,32*** |  | |  |  |
| Ri-D1 **\*** | 0747-736 | 1 administration 5 mL solution injectable, 370 MBq | | 1 toediening 5 mL oplossing voor injectie, 370 MBq | |  |  | 29,7500 | |  |  |
| Ri-D1 **\*\*** | 0747-740 | 1 administration 5 mL solution injectable, 370 MBq | | 1 toediening 5 mL oplossing voor injectie, 370 MBq | |  |  | 29,7500 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| MIBG-I-123 74 MBq/ml | | | CURIUM BELGIUM BV | |  | | | | ATC: V09IX01 | | |
|  | ***0747-736*** | ***1 flacon injectable 2 ml solution injectable, 148 MBq*** | | ***1 injectieflacon 2 ml oplossing voor injectie, 148 MBq*** | |  | ***491,76*** |  | |  |  |
| Ri-D1 **\*** | 0747-736 | 1 administration 2 mL solution injectable, 148 MBq | | 1 toediening 2 mL oplossing voor injectie, 148 MBq | |  |  | 29,7500 | |  |  |
| Ri-D1 **\*\*** | 0747-740 | 1 administration 2 mL solution injectable, 148 MBq | | 1 toediening 2 mL oplossing voor injectie, 148 MBq | |  |  | 29,7500 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| MIBG-I-123 74 MBq/ml | | | CURIUM BELGIUM BV | |  | | | | ATC: V09IX01 | | |
|  | ***0747-736*** | ***1 flacon injectable 3 ml solution injectable, 222 MBq*** | | ***1 injectieflacon 3 ml oplossing voor injectie, 222 MBq*** | |  | ***707,64*** |  | |  |  |
| Ri-D1 **\*** | 0747-736 | 1 administration 3 mL solution injectable, 222 MBq | | 1 toediening 3 mL oplossing voor injectie, 222 MBq | |  |  | 29,7500 | |  |  |
| Ri-D1 **\*\*** | 0747-740 | 1 administration 3 mL solution injectable, 222 MBq | | 1 toediening 3 mL oplossing voor injectie, 222 MBq | |  |  | 29,7500 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| MIBG-I-123 74 MBq/ml | | | CURIUM BELGIUM BV | |  | | | | ATC: V09IX01 | | |
|  | ***0747-736*** | ***1 flacon injectable 1 ml solution injectable, 74 MBq*** | | ***1 injectieflacon 1 ml oplossing voor injectie, 74 MBq*** | |  | ***275,88*** |  | |  |  |
| Ri-D1 **\*** | 0747-736 | 1 administration 1 mL solution injectable, 74 MBq | | 1 toediening 1 mL oplossing voor injectie, 74 MBq | |  |  | 29,7500 | |  |  |
| Ri-D1 **\*\*** | 0747-740 | 1 administration 1 mL solution injectable, 74 MBq | | 1 toediening 1 mL oplossing voor injectie, 74 MBq | |  |  | 29,7500 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| MIBG-I-123 74 MBq/ml | | | CURIUM BELGIUM BV | |  | | | | ATC: V09IX01 | | |
|  | ***0747-736*** | ***1 flacon injectable 4 ml solution injectable, 296 MBq*** | | ***1 injectieflacon 4 ml oplossing voor injectie, 296 MBq*** | |  | ***763,80*** |  | |  |  |
| Ri-D1 **\*** | 0747-736 | 1 administration 4 mL solution injectable, 296 MBq | | 1 toediening 4 mL oplossing voor injectie, 296 MBq | |  |  | 29,7500 | |  |  |
| Ri-D1 **\*\*** | 0747-740 | 1 administration 4 mL solution injectable, 296 MBq | | 1 toediening 4 mL oplossing voor injectie, 296 MBq | |  |  | 29,7500 | |  |  |
|  |  |  | |  | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | | |  | | | | | |
| **Paragraphe 30007** | | | | **Paragraaf 30007** | | | | | |
| Produits radio-pharmaceutiques à base de iobengane (I-123) - catégorie de remboursement Ri-D1 - domaine d’application diagnostique: coeur | | | | Radiofarmaceutische producten op basis van iobenguaan (I-123) vergoedingscategorie Ri-D1 – toepassingsgebied diagnostiek: hart | | | | | |
|  | | | |  | | | | | |
| Dénomination / Benaming (Demandeur/Aanvrager) | | | | | | | | | |
| Cat. | Code | Conditionnements | Verpakkingen | | Obs  Opm | Prix  Prijs  ***ex-usine / buiten bedrijf*** | Base de remb  Basis v tegem  ***ex-usine / buiten bedrijf*** | I | II |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ADREVIEW 74 MBq/ml | | | GE HEALTHCARE | |  | | | | ATC: V09IX01 | | |
|  | ***0746-130*** | ***1 flacon injectable 1 ml solution injectable, 74 MBq*** | | ***1 injectieflacon 1 ml oplossing voor injectie, 74 MBq*** | |  | ***330,00*** |  | |  |  |
| Ri-D1 **\*** | 0746-130 | 1 administration 1 mL solution injectable, 74 MBq | | 1 toediening 1 mL oplossing voor injectie, 74 MBq | |  |  | 29,7500 | |  |  |
| Ri-D1 **\*\*** | 0746-141 | 1 administration 1 mL solution injectable, 74 MBq | | 1 toediening 1 mL oplossing voor injectie, 74 MBq | |  |  | 29,7500 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ADREVIEW 74 MBq/ml | | | GE HEALTHCARE | |  | | | | ATC: V09IX01 | | |
|  | ***0746-130*** | ***1 flacon injectable 3 ml solution injectable, 222 MBq*** | | ***1 injectieflacon 3 ml oplossing voor injectie, 222 MBq*** | |  | ***545,00*** |  | |  |  |
| Ri-D1 **\*** | 0746-130 | 1 administration 3 mL solution injectable, 222 MBq | | 1 toediening 3 mL oplossing voor injectie, 222 MBq | |  |  | 29,7500 | |  |  |
| Ri-D1 **\*\*** | 0746-141 | 1 administration 3 mL solution injectable, 222 MBq | | 1 toediening 3 mL oplossing voor injectie, 222 MBq | |  |  | 29,7500 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ADREVIEW 74 MBq/ml | | | GE HEALTHCARE | |  | | | | ATC: V09IX01 | | |
|  | ***0746-130*** | ***1 flacon injectable 3,5 ml solution injectable, 259 MBq*** | | ***1 injectieflacon 3,5 ml oplossing voor injectie, 259 MBq*** | |  | ***610,00*** |  | |  |  |
| Ri-D1 **\*** | 0746-130 | 1 administration 3,5 mL solution injectable, 259 MBq | | 1 toediening 3,5 mL oplossing voor injectie, 259 MBq | |  |  | 29,7500 | |  |  |
| Ri-D1 **\*\*** | 0746-141 | 1 administration 3,5 mL solution injectable, 259 MBq | | 1 toediening 3,5 mL oplossing voor injectie, 259 MBq | |  |  | 29,7500 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ADREVIEW 74 MBq/ml | | | GE HEALTHCARE | |  | | | | ATC: V09IX01 | | |
|  | ***0746-130*** | ***1 flacon injectable 4 ml solution injectable, 296 MBq*** | | ***1 injectieflacon 4 ml oplossing voor injectie, 296 MBq*** | |  | ***675,00*** |  | |  |  |
| Ri-D1 **\*** | 0746-130 | 1 administration 4 mL solution injectable, 296 MBq | | 1 toediening 4 mL oplossing voor injectie, 296 MBq | |  |  | 29,7500 | |  |  |
| Ri-D1 **\*\*** | 0746-141 | 1 administration 4 mL solution injectable, 296 MBq | | 1 toediening 4 mL oplossing voor injectie, 296 MBq | |  |  | 29,7500 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ADREVIEW 74 MBq/ml | | | GE HEALTHCARE | |  | | | | ATC: V09IX01 | | |
|  | ***0746-130*** | ***1 flacon injectable 4,5 ml solution injectable, 333 MBq*** | | ***1 injectieflacon 4,5 ml oplossing voor injectie, 333 MBq*** | |  | ***740,00*** |  | |  |  |
| Ri-D1 **\*** | 0746-130 | 1 administration 4,5 mL solution injectable, 333 MBq | | 1 toediening 4,5 mL oplossing voor injectie, 333 MBq | |  |  | 29,7500 | |  |  |
| Ri-D1 **\*\*** | 0746-141 | 1 administration 4,5 mL solution injectable, 333 MBq | | 1 toediening 4,5 mL oplossing voor injectie, 333 MBq | |  |  | 29,7500 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ADREVIEW 74 MBq/ml | | | GE HEALTHCARE | |  | | | | ATC: V09IX01 | | |
|  | ***0746-130*** | ***1 flacon injectable 5 ml solution injectable, 370 MBq*** | | ***1 injectieflacon 5 ml oplossing voor injectie, 370 MBq*** | |  | ***805,00*** |  | |  |  |
| Ri-D1 **\*** | 0746-130 | 1 administration 5 mL solution injectable, 370 MBq | | 1 toediening 5 mL oplossing voor injectie, 370 MBq | |  |  | 29,7500 | |  |  |
| Ri-D1 **\*\*** | 0746-141 | 1 administration 5 mL solution injectable, 370 MBq | | 1 toediening 5 mL oplossing voor injectie, 370 MBq | |  |  | 29,7500 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ADREVIEW 74 MBq/ml | | | GE HEALTHCARE | |  | | | | ATC: V09IX01 | | |
|  | ***0746-130*** | ***1 flacon injectable 2,5 ml solution injectable, 185 MBq*** | | ***1 injectieflacon 2,5 ml oplossing voor injectie, 185 MBq*** | |  | ***480,00*** |  | |  |  |
| Ri-D1 **\*** | 0746-130 | 1 administration 2,5 mL solution injectable, 185 MBq | | 1 toediening 2,5 mL oplossing voor injectie, 185 MBq | |  |  | 29,7500 | |  |  |
| Ri-D1 **\*\*** | 0746-141 | 1 administration 2,5 mL solution injectable, 185 MBq | | 1 toediening 2,5 mL oplossing voor injectie, 185 MBq | |  |  | 29,7500 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ADREVIEW 74 MBq/ml | | | GE HEALTHCARE | |  | | | | ATC: V09IX01 | | |
|  | ***0746-130*** | ***1 flacon injectable 1,5 ml solution injectable, 111 MBq*** | | ***1 injectieflacon 1,5 ml oplossing voor injectie, 111 MBq*** | |  | ***350,00*** |  | |  |  |
| Ri-D1 **\*** | 0746-130 | 1 administration 1,5 mL solution injectable, 111 MBq | | 1 toediening 1,5 mL oplossing voor injectie, 111 MBq | |  |  | 29,7500 | |  |  |
| Ri-D1 **\*\*** | 0746-141 | 1 administration 1,5 mL solution injectable, 111 MBq | | 1 toediening 1,5 mL oplossing voor injectie, 111 MBq | |  |  | 29,7500 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ADREVIEW 74 MBq/ml | | | GE HEALTHCARE | |  | | | | ATC: V09IX01 | | |
|  | ***0746-130*** | ***1 flacon injectable 2 ml solution injectable, 148 MBq*** | | ***1 injectieflacon 2 ml oplossing voor injectie, 148 MBq*** | |  | ***415,00*** |  | |  |  |
| Ri-D1 **\*** | 0746-130 | 1 administration 2 mL solution injectable, 148 MBq | | 1 toediening 2 mL oplossing voor injectie, 148 MBq | |  |  | 29,7500 | |  |  |
| Ri-D1 **\*\*** | 0746-141 | 1 administration 2 mL solution injectable, 148 MBq | | 1 toediening 2 mL oplossing voor injectie, 148 MBq | |  |  | 29,7500 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ADREVIEW 74 MBq/ml | | | GE HEALTHCARE | |  | | | | ATC: V09IX01 | | |
|  | ***0746-130*** | ***1 flacon injectable 0,5 ml solution injectable, 37 MBq*** | | ***1 injectieflacon 0,5 ml oplossing voor injectie, 37 MBq*** | |  | ***310,00*** |  | |  |  |
| Ri-D1 **\*** | 0746-130 | 1 administration 0,5 mL solution injectable, 37 MBq | | 1 toediening 0,5 mL oplossing voor injectie, 37 MBq | |  |  | 29,7500 | |  |  |
| Ri-D1 **\*\*** | 0746-141 | 1 administration 0,5 mL solution injectable, 37 MBq | | 1 toediening 0,5 mL oplossing voor injectie, 37 MBq | |  |  | 29,7500 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| MIBG-I-123 74 MBq/ml | | | CURIUM BELGIUM BV | |  | | | | ATC: V09IX01 | | |
|  | ***0746-130*** | ***1 flacon injectable 5 ml solution injectable, 370 MBq*** | | ***1 injectieflacon 5 ml oplossing voor injectie, 370 MBq*** | |  | ***841,32*** |  | |  |  |
| Ri-D1 **\*** | 0746-130 | 1 administration 5 mL solution injectable, 370 MBq | | 1 toediening 5 mL oplossing voor injectie, 370 MBq | |  |  | 29,7500 | |  |  |
| Ri-D1 **\*\*** | 0746-141 | 1 administration 5 mL solution injectable, 370 MBq | | 1 toediening 5 mL oplossing voor injectie, 370 MBq | |  |  | 29,7500 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| MIBG-I-123 74 MBq/ml | | | CURIUM BELGIUM BV | |  | | | | ATC: V09IX01 | | |
|  | ***0746-130*** | ***1 flacon injectable 2 ml solution injectable, 148 MBq*** | | ***1 injectieflacon 2 ml oplossing voor injectie, 148 MBq*** | |  | ***491,76*** |  | |  |  |
| Ri-D1 **\*** | 0746-130 | 1 administration 2 mL solution injectable, 148 MBq | | 1 toediening 2 mL oplossing voor injectie, 148 MBq | |  |  | 29,7500 | |  |  |
| Ri-D1 **\*\*** | 0746-141 | 1 administration 2 mL solution injectable, 148 MBq | | 1 toediening 2 mL oplossing voor injectie, 148 MBq | |  |  | 29,7500 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| MIBG-I-123 74 MBq/ml | | | CURIUM BELGIUM BV | |  | | | | ATC: V09IX01 | | |
|  | ***0746-130*** | ***1 flacon injectable 3 ml solution injectable, 222 MBq*** | | ***1 injectieflacon 3 ml oplossing voor injectie, 222 MBq*** | |  | ***707,64*** |  | |  |  |
| Ri-D1 **\*** | 0746-130 | 1 administration 3 mL solution injectable, 222 MBq | | 1 toediening 3 mL oplossing voor injectie, 222 MBq | |  |  | 29,7500 | |  |  |
| Ri-D1 **\*\*** | 0746-141 | 1 administration 3 mL solution injectable, 222 MBq | | 1 toediening 3 mL oplossing voor injectie, 222 MBq | |  |  | 29,7500 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| MIBG-I-123 74 MBq/ml | | | CURIUM BELGIUM BV | |  | | | | ATC: V09IX01 | | |
|  | ***0746-130*** | ***1 flacon injectable 1 ml solution injectable, 74 MBq*** | | ***1 injectieflacon 1 ml oplossing voor injectie, 74 MBq*** | |  | ***275,88*** |  | |  |  |
| Ri-D1 **\*** | 0746-130 | 1 administration 1 mL solution injectable, 74 MBq | | 1 toediening 1 mL oplossing voor injectie, 74 MBq | |  |  | 29,7500 | |  |  |
| Ri-D1 **\*\*** | 0746-141 | 1 administration 1 mL solution injectable, 74 MBq | | 1 toediening 1 mL oplossing voor injectie, 74 MBq | |  |  | 29,7500 | |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| MIBG-I-123 74 MBq/ml | | | CURIUM BELGIUM BV | |  | | | | ATC: V09IX01 | | |
|  | ***0746-130*** | ***1 flacon injectable 4 ml solution injectable, 296 MBq*** | | ***1 injectieflacon 4 ml oplossing voor injectie, 296 MBq*** | |  | ***763,80*** |  | |  |  |
| Ri-D1 **\*** | 0746-130 | 1 administration 4 mL solution injectable, 296 MBq | | 1 toediening 4 mL oplossing voor injectie, 296 MBq | |  |  | 29,7500 | |  |  |
| Ri-D1 **\*\*** | 0746-141 | 1 administration 4 mL solution injectable, 296 MBq | | 1 toediening 4 mL oplossing voor injectie, 296 MBq | |  |  | 29,7500 | |  |  |
|  |  |  | |  | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | | |  | | | | | |
| **Paragraphe 30008** | | | | **Paragraaf 30008** | | | | | |
| Produits radio-pharmaceutiques à base de norcholestérol iodé (I-131) - catégorie de remboursement Ri-D1 - domaine d’application diagnostique: glande surrénale | | | | Radiofarmaceutische producten op basis van norcholesteroljodide (I-131) - vergoedingscategorie Ri-D1 – toepassingsgebied diagnostiek: bijnier | | | | | |
|  | | | |  | | | | | |
| Dénomination / Benaming (Demandeur/Aanvrager) | | | | | | | | | |
| Cat. | Code | Conditionnements | Verpakkingen | | Obs  Opm | Prix  Prijs  ***ex-usine / buiten bedrijf*** | Base de remb  Basis v tegem  ***ex-usine / buiten bedrijf*** | I | II |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| NORCHOL-131 | | | CIS BIO INTERNATIONAL SAS | |  | | | | ATC: V09XA01 | | |
|  | ***0746-152*** | ***37 MBq solution injectable*** | | ***37 MBq oplossing voor injectie*** | |  | ***900,40*** |  | |  |  |
| Ri-D1 **\*** | 0746-152 | 1 administration, 37 MBq | | 1 toediening, 37 MBq | |  |  | 29,7500 | |  |  |
| Ri-D1 **\*\*** | 0746-163 | 1 administration, 37 MBq | | 1 toediening, 37 MBq | |  |  | 29,7500 | |  |  |
|  |  |  | |  | |  |  |  | |  |  |

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | | |  | | | | | |
| **Paragraphe 30009** | | | | **Paragraaf 30009** | | | | | |
| Produits radio-pharmaceutiques à base d’ albumine humaine iodée (I-125) - catégorie de remboursement Ri-D1 | | | | Radiofarmaceutische producten op basis van jood (I-125) humaan albumine - vergoedingscategorie Ri-D1 | | | | | |
|  | | | |  | | | | | |
| Dénomination / Benaming (Demandeur/Aanvrager) | | | | | | | | | |
| Cat. | Code | Conditionnements | Verpakkingen | | Obs  Opm | Prix  Prijs  ***ex-usine / buiten bedrijf*** | Base de remb  Basis v tegem  ***ex-usine / buiten bedrijf*** | I | II |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SERALB-125 | | | CIS BIO INTERNATIONAL SAS | |  | | | | ATC: V09GB02 | | |
|  | ***0746-174*** | ***1 flacon injectable 1,7 ml solution injectable, 320 kBq*** | | ***1 injectieflacon 1,7 ml oplossing voor injectie, 320 kBq*** | |  | ***464,60*** |  | |  |  |
| Ri-D1 **\*** | 0746-174 | 1 administration 1,7 mL solution injectable, 320 kBq | | 1 toediening 1,7 mL oplossing voor injectie, 320 kBq | |  |  | 29,7500 | |  |  |
| Ri-D1 **\*\*** | 0746-185 | 1 administration 1,7 mL solution injectable, 320 kBq | | 1 toediening 1,7 mL oplossing voor injectie, 320 kBq | |  |  | 29,7500 | |  |  |
|  |  |  | |  | |  |  |  | |  |  |

|  |  |
| --- | --- |
|  |  |